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PREFACE AND ACKNOWLEDGEMENTSeretMîeKaiaT]aiCttTeue-J«iVnaitii3BrtMrie»vÈ^ ira.ra'sea«K*wn.-wr#flL'B’SM6îMywiRl«™e*'Wj'T«rK*ti»
Tiiis thesis is necessarily lengthy to accommodate the innumerable 
results presentedo I apologise for the voluminous nature of this work 
although the reader may note that this thesis contains many figures 
and tables throughout the text, whilst a further 81 pages of individual 
patient results (Chapter S) are included for perusal by the interested 
reader «
1
The studies presented in this thesis were carried out by the author 
in the Steroid Laboratory of the University Department of Child Health,
Royal Hospital for Sick Children, Glasgow. The investigation was supported 
by a gra^ nt to Dr William Hamilton from the New Medical Development Fund 
of the Scottish Home and Health Department.
These investigations were developed as a service to clinicians 
throughout Scotland and X am indebted to all those concerned for permission 
to study their patients. I am also grateful to Dr J« Williamson, Carlislej 
Dr A. MeCandless, Liverpool; Dr E. De Lobo, Luton; Dr G. Komrower, 
Manchester; Dr C. Cooper, Newcastle upon Tyne, Bî^gland, and 
Professor W. Sttoboda is Vienna, Austria, for the opportunity to study 
their patients.
I am especially indebted to Dr W. Hamilton for his helpful criticism 
ïmd constant encouragement throughout this investigation. ï am &l@o 
grateful to Professor R.M.S, Smellie for advice and encouragement.
Initial technical experience in gas liquid chromatography and 
steroid derivative formation was gained under the supervision of 
Dr T. Simpson, Torry Research Station, Aberdeen, whilst excellent laboratory 
facilities in Glasgow provided by Professor J.H. Hbtchison furthered this 
iave stig&tion.
In the later stages of this work the skilled technical assistance 
of Mr De Watson and formerly of Mrs Le, Judge, BSc, and Mr L« Yuille
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v/ere invaluable in the. initial preparation and purification of urine 
and plasma extracts®
%anks are also due to Dr D.R. Appleton at the Department of 
Medical Statistics, University of Newcastle upon Tyne, for advice on 
statistical treatment of the results presented in this thesis, and 
Dr J«R. Leece of the Computing Laboratory of that university for advice
on the use and interpretation of statistical programs,
1
I remain grateful to Dr A, Gibson for histological preparation of 
tissues and Mr A, Herd (Department of Medical Illustration) for 
preparation of the photographs in Chapter 2, The patience of ray wife 
in typing this volume exceeded my expectations,
parts of this work have been presented at the first, second and 
third meetings of the British Paediatric Endocrine Group (Lancaster, 
April 1973; Harrogate, April 1974; Birmingham, November 1974).
COMPUTING AMD STATISTICAL PROCEDURES
nwi>i.imiL-4ih/!C»wwgmtttca
The results in this thesis ha.ve been analysed by the writer using 
the Statistical package for the Social Sciences (SPSS) on the I M  370 
computer Installation at the University of Newcastle upon Tyne.
The results presented and the published normal ranges used for 
comparison were routinely analysed for skevmcss^and kurtosis. Skewed 
and kurtotic distributions were compared statistically following 
logarithmic transformation to a normal distribution. Although logarithmic 
transformation is shov/n graphically only for plasma testosterone (Figure 
3o4, page 133) it should be noted that most of the individual urinary 
steroids results in the literature required transformation to a normal 
distribution before statistical analysis.
Statistical results following logarithmic transformation were 
similar to results obtained using nonparametric statistics alone.
s.I. UNITS
Since writing this thesis the' Système International d^Unites 
(S,I, Units) has been adopted on DHSS instructions (HSC (IS) 140. 
Metrications Introduction into Medicine of the International System of 
Units). The relevant factors for conversion of the results presented 
in this thesis to S.I. Units are given below.
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ABBREVIATIONS
Tlie main abbreviations used in this thesis are listed below
ACTH
d.p.m.
BCD
EDTA
FÎD
FSH
GLC
HCG
hGH
ICSH
LH
UÎRH
NAD'''
NADPH
Adrenocort icotrophic hormone 
Disintegrations per minute 
Electron capture detection
1
Ethylenediaminetetra^acetate 
Flame ionization detection 
Follicle stimulating hormone 
Gas liquid chromatography 
Human chorionic gonadotrophin 
Human growth hormone 
Interstitial cell stimulating hormone 
Luteinizing hormone
Luteinizing hormone releasing hormone
Nicotisiamide^^adenine dinucleotide 
(oxidised form)
Nicotinamide^adenine dinucleotide phosphate 
(reduced form)
Probability
Correlation coefficient
S.A. 
TeBG 
TLC
Specific activity
Te s t o st e r one**-* bin ding p ™ g 1 o bu 1 in
Thin layer chromatography
CHAPTER 1«icnnmunamrjiciiftUTiï^dSTUWKr»
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HISTORICAL REVIEW 
"Let it not be supposed that the use of the homoaes is a 
new discovery, far from it, it is as old as life itself 
As evidence that gland therapy is not new it is interesting 
to know that as far back as 600 BC or chit ic substance tv&s 
used as a remedy for obesity and orchitic extract was also
extensively used by the ancient Egyptians and Romans for the
i
purpose of rejuvenation and the perpetuation of youth."
C. Kempster, MRCS LRCP (1935)
In 1849 Berthold, studying testicular implants in capons, concluded 
that the testes possessed a dual function - the production of spermatozoa 
and the elaboration of an internal secretion. Forty years later, 
Brown^Sequard gave great impetus to the concept of internal secretion by 
the injection of testicular extract in his famous rejuvenation experiments. 
Although his work CBrowQ‘*Sequard, 1889) has been generally discredited, he 
did create great interest in the study of sex glands.
During the following thirty years, hypogonadism was treated by the 
administration of testicular extracts or by the transplantation of gonadal 
tissue. In 1891 Poehl, a Russian physiologist, claimed that spermine, an 
organic amine present in semen, was the active secretion of the testis.
He treated numerous conditions ranging from scurvy to syphilis with spermine, 
apparently successfully. Although the pharmaceutical industry began the 
manufacture of spermine, Poehl^s 'spermine theory* aroused much controversy, 
was subjected to severe criticism, and was finally totally rejected.
Bouin and Ancel <1903, 1904) first ascribed the role of hormone 
production to the Leydig cells. This was confirmed by numerous experiments 
on the selective destruction of the seminiferous tubules in animal testes 
by irradiation, Androgeoicity remained unimpaired (Bergoioe and Tribondeau,
1904; Regaud and Dubreuil, 1907) in the treated animals. Not everybody 
accepted that the testes were capable of hormone production. According to 
the older physiologists the effects of the testes were mediated through the 
nervous system (Nussbaum, 1906). However, the numerous résulta obtained 
by the transplantation of gonadal tissue into previously castrated animals 
proved Nussbaum to be wrong.
Many workers offered evidence for a secretion within the Leydig cells
t
and in the neighbouring blood capillaries and lymphatics (Duesburg, 1918).
This diffuse secretion was believed to be lipid in nature and the precursor 
of a true secretion (MuIon, 1910). These observations have been recently 
confirmed by Baillie (1964), who demonstrated the presence, in high concen­
tration, of cholesterol in the Leydig cells of mature mice.
Research on the internal secretions was furthered by the work of 
Zondek (1926), Smith (1926) and Smith and Engle (1927). These authors 
reported undisputed evidence of the effect of the anterior pituitary on the 
groirth and function of the gonads. Aschheim and Zondek (1928) subsequently 
found a substance in the urine of pregnant women which stimulated the gonads.
The discovery by McGee (1927) that a concentrated lipid extract of bull 
testis produced measurable comb-growth in the Leghorn capon within five days 
(McGee et al., 1928) laid the foundations for subsequent extraction pro-mint* " *
cedures and for quantitative methods of assay.
After the isolation of oestrone from human pregnancy urine (Doisy ,
1930) investigations turned to human urine for androgenic activity. Following 
the isolation of crude extracts possessing little androgenic activity (Loewe 
and Voss, 1930; Funk , 1930), rapid progress was made by Butenandt
(1931, 1932) who isolated and subsequently characterized (1934) androsterone 
and dehydroepiandrosterone (Butenandt and Dannenbaum, 1934) from human 
urines. Buteoandt believed he had isolated the male hormone in androster erne. 
However, it was found that its effects differed in. many respects from those 
produced by testicular extracts.
Gallagher and Koch (1934a, 1934b) had shown that extracts of testicular 
tissue could be purified to yield a concentrate 6-10 fold more active than 
androsterone. The potency of this extract decreased when boiled with alkali. 
Instability to alkali was not characteristic of any of the known urinary 
androgens but was known to be exhibited by ct, ^-uasaturated ketones 
(progesterone). David £l* (1935) subsequently isolated from bull
testis extracts pure testosterone in crystalline form.
1
Shortly after the relation of aodrosteroae to cholesterol had been 
established (Ruzicka et _al,, 1934) many related compounds were prepared and 
their androgenic activities determined. The search for new compounds more 
potent than androsteroae was on. In the decade following the synthesis of 
testosterone from cholesterol by Butenandt and Hanisch (1935) and Ruzicka 
et al. (1935) these two research groups, working in co-operation with 
Schering in Berlin and Ciba in Basel respectively, prepared and assayed 
numerous analogues of testosterone. The only compounds found with androgenic 
activity comparable to that of testosterone were 5a“^ dihydrotestosterone and 
the methyl esters of testosterone and 5cf-dihydrotestosterone.
The advent of the Zimmermami reaction (Ziramermann, 1935) for ketones 
marked the first chemical assay in the study of endocrinology. The 
recognition of 17-ketosteroids as the quantitatively most important group 
of steroids giving this reaction gave impetus to numerous investigations 
attempting to correlate the urinary excretion of neutraji 17-ketosteroids 
with clinical features of androgen action. Modifications of this method have 
been proposed (Callow et al., 1938; Holtorff and Koch, 1940) and these* *• euaatoi «usacua 4 * *
were reviewed by Zimraemann (1955). Although testicular androgens and 
their metabolites contribute to the 'Zinimermann chromogens', approximately 
two-thirds of the urinary excretion of neutral 17-ketosteroids are now 
known to derive from dehydroepiandrosterooe and corticosteroid metabolites 
of adrenal origin (Callow, 1939). The estimation of urinary neutral
17-ketosteroids has, however, been standardized (17-oxosteroids; Medical 
Research Council, 1963) and the assay has been retained for routine urinary 
steroid analyses.
It was soon realised that more information could be obtained from 
the separation of the neutral 17-ketosteroids either into groups with 
common characteristics or into individual compounds. The most simple
fractionation described separates the neutral 17-ketosteroids into the
1
3a-hydroxy and 3(3“hydroxy fractions (cc~ and p-fractions ) by the precipitation 
of the 3P“hydroxy-17~ketosteroids with digitonin (Butt ^  , 1948; Haslam
and Klyne, 1952).
The differential separation of neutral 17-ketosteroids was first 
described by Dingemanse ^  (1946, 1952). This method utilizes acid
hydrolysis of the urine with subsequent separation of the neutral 
17-ketosteroids by aluminium oxide adsorption chromatography, into eight 
individual fractions, each subsequently quantitated by the Ziramermann 
reaction. This method has been modified many times without successfully 
overcoming the inherent difficulties (Dorfraan, 1968). However, the peiper 
chromatographic .separation of individual 17-ketosteroids introduced by 
Rubin et al. (1953) and the gradient elution methods used by LakshraananWcfwa «cF«=a *
and Lieberraan (1954) and Kellie and Wade (195?) gave more satisfactory 
results.
Numerous attempts to determine testosterone in biological samples 
have been reported, but only in the last 14 years have techniques been
available for the estimation of testosterone in plasma ruid urine.
Circulating testosterone was first isolated and identified in spermatic 
vein blood of the dog (West et al., 1952) and later in human spermatic«»sKU«  ^ *■
vein blood (Lucas et al., 1957; Hollander and Hollander, 1958).
u^vu» «UWIWT* r * i
The work of Hollander and Hollander (1958) had shown that human 
testicular blood contained between 3 and 160 pg testosterone per 100 ml.
- o
No testosterone was, however, detected in the peripheral venous blood of 
the subjects investigated. Oertel and Eik-Nes (1959) confirmed this 
finding but they succeeded in isolating testosterone in systemic blood of 
the normal male after the administration of large doses of human chorionic 
gonadotrophin (HCG). In 1961 Finklestein et al. were the first to describe 
a method for the estimation of testosterone in peripheral venous plasma.
By their method testosterone was enzymatically converted to 17(3-oestradiol 
and measured thereafter fluorinietricaily. Although this method required 
large amounts of blood for adequate assay, it confirmed the presence of 
testosterone in the peripheral circulation of normal men and women.
Sensitive methods for the estimation of testosterone in small amounts of 
human plasma v/ere subsequently reported (Riondel ^  ÜjL* > 1963; Hudson et al., 
1963; Brov/nie et al., 1964; van der Molen et al., 1966). More recent methods'  «a-»*# * * Imicaup ^
applicable to the quantitation of plasma testosterone in prepubertal children 
vdll be reviewed in Table 3,VIII (Chapter 3).
Numerous but unsuccessful attempts were made to demonstrate testosterone 
in the urine. In 1950, Dobriner and Lieberman reported that administration 
of large amounts of testosterone to normal subjects resulted in the excretion 
in the urine of only trace amounts of the hormone. Ten years later, 
however, Schubert and V/ehrberger (1960) demonstrated that testosterone is an 
excretory product in man. Values for the urinary excretion of testosterone 
have been reported for humans in health and disease (Camacho and Kigeon,
1963, 1964). Tlieir method employed hydrolysis with a commercial preparation 
of p-glucuronidase. Thus testosterone is present as the glucuronoside. 
Subsequent work has shown that testosterone may also be excreted 'free* 
(unconjugated) (Dulmanis et al., 1964) aad as a sulphate (Dessypris el; al., 
1966). Again, more recently published methods applicable to the 
quantitation of urinary testosterone excretion in prepubertal children will 
be reviewed in Table 3.V (Chapter 3).
STEROID BIOSYNTHESIS IN THE TESTIS*wCa*sB»M*ai2UHziU 1 sutf.urs^BC3KO 7 p«tiapa?s3i7Sjwaaaaas{aai»gByajailKKBi"r—WwTi Ttt,xc»*WKaf«tT<iairfr n
Although this thesis is primarily concerned with the metabolism of 
testosterone it is perhaps pertinent to review briefly the biosynthesis 
of testosterone within the testis.
The interstitial cells of the testis were first described by Leydig in 
1050. He noted these cells as clear, round cells, analogous to embryonic 
connective tissue, vacuolated and containing pigment granules and fat droplets
t
Mulon (1910) believed these fat droplets to increase during secretory
activity and envisaged this lipoidal substance to be the precursor of the
true testicular secretion.
Baillie (1964) reported the presence of high concentrations of cholestero 
in Leydig cells of mature mice, whilst Christensen (1965) correlated the 
cholesterol production in the testis with the amount of agranular reticulum 
in the Leydig cells. Further work by Christensen and Fawcett (1966) 
suggested that cholesterol is stored in the agranular reticulum en route
^  riaojiîii M-suartfïissmjta
to the mitochondria of these cells where it will be converted to pregnenolone.
Experiments in vivo (Mason and Samuels, 1961) and in vitro (Hail and
* meenatssaeaut *  #3734» aura
Eik-Nes, 1962) have demonstrated that cholesterol is formed from acetate in 
the testes. Intermediates in the testicular formation of cholesterol have 
been identified (Tsai et ai., 1964; Salokangas et al, 1964. 1965) which 
strongly support the view that cholesterol formation within the testes 
is similar to that in the liver.
The total concentration of cholesterol in the testes is relatively high, 
but as a considerable amount of this testicular cholesterol is associated 
with the germinal epithelium, the pool of cholesterol involved in the 
biosynthesis of androgens is small (Hall, 1963). Although the high con- 
' centration of germinal cells in the testes and the low solubility of 
cholesterol in aqueous phases confuse the role of cholesterol as a precursor 
of testicular androgens (Hall, 1963), recent experiments indicate that
cholesterol is the physiological source of all testicular steroids (Kali, 
1970).
The side chain cleavage of cholesterol to yield pregnenolone and 
isocapraldehyde takes place in the mitochondria within the Leydig cells 
(Toren et , 1964). Halkerston £t al. (1961) have sho^m that this cleavage 
requires reduced nicotinamide adenine dinucleotide phosphate (NADPH) and 
molecular oxygen and they conclude that hydroxylation of the side chain of 
cholesterol occurs before scission. 20a-Hydroxy-cholesterol (Solomon _et 9^ 1., 
1956) and 203,22/-dihydroxy«cholesterol (Shimizu al., 1962) have been 
suggested as hydroxyla.ted intermediates for this reaction.
Hall and Young (1968), accepting this proposed pathway, examined the
iîsfluence of interstitial cell stimulating hormone (ICSH) on the conversion
3 3of 20oC“hydroxy-cholesterol-''H to testosterone- H in the testes. They found
ICSH did not increase testosterone formation and since the point of trophic
hormone action occurs later than the cholesterol side chain cleavage step
(Koritz and Hall, 1965), they concluded that the 20a:--»hydroxylase system is
specifically stimulated by ICSH. Unis confirmed the earlier suggestion of
Halkerston al. (1961) and Koritz (1962).
j)e novo synthesis of testosterone from acetate and cholesterol has been 
established in the human testis by both in vitro and in vivo methods 
(Brady, 1951; Savard et al., 1952; Rice et al., 1966; Knapstein et al.,
1968; Serra ^  , 1970). Although these authors have isolated many of the
intermediates there has been no systematic elucidation of the preferred 
pathway from A^-pregnenolone to testosterone.
In 1937, Koch presented a theoretical scheme for the biosynthesis of 
testosterone and oestrogens. He suggested that cholesterol v/as converted via 
dehydroepiandrosterone and A^-androstene-30,17j)“diol to testosterone. Koch 
also suggested that dehydroepiandrosterone was oxidized to A^-androstenedione 
and the possibility that A^-androstencdione and testosterone were aromatized 
to form oestrogeos.
Tlie A^-pathway for testosterone biosynthesis (progesterone,
l7a-hydroxyprogesteron€, A^=-androstenedicne) in the testis was initially
demonstrated in the rat (Slaimwhite and Samuels, 1956) and in the human
(Slamiwhite ^  Bi*> f962a) by studies using radioactively labelled A^-steroid
5 5precursors of testosterone. Subsequently, the à -pathway (A -pregnenolone,
517oC"hydroxypregnenolone, dehydroepiandrosterone, A -androstene-Sp,173-diol)
was demonstrated in normal (Axelrod, 1965; Rosner and Macome, 1970) and
1
abnormal (Gual et al., 1962: Charreau and Villee, 1968) human testes.
However, it should be noted that these two predominant pathv/ays may overlap
since ^  vivo experiments on the canine testis (Hagen and Eik-Nes, 1964)
demonstrate that 17a'-»hydroxypregnenolone can be converted to
17a“hydroxyprogesterone. Rosner et (1965a) have found that progesterone
5can be converted to A -pregnenolone by sliced rabbit testis in vitro although
the physiological significance of this reverse reaction remains obscure.
Regardless of the pathway, five enzymes are required for the synthesis 
5of testosterone from A -pregnenolone (Figure 1.1). All these CE^zymes, 
17a"hydroxylase, 17,20-desrnolase, 17(3“reductase, 3]3-hydroxysteroid 
dehydrogenase and isonierase, are contained in the microsomal fraction within 
the Leydig cells (Shilita and Tamaoki, 1965).
FACTORS affecting ANDROGEN PRODUCTION
It has been reported (Acevedo et al., 1961, 1963; Bloch, 1964; Bloch
■* CiV-rtat «aaCGCli 4 4 4 4 r
et al., 1962; Ikonen and Nierai, 1966; Hamilton, 1971a) that human foetal
5
testes are able to convert A -pregnenolone, progesterone and other precursors
to testosterone. Lipsett and Tuller (1965) have demonstrated that the 
5conversion of A -pregnenolone to testosterone increased markedly just before 
and during differentiation of the rabbit foetal Wolffian duct derivatives 
and they correlated this differentiation of the male reproductive system 
with the appearance of the Leydig cells.
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Figure 1.1 Testosterone biosynthesis in the testis from
A «pregnenolone
Lindner (1961) studied testosterone and ands'ostenedione concentrations 
in bovine spermatic vein blood* His important observation that the 
testosterone concentration rose sharply at puberty and the correlation 
of this rise with the first production of fructose by the seminal 
vesicles marked the first true assay of testicular function.
Snipes et al. (1965) found that in vitro incubation of testicular
* Mieee ci««sr> Cüra» msiasmemvsxnim
tissue from younger guinea pigs produced more andxostenedione but less 
testosterone from progesterone and concluded that the activity of 
17(3“dehydrogenase increased with age until full maturation* Nayfeh et aj.. 
(1966) showed that in immature rats the testosterone synthesized from 
progesterone by testicular tissue was further metabolized to 5a«androstane“ 
3a,i7(3“diol. These authors suggested a specific function for this metabolite 
in sexual maturation. Hamilton et al, (1970) stressed the importance of the 
A'^ «3(3“hydroxysteroid pathway in early foetal life.
Wlien animals were treated with gonadotrophin (HCG, LH and FSH), the 
overall synthesis of testosterone from acetate was enhanced (Hall and 
Eik“Nes, 1962; Hall, 1963j Eik-Nes and Hall, 1965)* Gonadotrophin has been
5
reported to stimulate specifically the action of A -3p™hydroxysteroid 
dehydrogenase (Samuels and Heltnreich, 1956) and 20cc-hydroxylase (Hall and 
Young, 1968)*
X“irradiation of the testis causes complete destruction of spermatogenesis 
without appreciable histological damage to the interstitial cells* However, 
it has been reported that X«*irradiated testes have reduced biosynthetic 
potential due to the reduced activity of 17a“hydroxylase and 17,20“desmolase 
(Schoen, 1964)* Recently the activity of 17[3-dehydrogenase has also been 
reported to be reduced after X-irradiation of the testes (Inmo and Tamaoki, 
1968b). As 17|3-dehydrogena.se doss not require NADPH as a co-factor it would 
appear that the action of irradiation of the testis is not on the NADPH 
generating system within the Leydig cell as previously suggested by Berliner 
et al* (1964).
METABOLISM OF TESTOSTERONE
The principal site of steroid catabolism is the liver. The hepatic 
metabolism of androgens results in the formation of relatively nonandrogenic 
steroids conjugated with sulphuryl or glucuronyl residues. This hepatic 
metabolism is mainly reductive and consists of the reduction of the double 
bond to form dihydrosteroids, the reduction of the 3“Oxo“dihydrosteroids to 
form the corresponding l7”Oxosteroids and the conjugation of these 17-oxostero; 
or the further metabolized androstanediols, with sulphuryl or glucuronyl 
residues forming the corresponding sulphates and glucuronides (Heftttiami, 1970)
Although only small amounts of androgenic steroids are metabolized 
outside the liver, this extra-hepatic metabolism may represent an important 
aspect of the action of such steroids. It is now generally accepted that 
testosterone action is mediated through several closely related steroids in 
androgen dependent tissues. Bruchovsky and Wilson (1968) have shown that 
5a«dihydrotestosterone (17p«hydroxy“5a™&ndrostan-3«one) is the major 
metabolite of testosterone in androgen dependent tissues both in vivo and in
«Ksa;» anPH.-t&juz9B iwvpa
vitro, lliese authors located NADPH dependent 5&™reductase in the nuclearmnmrJB'carenLasi
and cytoplasmic fractions, postulated selective nuclear binding of 
5a»-dihydrotestosteroneJ and demonstrated subsequent metabolism within the 
cytoplasm to fcc-androstsjaediol.
Unhjem and Tveter (1969) first isolated a high affinity androgen-binding 
protein in the prostate cytosol fraction. Fang and Liao (1971) were able to 
separate two soluble androgen binding proteins in the prostate cytosol one 
of which is highly specific for Sa-dihydrotestosterone. These authors 
postulated that 5a“dihydrotestosterone was selectively bound to a cytoplasmic 
receptor protein, this steroid-receptor complex is then transferred to the 
nucleus of the prostatic cells where it binds to acidic proteins of nuclear 
chromatin. Nuclear acceptor sites for 5a-dihydrotestostercne-receptor 
completes were subsequently reported by O'Malley (1971). Tlîc entry of
Sa’-dihydrotestosterone into the prostatic cell nucleus is believed to 
facilitate R M  synthesis, protein synthesis and androgen directed growth 
(Williaras-Ashman and Reddi, 1971).
Baulieu et al. (1968) studied the ^ostatic effects of testosterone«e<staua
metabolism and concluded that 5a«dihydrotestosterone caused cell division 
and eventual hyperplasia of the tissues whilst Str-androstane^-Sp , l?P“diol
caused hypertrophy and secretion. Later Baulieu (1970) in a review of the
i
"endocrinology of metabolites' concluded that as testosterone action within 
the prostate can be explained by the discrete actions of testosterone 
metabolites, testosterone may act as a prehormone, rather than a hormone in 
certain target organs. This diversity of testosterone action may then 
explain the different activities of testosterone in target tissues.
Much of the work on testosterone metabolism was carried out by studying 
urinary metabolites. Early investigations demonstrated that when large 
amounts of testosterone were administered to humans there was an increase in 
"bioassayable" androgen in the urine. The classic work of Callow (1939) 
showed that the main urinary metabolites of testosterone in the human were the 
conjugates of androsterone and aetiocholanolone. Dorfman (1941) reported 
the isolation of epiandrosterone from the urine of a hypogonadal male who 
had been given testosterone propionate. Further work by 'Vest ejt al. (1951) 
showed that the main metabolites of testosterone were excreted as the 
glucuronosides-
With the advent of radioactively labelled testosterone, urinary studies 
on the metabolites of testosterone were simplified» Both ^^C^testosterone
3
and H-testosterone were used in early investigations (Gallagher ef , 1951; 
Fukushinsa et al.. 1954) and similar results were obtained with both isotopes.
rMx.T»si *
These workers confirmed that androsterone and aetiocholanolone were the main 
metabolites but in addition they isolated Sa-'androstanedions and 53- 
androstanedione as intermediates.
.L4
5or'.“Androstane”’3of,l7(3”diol and Sp-androstane-3a, 17(3"diol, minor metabolite: 
of testosterone, were believed to be reduction products of androsterone and 
aetiocholanolone respectively (Schiller , 1945) and it was presumed
that the pathway to the androstanediols passed through androstenedione and 
the corresponding IT-oxosteroids. Baulieu and Mauvais-Jarvis (1964) have, 
however, suggested a direct *17p"hydroxyl pathway* from studies using 
^ 4"^^C,17a-^H^/testosterone (Figure 1.2). ^
Other minor metabolites of testosterone have been isolated from urine 
(A^^-androstene“3a™ol, Bulbrook ^  , 1963; 6P“hydroxytestosterone and
llp-hydroxytestosterone, Schubert £t , 1964) although the physiological 
significance of such metabolites remains obscure.
The metabolism of radioactively labelled testosterone glucuronoside 
has been studied by Robel et al. (1966a, 1966b). These workers found only* r^ iew 4&U6Ü» * •
5p-raetabolites (aetiocholanolone and 53“androstarie"3a,17P"diol) and 
postulated a 'direct* 5!3“metabolisra of testosterone glucuronoside, showing 
that this conjugate is not merely an end-product of steroid metabolism.
The work of Vande Wiele et al. (1963), Korenman et al, (1964),usfKvv* ' «rses»r* Ktwufcn *
Baulieu and Mauvais^Jarvis (1964), Rivarola ^  (1966), Horton and Tait
(1966) and Baulieu (1967) on the transformation of circulating 
A^«androstenediol, androstenedione, dehydroepiandrosterone and 
dehydroepiandrosterone sulphate to testosterone glucuronoside showed that 
some of the testosterone is formed in the liver from these precursors. Most 
of this hepatic testosterone does not leave the liver, but is extensively 
catabolized -hi situ, particularly to testosterone glucuronoside, this then 
being excreted in the urine. The apparent * compartmentalization' of testostere 
metabolism ajsd the mathematical analyses performed on such investigations 
have been reviewed by B&ulieu (1967). Such studies have demonstrated 
that the same steroid hormone may be differently metabolised depending on the 
precursor from which it is derived, its place of formation, and its state of 
conjugation.
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Nearly all the catsbolites of testosterone are ultimately excreted in 
the urine^ However, the urinary excretion rates of many of the androgen 
metabolites may not reflect their production rates since they may be exposed 
to further catabolism (Baulieu et al., 1965; Robel et al., 1966a).Who:* «gura* ' * #***«# cuneo*» *
Study of the urinary androgen metabolites remains of clinical diagnostic 
significance. Accepting that testosterone is not the only source of such 
metabolites and these therefore reflect a composite endocrinological spectrum
t
of testicular, adrenal, hepatic and peripheral metabolism the study of urinary 
androgen metabolites may still give information on the actual utilization 
of testosterone within the patient.
In the last decade many methods which estimate the majority of urinary 
steroid, metabolites important for differential endocrinological diagnosis 
have been published. Most of these methods utilize gas-liquid chromatography 
as the only chromatographic separation (Haahti et , 1961; Sparagana £t ^1 •, 
1963; De Paoli jet , 1963; Ruchelmaa and Cole, 1966). The profiling of 
urinary steroids first introduced by Gardiner and Horning in 1966 has been 
of diagnostic use in many types of endocrinological disturbances (Van Karapen 
and Hoek, 1967; Hock and Van Kampen, 1968). Recent methods, however, have 
the added advantage of allowing calculation of the rates of excretion of 
individual steroids from such profiles (Horning j|t al., 1969; Garmeridia 
et al., 1971).
es«eB» n K x n  '
NORML SEXUAL DIFFERENTIATION IN THE MALE FOETUS 
The development of the male phenotype and of normal testicular function 
is dependent on several determinating processes exerted from the time of 
ovum fertilization. A very brief review of such factors is pertinent to the 
aetiology of the pathological conditions later to be considered in this thesis 
The gonads develop from primitive germ cells of extragooadal origin 
(Mitschi, 1943), coelomic (germinal) epithelial cells, and cells of the 
mesonephric mesenchyme. The gonadal ridges develop about the fourth week of
foetal life and appear as elongated ridges on the ventral surface of the 
mesonephros. By the sixth week of gestation germ cells can be recognised in 
the now rounded gonad. At this indifferent stage of developments the gonad 
consists of an outer cortex (potentially the definitive ovary) and an inner 
medulla (potentially the definitive testis).
V/itschi (1951) postulated a dual system of intragonadal inductors
released from the medulla and cortex of the amphibian gonad. Under the
1
influence of the male sex chromosomes these inductor substances from the 
rudimentary sex cords suppress cortical development and favour differentiation 
of the medulla into a testis. Burns (1955) believed these inductor sub­
stances to be steroids, similar to the androgens and oestrogens, although 
Witschi (1965) does not accept that they are steroidal in nature. Jost (1970) 
has recently postulated a mammalian masculinizatlon factor released under the 
influence of the Y chromosome, whilst Mittwoch (1970) reported that testicular 
differentiation of the indifferent gonad may be caused by the differential 
growth rates of the two components.
At this indifferent stage a double set of sexual ducts are present, the 
male (Wolffian) ducts and the female (Müllerian) ducts, together with the 
bipotential primordia of the external genitalia. On testicular differeii-
ft
tiation, the Mullerian ducts regress whilst the Wolffian ductus undergo 
further growth and differentiation, thus forming the epididymis, vas deferens, 
seminal vesicles and ejaculatory duct. I'he development of the internal and 
external genitalia correlates with the appearance of the Leydig cells 
(Table 1.1).
Since the observations of Bouin and Ancel (1904) of testicular secretion 
in pig embryos and their correlation of this with masculine-orientated 
organogenesis, many investigations of the role of the gonadal hormones in the 
differentiation of the internal and external genitalia have been performed 
using animal experiment. The classical in vivo studies on rabbit foetuses
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by Jost (1947, 1953, 1970) have shown that castration in utero after the 
gonads were histologically sexually differentiated, but before differen­
tiation of the internal and external genitalia, produced feminization of 
the genital tract regardless of the genetic sex. Both in vivo (Jost, 1955)
and in vitro (Picon, 1969) grafts of testicular tissue into castrated
CMtSai Wi>.iif.laftrgcaMB *
foetuses produced masculinization.
The observation that androgens, such as testosterone, can act in place 
of foetal testes in their masculinizing effects, although exogenous androgens 
fail to inhibit the Mullerian ducts (Jost, 1953), suggests that the testis
ft
produces a Mullerian duct inhibiting factor in addition to a masculinizing 
hormone. Further work with the potent antiandrogen, cyproterone acetate, 
in rabbit foetuses has confirmed this hypothesis (Eiger, 1966; Jost, 1967; 
Neumann ^t a1., 1969). More recent work by Josso (1971, 1972) using explants 
of foetal rat reproductive tracts in organ culture with human foetal testes 
has sho^m the interspecific character of the Mullerian duct inhibiting factor
and shown that this is not a “free* steroid.
Recent animal experimentation has further shown that testosterone 
secreted by the foetal testes induces male differentiation of the urogenital 
tract by two different mechanisms. Testosterone itself is responsible for 
initiation of differentiation of the Wolffian duct into the epididymis, 
vas deferens and seminal vesicle, whilst 5a-dihydrotestosterone is 
responsible for the development of the urogenital sinus, genital tubercle 
and labioscrotal swellings into the prostate, penis 04id scrotum (Wilson 
and La sn i t ZÎC i, 1971).
Failure of the foetal testes to produce testosterone during 
differentiation of the external genitalia results in varying degrees of 
hypospadias to a complete lack of fusion of the labioscrotal folds. Foetal 
testicular insufficiency, in which there is a secretory failure of both 
testosterone and the Mullerian duct inhibiting factor, results in a
phenotypic female though infertile, whilst failure of testosterone production 
alone results in the formation of female external genitalia but with a blind 
ending vagina. The degree of ambiguity of the external genitalia, the 
degree of development of the Wolffian duct structures and the extent to which
tr
Mullerian elements persist depends on testicular function, the stage of 
development at which the defect occurs and the sensitivity of the end-organ 
tissues to these stirauli.
)
TESTICUU^R FUNCTION IN MALE HYPOGONADISM
In the remaining part of this introduction I will discuss patients with 
abnormal sexual development and attempt to describe the underlying biochemical 
dysfunctione
Most classifications of male hypogonadism separate hypogonadism caused 
by primary testicular failure and hypogonadism secondary to a deficiency of 
pituitary gonadotrophin secretion. This subdivision will be used here 
(Table l.II).
PRIMARY TESTICULAR FAILURE
Primary testicular failure can be subdivided into three groups: those
of genetic origin, those due to developmental defects and those due to 
failures of spermatogenesis but with apparent normal Leydig cell function. 
Klinefelter*3 Syndrome
In 1942 Klinefelter, Reifenstein and Albright described the syndrome 
characterized by small testes, azoospermia, normal external genitalia, 
gynaecomastia and a high urinary excretion of gonadotrophin. Although their 
paper first grouped such symptoms as a definite clinical entity, case 
reports of similar patients had been published in the early 19th century.
In the original publication (Klinefelter .et .al-, 1942), gynaecomastia was 
considered a necessary symptom, whilst Heller and Nelson (1945) described 
patients without gynaecomastia but with the other characteristics of the 
syndrome. Becker ct aj^,. (1966) reported that approximately one-third of 
such patients have behavioural problems whilst 4 per cent are mentally retarde»
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In 1956, Bradbury et al., Riis et al., and Plunket and Barr almost' f Il ■ma * OKJvrw mpn^mm *
simultaneously described a positive sex chromatin pattern (ie Barr body 
present) in many patients with Klinefeltersyndrome. Jacobs and Strong 
(1959) subsequently reported the chromosomal constitution 47,XXY in such 
patients. Not all apparent cases of Klinefelter*s syndrome are, however, 
chromatin^-positive. Approximately 25 per cent of cases reported in the 
literature are chromatin-negative (Barr, 1966) and it is possible that 
many of such cases may have mosaicism. Paulsen et (1968) described 
four such chromatin-negative cases of the syndrome, all of whom had an XY 
karyotype as judged from skin study. One case had an XY/XXY mosaic in 
blood and testis, whilst the other three cases had XY in the blood and 
XY/XXY in the testis alone. Thus the somatic features of Klinefelter 
syndrome can be caused by an XXY stem-line in the testis.
Although the true clinical picture only develops at puberty, prepubertal 
patients have been described (Bunge and Bradbury, 1957; Tanner e^ ^ 1., 1959; 
Fergusom-Smith, 1959; Hamilton, 1971b) in patients with mental retardation, 
micro-orchidism or skeletal disorders.
No adequate explanation for the histological changes in the testes 
has yet been reported, although the testes fail to respond normally to 
pituitary follicle stimulating hormone (FSH), During the initial stages 
of puberty, the testes are characterized by the development of fibrous 
tissue, and only Sertoli cells in the seminiferous tubules. Although the 
proliferation of the fibrotic tissue may result in complete hyalinizatioa 
of the tubules during adolescence, a wide range of pathological changes has 
been reported in patients with this syndrome. These range from normal 
spermatogenesis (Bunge and Bradbury, 1956) to complete atrophy of the 
seminiferous tubules. The Leydig cells characteristically show adematous 
clumping although the actual numbers may not be increased. Burt (1954
using hifitochemical techniques for lipoidal substances, reported decreased 
function of the Leydig cells*
Slaunwhite ^  ^ 1. (1962b), studying _in vitro incubation of testicular 
tissue from patients with Klinefelter*s syndrome, found normal testosterone 
biosynthesis and concluded that such patients (XXY karyotype, atrophic 
testes, hyalinized seminiferous tubules with azoospermia and abundant 
Leydig cells) may possess a modified target organ insensitivity to 
testosterone. The defect in such patients has been ascribed to a decreased 
biosynthesis of testosterone (Gabrilove ^t al.,,l963: Gabrilove, 1964) 
although recently an increased conversion to oestrogens has been suggested 
(Gabrilove et , 1970) and confirmed by Shsrtna and Gabrilove (1971).
Hamilton (1971b) has recently confirmed normal testosterone biosynthesis in 
younger patients with Klinefelter*s syndrome but found a progressive 
failure with age.
Most of the indices of testosterone secretion have been found to be 
reduced in Klinefelter's syndrome. Low levels of testosterone in peripheral 
plasma (Lipsett et al., 1966; Hudson et al,, 1967; Paulsen et al,, 1968)*■ teHîïr» * * CtJSfCtM ' * ■IMM-IJ *
and in testicular venous plasma (Dupre et al., 1964; Jeffcoate et al., 1967) 
have been reported. Testosterone production rates are also reduced 
(Lipsett et al., 1966; Hudson et al., 1967; Jeffcoate et al., 1967).*  mssitcm '  *  ■ytaion rdMocat f  '  « « rw , '
Several studies have suggested that the Leydig cells are maximally 
stimulated by endogenous gonadotrophin and respond poorly to administered 
IKG as measured by plasma testosterone (Lipsett et al., 1966; Hudson et al-,' tovwa* fctiwt, f *• asnsn i_> *
1967) whilst Paulsen (1968) reported normal, although limited, response in 
plasma testosterone following HCG administration.
Tîie neutral 17-oxosteroids have been extensively studied in Klinefelter's 
syndrome and generally they are within (Stewart et al., 1959) or below* * mMaju /
(Giorgi and Sommerville, 1963) the low normal range of excretion.
Johnsen (1956), from fractionation studies of the urinary 17™oxosteroids, 
reported very low aetiocholanolone excretion in such patients whilst 
Gilbert-Dreyfus et al. (1956) found a relative increase in the 
3a- hy d r ox y-17- oxos t e r o ids.
Recent work by Garmendia (1971) using a GLC method for the
separation ;md. quantitation of individual neutral 17-*oxostsroids has con­
firmed these older fractionation studies. They found elevated androsterone, 
decreased aetiocholanolone and decreased dehydroepiandrosterone excretion 
in two patients with Klinefelter*s syndrome.
XX-Male Syndrome
f " ’ ■ ' *  i|i| 'II r , 4 H « w i S . - » C j A b
By definition these patients have a male phenotype, male psychosexual 
identification, tester absence of ovarian tissue, and absence of female 
genital organs. De la Chapelle al^ . (1964) described the first male 
patient with the XX chromosome karyotype and no ambiguity of the external 
genitalia. Subsequent reports by Therkelsen (1964), de la Chapelle et al. 
(1965), Lindsten et al. (1966), de Grouchy et al. (1967), Sebaoun et al,
* nuLUB * * amw»» ' vri*c« m'm im
(1969) and Bergman et al. (1970) have shown that this condition is a 
definite clinical entity. Clinically, XX-males resemble patients with 
Klinefelter*s syndrome in psychosexual orientation, intelligence, secondary 
sex characteristics, testicular histology and hormonal status, the main 
difference being their height. XX*»males are much smaller than patients 
with Klinefeltersyndrome, smaller than normal males but taller than 
normal females.
Although the penis and scrotum are generally of normal size in such 
patients, testicular size is invariably decreased, and their consistency 
ranges from firm (in young patients) to soft (mostly in older patients). 
Gynaecomastia has been reported in two such cases (Strauch £t j 1965; 
Sebaoun et ai., 1969). Histologically the testes generally show absence
rtzjrsm DW-XjrA ' W  .• ^
of Spermatogonia, diminished tubular diameter, hyalinization and obliteration 
of the tubules and Leydig cell hyperplasia,
Sebaoun et al. (1969) have reported hormone studies in a 15-year-old 
XX-male. They found diminished excretion of total urinary 17-oxosteroids, 
diminished excretion of urinary androsterone and aetiocholanolone, but
— iù J —
normal excretion of urinary dehydroepiandrosterone and the llp-hydroxy- 
and ll“oxo-17-oxosteroids, and concluded that there was normal adrenal 
function but poor testicular function. Ismail ^  (1968) reported an
abnormally low excretion of urinary testosterone in three adult patients 
with this syndromeo 
Noonan*3 Syndrome
In 1930 Ullrich reported an 8-year-old girl with congenital lymphedema,
1
retarded growth, ptosis, webbing of the neck, a low posterior hairline, 
cubitus valgus and hypoplastic nipples. Turner (1938) described similar 
congenital malformations together with sexual infantilism but not lymphedema 
in seven females aged 15 to 23 years. Later work by Ullrich (1949) claimed 
to have found the pathogenetic basis of all cases with Ullrich-Xurner 
syndrome in the myelencephalic bleb mutation of mice investigated by 
Bonnevie (1934).
Flavell (1943) first used the term *Turner*s syndrome in the male* 
to describe patients with hypogonadism in association with shortness of 
stature, webbed neck and abnormalities of the skeletal and cardiovascular 
systems. In 1963, Noonan recognised that this syndrome could occur in 
males and females and that it was nosologically and etiologically different 
from the Ullrich-Turner syndrome in females with the 45,XO karyotype. 
Perguson-Sniith (1965) has suggested that Turner's stigmata in males is 
caused by deletion of certain loci on the Y chromosome.
In males the penis and scrotum are generally of normal size or 
enlarged whilst testicular size is invariably decreased and cryptorchidism 
and aaorchia have been reported (Heller, 1965), Tlie seminiferous tubules 
are often small with moderate sclerosis, sometimes lined with only Sertoli 
cells ('testicular germinal dysgenesis' Fraccaro £t ^1 •, 1961). Leydig 
cells have been reported to be absent, reduced or normal. Thus there may 
be a nosological problem dependent on the extent of dysgenesis within the 
testes.
The urinary excretion of gonadotrophin is usually elevated in such cases 
whilst the urinary excretion of 17-oxosteroids is low with no increase 
following HCG administration (Sclioen, 1965).
Anorchia
These patients have a normal male karyotype (46,XY), normal prepubertal 
development of external genitalia, but lack development of secondary sex
characteristics. Tiie eunuchoidal stature characteristic of the older
1
patients with anorchia may be apparent even in the prepubertal period.
By definition these patients have no functioning testicular tissue although 
it is generally assumed that foetal testes must have been present and 
functioning throughout early masculine sex differentiation since absence 
of testes then would have resulted in a female phenotype (Jost, 1947).
In some cases interstitial cells present in the retroperitoneal tissue 
or along the epididymis and Wolffian duct structures may partially 
compensate for anorchia (McDonald and Calams, 1958). In the majority the 
etiology is obscure.
During adolescence the urinary gonadotrophin excretion is elevated 
in all patients with anorchia. The urinary 17-oxostei'oid excretion is 
decreased and the administration of HCG has no effect on either the 
17-oxosteroid excretion or on furthering masculinisation (Bergada et al.,
Cfao^ xta «jfastM '
1962). Recently Rivarola £t (1970) have measured plasma testosterone 
in five boys with anorchia before and after the administration of HCG.
They found basal levels of plasma testosterone (37 - 23 ng per 100 ml) 
that did not rise on HCG administration.
Cryptorchidism
Cryptorchidism is one of the most common congenital defects in the 
young male. Undescended testes may be classified as totally undescended, 
incompletely midesceiided or ectopic (ie descended along the wrong line). 
Cryptorchidism may be unilateral or bilateral and should be carefully dis­
tinguished from the highly retractile testis.
Scorer (1964) examined 3,612 male infants and found the Incidence 
of undescended testes to be 21 per cent in premature infants, 2.7 per 
cent in full-term infants and 0.77 per cent after one year. Ward and 
Hunter (I960) found an incidence of undescent of 1.6 per cent in 5*«year“Old 
boys, whilst in the adolescent age group, 14 to 17 years, only 0.3 per cent 
had undescended testes. This closely approximates to the incidence 
found in 12,535,824 military recruits (0.28 per cent; Campbell, 1959).
t
Histologically the cryptorchid testis shows progressive deterioration. 
Incomplete development of the seminiferous tubules and failure of the 
normal maturation of the germinal epithelium occur. Sertoli cells and 
Leydig cells are usually normal (Mancini ^  , 1965) (Figure 1.3). If
the testis remains undescended after puberty, interstitial fibrosis and 
tubular hyalinization occur and spermatogenesis is absent (Manciui ^  ai., 
1965).
Bilateral cryptorchidism associated with hypogonadism may be caused 
by prenatal hormone disturbances (Johnston, 1968) and genetic factors 
may be indicated by the familial occurrence of this disorder. Orchidopexy 
aims at preserving the testicular elements and hopefully the functional 
potential. Surgical intervention restores the testis to the normal 
scrotal position but the function of the testis can only be normal if 
no deterioration has occurred earlier.
Llaurado and Dominguez (1963) have shown decreased synthesis of 
testosterone from, progesterone and subnormal production of testosterone 
in response to administered HCG in cryptorchid rats. Similar studies 
by Inane and Taniaoki (1968a) have shomi a 60 per cent reduction in the 
activity of A^-3(3-hydroxysteroid dehydrogenase. These results are in 
agreement with the decreased testosterone secretion (Eik-Nes, 1966; 
Amatayahul et al., 1971) and decreased spermatogenesis (Clegg, 1965; 
Amatayakul et al., 1971) noted in experimental cryptorchid rats, and 
dogs rendered cryptorchid. Recently Hamilton _al« (1970) have
Figure 1.3 Testicular section from a patient with
bilateral undescended testes (Protocol 53, 
Chapter 5) aged 11 years 6 months at biopsy. 
Note extremely reduced diameter of the 
seminiferous tubules (A) when compared vith 
'near-normal* testis (Figure 1.5), and normal 
appearance of Leydig cells and Sertoli cells 
(B).
reported a 3|3“hydroxysteroid dehydrogenase deficiency in cryptorchid 
human testes.
Recently Rivarola ejt (1970) have reported normal Leydig cell 
function from determination of plasma testosterone before and after 
administration of HCG (800-5,000 I,U. per day for five days) in prepubertal 
patients with unilateral and bilateral cryptorchidism.
Germinal Cell Aolasia
1
Del Castillo et al. (1947) described the syndrome characterized by 
absence of the germinal epithelium without impairment of the Sertoli or 
Leydig cells. Phenotypically these patients were of normal stature, had 
small testes of normal consistency, normal genital development and were 
without gynaecomastia. Histologically the testes showed a complete 
absence of the germinal epithelium, the seminiferous tubules were of smaller 
diameter and contained only Sertoli cells. The Leydig cells appeared normal 
and there was no hyalinization of the basement membrane. Gonadotrophins 
were originally described as normal (del Castillo ^  , 1947) although
more recent reports indicate that the urinary excretion of these hormones 
is increased.
Patients with germinal aplasia have normal negative sex chromatin 
patterns in association with a normal male karyotype. This suggests that 
the syndrome is not genetically determined. Del Castillo ef si. (1947) 
have suggested a failure of migration of the primordial germ cells into 
the developing testis during foetal development.
Seminiferous Tubule Failure
The majority of males with infertility have normal secondary sexual 
characteristics and no evidence of endocrine disease. Whilst some may 
.have mechanical blockages caused by congenital defects of the epididymis 
and vas deferens (Girgis _et ^1., 1969), the remainder have abnormalities 
of the seminiferous tubules. Although in the majority of such cases with
seminiferous tubule failure there is no known aetiology, failure in some 
cases is secondary to specific diseases.
Mumps orchitis occurring in the adolescent or adult may result in 
subsequent testicular atrophy (Scott, 1960). Testicular biopsy shows 
atrophy of the seminiferous tubules whilst the Leydig cells normally remain 
unimpaired, except in extreme cases where complete logs of testicular 
function may occur. Serum FSH concentration is elevated (Rosen and Weintraub, 
1971) this in proportion to the tubular atrophy.
Irradiation damage to the germinal epithelium is well documented in 
the literature. The spermatogonia are much more sensitive to radiation 
than the Sertoli or Leydig cells (Mandl, 1964) although recent work has 
shown a biochemical lesion in the androgen biosynthetic pathways together 
with an increased gonadotrophin secretion and decreased testicular sensitivity 
to gonadotrophin (Ellis, 1970).
Spermatic failure may also be secondary to other factors including 
paraplegia and varicoceles of the spermatic cord (Hall et al., 1969).* m w • «MB* «trr&c* *
PITUITARY GONADOTROPHIN FAILURE
Hypogonadism and delayed puberty secondary to a failure of pituitary 
gonadotrophin secretion can be divided into two types: congenital lack of
gonadotrophins alone and those associated with general pituitary disease 
or lesions (Table l.II). Isolated gonadotrophin failure can be further 
subdivided into hypogonadotrophic hypogonadism, the fertile eunoch syndrome, 
and gonadotrophin failure associated with various congenital disorders. 
Hypogonadotrophic Hypogonadism
The aetiology of hypogonadotrophic hypogonadism is unknown. These 
patients are characterized by hypogonadism, delayed puberty and eunuchoidism. 
An association with anosmia, liyposmia, midline facial and neurological 
abnormalities is common. These associated defects suggest central nervous 
system abnormalities vdiich may prevent the gonadotrophin-releasing mechanism.
from functioning normally, so disrupting the normal pubertal processes. In 
these cases the seminiferous tubules are immature and spermatogenesis is 
generally absent. Sertoli cells may be present (Bardin ^  , 1969) or
absent (Paulsen, 1968) and the Leydig cells are poorly differentiated.
Total gonadotrophin excretion is low or undetectable (Heller and Nelson, 
1948; Bardin et ^1., 1969) and plasma gonadotrophins fail to respond to 
clomipbene (Bardin ej; 1969). Generally Leydig cell function is reduced
or absent. The plasma concentration of testosterone is very low and the 
response to administered HCG variable, although generally poor (Bardin £t al., 
1969).
Fertile Eunuch Syndrome
The term 'fertile eunuch' introduced by McCullagh ^  (1953) is
perhaps a misnomer, since only two authenticated cases of fertility have 
been reported. The characteristics of this syndrome are eunuchoidism with 
normal-sized testes, spermatogenesis in the absence of Leydig cells and an 
androgenic response to administered HCG.
McCullagh e_t al. (1953) postulated an isolated defect of LH secretion 
with normal FSH secretion. Later work by Faiman et al* (1968) confirmed 
this theory. They found normal urinary and plasma levels of FSH with 
undetectable LH before and after clomiphene.
Pituitary Gonadotrophin Failure Associated with Congenital Disorders
Secondary hypogonadism is frequently associated with other congenital 
defects in the Laurence-Moon^Biedl syndrome and the Prader-Willi syndrome.
The Laurence-Moon-Biedl syndrome is transmitted as an autosomal 
recessive characteristic and is characterized by hypogonadism, obesity, 
mental retardation, polydactylism and retinitis pigmentosa* In males the 
testes show histologically immature seminiferous tubules and poorly 
differentiated Leydig cells (Franks, 1950) (Figure 1.4). The gonadal 
dysfunction may be due to either primary testicular failure or hypogonridotropl" 
hypogonadism (Reinfrank and Nichols, 1964).
Figure 1.4 Testicular section from a patient with the 
Laurence-Moon-Biedl syndrome (Protocol 59, 
Chapter 5) aged 5 years 5 months at biopsy. 
Although this testis shows the characteristics 
of the syndrome, immature seminiferous 
tubules and sparse Leydig cells, these 
characteristics are found in the testes of 
normal boys of this age.
-The Prader-Willi syndrome is characterized by hypogonadism, hypomentia, 
hypotonia, obesity and pleasant facial features* Diabetes mellitus occurs 
in approximately half the patients post-pubertally (Dunn, 1968). Males 
also have a hypoplastic scrotum, undescended testes and delayed puberty.
The urinary excretion of l?-oxogenic steroids is elevated and this is con­
sistent with the obesity noted in these cases whilst the urinary excretion 
of 17“Oxosteroids is very low and consistent with reduced testicular Leydig 
cell function (Dunn, 1968; Mormens and Kenis, 1965).
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Patients with panhypopituitarism usually show only immaturity and small 
stature in childhood. Puberty does not occur at the expected time and the 
genitalia remain infantile. Histologically the testes are similar to other 
types of prepubertal gonadotrophin failure and show immature seminiferous 
tubules, poor development of the germinal epithelium and poorly differen­
tiated Leydig cells (Albert et , 1953). Urinary gonadotrophin excretion 
cannot be detected and the excretion of urinary 17-oxosteroids is low.
Plasma testosterone is very low and the response to administered HCG 
is subnormal (Stuiver et al., 1966).
TESTICULAR FUNCTION IN PHENOTYPIC FEMALES 
Tests of Leydig cell function and reserve, although originally 
designed to study hypogonadism, are applicable to several types of phenotypic 
females including those with the testicular feminization syndrome, XO/XY 
mosaicism and true hermaphroditism. Such patients present varying degrees 
of masculinization and the gonads may range from normal testes to 
undifferentiated stre&ks.
■TESTICULAR FEMINIZATION SYNDROME
The complete form of testicular feminization is characterized by a 
female phenotype with normal feminization, near normal breast development.
female external genitalia (small or normal clitoris, blind ending vagina),
tJ
absent Mullerian derivatives and sparse or absent pubic and axillary hair 
in association with a 46,XY karyotype and cryptorchid testes (Morris, 1953; 
Morris and Mahesh, 1963). Taillard and Prader (1957) hg;ve reported 
similar patients who show some degree of secondary sexual development and 
partial virilization, especially at puberty, and they classify these as 
incomplete forms of the syndrome.
Complete Testicular Feminization Syndrome
These patients fail to virilize at adolescence even though the testes 
are able to synthesize testosterone normally (Griffiths ^  » 1963;
Sharma et al., 1965) and maintain plasma levels of testosterone similar to■nann weeai * *
those of normal males (French et al,, 1965; Southren et al., 1965). French 
et al. (1965, 1966) have postulated an antenatal target organ defect in 
these patients. Such a target organ defect in foetal development would 
explain the failure of penile urethral formation, the failure of androgens 
to inhibit the formation of breast anlage (Goldman and Neumann, 1969) and 
the presence of feminine psychosexual differentiation of the brain (Money 
et al., 1968).««sqisj *
Histologically the gonads have been described extensively and interpreted
as resembling immature (Pion et al,, 1965), foetal (Turner, 1964), infantile
(Neubecker and Theiss, 1962), or undescended testes (Morris, 1953). The 
seminiferous tubules are usually tightly packed, often devoid of a tubular 
lumen without evidence ox sperraatogenesis, peritubular fibrosis, or 
hyalinization. The Leydig cells are generally believed to resemble those 
of the mature foetus and do not contain Reinke's crystals. Leydig cell 
hyperplasia is often described as secondary to the elevated gonadotrophin 
in the absence of a negative feedback control (Morris, 1953).
Gual _et (1962) studied 'abnormal' testicular tissue from a patient 
with the testicular feminization syndrome and reported that
A^“aiidrostene-3j3 ,l7f3“diol was not further metabolised to testosterone.
Griffiths ^  aT• (1963), incubating tissue from similar patients, reported 
normal testosterone synthesis from A*^-steroid precursors although they were 
unable to identify oestrogens in the incubation effluent of their experiments. 
Normal testosterone biosynthesis in testicular tissue from a patient with 
the testicular feminization syndrome was also found by Morris and Mahesh 
(1963) whilst Sharma ^  (1965) confirmed normal testosterone biosynthesis
in such patients and demonstrated oestrogen biosynthesis from androgen 
precursors. Further work by French £t ad, (1965, 1967), Kase and Morris 
(1965), David et al, (1965), and Gwinup et al, (1966) has confirmed the• knwna ' * «3i«a
normal testosterone biosynthesis in the testicular feminization syndrome.
Patients with testicular feminization have a normal or slightly 
elevated excretion of 17-oxosteroids. The secretion of gonadotrophins may 
be either normal or elevated and increases following castration (Morris,
1953; Morris and Mahesh, 1963), The urinary excretion of testosterone
(Rivarola et al., 1967; Jeffcoate et al., 1968), and the fractionatedrwsnt* ' rnxsmEm • *
17“oxosteroids (Morris and Mahesh, 1963; Philip and Sele, 1965), are within 
the normal male range. Similarly the plasma concentration of testosterone, 
dehydroepiandrosterone sulphate and androsterone sulphate are in the normal 
male range. They increase on administration of HCG but do not decrease on 
administration of dexamethasone. This is in accord with their testicular 
origin (Pion et al., 1965; Morris and Mahesh, 1963).# «nsi£rui * * * '
Urinary oestrogens are generally described as being in the low female 
range or male range and there is no evidence of a cyclic activity of 
oestrogen excretion (David £t , 1965).
Partial Testicular Feminization Syndrome
These patients often fail to feminize at puberty and may even virilize 
further. The external genitalia are often ambiguous and there Is an associated 
hypospadias. The size of the phallus is variable, often adequate for
functioning as a male organ, or described as an enlarged clitoris. Of the 
published cases, approximately half have been raised as males and half as 
females, whilst four changes of rearing sex have been effected (Park and 
Jones, 1970).
The aetiology of this syndrome is not known, although both testicular 
deficiency and partial non-responsiveness of the target organ have been 
suggested as likely causes.
1
Histologically the testes of the prepubertal patient are normal 
although slight hyalinization of the tubules may occur. In the pubertal 
and adolescent age groups the testes show signs of atrophy as seen in 
undescended testes (hyalinization of the seminiferous tubules, decrease in 
Sertoli cell numbers, Leydig cell hyperplasia and absence of spermatogenesis) 
(Figure 1.5).
Bowen (1965) reported a normal urinary excretion of 17*»oxosteroids
but a decreased excretion of testosterone glucuronoside in such patients. 
Urinary gonadotrophins have been described as normal or increased. Recently 
Rosenfield e^ al.. (1971) found plasma testosterone and plasma androgens in 
the male range with an increase on administration of HCG. They concluded 
that their patient showed partial target organ insensitivity to testosterone, 
whilst Saez et al. (1971) postulated a defect in testicular 17R-reductase 
from studies of plasma and urinary androgen metabolites in similar patients.
XO/XY MOSAICISM
XO/XY mosaicism produces a spectrum of phenotypes ranging from 
Turner's syndrome without evidence of masculinization (XO effect) to a 
normal male phenotype (XY effect). These extreme phenotypes will not be 
considered here but rather the phenotypes of intersex, presumably due to 
commensurate effects of both the XO and XY cell lines.
Sohval (1964) introduced the term 'mixed' gonadal dysgenesis to 
classify cases with a unilateral testis and a streak gonad on the
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Figure 1.5 Testicular section from a patient with female phenotype 
and partial form of the testicular feminization 
syndrome. The patient was aged 12 years 6 months at 
biopsy. Note the abundance of leydig cells betv.-een 
the normal-sized seminiferous tubules (A), the early 
hyalinization of the seminiferous tubular membrane 
and hyperplastic Leydig cells (B) characteristic of 
this syndrome.
contralateral side. Such patients may present as phenotypic males or 
females. The female phenotype is characterized by poorly developed 
secondary sexual characteristics, with evidence of virilization (enlarged 
clitoris, hypertrichosis and masculine voice) whilst the male phenotype 
is characterized by hypospadias, bifid scrotum, small penis and normal 
masculine body form. Both male and female phenotypes have negative sex 
chromatin, a unilateral testis with a contralateral streak gonad and 
unilateral or bilateral Mullerian duct derivatives (fallopian tube, uterus) 
and often stigmata of Turner's syndrome.
The competence of the unilateral testis to suppress the development of
fT
the Mullerian ducts is of interest in several cases where a unicorrmte 
uterus and single fallopian tube have been described (Zourlas and Jones, 
1965; Hortling et , 1970). In cases where bilateral Mullerian 
derivatives have been described (Sohval, 1964; Mellman et 1963) a
If
deficiency of Mullerian duct inhibiting substance is implied in addition to 
a failure of the foetal testis to produce androgen (ambiguous genitalia).
Histologically the testis is variable and has been described as normal 
(Bergada et , 1962), intermediate between 'pure' gonadal dysgenesis and 
'true' hermaphroditism (Sohval, 1964), dysgenic (Mellman ef 1963) or
Sertoli cells only (Hortling et 1970). Spermatogenesis is normally
absent (Sohval, 1964; Hortling et al., 1970) and the tubules may be» • «u«Ei*ra ^ r
hyalinized (Figure 1.6) or normal (Hortling ejt £i., 1970). Leydig cells 
are often hyperplastic and clumped (Figure 1.6).
% e  streak gonad is composed predominantly of fibrous connective 
tissue often resembling ovarian stroma. Tubular structures representing 
remnants of rete or mesonephric ducts are infrequently present (Willemse 
et al., 1962). Leydig-tyoe cells have been noted (Hortling et al., 1970), 
The streak gonad represents the rudimentary remnant of an enibryonic gonadal 
ridge before testicular or ovarian differentiation.
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Figure 1.6 Testicular section from a patient with the XO/XY 
syndrome and female phenotype (Protocol 6,
Chapter 5) aged 12 years 3 months at biopsy. Note 
the severe hyalinization of the seminiferous tubules 
and abundant hyperplastic Leydig cells (A) often 
clumped (B).
TRI3E HERMAPHRODITISM .«L'cÆjlRSMi vkBr»T'*3ti*t:cer3CCt<n6'''i I f iff; ' -axr»
By definition patients with true hermaphroditism contain both ovarian 
and testicular tissue. Such patients are generally classified according to 
the position of the gonadal tissue, '.rhe lateral variety (testicular tissue 
one side, ovarian tissue contralaterally), the bilateral variety (testicular 
and ovarian tissue on both sides) and the unilateral variety (testicular and
ovarian tissue on one side, testicular or ovarian tissue contralaterally)
I
are noted. Ovotestes are found in some such patients, particularly in the 
bilateral variety (either unilaterally or bilaterally) and in the unilateral 
variety of hermaphroditism.
These patients are characterized by a complete range of developmental 
abnormalities of both the internal and external genitalia and cannot be 
distinguished clinically from other forms of intersexuality. Somatic 
abnormalities are occasionally present in hermaphroditism with chromosomal
f1
mosaicism. The degree of differentiation of either the Mullerian or 
Wolffian ducts and the extent of raasculinization of the external genitalia 
are an index of foetal testicular function.
Chromosomal analysis has shoim that the majority of such cases have 
an XX karyotype although other karyotypes have been described (XY, XX/XY, 
XO/XY, XX/XXYY and other forms of mosaicism). Josso et al. (1965)* rp iwri
investigated a patient with XX/XY mosaicism and concluded that the mosaicism 
was related to double fertilization of the ovum. In cases with either XX 
or XY karyotypes it is possible that mosaicism has been overlooked 
although further investigations in such patients have failed to find a 
second cell line (Root et al., 1964),
Histologically the separate ovary or testis in these patients have been 
described as normal although Overzier (1963), in a review of 171 patients, 
reported that patients with negative sex chromatin had generally under™ 
developed gonads. The ovotestis is of interest since it usually appears in
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the prepubertal patient as a foetal or immature testis separated by fibrous 
tissue (tunica albuginea) from typical ovarian stroma rich in oocytes and 
primordial follicles (Figure 1.7). After puberty the germ cells degenerate 
and tubular atrophy with hyalinization is often seen, Leydig cell 
hyperplasia is noted post-pubertally and is probably secondary to the 
almost constantly elevated serum gonadotrophin.
1
THE NATURE OF THE PROBLEM
What is to be the treatment of these patients with ambiguous sexual 
development? Does one sex predominate and if so how do we recognize it? 
Whatever the sex of rearing, the degree of virilization of the external 
genitalia at puberty may necessitate further surgery or hormone treatment 
unless such a prognosis is available for the neonate.
In the prepubertal patient with hypogonadism the problem is to make the 
external genitalia conform to the sex of rearing. Again surgery or hormone 
treatment are usually indicated although in some cases this may not have the 
desired effects. Ideally we need to know the functional integrity of the 
gonads, the levels of hormone production and their metabolism within the 
target organ tissues so that a prognosis can be given for subsequent 
development of the secondary sexual characteristics at puberty.
THE PRESENT INVESTIGATION 
In this investigation various parameters of Leydig cell function and 
reserve were determined by response to administered human chorionic gonado­
trophin (HCG). The peripheral plasma concentration of testosterone and the 
daily urinary excretion of total 17™oxosteroids, testosterone and individual 
androgen metabolites were quantitated, before and during administration of HCG 
in a variety of pathological conditions. Results are presented of an investi­
gation of SO patients and later (Chapter 4) I shall attempt to enunciate the 
principles on which I think treatment may be justified.
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Figure 1.7 Section of an ovotestis from a patient with the
XX/XY genotype and true hermaphroditism (Protocol 
5, Chapter 5) aged 6 years at biopsy. Note the 
combination of typical ovarian stroma (with follicle) 
with seminiferous tubules within this tissue (A).
The testicular component is poorly developed (B), 
the seminiferous tubules resembling those seen in 
the foetus.
CHAPTER 2
M E T H O D O L O G Y
MATERIALS
RADIOACTIVE-IJ\BELLED STEROIDS
Ail radioactively labelled steroids used in this investigation, with 
. - 3 -
the exception o± / 1,2- H__/androsterone, were obtained from the Radiochemical
MU ^  4M
Centre, Amersham, Buckinghamshire, England. / 1,2,6 ,7- H_/Testosterone, 
specific activity (S.A.) 87 Ci/mM, was used in tracer amounts to estimate 
the recovery of methods developed to quantitate testosterone in plasma a,nd 
urine. / 4- C___/Tes teste rone (S.A. 59 mCi/mM) was used to test the stability
K. 3 •“
of the tritium labelled testosterone, whilst / 7oc- H_/dehydroepiandrosterone 
sulphate (S.A. 4.6 Ci/mM) was used to test the hydrolysis technique.
/ 1,2- H^/Androsterone (S.A. 40 Ci/mM) was obtained from New England Nuclear, 
Albany Street, Boston, Mass., USA, and used in tracer amounts to estimate 
the efficiency of derivative formation of androsterone-3-heptafluorobutyrate, 
the internal standard used for gas-liquid chromatography quantitation of 
testosterone in biological samples.
All radioactively labelled steroids required purification by thin layer 
chromatographic (TLC) systems before use. A single peak of Gaussian form 
obtained on radiochromatogram scanning was taken as the indication of purity. 
Generally development in at least three separate TLC systems was required 
to obtain such a peak. Then as much as 5 per cent of the radioactivity in 
the commercially supplied radioactively labelled steroid was removed as 
impurity. All purified radioactively labelled steroids exhibited the same 
chromatographic mobility as a corresponding unlabelled reference standard. 
Working solutions of the purified radioactively labelled steroids were made 
with benzene ; chloroform (6 :1) for free steroids, and with ethanol for 
conjugated steroids. The working solutions were stored at 5^C.
UNLABELLED REFERENCE STEROIDS
Standard steroids were obtained from Koch-Light Laboratories Ltd 
(Colnbrook, Buckinghamshire, England) and Sigma London Chemical Co, Ltd
(Norbiton Station Yard, Kingston upon Thames, Surrey, England). Small 
quantities of epitestosterone (17a-hydx‘oxyandrost"-4ene-3one),
A"^-androstene-3j3 ,17(3“diol and the glucuronoside and sulphate conjugates of 
epiandrosterone (3(3“hydroxy-’5o:“androstane-17“One) were obtained from the 
M.R.C. Steroid Reference Collection (Chemistry Department, Westfield College, 
Hampstead, London NW3).
REAGENTS
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Absolute ethanol (A.R. quality) was obtained from James Burrough Ltd 
(Fine Alcohols Division, Montford Place, London SEll, England). 'Peroxide- 
free* diethyl ether was purchased from May and Baker Ltd (Dagenham, Essex, 
England). Keptafluorobutyric anhydride and toluene 'scintillation grade' 
were obtained from Koch-Light Laboratories Ltd. PPO and POPOP, the primary 
and secondary solutes dissolved in toluene to produce the liquid scintillator, 
were obtained from Hopkin and Williams Ltd (Asschem, Redding Industrial 
Estate, Redding, Falkirk, Scotland). All other chemicals, unless otherwise 
noted in the text, were purchased from B.D.H, Chemicals Ltd (Poole, Dorset, 
England) and were normally of 'Analar' specification.
ENZYME preparation
The enzyme p-glucuronidase, used for the hydrolysis of urinary steroid 
glucuronosides, was prepared in this laboratory according to the M.R.C. 
method (1963). Limpets (Patella vulgata) were collected from the rocky 
shore of the Clyde Estuary, two hours after high tide and immediately 
brought back to the laboratory in sea water. The molluscs were removed 
from their shells and the black viserai hump was dissected from the muscular 
foot. Batches of approximately 150 g of visceral humps were homogenized for 
two minutes with twice the volume of ice-cold water. After centrifugation 
(1000 r.p.m.) the supernatant was decanted and acetone added to bring the 
concentration to 60 per cent acetone in water in order to precipitate the 
proteinous enzyme. The mixture was allowed to stand overnight in the
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refrigerator (5°C) at this stage. The supernatant was then removed after 
centrifugation at 1000 r.p.m. and discarded. The acetone precipitate was 
resuspended in acetone, washed by thorough mixing and centrifuged. The 
washing and centrifugation were repeated until all the chromogenic material 
had been removed by the acetone. The precipitate was dried at 25^C, 
powdered and assayed for p-glucuronidase activity.
Assay of 8-Glucuronidase Activity
The method developed by Talalay et al. (1946) was used to assay the 
potency of the p-glucuronidase extract. The limpet powder (200 mg) was 
dissolved in deionised water (40 ml) and 1 ml of the resulting suspension was 
made up to 12,5 ml with deionised water. 0.5 ml of this dilute solution 
(equivalent to 200 pg of enzyme powder) was used for estimation of 
P«glucuronidase activity.
0.1 M acetate buffer (4 ml) (5.785 g sodium acetate and 3.25 ml glacial 
acetic acid per litre of deionised water, adjusted to pH 4.6) was placed in 
four tubes. Phenophthalein glucuronoside (50 (ig) was added to the two 
experimental tubes but not to the two control tubes. All tubes were then 
placed in a water bath at 38°C and allowed to equilibrate. The enzyme 
solution (0.5 ml) was added to each tube at timed intervals, mixed, stoppered 
and incubated for exactly 60 minutes. The reaction w^ as stopped and the 
colour developed in all tubes by the addition of 0.4 M glycine buffer (5 ml) 
(16.3 g aminoacetic acid, 12.65 g sodium chloride and 10.9 ml concentrated 
sodium hydroxide 1:1 (w/v)). Finally, phenolphthalein glucuronoside (50 }ig) 
was added to the two control tubes. The optical densities of the experimental 
and control tubes were read against standards of phenolphthalein (5-30 pg) 
in a Unicam SP600 spectrophotometer (Pye Unicam Ltd, York Street, Cambridge, 
England) set at 540 nm and employing matched glass cuvettes of 10 mm light 
path (Starna Ltd, Queens Road West, London B13, England). The potency of 
p-glucuronidase is then expressed in Fishman Units per gramme enzyme
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preparation where one Fishman unit is equivalent to 1 fig phenolphthalein 
liberated from the substrate (phenolphthalein glucuronoside) by 1 g 
of enzyme powder.
Optical densities (OD) obtained on assay of the p-glucuronidase used in 
this investigation are given below. The spectrophotometer was zeroed 
against deionised water.
READINGS ^
OD 540 Control 003.....  (A)
OD 540 25 f.ig Standard (phenolphthalein) 211.....  (B)
OD 540 Experimental test 223 ..... (C)
calculation
25 gg phenolphthalein = (B - A) = OD 208
.*. 26.44 pg phenolphthalein s (C - A) - OD 220
200 |ig enzyme powder liberates 26.44 (ig phenolphthalein
1 g enzyme powder liberates 26.44 x 10  ^ |.ig phenolphthalein
200
ie 132,200 jig phenolphthalein 
Thus 1 g enzyme powder contains 132,200 Fishman units.
BASIC METHODOLOGY
THIN layer CHROMATOGRAPHY
Merck pre-coated thin layer plates of silica gel 60 ^254 Cpre-coated 
layer thickness 0.25 mm) were purchased from Anderman and Co. Ltd (Central 
Avenue, East Molesey, Surrey, England). These plates were used without 
further washing or activation by heat for purification of testosterone 
extracts from plasma and urine.
Chromatography
Samples were applied to the thin layer using disposable micropipettes, 
a TLC tray and a spotting guide (Baird and Tatlock (London) Ltd, Asschem), 
After the application of samples, the chromatogram was developed in a TLC
tank lined with Whatman 3 MM chromatography paper (H. Reeve Angel & Co. Ltd, 
Ne»; Bridge Street, London EC4, England) using 100 ml of the appropriate 
solvent system for each development.
Detection of Steroids on TLC Plates by Ultraviolet Light
A.^-3-Oxosteroids were visualised on TLC plates using light emitted 
at 254 nm from a 'BTL Ultraviolet lamp for TLC' (Baird and Tatlock (London) 
Ltd), The fluor content of the silica gel, described above, facilitated 
detection. Other standard steroids were located after spraying with 
Rhodamine 6 G (0.1 per cent w/v in ethanol).
Radiochromatogram Scanning
Radioactively labelled steroids were located on TLC plates using a 
Panax 'Thin Layer Radiochromatogram Scanner, Model RTLS la' (Panax 
Equipment Ltd, Redhill, Surrey, England), in conjunction with a Smith's 
Flatbed Recorder (Smith's Industries Ltd, Industrial Instrument Division, 
Wembley Park, Middlesex, England). Tiie detector gas was a mixture of 
argon (2 per cent) and propane (98 per cent) (British Oxygen Company Ltd, 
Special Gases Department, Deer Park Road, London SW19, England) regulated 
to a gas flow rate of 50 ml per minute. All plates were scanned at the
15 X 2 mm detector aperture, adjusted to a height of approximately 1 mm
above the TLC plate. The detector voltage was set at 1,040 V, detector 
dead time 200 \iS and discriminator bias at 10 mV. A time constant of 100 
seconds and a scanning speed of 30 mm per hour were employed. The range 
of counting varied with the amount of radioactivity to be scanned.
Elution procedure
The silica on areas of thin layers to be eluted was loosened free
from the TLC plate glass using a disposable scapel blade. The loosened
silica was drawn by suction into a vacuum thimble filter. These filters 
consist of a sintered glass filter disc (approximately 1 cm diameter) 
encased in, and at one end of, glass tubing (4 cm long) to which at each
•" 4 V “
end narrower tubing (3 mm diameter, 2 cm long) is fused. These devices
are a simplified version of the 'vacuum cleaners' described by Matthews et aî.
(1962) and are made to the above specification by Glass Appliances Ltd
(488 Holburn Street, Aberdeen, Scotland). The eluent, normally methanol
and/or ethyl acetate unless otherwise specified, was added to the inverted
vacuum thimbles and the resulting eluate, which emerged through the filter,
collected in test tubes (Figure 2,1), ^
LIQUID SCINTILLATION COUNTING
Radioactivity was measured by liquid scintillation counting using a 
Nuclear Chicago Mark 1 Scintillation Computer (Nuclear Chicago Corporation, 
Inc., Des Plaines, Illinois, USA) calibrated for simultaneous counting of 
^^C and employing three channels. The scintillation fluid v;as toluene 
based and contained 4 g per litre PPO (2,5-diphenyloxazole) as the primary 
scintillator and 0.05 g per litre POPOP (l,4”di«(2-"(5-phenyloxozolyl))-benzenc 
as the secondary scintillator. Quenched standards (Nuclear Chicago 
Corporation, Inc.), containing an identical scintillation solution, were
used to establish quench correction curves employing external standard
133channels ratio techniques and the external standard of Ba incorporated 
into the scintillation counter.
All samples were counted in 20 ml scintillation fluid for 20 minutes. 
Aqueous samples containing free radioactively labelled steroids were blown 
to dryness under nitrogen at 40^C and then redissolved in the scintillation 
fluid, whilst radioactively labelled conjugated steroids were incorporated 
into the toluene based scintillator by dilution with 20 per cent methanol,
All results of quantitation by such liquid scintillation counting are 
expressed as disintegrations per minute (dpm) taking account of the channels
ratio with the external standard.
GAS LIQUID CHROMATOGRAPHY
A Pye Series 104, Model 84 gas chromatographic system (Pye Unicam Ltd, 
York Street, Cambridge, England) w<is employed.
E H
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Figure 2.1 Extraction thimbles used for the collection and 
elution of silica from TLC plates. Elution of 
steroids from the silica was facilitated by 
percolation of solvent through the silica and 
sintered glass filter disc of the inverted thimble 
The eluate was collected in test tubes.
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Flame ionization detection (FID) was used to determine column 
separating powers and for detection of androgens and androgen metabolites 
in urine. The following gas flow rates were used with FID: oxygen-free
nitrogen carrier gas - 40 ml per minute; hydrogen - 40 ml per minute; 
air - 650 ml per minute. Oxygen-free nitrogen and air were supplied by 
British Oxygen Co. Ltd, hydrogen was purchased from Messer Griesheim Ltd 
(43 Knights Hill, West Norwood, London SE27, England). Gas purification 
bottles were used with all gases.
Electron capture detection (BCD), using a Ni source and a pulse 
voltage of 150 pS, was used in the final quantitation of extracts from 
urine and plasma. Column details and running conditions will be indicated 
in the text.
The samples were injected into the column using a 10 pi SGE syringe 
(Phase Separations Ltd, Queensferry, Flintshire, Wales). The recorder v/as 
a Philips Flat Bed Recorder, Model PM8000 (Pye Unicam Ltd) and a chart 
speed of 5 mm per minute (30 cm per hour) was used throughout the investigatioi
PRELIMINARY URINE TESTS
COLLECTION OF SAMPLES
Complete 24-hour urine collections were made from patients in hospital, 
under the supervision of the nursing staff. Specimens were collected in 
screw-top bottles to which chloroform (5 ml) was added as a preservative.
Urine specimens were stored at 5°C.
DETERMINATION OF CREATININE
A modified Folin (1905) adaptation of the colour reaction of creatinine 
with alkaline sodium picrate first described by Jaffe (1886) was used for 
the determination of creatinine in 24-hour urine collections. Several of 
the modifications suggested by Bonsnes and Taussky (1945) were applied 
in the method.
After measuring the total urine volume, duplicate aliquots (0.5-2 ml) 
containing 0.7 to 1,2 mg creatinine were pipetted into 100 ml volumetric 
flasks. A reagent blank containing deionised water (1 ml) and a standard 
flask containing creatinine stock standard (creatinine 1 g/1 in 0.1 N HCL)
(1 ml 5 1 mg) were prepared in similar flasks. Saturated picric acid 
(15 g picric acid per litre deionised water) (2 ml) was added to each flask 
followed by the addition, at timed intervals, of 1 M sodium hydroxide (1 ml). 
The flask contents were thoroughly mixed and allowed to stand exactly 10 
minutes at room temperature before dilution to volume with deionised water. 
After dilution the contents were thoroughly mixed again and an aliquot 
transferred by Pasteur pipette to a cuvette of 10 mm light path. Optical 
densities were read at 490 nm on a Unicam SP600 spectrophotometer with zero 
set against the reagent blank.
The milligram equivalents of the test samples relative to the standard 
creatinine were calculated, and after adjustment for the aliquot of urine 
taken, and for the total 24-hour urine volume, the final results were 
expressed as mg creatinine per 24 hours.
Standard creatinine was found to obey the Beer-Larabert Law (Figure 2,2) 
at the concentrations used. This permitted direct quantitation of creatinine 
in test samples. The recovery of creatinine added to urine was con­
sistently greater than 95 per cent. Results of typical recovery experiments 
are shown in Table 2,1. Duplicates were consistently within 3 per cent 
and inter-batch difference was less than 5 per cent.
CREATININE AS AN INDEX OF ACCURACY OF 24-HOUR URINE COLLECTIONS
Serial 24-hour urine specimens (4-5 days) were collected from children 
in hospital, under the supervision of the nursing staff. Considerable 
fluctuation was found in the volume of some 24-hour urine collections over 
the period of test. The completeness of certain specimens v.^ s therefore 
questioned.
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Figure 2.2 Optical density of creatinine as assayed by the Jaffe 
colour reaction. The results were corrected for 
reagent blank. Note the obedience of the results to 
the Beer«Lambert Law at creatinine concentrations 
between 0.5 and 1.1 mg/lOO ml.
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TABLE 2.1 RECOVERY OF CREATININE ADDED TO URINE
Test Optical Density @ 490 nm
Recovery of 
Creatinine
%
Standard creatinine (1 mg) 1.20
Urine A 0.25 —
Urine A + creatinine (1 mg) 1,40 95.8
Urine A + creatinine (0,75 mg) 1.13 97,8
Urine A + creatinine (0.5 mg) 0.865 102.5
Urine A creatinine (0.2 rag) 0,47 91,7
Urine A + creatinine (0,1 mg) 0,365 95.8
Urine A + creatinine (0.05 mg) 0.30 83.3
Urine A + creatinine (0,02 mg) 0.268 75,0
Recovery is acceptable (98,7 per cent) if aliquot analysed 
contains between 0.7 and 1.2 mg creatinine
As long ago as 1905 Folin (1905b) observed that although considerable 
individual variation was noticed, the daily quantity of urinary creatinine 
was remarkably constant for the individual and that this constancy of 
creatinine excretion could be used as a gauge of the completeness of a 
24-hour urine specimen. Smith (1942) found the creatinine test of great 
use in assessing accuracy of collection of 24-hour specimens. Wray and
Scott Russell (1960) and Paterson (1967) confirmed that the 24-hour
1
excretion of creatinine was significantly more constant than the 24-hour 
urine volume.
In this work results of the determination of creatinine in serial 
24-hour urine specimens were viewed critically. After rejection of 
significant outliers (Dixon, 1951) the mean creatinine excretion was cal­
culated for each patient. Division of this mean creatinine excretion by 
the individual daily creatinine excretion gave the creatinine correction 
factor for each urine collection. All results of urinary steroid deter­
minations were adjusted to a constant creatinine excretion over the test 
period by multiplication of the 24-hour urinary excretion of steroids by 
the creatinine correction factor. Approximately 2 per cent of the urine 
specimens were discarded as 'insufficient' for analysis.
GROUP DETERMINATION OF 17-OXOSTEROIDS
After measuring the total urine volume, duplicate 10 ml aliquots 
of undiluted urine were pipetted into boiling tubes of approximately 
40 ml capacity. Tlie tubes were placed, unstoppered, in vigorously 
boiling water and allowed to come to temperature. Concentrated hydrochloric 
acid (1 ml) was added to each tube, and boiling was continued for exactly 
10 minutes to hydrolyse conjugated 17-oxosteroids.
The tubes were cooled rapidly in ice prior to extraction of steroids 
with chloroform (10 ml). After inversion of the tubes 20 times, the upper 
aqueous layer v?as removed using a Pasteur pipette attached to a water
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suction pump. The chloroform was washed with 1 M sodium hydroxide (2 ml) 
and then with deionised water (2 ml). After each wash the aqueous layer 
was removed by suction. The organic phase was filtered through Whatman 
No. 1 phase separating paper to remove the water and an aliquot (5 ml) 
of the filtrate transferred to a 10 ml test tube. Evaporation was 
accomplished under nitrogen, the tubes standing in a water bath at 40°C.
The 17-oxosteroid content of the dried residue was estimated colorimetrically 
by the Zimmermann reaction.
THE ZIMMERMANN REACTION
The James and de Jong (1961) modification of the Zimmermann reaction 
was used throughout this study. These authors recommend the use of 
tétraméthylammonium hydroxide in preference to the less stable potassium 
hydroxide. A reaction mixture of 0.5 per cent dinitrobenzene and 25 per 
cent tétraméthylammonium hydroxide in proportions 2:1 was used. The 
separate reagents were stored at 5^0 until used.
The freshly constituted reaction mixture (0.25 ml) was added to the 
dried urine extracts from the above procedure. Duplicate reagent blank 
tubes and duplicate standard tubes containing dehydroepiandrosterone (10 pg) 
plus the reaction mixture were processed with each assay. The tubes were 
stoppered and incubated in the dark at 25^0 for one hour (Figure 2.3). 
Ethanol (50 per cent) (2 ml) was pipetted into each tube and the Zimmermann 
colour extracted into diethyl ether (3 ml).
After separation of the phases, the upper ether layer was transferred 
by Pasteur pipette to a cuvette of 10 mm light path (Starna. Ltd). Optical 
densities were read at 435, 515 and 595 nm (Figure 2.4) on a Unicam SP600 
spectrophotometer with the zero reading set against diethyl ether. To 
correct for interfering chromatogens the Allen correction formula (1950) 
was applied to the optical densities at the wavelengths given above.
The corrected optical density at 515 nm (COD^^^) is given by:-
- 57
J il
5  1
" Ii
N
l O O l
7 5 i
50
25
10025 7550
IN C U B A T IO N  T IM E  ( m in s )
Figure 2.3 The increase in optical density of the Zimmermann
chromatogens with time. Routinely the reactants were 
incubated for 1 hour at 25°C in the dark. The reaction 
mixture consisted of dinitrobenzene and tétraméthylammonium 
hydroxide (2:1, v/v) (0.25 ml) added to the dry residue. 
Standard DHA (10 ^g) was used in the above experiment and 
the Zimmermann chromatogens extracted into diethyl ether 
from the aqueous phase.
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Figure 2.4 Optical density spectra of Zimmermann positive 
colour at varying wavelengths. DHA (15 |ig) was 
incubated in the dark at 25°C for 1 hour with 
Zimmermann reagent (Figure 2,3), Routinely 
optical densities were measured at 435, 515 and 
595 nm and the Allen correction (Allen, 1950) 
applied.
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COD = ODD -/°°°435  ^°°’59S 7
515 515 l_ -----“2----- J
Where 0 0 is the observed optical density at 515 nm
000^22 is the observed optical density at 435 nm
OOD^g^ is the observed optical density at 595 nm
The reagent blank reading was subtracted from standard and test 
readings. The microgram equivalents of the test samples relative to the 
standard DHA were calculated, and after adjustment for the aliquot of
chloroform extract taken, and for the total 24-hour urine volume, the
final results were expressed as mg 17-oxosteroids per 24 hours.
Standard dehydroepiandrosterone (DHA), in the diethyl ether phase, 
was found to obey the Beer»*Lambert Law (Figure 2.5).
Recovery experiments were carried out frequently. The recovery of 
DHA added to water and urine and processed through the method was con­
sistently above 80 per cent. Typical results of recovery experiments are 
given in Table 2.II.- Replicate estimations of 17-oxosteroids were always 
made. When the results of duplicates differed by - 5 per cent from the 
mean the test was repeated.
ESTIMATION OF PLASMA TESTOSTERONE
All patients were investigated by permission of fully informed 
parents and in accordance with the ethical standards of the establishment.
Peripheral venous blood (1020 ml) was delivered immediately to a 
tube containing lithium heparin. The plasma was separated by centrifugation 
and transferred to a plain tube. The plasma was either processed 
immediately or stored at ~15^C until assayed.
A flow diagram of the methods used for extraction, purification and 
quantitation of testosterone in plasma is shovm in Figure 2.6.
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Figure 2,5 Optical density of the Zimmermann colour for DHA in the 
range 5»-25 |ig. The results were corrected for reagent 
blank. Note the obedience of the results to the 
Beer'-Lambert Law,
TABLE 2. II RECOVERY OF DHA FRQM WATER AND URINE.
THE COMPLETE, METHOD OF ASSAY FOR 17-OXOSTEROIDS WAS USED.
Extraction was made with chloroform (10 ml). 
Aliquot of 5 ml taken for the Zimmermann reaction
Test
Wavelength 
435 515
(nm)
595
AC
1
AC-RB
Percentage 
Recovery 
of DHA
Reagent Blank 054 044 012 Oil
000
047 040 Oil Oil
Standard DHA 077 188 073 113
(10 jJLg) 099
072 178 070 107
Water 010 018 002 012
001
012 018 000 012
Water 074 184 062 116
plus DHA 098 97.98*
(20 |ig) 072 168 060 102
Urine A 174 317 146 157
(adult) 143
356 400 142 151
Urine A 294 491 196 246
plus DHA 229 86.87*
(20 pg) 292 476 192 234
AC = Allen correction (Allen, 1950)
RB = Reagent Blank
* Adjusted for aliquot taken for Zimmermann reaction
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EXTRACTION
3 “
/ 1,2,6,7- H_/Testosterone (S.A. 87 Ci/mM, 0.035 pCi) was added to 
each sample of plasma for estimation of the recovery. ITie plasma was made 
alkaline by the addition of 1 M sodium hydroxide (1 ml) to restrict the 
quantity of lipids likely to be extracted (O'Gata and Hirano, 1933).
After the addition of the sodium hydroxide the plasma was immediately 
extracted three times with diethyl ether (3 x 20 ml). The diethyl ether 
extract was washed with 10 per cent acetic acid (5 ml) and deionized water 
(5 ml). Washing with water was repeated until the extract was neutral.
The neutralized ether extract was transferred to a boiling tube (50 ml) 
which was then placed in a water bath at 40°C. The ether was removed by 
blowing to dryness under a stream of nitrogen. The dried extract was 
dissolved in 70 per cent methanol (10 ml) and partitioned against hexane 
(2 X 10 ml) (Oertel, 1961). Tlie lower aqueous methanol layer was removed 
and blown to dryness under a stream of nitrogen as before,
THIN layer CHROMATOGRAPHY OF FREE STEROIDS
The dried extract was quantitatively applied to the origin of a silica
thin layer using dichloromethane (3 x 20 pi) and methanol (2 x 20 pi) as
vehicles. The chromatogram was developed in the solvent system,
benzene : methanol (85:15, v/v) (Guerra-Garcia , 1963) for two,
one-hour periods, allowing the plate to dry in air before the second
development. In this solvent system the R^ of testosterone is 0.58. The
R^ (testosterone) values of standard steroids and their sulphate and
glucuronoside esters are given in Table 2,111, The silica over the
3radioactive area, representing the H-testosterone initially added to the 
plasma, and located by radiochromatographic scanning, was removed and 
eluted first with dichloromethane ( 3 x 2  ml) and then methanol (3 x 2 ml).
The eluate was collected in a conical centrifuge tube (10 ml), reduced 
to small volume under nitrogen, and applied quantitatively as a spot to the
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Figure 2.6 Plow diagram of the procedures used in the 
estimation of plasma testosterone 
concentration.
TABLE 2.Ill SEPARATION OF STEROIDS AND STEROID CONJUGATES BY THIN LAYER 
CHROMATOGRAPHY IN BENZENE:METHANOL (85:15, v/v)
Testosterone p^D^glucuronosicle 
Dehydroepiandrosterone glucuronoside
R„ value* 
0.01 
0.01
Androsterone sulphate 
Dehydroepiandrosterone sulphate
0.07
0.08
Oestriol
Cortisol
ll(3-Hydroxytestosterone 
5oC“Androstane-3j3 ,17j3"diol 
53“Androstane-3a, 17(3-diol 
5a-Androstane“3oc, 173“diol 
17oc-Hydroxy pregnenolone 
17o:-Hydroxyprogesterone 
liP“Hydroxyaetiocholanolone 
llp-Hydroxyandrosterone 
173“Oestradiol
0.23
0.46
0.49
0.55
0.67
0.75
0.76
0.79
0.80
0.88
0.88
Testosterone l.CO
11-Oxoan d r OS t e r one
Epitestosterone
11"Oxo a e t i o ch o1an o1on e
Epiandrosterone
Dehydroepiandrosterone
5(3" Dihydrotestosterone
A^-Pregnenolone
Aetiocholanolone
5o™Dihydrotestosterone
Androsterone
A^-Androstenedione
Oestrone
Progesterone
5a"Androstanedione
1.01
1,03
1.07
1.13
1.14
1.17
1.18 
1.18 
1.19 
1.21
1.31
1.32 
1.38 
1.41
Development 2 x 1  hour
* s = testosterone R _ 0.58
£
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origin of a second silica thin layer using ethyl acetate (4 x 10 ill) and 
methanol (2 x 10 fil ) as vehicles. The chromatogram was developed in the 
solvent system, benzene : ethyl acetate (6:4, v /v) (Korenman et a_l. , 1963) 
for two, one-hour periods as before. values (relative to testosterone,
RjP 0.30) of standard steroids developed in this solvent system are given 
in Table 2.IV. The silica over the radioactive testosterone area as located 
by radiochromatographic scanning, was removed and eluted with ethyl acetate 
( 3 x 2  ml) and dichloromethane ( 3 x 2  ml). The eluate was dried under a 
stream of nitrogen as above and esterified with heptafluorobutyric anhydride 
(page 71).
ESTERIFICATION OF STEROIDS
The low level of testosterone in urine and plasma of children demands 
sensitive methods for its detection. Clark and Wotiz (1963) first observed 
that heptafluorobutyrate derivatives of steroids exhibited a high electron 
affinity, due to the introduction of 7 fluorine atoms into the steroid 
molecule. Nakagawa et af. (1966) investigated several halo-alkyl esters of 
testosterone with regard to their sensitivity to electron capture detection. 
They found testosterone mono->heptafluorobutyrate one of the most sensitive, 
although the di-heptafluorobutyrate, monochlorodifluoroacetate and perfluoro- 
octanoate esters showed an even higher electron affinity. Van der Molen el: aj., 
(1967), using the mono'^heptafluorobutyrate ester of testosterone for the 
detection of testosterone in plasma, were able to detect its presence in 
nanogram (ng) and picogram (pg) quantities. Plasma extracts and steroid 
standards were treated with heptafluorobutyric anhydride using a modified 
method for estérification.
Preparation of Standard Testosterone-17-heptafluorobutvrate
Estérification of testosterone may occur at C17 and also at C3 by 
enolization of the 3-keto-group. The reaction of testosterone with 
heptafluorobutyric anhydride under different conditions gives high yields of
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TABLE 2.IV SEPARATION OF STEROIDS BY THIN LAYER CHROMATOGRAPHY IN 
BENZENE:ETHYL ACETATE (6:4, v/v)
Free steroid R value*
lip-Hydroxyaetiocholanolon e oLôl
ll*”Oxoaetiocholanolone 0.62
116-Hydroxyandrosterone 0.74
11-Oxoandrosterone 0.74
Testosterone 1.00
Epitestosterone 1.06
A^-Pregnenolone 1.24
5p-Dihydrotestosterone 1.28
Epiandrosterone 1.30
Dehydroepiandrosterone 1.45
Androsterone 1.47
Aetiocholanolone 1.50
Scx-Dihydrotes tost erone 1.50
17B“0estradiol 1.63
A^-Androstenedionc 1.65
Development 2 x 1 hour
* 8 = testosterone R^ , 0.30
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testosterone“'17~mono™heptafluorobutyrate and two isomeric enol esters, the 
diheptafluorobutyrates of androst-2,4”-diene-3p,17p-diol and 
androst”3,5”diene“33,17p“-diol (Devaux and Horning, 1969). As both the 
diheptafluorobutyrates are reported to be unstable on silica gel thin layer 
chromatography (Van der Molen et , 1967; Devaux and Horning, 1969) 
reaction conditions were used to form testosterone“17*"heptafluorobutyrate 
in high yield. ^
Testosterone (1 mg) was dissolved in dichloromethane (1 ml) and 
heptafluorobutyric anhydride (50 gl) added. After thorough mixing on a 
Vortex mixer, the reactants were allowed to stand at room temperature for 
30 minutes. Excess reagent was removed by evaporation to dryness at room 
temperature under a stream of nitrogen. /"°1,2,6,7"^H_7Testosterone (S.A.
87 Ci/mM; 20 nCi) was added to the standard testosterone, prior to estérifi­
cation, for recovery purposes. The dried esterified testosterone was 
quantitatively applied to the origin of a silica thin layer using ethyl 
acetate (5 x 20 |il) and the chromatogram developed in cyciohexane:ethyl 
acetate (1:1, v/v), A two-dimensional development was used, each development 
period being 55 minutes. The TLC plate was allowed to dry after the first 
development before being turned through 90*^  for the second development.
The location of the UV^absorbing steroids is shovm in Figure 2.7. The 
silica area containing testosterone-17~heptafluoSobutyrate was scraped 
from the plate and eluted with ethyl acetate (3 x 2 ml) and acetone ( 3 x 2  ml).
The solvent was removed by evaporation under a stream of nitrogen. The 
ester was dissolved in ethyl acetate (1 ml). An aliquot (0.1 ml^ was taken 
for liquid scintillation counting of radioactivity and from this count the 
percentage conversion to the mono-heptafluorobutyrate was calculated. A 
conversion of 85 per cent of testosterone to testosterone-17-heptafluorobutyrat 
(T-HFB) was consistently achieved by this method. Calculated dilutions of the 
ester were made in ethyl acetate such that 1 Rl contained 1 |ig T-HFB for FID 
and 1 )il contained 1 ng T-HFB for BCD.
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Figure 2,7 Two-dimensional TLC separation of testosterone
heptafluorobutyrates in cyciohexane:ethyl acetate 
(1:1, v/v). Development for 2 x 55 minutes.
Note breakdown of testosterone-3,17-HFB on second 
development.
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A single peak was obtained by GLC analysis of the T™HFB (Figure 2.8). 
Preparation of Standard Androsterone-3-heptafluorobutyrate
Estérification of androsterone only occurs at the hydroxyl on the C3 
position. Androsterone-3”heptafluorobutyrate was therefore prepared under 
the same reaction conditions as for testosterone-17-heptafluorobutyrate, 
Androsterone (1 mg) v/as dissolved in dichloromethane (1 ml) to which 
was added heptafluorobutyric anhydride (50 gl). ^After thorough mixing on a 
Vortex mixer, the reactants were allowed to stand at room temperature for 30 
minutes. Excess reagent was removed by evaporation to dryness at room 
temperature under a stream of nitrogen. / lot,2cc«^H_7Androsterone (S.A. 40 Ci/n
20 nCi) was added to the standard prior to estérification, for recovery
3purposes. Partition of H-androsterone between n-hexane and 70 per cent 
aqueous methanol (1:1, v/v) gave a quantitative recovery of radioactivity 
from the aqueous methanol phase. When partition between the above solvents 
was repeated after estérification 99.8 per cent of the original radioactivity 
was recovered in the hexane phase indicating a quantitative conversion of 
androsterone to androsterone-3-heptafluorobutyrate.
This phase was then reduced to a small volume under nitrogen and applied 
quantitatively to the origin of a silica thin layer using ethyl acetate
(2 X 20 fil) and acetone (2 x 20 pi). The TLC plate was then developed in
cyciohexane:ethyl acetate (1:1, v/v) for one hour. Following radiochromato­
graphic scanning the silica on the radioactive area was scraped off and 
eluted with ethyl acetate ( 3 x 2  ml) and acetone ( 3 x 2  ml). The eluate 
was blown to dryness under a stream of nitrogen and the ester redissolved
in ethyl acetate (1 ml). An aliquot (0.1 ml) was taken for liquid
scintillation counting of radioactivity and from this count the percentage 
conversion to androsterone"3"*heptafluorobutyrate was calculated. A conversion 
of 90 per cent of androsterone to androsterone-3-heptafluorobutyrate (A-HFB) 
was consistently achieved by this method. Calculated dilutions of the ester 
were made in ethyl acetate such that 1 j.il contained 1 pg A-HFB for FID and
G L C - ECD 
Testosterone-17- HF8 
(purified: 2dimensional 
TLCtCyclohex.EtOAc. I I )
Figure 2.8 Gas liquid chromatographic analysis with
electron capture detection of testosterone-17~FiFB 
following purification on a two-dimensional TLC 
separation in cyciohexane:ethyl acetate (1:1, 
v/v). This and subsequent tracings have been 
overlined in black ink to facilitate photography.
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1 ^1 contained 1 ng A-HFB for ECD. Gas liquid chromatography of standard 
androsterone esterified by this method gave a single peak.
Estérification of Plasma Extracts
The dried residues obtained from the TLC plates developed in 
benzene:ethyl acetate (6:4, v/v) were placed in a vacuum desiccator overnight 
The residues were dissolved in dichloromethane (1 ml) and esterified with 
heptafluorobutyric anhydride (50 p.1) at room temperature for 30 minutes. 
Excess reagent was removed by evaporation to dryness at room temperature 
under a stream of nitrogen. The dried residue was applied to the origin of 
a silica thin layer using ethyl acetate (2 x 20 fil) and acetone (2 x 20 pi). 
The TLC plate was developed in the solvent system eyelohexane; ethyl acetate 
(1:1, v/v) for one hour. values of free standards and esterified steroids 
are given in Table 2.V. The TLC plate was then scanned and the area of 
silica under the peak of radioactivity (corresponding in with that of 
standard testosterone-17-HFB) was removed and eluted with ethyl acetate 
( 3 x 2  ml) and then acetone ( 3 x 2  ml). The extract was dried under nitrogen 
in a water bath at 40*^ C. The dried extract was redissolved in ethyl acetate 
(dried over anhydrous magnesium sulphate) (50 pi). An aliquot (5 pi) was 
then removed for liquid scintillation counting to permit assessment of the 
overall recovery rate and an aliquot injected into the GLC-ECD system 
(page 76).
GAS LIQUID CHROMATOGRAPHY
Hartman and Wotiz (1963) have found neopentyl glycol sebacate (N.G.Seb.) 
a suitable liquid phase for the separation of the trimethyl-silyl ether 
derivatives of androgen and progesterone metabolites. After preliminary 
experiments it was decided to use the temperature stabilized form of this 
polyester in the present investigation to allow the use of higher operating 
temperatures, so obviating long retention times.
Id.
TABLE 2.V SEPARATION OF STANDARD STEROIDS (FREE AND HEPTAFLUOROBDTYRATE 
ESTERS) IN CYCLOHEXANE;EIHYL ACETATE (1:1, v/v)
Free Steroid
*
Heptafluqrobutyrate 
Ester (HFB)
*
ll(3"Hydroxyandrosterone 0.30 3a->Hydroxyl HFB 1.09
3a,llp™Kydroxyl HFB 1.26
Testosterone 0.40 17(3'™Hydroxyl HFB 1.00
3-enol, 17p“-Hydroxyl HFB 1.62
Epitestosterone 0.43 17a»Hydroxyl HFB 1.02
3™enol, l?o:“Hydroxyl HFB 1.74
Epiandrosterone 0.52 3(3“Hydroxyl HFB 1.22
5(3“ Dihydrotestosterone 0.55 17p“Hydroxyl HFB 1.01
Dehydroepiandrosterone 0.59 3p-Hydroxyl HFB 1.01
ll'-Oxoandrosterone 0,59 3oc*»Hydroxyl HFB 1.29
^^“•Pregnenolone 0,62 33“Hydroxyl HFB 1.32
Development for 1 hour
* R^ relative to testosterone-17-HFB (R^ 0.45)
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1 of the Column
Prior to packing, the empty glass column (5 ft, 4 mm I,D.) was rinsed 
with concentrated hydrochloric acid, washed with deionized water and then 
silanized with 5 per cent (v/v) dimethyldichlorosilane in toluene for 15 
minutes. The column was emptied, washed several times with methanol and 
thoroughly dried at lOO-llO^C for one hour. This procedure is recommended 
by Horning (1968), ^
Preparation of Column Packing Material
Gas Chrora Q, 100-120 mesh (Phase Separations Ltd) was used as the support 
without further purification. A solution of N.G.Seb. (0.5 per cent, wt/v), 
was prepared by dissolving N.G.Seb. (0.5 g) in chloroform (100 ml). This 
concentration of liquid phase was routinely used to give a 1 per cent coating 
of the Gas Chrom Q. The relationship between the concentration of the 
liquid phase in solution and the percentage of liquid phase coating the 
support material is fortuitous. However, the procedure was recommended by 
Dr T. Simpson of Torry Research Station, Aberdeen (personal communication).
Tlie liquid phase (100 ml) was slowly added to Gas Chrom Q (15 g) 
in vacuo by the filtration method. The flask contents were slowly swirled 
so as to dislodge trapped air and to facilitate an even coating of the 
support. The vacuum was then broken and the contents quickly filtered 
through a Buchner system. Suction was continued for five minutes to remove 
the chloroform. The coated support, retained in the filter funnel, was then 
transferred, without washing, onto a 20 cm diameter watch glass. It v/as 
then dried in air at 37°C.
Packing and Conditioning the Column
A small glass filter funnel was attached by tubing to the injection end 
of the column. The coated support was then added in small amounts to the 
funnel and filling of the column facilitated by suction applied to the 
detcctor^ersd of the column. Gentle vibration was applied along the length
»  y *a*
of the column using a hand-vibrator (Phase Separations Ltd). The injection 
end of the column was not completely filled so as to accommodate the flash 
heater. A silanized glass wool plug was tamped into position at the 
injection end of the column.
The packed column was placed in the column oven of the GLC system and 
conditioned at 220°C whilst a slow flow of oxygen-free nitrogen, as carrier 
gas, was maintained through the column. The carrier gas flow rate was 
slowly increased to 50 ml per minute. Conditioning in this environment was 
continued overnight to remove excess liquid phase from the column, before 
coupling the column to the detector.
Operating Conditions
The separating powers of the column were preliminarily determined using 
flame ionization detection (FID). Urine and plasma extracts were quanti­
tatively analysed for testosterone using electron capture detection (ECD). 
Recovery of radioactivity which had been initially added to the biological 
material permitted assessment of recovery.
The column oven was operated at 190^C, the injection heater at 210^0 
and the detector oven at 250^C when using ECD. Samples were injected into 
the column using an S.G.E. 10 pi syringe fitted with an 11.5 cm needle. 
Linearity of the Detector
The response for both testosterone-17--heptafluorobutyrate and the 
internal standard, androsterone-3-heptafluorobutyrate, was proportional 
to the amount injected (Figure 2.9). An internal standard 
(androsterone-3-heptafluorobutyrate) was injected with each sample.
Linearity of detector response to varying amounts of steroid 
derivative was determined
(a) by using peak height only,
(b) by using peak area determined from the product of the peak 
height and the width of the peak at half peak height,
75 "
600
300
150 300 450
Figure 2.9 Electron capture detector response (peak areas) 
to varying amounts of testosterone«l7«HFB and 
androsterone^3wHFB.
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(c) by using peak area determined by triangulation, the area
being determined by halving the product of the peak height 
and the peak width at the baseline.
The linearity of detection using all three modes of quantitation is shown 
in Figure 2.10. Quantitation of peaks using the peak area determined from 
the product of the peak height and the width of the peak at half peak 
height was used routinely throughout this investigation.
QUANTITATION OF TESTOSTERONE IN PLASMA
Standard amounts of testosterone“17-heptafluorobutyrate and 
androsterone-3-heptafluorobutyrate were injected daily prior to sample 
analysis. A known amount of androsterone-HFB was injected as an internal 
standard together with 5-8 pi of the esterified plasma extract. Quanti­
tation of the testosterone-17™HFB in the test samples was made by 
comparison of the ratios of the peak area of the standard testosterone-17-HFB 
to the peak area of the standard androsterone-HFB with the peak area of 
testosterone-17-HFB in the plasma extract to the peak area of androsterone- 
3-HFB added as the internal standard. Correction was made for the aliquot 
injected, and for the experimental recovery as estimated by the recovery
3
of H“testosterone added initially to each sample. The mass of 
3H-testosterone-UFB injected into the GLC system with the plasma extract 
was deducted from the final quantitation. The results were adjusted to 100 ml 
plasma volumes. An example of the estimation of testosterone in a plasma 
sample is given in Figure 2.11 and the accompanying explanatory text.
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Figure 2.10 Linearity of electron capture detector response
determined from peak height and peak area measurements
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Figure 2.11 The estimation of plasma testosterone 
concentration. GLC-ECD tracing of a 
plasma extract from a patient under 
investigation.
A , Standard trace
2
12.5 ng A-HFB gives a peak area of 699 mm .
5 ng T-HFB gives a peak area of 1,477 mra .
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B. Plasma extract
2
12.5 ng of the internal standard A-HFB gives a peak area of 638 mm , 
Since this peak area differs from that obtained in the standard trace 
(Figure 2.11A) the corresponding peak area for 5 ng T-HFB in the 
second trace is therefore;
1,477 X 638 2
" 699----
But the peak area of native T-HFB in the second trace is 210 rara^ .
Therefore there are 
699 X 5 X 210
1,477 X 638 
and 699 x 5 x 210 x ‘50
T-HFB in the sample injected (9.4 |il of 50 |il)
1.477 X 638 X 9.4 T«HFB in the plasma residue.
But ^/lO of the residue \vas removed previously for calculation of 
recovery. This recovery was 29.42 per centt Therefore if the 
recovery of the native steroid is equivalent to the recovery of
3
H-T added initially to the plasma, then there were
699 X 5 X 210 X 50 X 100 x 10 ng of testosterone in the plasma
1.477 X 638 X 9.4 x 29.42 x 9 extract (10.5 ml)
Therefore in lOO ml of plasma there are
699 X 5 x 210 X 50 x 100 x 10 x 100
1,477 X 638 X 9.4 x 29.42 x 9 x 10.5 testosterone
ie 149 ng of testosterone per 100 ml.
Low recovery* Normal recovery range 3S“S0 per cent#
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ESTIMATION OF URINARY TESTOSTERONE 
Horton ejt aT. (1963) and Dulmanis e_t (1964) have shown that 
testosterone is present in urine in the free form, conjugated as the 
glucuronoside and in a pH 1 hydrolysable form (probably as a sulphate).
As the quantity of urinary testosterone in prepubertal children is 
very small (and the excretion of testosterone in the patients selected was 
likely to be below normal) it was decided that a single, 'near total* 
extraction of all urinary steroid conjugates would give more workable levels 
of testosterone for subsequent purification and detection than three separate 
extracts obtained from a fractionated extraction procedure.
HYDROLYSIS OF TESTOSTERONE GLUCURONOSIDE
Some authors have extracted free testosterone from urine prior to 
hydrolysis (Camacho and Migeon, 1963; Sandberg ^  , 1964; Van der Molen
et al., 1966) but most methods for the estimation of urinary testosterone
AMOaa taa^ zcn * •
employ p-glucuronidase hydrolysis without preliminary extraction (Vermeulen 
and Verplanke, 1963; Futterweit et al., 1963; Korenman et al,, 1963;
Korenman ^  âi*j 1964; Brooks, 1964; Schubert and Frankenberg, 1964;
Ibayashi ^t ^1., 1964). In this investigation free testosterone was not 
extracted before hydrolysis.
The hydrolysis of urinary testosterone glucuronoside was effected by 
adding ^-glucuronidase (75,000 F.u.) to urine (100 ml) at pH 4,6 and 
incubating the mixture at 37°C for 72 hours. The pH was maintained by the 
addition of 2 M acetate buffer (272 g sodium acetate trihydrate and 120 ml 
glacial acetic acid diluted to 1 litre with deionized water) (10ml). No 
attempt was made to inhibit the sulphatase activity of the p-glucuronidase 
enzyme preparation.
The hydrolysed urine was filtered through Whatman GF/A glass fibre 
paper (H. Reeve Angel & Co. Ltd) into a separating flask (500 ml).
/ 1 , 2 , 6 , 7 - /Test08terone (S,A„ 87 Ci/mM, 36 nCi) was added to the filtrate
8U
for recovery purposes. The filtrate was extracted with diethyl ether
(4 X 100 ml) and the extract reduced to approximately 200 ml under a stream
of nitrogen in a water bath at 40^0. The extract was washed with 5 M
sodium hydroxide (10 ml) and deionized water (20 ml) until the water washings
were neutral. The extract was then dried by filtration through anhydrous
3
sodium sulphate. The recovery of H-testosterone (added initially to urine 
samples) indicated that at this stage the recovery of free testosterone was
99,4 per cent. Thereafter samples were subjected to thin layer chromatography 
as for the plasma extract (page 85).
Evaluation of the Hydrolysis Method
The potency of the j3-glucuronidase preparation used throughout this 
study v/as estimated using phenolphthalein glucuronoside as substrate. The 
enzyme preparation vras also knovm to have significant sulphatase activity.
The sulphatase activity was estimated using radioactively labelled
3
dehydroepiandrosterone sulphate ( H-DHAS) as substrate. Incubation studies 
were carried out at pH 4.6 in aqueous solution, the pH being maintained with
2 M acetate buffer. Inhibition of sulphatase in control samples was achieved 
by addition of potassium dihydrogen phosphate (500 mg) to the incubation
mixture. Free radioactively labelled dehydroepiandrosterone released from
3 3 H-DHAS was extracted with chloroform (2 x 50 ml). As partition of H-DHAS
between water and chloroform resulted in 3,4 per cent of the radioactivity
being recovered from the organic phase, control values were subtracted from
the test samples. Results are shown in Figure 2,12.
The effect of increasing concentration of the p-glucuronidase
preparation on sulphatase activity is shown in Figure 2,13, Fïere unlabelled
3
testosterone sulphate was used rather than DHAS- H and it was assumed that 
sulphatase was equally active for both the 3- and 17-sulphate. Testosterone 
sulphate (100 pg) was added to 50 ml aliquots of water. A series of 12 
flasks were incubated at 37^C for 72 hours, with varying amounts of
81 ^
Partitioning H-DHAS between
water and chloroform resulted
in 3.4 per cent of the
radioactivity being recovered
from the organic phase
120
Incubation time hours
3 SFigure 2.12 The recovery of H-DHA from H-DHAS added 
to aliquots of water (50 ml) and incubated 
with p-glucuronidase (750 F.u. per ml) for 
varying lengths of time.
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Figure 2.13 The recovery of androstenedione from testosterone
sulphate (lOO |ig) added to aliquots of water (50 ml) 
and incubated with varying concentrations of 
(3'-glucuronidase for 72 hours at 37°C. Androstenedione 
formed by the oxidation of testosterone was assayed 
by the Zimmermann reaction*
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p~glucuronidase powder. A control flask was incubated as above but with 
potassium dihydrogen phosphate (500 mg) to prevent sulphatase activity.
Free testosterone was extracted with dichloromethane (2 x 50 ml). The 
extract was dried under a stream of nitrogen in a water bath at 40°C and 
redissolved in acetone (500 pi). Subsequently, testosterone was oxidised 
with Kiliani reagent (500 pi) (Kiliarii and Mark, 1901) at room temperature 
for 20 minutes. Water (2.5 ml) was added and the A'^-androstenedione so 
formed was extracted with benzene : chloroform (6:1, v/v) (2 x 2 ml). Assay 
of androstenedione was by the Zimmermann reaction using androstenedione 
(50 pg) as the standard. From Figure 2.13 it will be seen that maximum 
hydrolysis is achieved using more than 30,000 F.u. of (3-glucuronidase per 
50 ml (600 F.u. per ml). Routinely 750 F.u. p«glucuronidase per ml were 
employed for the hydrolysis of urine samples.
The effect of increasing concentrations of p-glucuronidase on 
glucuronidase activity was assayed using unlabelled testosterone glucuronoside 
as substrate. Testosterone glucuronoside (100 pg) was added to 50 ml 
aliquots of water. A series of 12 flasks were incubated at 37^C for 72 
hours with varying amounts of ^«glucuronidase. A control flask was incubated 
as above but without p-glucuronidase. Testosterone was extracted with 
dichloromethane (2 x 50 ml). The extract was dried under nitrogen in a 
water bath at 40°C and oxidised by the Kiliani reaction. The androstenedione 
so formed was extracted with benzene : chloroform (6:1, v/v) (2 x 2 ml) and 
assayed by the Zimmermann reaction using androstenedione (50 pg) as 
standard. From Figure 2.14 it will be seen that maximum hydrolysis is 
achieved using more than 20,000 F.u. of ^^glucuronidase per 50 mi 
(400 F.u. per mi). Routinely 750 F.u. per ml were used for the hydrolysis 
of urine samples.
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Figure 2.14 The recovery of androstenedione from testosterone 
glucuronoside (100 pg) added to aliquots of water 
(50 ml) and incubated with varying concentrations 
of P'^'glucuronidase for 72 hours at 37°C. 
Androstenedione formed by the oxidation of 
testosterone was assayed by the Zimmermann 
reaction.
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Purification of Urine Extracts
Following extraction the dried residues were applied to the origin of
a silica thin layer using dichloromethane (3 x 20 pi) and methanol (2 x 20 pi)
The chromatogram vjas developed in the solvent system benzene:methanol
(85:15,v/v) for two, one-hour periods, allowing the plate to dry in air
before the second development. values of standard steroids in this system
3are shown in Table 2,111. The radioactive area, representing H-testosterone 
added initially to the urine, was located by radiochromatographic scanning, 
scraped from the plate, and transferred to a 'thimble vac* under vacuum.
The steroid was eluted from the silica with dichloromethane (3 x 2 ml) and 
methanol (3 x 2 ml) into a conical centrifuge tube (10 ml). The purified 
extract was reduced to small volume under nitrogen in a wrater bath at 40^C, 
and applied quantitatively to a silica thin layer using ethyl acetate 
(4 X 10 pi) and methanol (2 x 10 pi) as solvents. The chromatogram was then 
developed in the solvent system benzene;ethyl acetate (6:4, v/v) for two, 
one-hour periods, allowing the plate to dry before the second development.
The R^ values of standard steroids in this system are shovm in Table 2.IV.
3
The radioactive area, representing H-testosterone added initially to the 
urine, was located by radiochromatographic scanning and again the silica 
over the area was transferred to a 'thimble vac’. The steroid material 
was eluted from the silica with ethyl acetate ( 3 x 2  ml) and dichloromethane 
( 3 x 2  ml) into a conical centrifuge tube (10 ml). The purified extract 
was dried under nitrogen in a water bath at 40°C and placed in a vacuum 
desiccator for one hour.
The dried residue was subsequently dissolved in dichloromethane (1 ml) 
and esterified with heptafluorobutyric anhydride (50 pi) at room temperature 
for 30 minutes. Excess reagent was removed under a stream of nitrogen at 
room temperature. The dried esters were then applied to a silica thin layer 
plate using ethyl acetate (2 x 20 pi) and acetone (2 x 20 pi) and the thin
m 36 *"
layer plate was developed in the solvent system cyciohexane:ethyl acetate 
(1:1, v/v) for one hour. values of standard steroids in this system
are shown in Table 2.V. The thin layer plate was scanned using a radio- 
chromatogram scanner and the area of the peak corresponding to standard 
tritiated testosterone-lT^HFB was located and the silica of that area 
transferred to a ‘thimble vac'. The steroid was eluted from the silica with 
ethyl acetate ( 3 x 2  ml) and then acetone ( 3 x 2  ml) into a conical centri­
fuge tube (10 ml) and the extract dried under nitrogen in a water bath at 
40°C. The extract was redissolved in ethyl acetate (dried over anhydrous 
magnesium sulphate) (50 pi). An aliquot (5 pi) was then removed for liquid 
scintillation counting to permit assessment of the overall recovery.
QUANTITATION OF TESTOSTERONE IN URINE
Standard amounts of testosterone«17-heptafluorobutyrate and
androsterone-3“heptafluorobutyrate were injected daily prior to sample
analysis. A known amount of andrcsterone.-lîFB was injected as an internal
standard together with 5=^ 8 pi of the esterified urine extract. Quantitation
of the testosterone-17'='HFB in the test samples was made by comparison of
the ratios of the peak area of the standard testosterone«17-HFB to the peak
area of the standard androsterone-HFB with the peak area of testosterone-
17-HFB in the urine extract to the peak area of androsterone-3-HFB added as
the internal standard. Correction was made for the aliquot injected, and
3for the experimental recovery as estimated by the recovery of H-testosterone
3
added initially to each sample. The mass of H-testosterone-HFB injected 
into the GLC system with the urine extract was deducted when significant.
The results were corrected to the total 24-hour urine volume. An example 
of the estimation of testosterone in a urine sample is given in Figure 
2.15 and the accompanying text.
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Figure 2.15 The estimation of testosterone in urine.
GLC-ECD tracing of a urine extract from a 
patient with bilateral undescended testes,
A, Standard trace
2
12.5 ng A-HFB gives a peak area of 699 mm .
5 ng T-HFB gives a peak area of 1,477 ram .
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B. Urine extract
2
12,5 ng of the internal standard A*»HFB gives a peak area of 603 mm . 
Since this peak area differs from that obtained in the standard 
trace (Figure 2.15A) the corresponding peak area for 5 ng' T-™HFB 
in the second trace is therefore;
1,477 X 603 2
1
2
But the peak area of native T-HFB in the second trace is 1,020 mm . 
Therefore there are
ng T“HFB in the sample injected (9.8 |il of 100 pi)
and 699 x 5 x K020 x 100 _ ., . . ,
urine residue.
Now ^/lO of the residue v/as removed for calculation of recovery.
The recovery was 27.95 per cent,*
Therefore if the recovery of the native steroid is equivalent to the
3
recovery of ‘ H-T added to the urine, then there were
699 X 5 X 1/020 x 100 x 100 x 10 ng of testosterone in the
1,477 X 603 X 9.8 x 27,95 x 9 urine extract (100 ml).
The total 24-hour urine volume was 1,540 ml.
Therefore there are 699 x 5 x 1,020 x 100 x 100 x 10 x 1,540
- ng1,477 X 603 X 9.8 X  27.95 X 9 x 100 
of testosterone excreted per 24 hours;
ie 699 X 5 x 1,020 x 1,540 _ , . . , ,|jg Qf testosterone excreted per
■ * " ' 24 hours ;
ie 2.501 ug of testosterone oer 24 hours.
* Low recovery* Normal recovery range 40^60 per cento
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DETERMINATION OF URINARY ANDROGEN METABOLITES 
The persistent use of 17*oxosteroid excretion assays in clinical 
medicine is attributed to historical and technological factors rather than 
endocrinological rationale. The urinary ll-deoxy-iy-oxosteroids CC^^O^ 
steroids) of gonadal origin are measured with identical metabolites 
derived from the adrenal secretion of dehydroepiandjrosterone sulphate. The 
urinary ll-oxo-17-oxosteroids (C^gO^ steroids) have an entirely different 
origin and significance (Goldzieher and Beering, 1969) being metabolites of 
corticosteroids and ll(3'-hydroxyandrostenedione, and yet these latter are 
included in the determination of total urinary 17-oxosteroids. The 
estimation is further complicated by the non-specificity of the Zimmermann 
colour reaction. This non-specificity has been found misleading in the study 
of various endocrinological states (Mahesh et al., 1964; Gleispach et al., 
1969).
As the total urinary 17»*oxosteroid excretion in children is low and, 
moreover, the urinary excretion of 17-oxosteroids in the patients selected 
was likely to be subnormal, a method to quantitate individual androgens and 
androgen metabolies in such patients must have both sensitivity and spécifiait 
A fractionation of 17-oxosteroids subsequently separately quantitated by the 
Zimnierraann colour reaction (Kellie and Wade, 1957; Vestergaard and Claussen, 
1962) was dismissed as the method had insufficient sensitivity and specificity 
In the last decade many methods, which estimate the majority of urinary 
steroid metabolites important for differential endocrinological diagnosis, 
have been published. Most of these methods utilise gas-liquid chromatography 
as the only chromatographic separation (Haahti ^  al_. , 1961; Sparagana ^ , 
1963; De Paoli Jil. v 1963; Ruchelman and Cole, 1966; Van K.ampen and Hoek,
1967; Horning et , 1969). The method used in this investigation
utilises gas^liquid chromatography as the only chromatographic step although 
significant initial purification is given to the urinary extract. The method
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was developed for routine analyses of urinary androgen metabolites with a 
view to assisting in the diagnosis of patients with various gonadal problems. 
A flow diagram of the method is shown in Figure 2.16.
HYDROLYSIS OF URINARY CONJUGATES
The principal problem in the analysis of urinary steroids is the method
of hydrolysis (Cawley ^  , 1965), Most methods employ p-glucuronidase
1
hydrolysis and subsequent acid hydrolysis of steroid sulphates. Hydrolysis 
of both conjugates in one step by perchloric acid in anhydrous tetrahydrofuran 
(Jacobsohn and Lieberman, 1962; De Paoli ejt al^ *, 1963) was advanced as a 
method of quantitative hydrolysis of 17-oxosteroids. Subsequent utilisation 
of this hydrolysis (Berret and McNeil, 1966; Matthijssen and Goldzieher, 1971) 
has revealed contaminating substances which prevent accurate quantitation of 
the 17-oxosteroids. Horning ^ . (1969) used enzymic hydrolysis utilizing 
both the p-glucuronidase and sulphatase activity of their enzyme preparation.
As the p-glucuronidase powder prepared in this laboratory and used in 
this investigation was known to have significant sulphatase activity, the 
powder was used as the basis for enzymatic hydrolysis.
Tlie hydrolysis of androgen conjugates in urine (100 ml) was effected 
at pH 4.6 by incubation with (3-glucuronidase (750 F,u. per ml urine;
75,000 F.u.) for 72 hours at 37^C. The pH was maintained by the addition 
of 2 M acetate buffer (10 ml). The sulphatase activity of the enzyme was 
not inhibited. Following hydrolysis the urine v/as extracted ( page 91). 
Evaluation of the Hydrolysis Method
The potency of the (B-glucuronidase preparation used throughout this 
investigation was estimated using phenolphthalein glucuronoside as substrate. 
The enzyme preparation was also known to have significant sulphatase activity, 
estimated using radioactively labelled dehydroepiandrosterone sulphate as 
substrate (Figure 2.12).
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Figure 2.16 Flow diagram of procedures used in the
estimation of urinary androgen metabolites
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Conjugates of epiandrosterone were used as representative of urinary 
androgen conjugates to assess the efficiency of the hydrolysis technique.
The following experiment was undertaken. Flasks were set up in duplicate 
containing: epiandrosterone (30 pg) in water (50 ml); epiandrosterone-3“
glucuronide (30 pg) in water (50 ml); epiandrosterone-3-sulphate (30 pg) 
in water (50 ml); epiandrosterone (10 pg), epiandrosterone-3-glucuronide 
(10 pg) and epiandrosterone-3«sulphate (10 pg) in water (50 ml); and 
control flasks containing water (50 ml). To all flasks were added 2 M 
acetate buffer (5 ml) and p-glucuronidase (750 F.u. per ml) (37,500 F.u.).
The pH was adjusted to 4.6 and all flasks were incubated at 37°C for 72 
hours. Free epiandrosterone in the flasks was extracted with diethyl ether 
(2 X 50 ml). The extracts were dried under a stream of nitrogen in a water 
bath at 40^0. Assay of epiandrosterone was by the Zimmermann reaction using 
epiandrosterone (30 pg) as the standard. The results are shown in Table 2.VI. 
Under the hydrolysis conditions used in this investigation there was 97 per 
cent hydrolysis of the glucuroside conjugates, 81 per cent hydrolysis of the 
sulphates and negligible destruction of free epiandrosterone. Thus this 
method of hydrolysis is adequate for the hydrolysis of androgen conjugates 
in urine.
Extraction and Preliminary Purification of Hydrolysed Urine
The hydrolysed urine was filtered through Whatman GF/A glass fibre 
filter into a separating flask (500 ml). / l,2,6,7-^H_/Testosterone (S.A.
87 Ci/mM, 36 nCi) was added to the filtrate for recovery purposes. The 
filtrate was extracted with diethyl ether (4 x 100 ml). The extract was 
reduced to small volume under nitrogen in a water bath at 40^C and washed 
back into the empty extraction flask with diethyl ether (100 ml). The 
diethyl ether was washed with 5 M sodium hydroxide (10 ml) and deionised water 
(20 ml) and water washing repeated until the washings were neutral to pH 
indicator paper. The extract was dried under nitrogen in a water bath at 40^0
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TABLE 2.VI RECOVERY OF EPIANDROSTERONE FROM VARYING AMOUNTS OF EPIANDROSTERONE 
(EpiA), EPIANDROSTERONE GLUCURONOSIDE (EpiA-G) AND EPIANDROSTERONE SULPHATE 
(EpiA-S) ADDED TO WATER (50 ml) AND INCUBATED WITH p“GLUCURONIDASE (750 F.u. 
per ml) FOR 72 HOURS AT 37°C. ASSAY WAS BY THE ZIMMERMANN REACTION.
Test
Optical Density @ 
Wavelength (nm)
435 515 595
1
AC AC-RB
Percentage 
Recovery 
of EpiA
Reagent Blank 023 028 013 010
000
020 024 008 010
Standard EpiA 214 485 219 268
(30 |ig) 262
218 486 202 276
Incubated EpiA 217 473 208 260
(30 \ig) 256 97.7
217 488 215 272
Incubated EpiA-G 219 485 199 276
(30 pg) 254 96.9
228 473 214 252
Incubated EpiA“S 202 418 196 219
(30 p.g) 212 80.9
200 420 189 225
Incubated EpiA + 219 452 206 239
EpiA" G + EpiA'-S 234 89.3
(10 pg each) 232 470 209 249
■.............. . _ ,
AC = Allen correction (Allen, 1950) 
RB -• Reagent Blank
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The recovery of H-testosterone added initially to the urine samples 
indicated that recovery of free androgens (testosterone) after extraction 
was 99.4 per cent.
The dried extract was redissolved in 70 per cent (v/v) methanol in 
water (10 ml) and partitioned against hexane (10 ml) to remove lipids and 
other non-steroidal material (Oertel, 1961). The hexane layer was discarded 
and the aqueous methanol dried under nitrogen in. a water bath at 40°C.
ESTERIFICATION OF STEROIDS
Derivatives of androgens have been used to facilitate electron capture 
detection, to exaggerate molecular shape of epimers and to decrease retention 
times on selective phases. The major 17-oxosteroids have been separated by 
gas-liquid chromatography as the free compounds (Haahti ^  aJL., 1961;
De Paoli ejk , 1963; Van Kampen and Hoek, 1967), as trimethylsilyl ethers 
(Van den Heuvel et al., 1962; Hartman and Wotiz, 1963; Horning et al., 1969), 
as ethylene-thioketal derivatives (Zmigrod and Lindner, 1966) and as 
chloromethyldiniethyIsilyl ethers (Matthijssen and Goldzieher, 1971).
In this investigation the heptafluorobutyrate derivatives of androgens 
and androgen metabolites were prepared. Conditions of derivatization were 
those developed for plasma and urinary testosterone derivatization. 
Estérification of Urinarv Extracts
Dried residues were placed in a vacuum desiccator for one hour. The 
residues were dissolved in dichloromethane (2 ml) and esterified with 
heptafluorobutyric anhydride (TOO pi) at room temperature for 30 minutes.
Excess reagent was removed by evaporation to dryness at room temperature 
under nitrogen. These reaction conditions favour estérification at hydroxyl 
groups but prevent enol formation (and thus estérification of A^-3-oxosteroids) 
Dried esters were then dissolved in hexane (2 ml) and partitioned against 
70 per cent (v/v) methanol in water to remove unesterified steroids. A 
recovery of 87 per cent radioactivity from the hexane fraction at this stage 
indicated a near total estérification of testosterone.
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Preparation of Standard Androgen Heptafluorobutyrates
A standard solution containing 5o:»androstane"*3cx, 17p-diol (1 mg),
5
Sp-androstane-Sa, 17(3-diol (1 mg), A -androstene-3(3 , lYp-diol (1 mg), 
5a-androstane-3p, 17(3--diol (1 mg), androsterone (1 mg), aetiocholanolone 
(1 mg), dehydroepiandrosterone (1 mg), epiandrosterone (1 mg), 
lip-hydroxyandrosterone (1 mg), ll(3-hydroxyaetiocholanolone (1 mg) and 
radioactively labelled / la,2a-^H_/androsterone (S.A. 40 Ci/mM, 20 nCi) 
was prepared in dichloromethane (5 ml). The steroids in this solution 
were esterified with heptafluorobutyric anhydride (100 pi) at room temperature 
for 30 minutes. Excess reagent was removed by evaporation to dryness at 
room temperature under a stream of nitrogen. The dried esterified steroids 
were dissolved in ethyl acetate (5 ml). An aliquot (100 pi) was applied to 
a silica thin layer and, after the application of standard androsterone and 
androsterone~3“heptafluorobutyrate, the TLC plate v^ as developed in the solvent 
system cyclohexane: ethyl acetate (1:1, v/v). The standard steroids were 
located under UV light (356 nm) after spraying with Rhodamine 6G (0.1 per 
cent, w/v, in ethanol). The 'ILC plate was radiochromatographically scanned 
and the areas of radioactively labelled androsterone and androsterone-3- 
heptafluorobutyrate were scraped from the plate and transferred to a counting 
vial. The percentage estérification was calculated from the results of 
liquid scintillation counting of these samples. A conversion of 92 per cent 
androsterone to auidrostercne-S-heptafluorobutyrate (as representative of 
the standard androgens) is achieved by this method.
GAS LIQUID CFROMATOGRAPHY
Liquid phase and operating conditions for the GLC method were required 
by which separation of the steroid esters present in the sample could be 
effected. After several liquid phases had been tested, the highly polar 
polyester, neopentyl glycol sebacate (N.G.Seb.) was chosen as this gave 
baseline separation of the steroid heptafluorobutyrates studied. Hartman 
and Wotiz (1963) described this liquid phase for separation of
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trimethylsilyl ether derivatives of androgen and progesterone metabolites,
A five-foot column with 3 per cent coating of temperature stabilized 
N.G.Seb. on Gas Chrom Q, 100^120 mesh, was prepared by the filtration method 
in vacuo previously described. The column v/as conditioned for 24 hours at 
220°C with a carrier gas flow rate of 60 ml per minute.
The following parameters were regulated for operation of FID. The 
column temperature was operated isothermally at IQO^C, and the injection 
port heater maintained at 220^C. The gas flow rates used with FID were: 
oxygen-free nitrogen (carrier gas) - 40 ml per minute; hydrogen « 40 ml per 
minute; air - 650 ml per minute.
Prior to the analysis of each group of samples, a known amount of the 
HFB-esters of standard steroids was injected into the gas chromatograph 
using a 10 pi S.G.E. micro-syringe. The average retention time for the 
last compound llp-bydroxyaetiocholanolone was 150 minutes and for the internal 
standard (5cc-dihydrotestosterone«17"heptafluorobutyrate) 45 minutes (Figure 
2.17). For the test samples 5“» 10 jil of the derivatized sample extract was 
used. The peaks were identified by comparing their relative retention 
times with those of the standard steroids (Figure 2.18).
Linearity of the Detector
Linearity of the detector response was determined using peak areas 
calculated from the product of the peak height and the width of the peak at 
half peak height. The internal standard, 5a-dihydrotestosterone«17-HFB, 
was injected with each sample. Although the response for the 
heptafluorobutyrates of 5a-androstane-3a,170-diol, androsterone and 
113-hydroxyandrosterone (as representative of the standard steroid esters) 
and also the internal standard, Sa-dihydrotestosteronc-17-T-ÎFB, was proportional 
to the amount injected (Figure 2,19), the response of individual steroid 
esters was slightly less so. Thus the relative response (tlie ratio of the 
peak area of each standard steroid HFB to the peak area of the same amount
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Figure 2.17 Gas liquid chromatographic analysis with flame 
ionization detection of a standard mixture of 
esterified androgen metabolites and the internal 
standard, Scc-dihydrotestosterone-’HFB (compound 9)
KEY: . 1 5a-Androstane-3a,ITp-dioi-HFB
2 Sp-Androstanc'-'Sa, 17(3-diol-HFB
3 A^“Androstene“3(3, i7p-diol“HFB
4 5a«Androstane"’3(3,17{3-diol-HFB
5 Androsterone-HFB
6 Aetiocholanolone-HFB
7 Dehydroepiandrosterone-HFB
8 Epiandrosterone-I-IFB
9 5a«Dihydrotestosterone-HFB (internal standard)
- yy M
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I I Injected: 200 ng each androgen
Sfead: Wain
□ □□D
f
4
CLC-FID 
T WtlNE EXTRACT HFB 
AManuatkm 2xM *
- -  Amount InieeM  Ü  j
Figure 2.18 Gas liquid chromatographic analysis with flame 
ionization detection of an esterified standard 
mixture of androgen metabolites (A) and a 
derivatized urine extract (B). Peaks were 
identified by comparison of their relative 
retention times with those of esterified standards
Peaks 1 to 9 were identified on the previous page 
(Figure 2.17).
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Figure 2.19 Linearity of the flame ionization detector to 
varying concentrations of 5a«diol (A), 
androsterone (B), ll(3*-*hydroxyandrosterone (C) 
and 5a<«dihydrotestosterone (D) determined from 
peak area measurements.
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of internal standard) was used in the quantitation of androgen metabolites. 
The relative response for each steroid ester ivas calculated from 50 GLC 
tracings of the mixture of HFB derivatives of standard steroids used at 
various times throughout this investigation (Table 2.VII). The 
coefficient of variation for different steroid esters ranged between
4.5 per cent and 9 per cent indicating satisfactory reproducibility of 
the method. ^
Quantitation of Urinary Androgen Metabolites
Prior to the analysis of each group of samples, a known amount of 
HFB-esters of standard steroids was injected into the gas chromatograph.
A known amount of 5a«dihydrotestosterone“17-HFB was injected as an 
internal standard together with the esterified urinary extract. Quantitation 
was made by comparison of the peak area of steroid HFB in the sample to the 
peak area of the internal standard injected with the sample, with the 
inverse of the relative response (ie peak area of internal standard 
injected with standard to peak area of standard steroid HFB), Correction 
was made for the aliquot injected, and for the percentage recovery as
3
estimated by the recovery of H-testosterone added initially to the samples. 
The results were corrected to the total 24-hour urine excretion. An 
example of the estimation of androgen metabolites in a urine sample is 
given in Figure 2.20 and the accompanying explanatory text.
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TABLE 2.VII THE RELATIVE RESPONSE OF THE HEPTAFLUOROBUTYRATS ESTERS OF 
STANDARD STEROIDS (50 SEPARATE GLC-FID ANALYSES)
Steroid
5a:-Androstane-3a,17p“diol
Mean
1.154
Relative Response*
Coefficient
0.070
of Variation
6.061
5p-Androstane~3a, 17(3-diol 1.115 0.058 5.202
A -Androstene-3pjIVp-diol 0.968 0.067 6.920
5cx-“Androstane“3p ,173~diol 1.385 0.098 7.074
Androsterone 1.013 0.075 7.404
Aetiocholanolone 1.074 0,047 4.376
Dehydroepiandrosterone 0.869 0.051 5.869
Epiandrosterone 1.117 0.063 5.640
llp-Hydroxyandrosterone 1.003 0.046 4,586
lip'"'Hydroxy aetiocholanolone 0.621 0.053 8.535
* Relative to the internal standard 5oC“dihydrotestosterone-i7“HFB
- XUl "
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Figure 2.20 The calculation of urinary excretion of androgen
metabolites. GLC-FID tracing of a urine extract from
a patient with delayed puberty.
A. Standard trace
2
200 ng of 5CT-DHT-HFB gives a peak area of 504 mm". The relative 
response (ratio of the peak area of standard steroid to the peak 
area of the internal standard) for each standard steroid ester was
102a -
5a-Androstane-3a,I73*dibl 1.198
5p"Androstane“3a,17p"diol 1.187
A^-Androstene-“3p ,176“diol 0.905
50C“Androstane-33 ,17p~diol 1.037
Androsterone 0.902
Aetiocholanolone 1.181
Dehydroepiandrosterone 0.806
Epiandrosterone 0.984
B. Urine extract
200 ng of 5a~DHT-HFB gives a peak area of 488 Since this peak area
differs from that obtained in the standard trace (Figure 2.20A) the 
corresponding peak area for 200 ng of steroid ester in the second trace 
is therefore:
488 X Relative response (RR)
But the peak areas of native androgen metabolites in the second trace 
(AREA) are:
5oc-Androstane-3oc, 17p--diol 
5(3~Andros tane'-Sa, l7P"diol 
A^-Androstene-30,17p-diol 
5a»Androstane-3p,17p«diol 
Androsterone 
Aetiocholanolone 
Dehydroepiandrosterone 
Epiandrosterone
Therefore there are 200 x AREA ng of steroid-HFB in the sample injected
488 x"RR (8.1 El of 100 gl),
and 200 x AREA x 100 . ^
— “"dd-------- — ng of steroid“HFB in the urine residue.
M O O  X  KK  X  o * J.
3
But /lO of the residue were removed previously for calculation of 
recovery and percentage esterified. Tiie recovery was 87.49 per cent 
and 88.4 per cent was esterified. Therefore if the recovery of the
3
native androgen metabolites is equivalent to the recovery of H-T 
added initially to the urine, then there were
40
2
mm
312 2mm
8
2mm
45 2mm
062 2mm
650 2mm
351 2mm
60 2mm
JLU^S
of steroid in the urine extract (100 ml)
488 X RR X  8.1 X  87.49 X 7 X  88.4
The total 24-hour urine volume was 1,280 ml 
Therefore there are
200 X A R M  X 100 x 100 x 10 x 1,280
488 X RR X 8.1 X 87.49 X 7 X 88.4 ° steroid excreted per 24 hours.
ie AREA x 0.1196  ^ . ., . . .
— --- ^ ---- - Eg of steroid excreted per 24^  hours.
Substitution then gives the following urinary excretions:
Eg per 24 hours
Sof-Androstane-Sci ,17p*™diol 4
5p-Androstarie»3a , 17p-diol 31
A^-Androstene-Sp,176-diol 1
5a"Androstane-3B,17p-diol 5
Androsterone 141
Ae tiocholano1one 66
Dehydroepiandrosterone 52
Epiandrosterone 7
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CLINICAL PROTOCOL FOR TESTICULAR FUNCTION TESTS 
It will be seen, in a subsequent chapter of this thesis (Chapter 3), 
that there are four results given for most urinary analyses and two 
results given for plasma analyses. At the clinical level these patients 
were given Human Chorionic Gonadotrophin (HOG) (6,000 X.U. intramuscularly 
at 6 am daily) for three days after the collection of a basal 24-hour 
urine sample and peripheral venous blood (20 ml|. Throughout the 
stimulation period 24-hour urine collections were made and a second 
sample of peripheral venous blood (20 ml) was taken on the third day of 
stimulation (ie the fourth day of test).
Blood was withdrawn between 11 am and noon, on the days of collection, 
into heparinized tubes, and the plasma ;^ as separated immediately by 
centrifugation. The plasma was either processed immediately or stored at 
-15°C until assayed. Urine specimens were collected in screw top bottles 
to which chloroform (5 ml) was added as a preservative. All collections 
were made under the supervision of the nursing staff.
Other forms of patient investigation (growth hormone response to 
insulin hypoglycemia, thyroid function tests and tests of the hypothalamic- 
pituitary axis) were carried out, when required, on the day preceding 
basal urine collection. The information derived from these tests has 
been used to support the thesis that by studying the nature of urinary 
testosterone metabolites in conjunction with the testicular ability to 
elaborate testosterone, an assessment of tissue sensitivity to (and 
probably dependence on) testosterone can be made.
The typical clinical protocol is given in Table 2.VIII.
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TABLE 2.VIII CLINICAL PROTOCOL USED FOR TESTICUIJVR FUNCTION TESTS
Day Test Day>*». tï&n Clinical Protocol
A Admission. Routine clinical tests.
Pretest Other investigations, as required,
Basal 24*”hour urine collection.
20 ml peripheral venous blood at 11 am..
D Day 1 24-hour urine collection. 
6,000 X.U. HOG IM at 6 am
Day 2 24-hour urine collection. 
6,000 Ï.U. HOG IM at 6 am.
Day 3 24-hour urine collection.
6,000 I.U. HCG IM at 6 am.
20 ml peripheral venous blood at 11 am,
G Discharge home.
— 105
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INTRODUCTION
In this work, plasma testosterone, urinary testosterone and most of the 
urinary testosterone metabolites have been assayed in the basal state and 
over a three-day course of human chorionic gonadotrophin (HCG; 6,000 I.U. 
intramuscularly daily at 6 am). These metabolites included the total 
17-oxosteroids, androsterone, aetiocholanolone, dehydroepiandrosterone
(DHA), epiandrosterone, Sa^androstanediol (5a-dfol), Sp-androstanediol
5 5(5p-dioi), A «androstenediol (A «diol) and 5a*»androstane-3p ,l7p«diol
(33-diol).
Additionally, for each compound a stimulation index was calculated by 
dividing the excretion on the third day of HCG stimulation by the basal 
level. Clearly values of this stimulation index above unity indicate 
increased excretion (stimulation) whilst values less than unity indicate 
decreased excretion (no stimulation) following HCG administration.
Since I was unable, for ethical reasons, to undertake a similar study 
on normal boys, I have utilized data reported in the literature for comparison
of the results from this series of ’abnormal* boysc
PATIENTS UNDER STUDY
The method for evaluating testicular function, as outlined in the
previous chapter, has been used to investigate several patients of abnormal
karyotype and some patients with various genital abnormalities. Of the 76 
cases presented, testicular function was assessed in 75 by their response 
to intramuscularly administered HCG* All urine collections, with the 
exception of those from one adult patient, were made in hospital under the 
supervision of the nursing staff.
The patients and their clinical conditions are tabulated in Table 3.1, 
Their ages ranged from 5 months to 26 years, although the majority were in 
the paediatric age range. The actual protocols for the patients are
- 107 «
TABLE 3.1 CLIÎ^ICAL CONDITION FOR miCH INVESTIGATION UNDERTAKEN
Genotype or phenotype No. of patientsj»Ta?AÆtt»?jWrt.tirT%Tnw r f r iT lm *  wt63iifaaMifln*«w«irtti>eafai<ree»*le5C*ttS3raae»
investigatedo*imual'Ë- n, "ipz, , ,
Testicular feminization syndrome (46,XY female) 4
Klinefelter*s syndrome (47,XXY)  ^ 1
Klinefelter's syndrome (46,XX) 1*
XO/XY syndrome (45,XO/46,XY) 2
XX/XY syndrome (46,XX/46,XY) 1
Short stature £er se 18
Short stature with hypogonadism (inicrogenitalia) 11**
Hypogonadism (microgenitalia clinically) 6
Hypogonadism with bilateral undescended testes 9
Hypogonadism with unilateral undescended testis 4
Delayed puberty 3
Cushing’s syndrome 4
Prader-Willi syndrome 3
Male Turner’s syndroms 2
Laurence-Mooi'i-Biedl syndroms 1
? Anorchia (clinically taadescended testes) 3
Precocious puberty 2
? Infertility 1
Post cyclophosphamide therapy (nephrotic syndrome) 1
* 1 patient re-investigated following therapy
** 2 patients re-investigated following therapy
- ruo -
collected in a later section of this thesis (Chapter 5). Patient
information, diagnosis and individual results of investigations are 
reported there. Patients in the text are thus identified by a protocol 
number.
URINARY CREATININE RESULTS 
Considerable fluctuation was found in the volumes of serial 24-hour
urine specimens from individual patients despite the well-organised ward
1
conditions for urine collection. The completeness of many specimens, 
particularly those from younger children, was therefore questioned* The 
daily urinary creatinine excretion was estimated on all 24-hour urine 
collections and that value used as a measure of the completeness of each 
collection. These results are shov^ i in Table 3.II»
From column E (Table 3.11), where the standard deviation (SD) for 
each group of urine collections is shown, it is clear that there was con­
siderable disparity in the daily urine volumes for many individuals* 
However, from analyses of the coefficient of variation (columns G and H, 
Table 3.11), it is clear that the urinary excretion of creatinine is a much 
more precise estimate of urinary volume completeness. Calculation of the 
mean values of columns G and H gave the mean coefficient of variation of 
urine volume and the mean coefficient of variation of daily creatinine 
excretion respectively. The mean coefficient of variation of urine volume 
was 29.52 per cent (SD - 11,66 per cent) and the mean value of the 
coefficient of variation of creatinine excretion was 16,84 (SD = 9.71 per 
cent). This difference is statistically highly significant (p<0.0001), 
justifying the use of the daily urinary excretion of creatinine as an index 
of the completeness of 24-hour urine collection in these patients.
When the patients investigated were grouped according to age, height 
and pubertal status, and the mean daily creatinine excretion (column D, 
Table 3.II) for each group plotted against the mean of the age group, 
interesting correlation was found. This is shown in the graph, Figure 3.1,
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Figure 3.1 The mean daily urinary creatinine excretion of patients 
grouped by age, height and pubertal status. The shaded 
area represents the mean - 1 SD of daily urinary 
creatinine excretion of patients with normal stature 
(height percentiles 10-90).
KEY: - o
- G
Patients with delayed puberty
Patients with small stature (height percentiles <^ 3) 
Patients with precocious puberty (height percentiles >9'
*■ 112 “
The shaded area o£ the graph represents the range (« 1 SD) of daily 
creatinine excretion for patients in the series of normal or near normal 
stature (height percentiles 10"90). This normal range of daily creatinine 
excretion is slightly lower, but not significantly different from those found 
by other workers (Clark et: ale, 1951; Applegarth et al., 1968). Note that 
the normal daily creatinine excretion rises throughout childhood and rapidly 
increases in parallel with the normal growth spurt at puberty. This rapid 
increase probably reflects the increasing muscle mass during adolescence.
The lower curve (Figure 3.1) represents the mean daily creatinine 
excretion in patients of short stature (height percentile <3)• The daily 
excretion of creatinine by such patients is significantly below normal 
throughout all the age groups studied (0.0005<p<0«05). It is of interest 
and probably of clinical significance that the creatinine excretion in these 
patients parallels, at a lower level, that of normal patients.
Also in Figure 3.1, the mean daily creatinine excretion in a group of 
patients with delayed puberty is also lower than normal. The creatinine 
excretion in these patients increases at the prepubertal rate and approaches 
the creatinine excretion found in older patients with short stature alone.
The creatinine excretion in these patients was significantly below normal 
(0.0l<p<0.05).
The two points above the normal range represent the creatinine excretion 
in two patients with precocious puberty. Individual creatinine excretions 
were significantly higher in these patients (0.002 < p < 0 . 02) than normal.
The creatinine excretion by these patients was more related to bone age.
The higher creatinine excretion in these patients is probably a combination 
of the early growth spurt and the increased androgens of adrenal and 
gonadal origin.
As expected from the above results, the urinary excretion of creatinine 
was significantly correlated with pubertal status (r - 0.680), age (r = 0,774) 
and bone age (r - 0.832).
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urinary 17-OXOSTEROÏD results
The excretion of 17*«oxosteroids was routinely estimated on all 24-hour 
urine collections to give an estimate of the amount of steroidal material 
present. The l7-oxosteroid response to ÎICG administered intramuscularly is 
shown in Table 3.III.
The basal excretion of l7™oxosteroids (column C, Table 3.Ill) is low 
in the majority of the patients investigated. This was particularly noted 
in patients in the adolescent age group. These values were analysed in 
relation to age, height and pubertal status. Owing to the small number of 
'near-normal* subjects investigated, normal values published by Prout and 
Snaith (1958) were used for comparison. It has been previously shown 
(Gray, 1973) that the values reported by these authors are not significantly 
different from normal values obtained in this laboratory (Royal Hospital for 
Sick Children, Yorkhill, Glasgow). Ti.e method nearest to that used in this 
investigation was used for comparison (ie method 4 of Prout and Snaith using 
spectrophotometric readings of the Zimmermann colour at three wavelengths and 
the application of the Allen correction).
The patients investigated were grouped according to age, height and 
pubertal status. In Figure 3.2 the mean basal 17-oxosteroid excretion for 
each group was plotted against the mean of the age group. The shaded area 
of the graph represents the range (-- 1 SD) of daily 17-oxosteroid excretion 
in the normal patients studied by Prout and Snaith (1958). The basal 
l7-oxosteroid excretion of all 'near-normal* patients in this investigation 
were within that range.
The basal urinary excretion of 17-oxosteroids in early prepubertal 
patients of short stature (height percentile <3) was not significantly 
different from the normal values of Prout and Snaith (1958). However, in 
older patients of short stature (8-11 years) the basal l7-oxos'teroid 
excretion was just significantly below normal (0.02<p < 0.05) whilst
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Figure The mean daily urinary 17-oxosteroid excretion by 
patients grouped by age, height and pubertal status. 
I'he shaded area represents the mean - 1 SD daily 
urinary 17-oxosteroid excretion by normal patients 
(Prout and Snaith, 1958).
KEY; O Patients with short stature (height percentiles<3)
O Patients with undescended testes
CJ Patients with hypogonadism (microgcnitali?.)
Patients with delayed puberty
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children in the early pubertalp pubertal and adolescent age groups (11-17 
years) with short stature had a basal l7“=oxosteroid excretion well below 
normale This difference is statistically highly significant (p<0.00005) 
and suggests reduced testicular function in patients of short stature.
The basal urinary excretion of l7«»oxosteroids by young patients (less 
than 8 years) with bilateral undescended testes was likewise not significantly 
different from normal. In the late prepubertal group (8^11 years) the urinary 
excretion of l7™oxosteroids by these patients was significantly below normal 
(0.02< p< 0«05) whilst in the early pubertal age group (11-14 years) the 
basal excretion of 17<->oxosteroids was well below normal. This difference 
is again highly significant (p< 0.00005) and indicates reduced testicular 
output of androgens in patients with undescended testes. No difference 
was noted in the urinary excretion of 17-oxosteroids between patients with 
unilateral and bilateral undescended testes.
The basal urinary excretion of 17-oxosteroids by young hypogonadal 
patients (micropenis, microscrotum with smaller than normal testes) was 
not significantly different from normal. In the late prepubertal age group 
(8-11 years) the urinary excretion of 17-oxosteroids by these hypogonadal 
patients was significantly below normal (0.0l< p <0.02) whilst in the early 
pubertal age group (11-14 years) the basal excretion of 17-oxosteroids was 
again very significantly reduced (p< 0.00005). These results indicate 
reduced testicular function and are in agreement with the clinical findings.
The basal urinary excretion of 17-oxosteroids in three groups of 
patients with delayed puberty (those aged 12-14 years with a pubertal stage 
of <2; those aged 14-16 years with a pubertal stage of <3 and those aged 
above 16 years with a pubertal stage of <4) was very significantly reduced 
(0.00005 < p< 0.001).
The urinary excretion of 17-oxosteroids was significantly correlated 
with age (r - 0,616), bone age (r = 0.596) and pubertal stage (r - 0.449).
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The shape of the curves in Figure 3.2 is worthy of note* The normal 
curve of Prout and Snaith (1958) shows a low l7-oxosteroid excretion for 
patients below 9 years. This then rises rapidly before puberty and continues 
to rise through the pubertal and adolescent ages. As the adrenal cortex 
is the main site of production of the precursors of the urinary 
l7“Oxosteroids before puberty, this rapid rise in the 17-oxosteroid 
excretion probably represents the phenomenon of *adrenarche*. By comparison 
the curves of the 17-oxosteroid excretion in the groups of patients 
investigated here show no rapid rise in either the prepubertal or pubertal 
period. It is pertinent, therefore, to comment that whatever the aetiology 
of the conditions investigated, there would seem to be impaired functioning 
of both the adrenal and the testis.
The response in l7“Oxosteroid excretion to HCG (6,000 I.U, per day) 
is remarkably variable. Of the 72 patients investigated, the response 
(columns D, E and F, Table 3.111) was increased, above the basal excretion, 
in 38 patients (52.78 per cent). No response occurred in 4 patients (5.56 
per cent), whilst for the remaining patients (41.66 per cent) there was a 
diminished excretion below basal levels.
To facilitate further study of the effect of HCG on the various
phenotypes, the patients investigated were grouped according to height 
and pubertal status and the mean stimulation index calculated for each 
group. As it was considered unethical to give normal children HCG, patients 
investigated with *near-normal* phenotype were used for comparison.’ The 
results are shown in Table 3.IV,
It will be noted from this table that the excretion of l7-oxosteroids
by *near*”normal® patients is approximately trebled after HCG administration.
Although patients with short stature bad a subnormal increase in the 
excretion of 17-oxosteroids after HCG stimulation, this was not significantly 
different from the increase found in the *near-normalsubjects.
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TABLE 3. XV EFFECT OF HUMAN CHOI IONIC GONADOTROPHIN ON THE 
IV-OXOSIEROID EXCRETION BY DIFFERENT PHENOTYPES
Phenotype and Number stimulation Index*
(Mean - 1 standard error)
*Near-normal® phenotype (n = 7) 2,74 - 0.55
Small stature (n = 31) 1.59 - 0.53
Unilateral undescended testes (n - 6) 1.26 - 0.31**
Hypogonadism (n = 23) 1.00 :: 0.12**
Bilateral undescended testes (n = 16) 0.96 - Ooll*'
Delayed puberty (n = 6) 0.62 - 0.23**
* stimulation Index =
Basal J.7“Oxosteroid excretion
** Significantly different from *near™normal? phenotype
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Patients with unilateral undescended testes had a subnormal increase 
in l7“»oxosteroid excretion after HCG administration. The rise in 
l7-oxosteroid excretion in those patients was just significantly below 
normal (0.02< p<0c05) but not significantly different from that of patients 
with bilateral undescended testes. Patients with bilateral undescended 
testes had no rise in the excretion of 17-oxosteroids following HCG admini­
stration, This absence of response to HCG was significantly below normal
(0.01<p< 0.02).
Hypogonadal patients (patients with microgenitalia) also showed no 
response in the 17-oxosteroid excretion to HCG administration. This sub­
normal response was again significant (0«02< p<10.05).
Patients with delayed puberty had a decreased urinary excretion of 
17-oxosteroids following administration of HCG, This decreased excretion 
of 17-oxosteroids is very significant (0.002<p<0,005).
URINARY TESTOSTERQNE RESULTS
Several authors have reported normal values for the daily excretion of 
testosterone in children. Normal values obtained from a review of the 
literature are shown in Table 3,V. The values obtained in this investigation 
were compared to the normal values reported by Dalzell and ElAttar (1973). 
They used a GLC method for the analysis of urine samples.
Many investigators have been unable to detect testosterone in the urine 
of prepubertal children, Sandberg et al. (1964) could not detect urinary 
testosterone in prepubertal children using either spectrophotometry or gas 
liquid chromatography with flame ionization detection. Likewise, Eechaute 
ct ad, (1973), using a fluorimetric method, and Zurbrugg et al. (1965), 
using spectrophotometry, were unable to detect urinary testosterone in pre­
pubertal children, Rosner et ^1, (1965), using spectrophotometry, were only 
able to detect urinary testosterone in 60 per cent of prepubertal males,
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TABLE 3.V DAILY EXCRETION OF TESTOSTERONE IN NORMAL MALE CHILDREN
(fig per 24 hours)
(A Review of the Literature)
Age Range 
(Years)
Testosterone 
Hg/24 hrs 
Mean (Range)
Author(s)
(Method of Quantitation)
Prepubertal <  5 Degenhart et al, (1965)
(Double isotope derivative)
Prepubertal 12.2 (3-27.3) Verrfieulen (1966) 
(GLC » FID)
7-12
17-24
3.6
151
(0-15)
i 22
Rosner et (1965) 
(Colorimetry)
6“7 <  5 Zurbriigg ^  (1965) 
(Colorimetry)
5-12 0—2.9 Rudd et al. (1973)wtuusw mr^3«9 ^
(Competitive protein binding)
4—8 0.4 (0.1-0.8) Vestergaard et al. (1966) 
(GLC ■» EGD)
6-13 
(3 pubertal)
1.3 (0.4-3,2) Pal (1971)
(Fiuorimetry)
9—11 0—14 Gupta (1967) 
(Colorimetry)
14-18 45-126 Ibayashi et al. (1964)* fk-Hunr» «jnukit*
(GW - F ID)
10 1.8 Brooks (1964) 
(GLC - FID)
Prepubertal
13-14
Not detected
4—180
Sandberg £t al, (1964) 
(GLC " FID)
4*»8
10-11
12
13
14
4
10
25
35
46
Knorr (1967)
(Spectrophotometry)
Testosterone with epitestosterone
6-11
11-12
13
14—16
17-19
6.3
8.2
31.3
125.9
106.0
Dalzell and ElAttar (1973)
(GLC - Dual Flame Ionization)
16—20
21—63
78.0
51.7
(60=103)
(40—64•5)
Ismail and Harkness (1966) 
(GLC - FID)
14-20
21-25
35.9
60.5
(25.3-46.5)
(36.7=84.3)
Schmidt and Starcevic (1967) 
(Spectrophotometry)
10-13
14
15-20
21-30
3.4
34.6 
37.9
71.7
Morer-Fargas and Nowakov/ski (1965) 
(S pe c t r ophoterne tr y)
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and Rudd (1973), using a competitive protein binding assay, could
only detect urinary testosterone in 80 per cent of their prepubertal males. 
However, Vernieulen (1966) detected urinary testosterone in all normal 
prepubertal children tested and Vestergaard et (1966) were able to detect 
very low levels of testosterone excretion in younger prepubertal children, 
using electron capture detection following GLC.
Only three groups have published normal results for testosterone 
excretion throughout the prepubertal, pubertal and adolescent periods. One 
of these (Knorr, 1967) unfortunately measured combined epitestosterone and 
testosterone whilst another (Morer-Fargas and Nowakowski, 1965) gives values 
from aged adult males with only a few prepubertal normal males, I have 
chosen the results of Dalzell and ElAttar (1973) for comparison of values 
obtained in this investigation, because their method and mine are most 
comparable.
The basal urinary excretion of testosterone for patients in this work 
is shown in column C, Table 3,VI. It will be noted there that the basal 
urinary excretion of testosterone is low in the majority of the patients, 
whilst extremely low levels (<1 pg per 24 hours) were found in 23 cases 
(41.1 per cent). These values of the basal urinary excretion of testosterone 
were analysed in relation to age, height and pubertal status. Owing to the 
small number of 'near^normal* subjects here investigated, the values recently 
published by Dalzell and ElAttar (1973) were used for comparison.
The patients were grouped according to age, height and pubertal status. 
The mean basal urinary excretion of testosterone of each group was plotted 
against the mean age of the group. This graph is shown in Figure 3.3.
It will be noted that the shaded area of the graph represents the range 
('"" 2 SD) of daily testosterone excretion calculated from the results of 
Dalzell and ElAttar (1973), This shaded area therefore represents, for the 
present purposes, the normal range of daily urinary testosterone excretion.
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Figure 3,3 The mean basal urinary testosterone excretion by
patients grouped by age, height and pubertoT status, 
The shaded area represents the mean ~ 2 SD of daily 
urinary testosterone excretion by normal subjects 
(Dalzell and ElAttar, 1973).
KEY: Patients with abnormal karyotype (protocols 3-9)
O Patients with short stature (height percent!3es< 3)
O Patients with bilateral undescended testes
Patients with hypogonadism (microgenitalia)
^ Patients with delayed puberty
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The basal urinary testosterone excretion of all *ncar™normal' patients here 
investigated are within these limits*
The shape of this curve is of interest. There is a low urinary 
excretion of testosterone for patients less than 12 years which nonetheless 
increases with age. In early puberty the excretion rate rapidly increases, 
later to rise very steeply during late puberty to reach adult levels by 
early adolescence.
1
The basal urinary excretion of testosterone by patients with short 
stature was extremely low and there was no rise during puberty. The 
excretion of urinary testosterone in these patients was significantly below 
the normal values of Dalzell and ElAttar (1973) during the prepubertal and 
pubertal age groups (O.OOOK p < 0.02) whilst in late puberty and adolescence 
the urinary testosterone excretion was highly significantly reduced 
(p< 0.00005) owing to the absence of the normal pubertal increase.
The aetiology of the short stature in these patients is known to be 
due to several factors and although no clinical subdivision is made here 
these factors will be considered individually later (Chapter 4), Eight of 
these patients (protocols 10“17) are known to have iiGH deficiency and the 
reduced urinary excretion of testosterone noted in these patients is suggestive 
of a strong correlation between hGH deficiency and impaired testicular 
function. However, since the majority of the patients with short stature 
are not hGH deficient, this indicates that at least part of the dwarfing in 
these patients may be related to a lack of androgen anabolic stimulus.
The basal daily urinary excretion of testosterone in patients with 
bilateral undescended testes is likewise subnormal and very similar to that 
seen in patients with short stature. In prepubertal patients with undescended 
testes the urinary excretion of testosterone is significantly (0.0000l< p <0.05 
below the normal range. In early puberty (12-^ 14 years) this excretion is 
likewise significantly (0.02 < p <  0*05) below normal and significantly
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(0.0Kp<0,02) below that seen in patients with unilateral undescended 
testes. The basal urinary excretion of testosterone in patients with 
unilateral undescended testes is likewise significantly subnormal 
(0.002<p<0*05) in all age groups studied and probably reflects the 
relative testicular hypofunction characteristic of such patients.
The basal urinary excretion of testosterone in patients with
hypogonadism (small testes, micropenis, microscotum) is likewise subnormal
1
throughout the prepubertal and pubertal age ranges (0.00005<p <0.05).
The mean urinary excretion of testosterone for these patients (4.12 (range 
0,3«-14.3) fig per 24 hours) is in good agreement with that found by Moxham 
and Nabarro (1968) in 11 'hypogonadal* subjects (5.7 (range 1“16.6) fig per 
24 hours).
The basal urinary excretion of testosterone in patients with delayed 
puberty is likewise subnormal, and it is at a prepubertal level. In patients 
with delayed puberty aged between 14 and 16 years the urinary excretion of 
testosterone is significantly below normal (0.002< p < 0.005) whilst in 
patients aged above 16 years this is highly significantly (p<0.00005) 
subnormal.
Four patients with the testicular feminization syndrome (protocols 1-4) 
all have a daily urinary excretion of testosterone in the low normal or 
normal range. The basal urinary excretion is not significantly below normal 
(0.05< p<0.20) and probably represents normal production of testosterone by 
the testes. The basal urinary excretion of testosterone in two patients 
with Klinefelter*s syndrome (XXY karyotype, protocol 8; XX karyotype, 
protocol 9) are significantly below normal (O.OOK p<0.02) and reflect the 
hypogonadism characteristic of these patients.
Again, the patients were grouped according to height azid pubertal 
status, and the mean stimulation index calculated for each group. Patients 
investigated with ^near-normal * phenotype were used for comparison. These 
indices are shown in Table 3,VII.
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TABLE 3.VII THE EFFECT OF HUMAN CHORIONIC GONADOTROPHIN 
ON THE URINARY EXCRETION OF TESTOSTERONE IN 
PATIENTS WITH DIFFERENT PHENOTYPES
Phenotype and Number  ^ S timu1at i on Index*
(Mean 1 standard error)
*Near«normal’ patients (n = 6) 2.46 « 0c57
Hypogonadism (n = 24) 1.73 i  0.26
Small stature (n “ 31) 1.74 « 0.21
Bilateral undescended testes (n = 16) 1.88 Z 0,26
Unilateral undescended testes (n = 6) 2.16 -  0.68
Delayed puberty (n = 6) 2*30 -  0.58
Testicular feminization syndrome (n - 4) 3.18 : 0.81
ip-W^i'X.Jartrt.UNlitWTJC'cTiirtJcWcTwfmngOauTsatgTitTtil^.'A.tmiagii I wi i,i ii » Hiii 1
* Stimulation Index » Urinary excretion of testosterone (3rd day) 
Basal urinary excretion of testosterone
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It will be noted from this table that the urinary excretion of 
testosterone by 'near^normal* patients in the investigation is increased 
two-and-a-half fold after HCG stimulation. Patients with other phenotypes 
have similar stimulation indices, not significantly different (0.30<p <0.90) 
from that of 'near^normal* patients. However, it is interesting that the 
stimulation of urinary testosterone following HCG administration in patients 
with hypogonadism is slightly lower than normal,whilst in patients with 
testicular feminization syndrome this stimulation index is slightly above 
normal. This high index probably reflects either the Leydig cell hyperplasia 
noted in this syndrome or the fact that testosterone is not metabolized by 
the tissues and therefore more is available for excretion unchanged.
PLASMA TESTOSTERONE RESULTS
Normal values for plasma testosterone in children, as reported in the 
literature, are given in Table 3.VIII. The results obtained in this investi? 
gation were compared to the normal values of Frasier £t _al, (1969) which 
they obtained using a double isotope dilution method of quantitation.
Reported levels of plasma testosterone in prepubertal children are very 
low and methods for testosterone quantitation must therefore be very 
sensitive. Thus Eechaute et al. (1973), using a fluorimetric method., and•itiWbur f
Sandberg ^  (1964), using flame ionization detection after gas-liquid
chromatography, were unable to detect plasma testosterone in prepubertal 
males. Similarly, the levels detected by Degenhart et £l. (1965), using a 
double isotope derivative technique, and Zurbriigg et ^1. (1965), using 
colorimetry, were below the sensitivity of the method. Dessypris and 
Adlercreutz (1972) and Rudd _al. (1973), using a competitive protein 
binding assay, could only quantitate plasma testosterone in some 75 per cent 
of the normal prepubertal children tested.
Van der Molen and Groen (1967), using electron capture detection of 
testosterone chloroacetate after gas-liquid chromatography, found low levels
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TABLE 3.VIII PLASMA LEVELS OF lIiSTOSTERÜNE IN NORMAL 
MALE CHILDREN AND ADULTS (ng per 100 ml) 
(A Review of the Literature)
Age Range 
(Years)
Testosterone 
ng/100 ml 
Mean (Range)
Authors 
(Method of Quantitation)
Prepubertal 16 (0-36) Dessypris and Adlercreutz (1972)
(Competitive protein binding)
5-13 0-40 Rudd et (1973)
(Competitive protein binding)
2-14 31.8 ™ 10 Saez and Bertrand (1968)
(Double isotope dilution)
0.3-12 25 Forest and Migeon (1970)
3-8 days 13.8 - 7.2 Forest et (1972)
1-10 6.58 - 2.48 (Radioimmunoassay)
Adult 565 - 146
1-10 15 Van der Molen and Groen (1967)
10-16 170 (GLC - BCD)
22-59 680
4“l0 42 - 9 Frasier and Horton (1966)
(Double isotope dilution)
2-5 8 Gandy and Peterson (1968)
5-8 13 (Double isotope dilution)
8-10 34
10—12 75
12—14 243
14^15 643
8 5 Wieland ^t (1970)
9 13 (Competitive protein binding)
10 43
11 94
12 124
14 604
5-9 18 — 4 Winter ej^  al. (1972)
9-11 33 - 6 (Competitive protein binding)
11—14 95 - 27
14—16 287 - 57
16-20 472 - 50
20-22 534 - 36
4-10 38 Frasier et ^1. (1969)
10«12 77 (Double isotope dilution)
12-13 262
13-14 235
14-15 327
15—16 494
Adult 660 - SO
” 131 ™
of plasma testosterone in prepubertal children. They noted that levels in 
older prepubertal children (above 10 years) were, however, greater. Further 
work by Gandy and Peterson (196S), using a double isotope dilution technique, 
gave similar low levels for children in the prepubertal age group. They 
found the levels of plasma testosterone began to rise between the ages of 
10 to 12 years and they correlated this with the increase in the size of the 
testes and vascularity of the penis which develop at this age. They found a
i
further, greater rise in plasma testosterone at puberty and noted that adult 
levels were reached by the time of ’young adolescence*,
Frasier ^  (1969), using a double isotope dilution technique, also
noted this prepubertal rise and the rapid rise at puberty, although they 
found plasma testosterone in young adolescents to be below adult levels. 
Likewise, Winter e^t cU. (1972), using a similar method of quantitation, 
studied plasma testosterone levels in the prepubertal, pubertal, adolescent 
and adult age ranges, and correlated these to the stage of pubertal development 
They noted the late prepubertal rise and related this rise to early testicular 
enlargement. They also found the large pubertal rise in plasma testosterone 
and found that adult levels were not reached below the age of 20 years.
Forest et (1972) studied plasma testosterone measured by a
radioimmunoassay technique, in neonates and in prepubertal males. They 
found higher levels just after birth (3-8 days) than in the prepubertal age. 
They also noted no significant difference between plasma testosterone levels 
in males and females in the prepubertal age,
August et (1972) correlated plasma testosterone with pubertal
development. They found low prepubertal levels and noted that the late 
prepubertal rise was correlated with early somatic pubertal changes.
Levels of plasma testosterone at puberty and during adolescence were similar 
to those found by Winter et al, (1972),
The basal level of plasma testosterone is shown in column G, Table 3.VI, 
These values of plasma testosterone were grouped according to patient age,
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height and pubertal status. The mean basal level of plasma testosterone 
of each group was plotted against the mean age of the group. This graph 
is shown in Figure 3.4. Owing to the small number of 'near-normal* subjects 
investigated, the values published by Frasier ^  ^1. (1969) were used for 
comparison following similar grouping.
It will be noted that the shaded area of this graph represents the 
range (- 2 SD) of plasma testosterone calculated from the results of Frasier 
et (1969). This shaded area therefore represents, for the present 
purposes, the normal range of plasma testosterone. The basal level of all 
•near-normal* patients here investigated is within this range.
The shape of this curve is of interest. There is a very low level of 
plasma testosterone in patients less than 11 years of age. This then 
increases rapidly throughout early puberty, puberty and adolescence to 
reach adult levels by approximately 20 years of age. The initial prepubertal 
rise in peripheral plasma testosterone concentration is consistent with the 
clinical observations that testicular size and vascularity of the penis 
also increase at this age.
The peripheral plasma concentration of testosterone in patients of short 
stature in this investigation (Figure 3.4) rose slowly from early childhood 
to adolescence. Although the mean plasma testosterone level was seemingly 
high in the younger age groups, the basal plasma testosterone in these 
patients was not significantly different (0.20< p <0.90) from the normal 
results of Frasier j^ t 3^,. (1969) at each age group measured.
The plasma concentration of testosterone in patients with bilateral 
undescended testes was quite variable. In patients aged between 4 and 12 
years the plasma testosterone concentration was not significantly different 
from normal, whi1st in the oldest patient with bilateral undescended testes 
(protocol 69, 12.1 years) the plasma testosterone concentration was signifi­
cantly raised (1,238 ng per lOO ml; p.c 0.0001).
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Figure 3,4
The mean basal plasma testosterone concentration in patients 
grouped by age, height and pubertal status© The shaded area 
represents the mean ® 2 SD plasma testosterone concentration 
in normal subjects (Frasier et al«, 1969).
As figure 3.4 A but following logarithmic transformation of 
results, to normalize the skewed distribution»
KBYî ©  patients with short stature (height percentile <3) 
O  Patients with bilateral undescended testes
©  patients with unilateral undescended testes
D  patients with hypogonadism (microgenitalia)
!,ri Patients with delayed puberty
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The plasma testosterone concentration in patients with unilateral 
undescended testes was also variable* In patients below 12 years the plasma 
testosterone levels were significantly raised (0.0002< p <0,005) whilst in 
older patients (above 12 years old) the plasma testosterone concentration was 
similar (p>0.80) to the normal levels of Frasier et al. (1969).
Raised plasma testosterone concentration in patients with undescended 
testes may arise from increased testosterone production by the cryptorchid 
testes owing to the increased ambient intra«»abdoniinal temperature or to the 
change in Leydig cells as described by Clegg (1961), However, as many of 
these patients have additional clinical features of hypogonadism such as 
micropenis and microscrotum, it is probable, whatever the aetiology of the 
elevated plasma testosterone concentration, that there is either an 
increased binding of testosterone in the plasma by testosterone binding 
globulin, thus preventing testosterone liberation, or there may be tissue 
insensitivity to testosterone. This latter might result in less degradation 
of circulating testosterone.
The plasma concentration of testosterone in patients with hypogonadism 
was similarly very variable. In young patients (4-10 years) the plasma 
testosterone levels were not significantly different from normal 
(0.20< p <0,80). Patients aged between 10 and 12 years with hypogonadism 
had a significantly raised plasma testosterone concentration (0.0002c p^Q.0005 
However, the expected rise in plasma testosterone concentrations did not 
occur at normal pubertal age and the plasma testosterone levels were then in 
the normal range. Again, it is probable that there could be either a tissue 
insensitivity to testosterone or an increased binding of testosterone in 
plasma in these hypogonadal patients who actually have adequate testosterone 
production.
As with older patients with hypogonadism, the mean plasma level of 
testosterone in patients with delayed puberty was not significantly different 
from normal (p>0,50)o
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Again, the patients were grouped according to height and pubertal status 
and the mean stimulation index calculated for each group. Again, patients 
investigated with ^near-normal® phenotype were used for comparison. These 
indices are shown in Table 3,IX,
It will be noted from this table that the peripheral plasma 
concentration of testosterone in *near-normal• patients in this investigation 
is increased approximately two-and-a-half fold following H(ÎG administration. 
Patients with other phenotypes have similar stimulation indices not 
significantly different (0.20<p <0,90) from that of ’near-normal® patients. 
However, it is interesting that the stimulation of plasma testosterone 
concentrations following HCG administration is above that of ’near-normal’ 
patients in all phenotypes with the exception of that of patients with 
delayed puberty. It is also interesting that the highest rise in testosterone 
concentrations following HCG is noted in patients with the testicular 
feminization syndrome. Again, the good increase in plasma testosterone 
concentrations seen in these patients following HCG administration is 
consistent with the Leydig cell hyperplasia often noted in association with 
this syndrome or the fact that testosterone is not metabolized by the tissues.
URINARY ANDROGEN METABOLITES 
The excretion of urinary androgen metabolites was studied in all of 
the 76 patients investigated. In two patients the study was repeated 
following treatment with HCG and HMG for one month. Complete results for 
individual patients will be found in a later section of this thesis 
(Chapter 5), To facilitate presentation of these results, individual 
steroids and groups of steroids (ll-deoxy™17-oxosteroids, the 
ll-oxo-l7-oxosteroids and thé dihydroxysteroids) will be considered 
separately.
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TABLE 3.IX THE EFFECT OP HUMAN CHORIONIC GONADOTROPHIN 
ON THE PLASMA CONCENTRATION OF TESTOSTERONE 
IN PATIENTS WITH DIFFERENT PHENOTYPES
Phenotype and Number S t imu I a t i on 
(Mean ™ 1 standard error)
’Near-normal’ phenotype (n - 4) 2.53 « Cell
Small stature <n = 31) 2.53 - 0.42
Hypogonadism (n “ 24) 2.75 «« 0,41
Bilateral undescended testes (n = 16) 2,67 « 0.58
Unilateral undescended testes (n = 6) 3.04 - 0.69
Delayed puberty (n - 6) 2,41 0,50
Testicular feminization syndrome (n - 4) 6.48 - 2.81
* Stimulation Index - Plasma concentration of testosterone (3rd day) 
Basal plasma concentration of testosterone
- 137 -
URINARY ll-DEOXY-17-OXOSTEROIDS
The daily excretion values for androsterone, aetiocholanolone and 
dehydroepiandrosterone are shown in Table 3.X« Corresponding values for 
epiandrosterone (3p™hydroxy-5a=androstane-17-one) will be considered 
separately (Table 3.XVI). In columns C, E and G (Table 3.X) are shown the
basal daily excretion rates of androsterone, aetiocholanolone and
■
dehydroepiandrosterone respectively. These basal levels are very variable
\
even for patients of similar age and phenotype (cf protocols 45 and 49). 
Generally, the daily excretion of androsterone was found to be much greater 
than that for aetiocholanolone. This, however, is the normal prepubertal 
pattern of excretion for these two steroids. The daily excretion of 
dehydroepiandrosterone is extremely low (<10 pg per 24 hours) in 11 patients 
and was not detected in a further 7.
On stimulation with HCG, the daily urinary output of these
ll-deoxy-l7"Oxosteroids was also noted to be very variable. However, the 
post-stimulation daily excretion of androsterone, aetiocholanolone and 
dehydroepiandrosterone in the ’near-normal® patients was not significantly 
different from and closely paralleled the rise in the daily excretion of 
the urinary 17-oxosteroids as assayed by the Zimmermann reaction.
To facilitate further analysis of the urinary ll-deoxy-17-oxosteroid 
excretion rates the values found in this study were compared with those 
reported by Vestergaard (1965), Paulsen et al. (1966) and Tanner and Gupta
(1968) obtained for normal children and adolescents. These normal values
are shown in Table 3.XI.
Androsterone
The patients were grouped according to age, height and pubertal status. 
The basal daily excretion of androsterone (column C, Table 3.X) for each 
group was plotted against the mean age of the group. This graph is shown 
in Figure 3,5.
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TABLE 3.XI EXCRETION OF INDIVIDUAL 11«DE0XY-17-0X0STER0IDS IN NORMAL
CHILDREN AT VARIOUS AGES*
Aetiocholanolone 
(lig/24 hr s)
Androsterone 
(lig/24 hrs)
Dehydroepiandrosterone 
(j.ig/24 hrs)
Age Range 
(years)
143 « 763-6 48 21 - 25
290 « 163 172 - 1056-9 57
13 = 16
9-13 418 - 302 253 - 161 lo i
42 42 = 42
1235 « 408 925 - 531 225 « 146
16+ 3950 - 240 2975 - 700 1490 - 1485
* Mean - 1 standard deviation calculated from combined 
results of Vestergaard (1965), Paulsen a^. (1966), 
and Tanner and Gupta (1968)
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riRure 3«f* The mean basal urinary androsterone excretion by
patients grouped by age, height and pubertal status. 
The shaded area represents the nean « 1 SD of daily
androsterone excretion by normal subjects as shown
in Table 3.XI.
KEY: 0  Patients v.ith short stature
O Patients with bilateral undescended testes 
©  Patients v/ith unilateral undescended testes 
CTJ Patients with hypogonadism (microgenitalia)
O  Patients v/ith delayed puberty
^ patients with abnormal karyotype (identified by 
protocol number)
It will be noted that the shaded area of the graph represents the 
range (« 1 SD) of daily androsterone excretion calculated from the combined 
results of Vestergaard (1965), Paulsen et (1966) and Tanner and Gupta 
(1968), as shown in Table 3.XI. This shaded area therefore represents, 
for the present purposes, the normal range of the daily androsterone 
excretion. The basal daily androsterone excretion of all *near“normal*
patients here investigated are within these limits.
i
The shape of this curve is of interest. There is a low, but increasing, 
daily excretion of androsterone for patients less than 9 years. This then 
rises more rapidly before puberty and at puberty there is a very steep rise 
in the daily androsterone excretion which then continues through adolescence 
to adulthood. As the adrenal cortex is the main site of production of 
androsterone before puberty, the initial prepubertal rise in androsterone 
excretion probably represents the phenomenon of 'adrenarche*, whilst the 
rapid pubertal rise in the daily androsterone excretion is probably more 
correlated to the increase in testicular secretion of precursors of 
androsterone.
It will be noted from Figure 3.5 that the basal daily excretion of 
androsterone in patients of short stature is very low and continues to rise 
at the prepubertal rate, there being neither adrenal nor testicular correlated 
rise. Below 6 years of age the basal daily excretion of androsterone in 
these patients, although very low, is not significantly different from the 
normal value (0.05< p< O.lO). In older prepubertal children of short 
stature (6-13 years) the daily excretion of androsterone is significantly 
below the normal range (0.0002< p < 0.005) whilst in the pubertal and 
adolescent age groups (13^20 years) this difference is statistically highly 
significant (0.00005 < p < 0,0005). Reduced testicular and/or adrenal 
function must be concluded,
llie basal daily excretion of androsterone in patients with bilateral 
undescended testes is likewise subnormal. Below 6 years of age, the daily
j.4 J
excretion of androsterone in these patients is extremely small (<20 pg 
per 24 hours) this being statistically significantly below normal 
(0.002< p <0.005). In older prepubertal children with bilateral undescended 
testes (6-13 years) the daily excretion of androsterone is significantly 
below normal (O.OOK p < O.Ol) and reduced testicular function must be 
concluded. Furthermore as no difference was found between the daily
androsterone excretion of a patient with bilateral undescended testes
i
(protocol 26, Table 3.X) and his two brothers following successful 
bilateral orchidopexy (protocols 27 and 28, Table 3.X) it must be concluded 
that although orchidopexy improves the spermatogenic potential of the testes 
abnormal steroidogenesis still persists.
The basal urinary excretion of androsterone in patients with hypogonadism 
(small external genitalia) is very low. Below 9 years of age the daily 
excretion of androsterone by these patients is significantly below normal 
(0.002< p < 0.005). In older prepubertal children the daily urinary 
excretion of androsterone is within the normal range whilst in hypogonadal 
patients of pubertal age (13-16 years) absence of a pubertal rise made this 
excretion significantly subnormal (0,Ol< p c 0.02).
The basal urinary excretion of androsterone in a group of patients with 
delayed puberty (aged. IS-^ 'lô years) is highly significantly below the normal 
range (0.0005< p <0.001). It is interesting and perhaps of clinical 
significance that this group of patients has neither adrenal nor pubertal 
correlated rises, whilst an older group of patients with delayed puberty 
had an adrenal but not a testicular correlated rise. The urinary . 
androsterone excretion in this group of older patients with delayed 
puberty was not significantly reduced (0.05< p<O.lO).
Tivo patients with the Prader-Willi syndrome (dwarfism, hypogonadism 
and obesity) (protocols 32 and 72, Table 3.X) had daily urinary androsterone 
levels within the low normal level for patient age, whilst one patient with
this syndrome and bilateral undescended testes had a subnormal urinary 
level of androsterone significantly below the normal level and equivalent 
to that found in patients with bilateral undescended testes. Similarly, 
a patient with the Laurence-Moon-Bledl syndrome with bilateral undescended 
testes had a basal daily urinary androsterone level equivalent to that 
found in patients with bilateral undescended testes.
Four patients with the testicular feminization syndrome (protocols 1-4)
1
all had daily androsterone excretion values within the normal range. The 
basal daily androsterone level in two patients with Klinefelter*s syndrome 
(protocols 8 and 9), although both below the normal range, were not 
significantly different (0.10< p <0.25) from normal. Similarly, the basal 
daily androsterone levels found in two patients with the XO/XY syndrome 
were within the lower normal range, whilst the basal daily urinary androsterone 
level in one patient with the XX/XY syndrome (protocol 5) was significantly 
below normal (0.02< p< 0.05).
The urinary excretion of androsterone was significantly correlated 
with age (r = 0,519), bone age (r = 0.610) and pubertal stage (r = 0.546).
To facilitate further study of the effect of HCG the patients were 
grouped according to height and pubertal status and the mean stimulation 
index calculated for each group. Patients investigated with 'near-normal’ 
phenotype were used for comparison. These indices are shown in Table 3.XII.
It will be noted from this table that the urinary excretion of 
androsterone by 'normal' patients in this investigation is increased 1.6 fold 
folloxving HCG stimulation. Patients of small stature (height percentile <3), 
having a very low basal urinary androsterone excretion, were found to have a 
very good increase in the urinary androsterone excretion after HCG 
stimulation. This was significantly above (0«02<p<0.05) the 'normal* 
stimulation values found in this investigation.
Patients with undescended testes, with hypogonadism or with delayed 
puberty, all had a good increase in the urinary androsterone excretion
- JU^ O
TABLE 3oXII EFFECT OF HUMAN CHORIONIC GONADOTROPHIN ON THE 
ANDROSTERONE EXCRETION BY DIFFERENT PHENOTYPES
Phenotype and Number Stimulation Index*
(Mean “ 1 standard error)
'Near-normal * phenotype (n = 7) 1.63 - 0.19
Short stature (n “ 31) 2.99 « 0.61**
Bilateral undescended testes (n = 16) 2.58 » 0.83
Hypogonadism (n - 24) 2.18 - 0.44
Unilateral undescended testes (n  ^6) 2.07 « 0.88
Delayed puberty (n = 6) 1.92 » 0.47
Testicular feminization syndrome (n = 4) 1.62 - 0.32
XO/XY syndrome (n = 2) 1,39 - 0.30
Klinefelter's syndrome (XXY, XX) (n = 2) 3.56 « 0.94**
XX/XY syndrome (n ~ 1) 1,18
* Stimulation Index = ary androsterone excretion (3rd day) 
Basal androsterone excretion
** Significantly above normal
after HCG stimulation from very low basal values. The stimulation of 
androsterone excretion in these patients was not statistically above that 
of the 'normal' patients investigated here. Thus it would appear that the 
primary failure in these patients is one of gonadotrophin lack and not 
testicular failure as such.
Four patients with the testicular feminization syndrome have a normal
increase in urinary androsterone excretion, after HCG, from normal basal
i
levels. It is interesting that in two patients with Klinefelter*s syndrome 
(protocols 8 and 9) with low normal basal urinary androsterone excretion, 
the response to HCG is significantly avbove normal (0.00005 < p < 0.0001),
In two patients with the XO/XY syndrome, having basal urinary androsterone 
excretions in the low normal range, the response to HCG stimulation is 
within the normal range. Similarly, a patient with the XX/XY genotype 
(protocol 5) has a normal response to HCG stimulation although the basal 
level is significantly below normal* Definite conclusions cannot be given 
here but these results will be further discussed later.
Ae t iocholanolone
Again, the patients investigated were grouped according to age, height 
and pubertal status. The basal urinary excretion of aetiocholanolone
(column B, Table 3.X) for each group was plotted .against the mean age of
the group. The graph is sho^ vn in Figure 3.6,
It will be noted that the shaded area of the graph represents the
range (mean - 1 SD) of the daily urinary aetiocholanolone excretion 
calculated from the combined results of Vestergaard (1965), Paulsen _et ^1. 
(1966) and Tanner and Gupta (1968), as shown in Table 3.XI. This shaded 
area therefore represents the normal urinary aetiocholanolone excretion.
The shape of this curve closely resembles that for the urinary androsterone 
excretion. Again, there is a lovf, but increasing, aetiocholanolone 
excretion rate during childhood. Between 11 years and puberty there is a
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Figure 3.6 The mean basal urinary aetiocholanolone cxcrcticn by 
patients grouped by age, height and pubertal status. 
The shaded area represents the mean « 1 SD of daily 
aetiocholanolone excretion by normal subjects as shown 
in Table 3.XI.
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Patients with hypogonadism (microgenitalia) 
Patients with delayed puberty
patients with abnormal karyotype (identified by 
protocol number)
more rapid increase in aetiocholanolone excretion, whilst at puberty 
there is a very rapid rise in the aetiocholanolone excretion rate which 
persists during adolescence until adult levels are attained. Likewise, as 
the adrenal cortex is the main site of production of aetiocholanolone 
before puberty, the initial prepubertal rise in the urinary aetiocholanolone 
excretion probably represents the phenomenon of *adrenarche*, whilst the 
rapid pubertal rise is probably correlated to the rise in testicular 
secretion of precursors of aetiocholanolone.
It will be noted from Figure 3.6 that the basal urinary excretion of 
aetiocholanolone in patients with short stature is very low and continues 
to rise at the prepubertal rate, there being neither adrenal nor testicular 
correlated rise. The basal urinary excretion of aetiocholanolone in these 
patients was significantly below normal (0.00005< p < 0.02) at all age groups. 
The basal urinary excretion of aetiocholanolone in patients with 
bilateral undescended testes is likewise subnormal. Below 9 years of age 
the urinary excretion of aetiocholanolone in these patients is significantly 
below normal (0,000l< p< 0.02) whilst in the older age group (9«13 years) 
the urinary excretion of aetiocholanolone remains significantly below normal 
(O.OK p<0.02) despite a significant (p ” 0.02) adrenal correlated rise.
No difference is found in urinary aetiocholanolone excretion between a 
patient with bilateral undescended testes (protocol 26, Table 3,X) and 
his two brothers following successful bilateral orchidopexy (protocols 27 
and 28, Table 3,X) and presumably testicular hypofunction persists.
The basal urinary excretion of aetiocholanolone in young patients with 
unilateral undescended testes is much higher, being in the normal range. 
However, absence of the normal pubertal rise causes the levels of 
aetiocholanolone excretion in these patients to be significantly below normal 
(O.OOK p <0,002) in older patients with unilateral undescended testes.
The basal urinary excretion of aetiocholanolone in patients with 
hypogonadism (small external genitalia) is very low. Below 9 years of age
the urinary excretion of aetiocholanolone in these patients is significantly 
below normal (0.00005< p <0,05) whilst in the older age groups (9«16 years) 
the urinary excretion of aetiocholanolone again remains significantly 
below normal (0.02 < p < 0.05) despite a very significant (O.OOK p< 0.002) 
adrenal correlated rise.
Hie basal urinary excretion of aetiocholanolone in a group of patients
with delayed puberty (aged 13-16 years) was highly significantly below
I
the normal range (OoOOOK p < 0,0002). It is again of possible clinical 
significance that this group of patients has neither adrenal nor pubertal 
correlated rises, whilst an older group of patients with delayed puberty 
had an adrenal but not a testicular correlated rise. The urinary 
aetiocholanolone excretion in this group of older patients with delayed 
puberty was still significantly subnormal (0.02< p< 0,05),
Two patients with the Prader^^Willi syndrome (protocols 58 and 72) 
have daily urinary aetiocholanolone levels significantly below normal 
(0*05< p< 0,10) whilst an older patient with this syndrome (protocol 32) 
has a low normal level. One patient with the Laurence^Moon-^Biedl syndrome 
with bilateral undescended testes has a basal urinary aetiocholanolone 
level equivalent to that found in patients with undescended testes.
Four patients with the testicular feminization syndrome (protocols 1-4) 
all have urinary aetiocholanolone excretions within the normal range.
The basal level of aetiocholanolone excretion in two patients with 
Klinefelter*8 syndrome (protocols 8 and 9) are significantly below normal 
(0,02< p < 0,05) and in agreement with the results of Johnsen (1956).
Basal urinary aetiocholanolone excretion in two patients with the XO/XY 
syndrome is very variable. One patient (protocol 6) has a normal daily 
excretion level whilst the other (protocol 7) has a just significantly 
subnormal excretion (0e05< p <0,10), The daily urinary aetiocholanolone 
excretion in a patient with the XX/XY syndrome is significantly subnormal.
The urinary excretion of aetiocholanolone was significantly correlated 
with age (r ” 0.685), bone age (r ~ 0,693) and pubertal stage (r = 0.613), 
Again, the patients investigated were grouped according to height 
and pubertal status and the mean stimulation index calculated for each 
group. The results found for patients with hiear-normal' phenotype 
were again used for comparison. The results are shown in Table 3,XIII.
It will be noted from Table 3,XIII that the daily excretion of 
aetiocholanolone by normal patients here is approximately increased 
1*7 fold following HCG stimulation. Although the stimulation index of 
urinary aetiocholanolone excretion is not significantly different from 
that of *near-normal* patients in each of the phenotypes studied, it 
will be noticed from Table 3.XIII that the levels found closely resemble 
those found for the urinary androsterone excretion. Thus patients with 
Klinefeltersyndrome and patients v/ith short stature (height percentile 
< 3) have, again, a very good stimulation of urinary aetiocholanolone 
excretion following HCG, whilst patients with the XO/XY syndrome have 
a poor increment in aetiocholanolone following HCG administration* 
Dehydroepiandrosterone
Ihe patients investigated were grouped according to age, height 
and pubertal status, as before. The daily basal urinary excretion of 
dehydroepiandrosterone (column G, Table 3,X) for each group was plotted 
against the mean age of the group* The graph is shov/n in Figure 3,7.
It will be noted that the shaded area of the graph represents the 
range (mecin - 1 SD) of daily urinary dehydroepiandrosterone (DHA) 
excretion calculated from the combined results of Vestergaard (1965), 
Paulsen _et aj.. (1966) and Tanner and Gupta (1968), as shown in Table 3,XI, 
This shaded area therefore represents the normal DHA excretion, during 
childhood, puberty and adolescence* It v/ill be noted that although the 
urinary excretion of DHA is much lower than that for either androsterone
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TABLE 3.Xin EFFECT OF HUMAN CHORIONIC GONADOTROPHIN ON
AETIOCHOLANOLQ^ro EXCRETION BY DIFFERENT PHENOTYPES
Phenotype and Numberrrj^ii II I !■! i i—nr r <[i r   i ~iir ii ■m inn miaa i iiiT i rn n iii
'Near^ ’-nomal* phenotype (n = 7)
1
Stimulation Index*
(Mean » 1 standard error)
1,69 •* 0.26
Short stature (n = 31) 3,07 - 0.71
Bilateral undescended testes (n = 16) 2.41 « 0.87
Delayed puberty (n ~ 6 ) 2,38 - 0.61
Unilateral undescended testes (n - 6 ) 2,31 « 0,40
Hypogonadism (n - 24) 2,31 Z 0,46
Testicular .feminization syndrome (n - 4) 2.09 0,59
XO/XY syndrome (n = 2)
Prader"Willi syndrome (n = 3)
1,59 - 0.42 
1,47 » 0,63
Klinefelter*s syndrome (n = 2)
XX/XY syndrome (n = 1)
7.35 - 3.50 
12.00
* Stimulation Index = Urinary aetiocholanolone excretion (3rd day) 
Basal urinary aetiocholanolone excretion
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Figure 3.7 The mean basal urinary dehydroepiandrostcrone excretion 
by patients grouped by age, height and pubertal status. 
The shaded area represents the mean - 1 SD of daily 
dehydroepiandrcsterone excretion by normal subjects 
as shown in Table 3.XI.
KEY:
O  Patients with short stature (height percentile ^ 3).
O patients with bilateral undescended testes.
□  Patients with hypogonadism (microgenitalia),
f) Patients with delayed puberty.
Patients with abnormal karyotype (identified by 
protocol number).
or aetiocholanolone, the general shape of the curve is very similar.
Again, there is a low, increasing daily DHA excretion during early child™ 
hood and a more rapid rise in the daily DMA excretion between 10 years and 
puberty. At puberty there is a very rapid increase which continues during 
adolescence to reach adult levels. It is probable that the initial 
prepubertal rise in urinary DHA excretion is correlated with increased
adrenal production of DMAS whilst the pubertal rise is probably related
1
to increased testicular activity.
It will be noted from Figure 3,7 that the basal urinary excretion of 
DHA in patients of short stature is very low, closely corresponding to the 
lower extremes of the normal range. Levels for these patients below 9 
years of age are not significantly below the normal levels of DHA excretion. 
However, the delay in the adrenal correlated rise causes the urinary 
excretion of DHA to be highly significantly below normal (0.0005< p <0.001) 
in patients with short stature aged 9-13 years, whilst in patients in the 
pubertal and adolescent age groups the urinary excretion of DHA remained 
significantly below normal (0.005< p < 0 .0 2).
The basal daily excretion of DHA in patients with bilateral undescended 
testes is likewise very low during early childhood. The basal excretion of 
DHA between 3 and 6 years of age is significantly below normal 
(0e0002< p < 0.0005), whilst in the next age group (6™9 years) it is just 
not significantly below normal (0-05< p < O.lO), Above 9 years of age the 
daily excretion of DHA is in the normal range in these patients and there 
appears to be a normal adrenal correlated rise in the excretion. Again, 
no difference was noted in the daily DHA excretion of a patient with 
bilateral undescended testes (protocol 26) and his two brothers following 
successful bilateral orchidopexy (protocols 27 and 28),
However, the basal daily excretion of DHA in patients with unilateral 
undescended testes in the prepubertal age group (9-13 years) is much higher.
being within the normal range, but absence of the normal pubertal rise 
causes the levels of DMA excretion in older patients (13-16 years) to be 
significantly below normal (O.OK p < 0.02),
The basal urinary excretion of DHA in patients with hypogonadism 
(small penis, small scrotum and microtestes) is within the normal range 
and increases normally with age. Similarly the basal urinary excretion 
of DHA in patients with delayed puberty, although at lower limits of normal, 
are not significantly different from normal (0 .1 < p < 0 .2 ).
Tlie basal daily excretion of DHA in three patients with the Prader-Willi 
syndrome (protocols 32, 58 and 72) is within the low normal range and 
appears to increase normally with age. One patient with the Laurence-Mocn- 
Biedl syndrome with bilateral undescended testes has a basal daily DMA 
excretion equivalent to that found in patients with undescended testes.
Four patients with the testicular feminization syndrome (protocols 1-4) 
all have a normal basal daily DHA excretion. The basal daily excretion in 
two patients with Klinefelter*s syndrome is just within the low normal 
range. Similarly, the basal DHA excretion in two patients with the XO/XY 
syndrome is within the low normal range. Tiie corresponding value in a 
patient with the XX/XY syndrome is just significantly below normal 
(0.05< p<0.10).
Many authors have disputed the presence of DHA in the urine of
prepubertal children. Paulsen ^  al.. (1966) could not detect DHA in the
urine of any child below 8 years. Similarly, Beas et (1962) found no
DHA in the urine of 5 boys aged 5 to 7 years. In this investigation
urinary DHA was not detected in 7 patients and very low levels (< 10 jig
per 24 hours) were found in a further 11 cases. It is interesting that 
6 out of the 7 patients with undetectable urinary DHA have undescended 
testes, and 6 out of the 11 patients with a very low urinary DHA excretion 
also have undescended testes. This is suggestive of a deficiency of 
17,20-desmolase in patients with undescended, testes.
X D D
The urinary excretion of DHA was significantly correlated with age 
(r = 0.394), bone age (r = 0.456) and pubertal stage (r = 0.462).
Again the stimulation index was calculated in respect of DHA 
excretion for each patient. The patients investigated were grouped 
according to height and pubertal status and the mean stimulation index 
calculated for each group. Patients investigated with ’near-normal’ 
phenotype were used for comparison. The results^are shown in Table 3.XIV, 
Here it will be noted that the daily excretion of DHA by normal 
patients in this investigation is approximately increased 1.8 fold following 
HCG stimulation. Note, too, that the stimulation index for the daily DHA 
excretion is very variable in patients with bilateral undescended testes 
and in patients with delayed puberty. Although the stimulation index of 
urinary DHA excretion is not significantly different from that of *near- 
normal* patients in each of the phenotypes studied, it will be noticed 
from Table 3.XIV that the levels found closely resemble (with the exception 
of those for patients with bilateral undescended testes and patients with 
delayed puberty) those found for the rise in urinary aetiocholanolone 
excretion following HCG (Table 3.XIII, page l5l).
Ratio of Androsterone to Aetiocholanolone
The principal end-products of androgen metabolism in man are the 
stereoisomers, androsterone and aetiocholanolone. They are formed in 
approximately equal quantities from the metabolism of the three main 
androgens, testosterone, androstenedione and dehydroepiandrostcrone, and 
thus the ratio of urinary androsterone to urinary aetiocholanolone. (A/Ae 
ratio) in normal subjects is approximately unity. (Baulieu and 
Mauvais-Jarvis, 1964; Johnsen, 1968),
Wilson and Schenker (1964) have shown that the A/Ae ratio is lowered 
by large doses of corticosteroids whilst Bradlow ^t (1956) found that 
the A/Ae ratio is dependent on the level of thyroid hormone, Johnsen (1968)
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TABLE 3.XIV EFFECT OF HUMAN CHORIONIC GONADOTROPHIN ON
DHHYDROEPIANDROSTERONE EXCRETION BY DIFFERENT PHENOTYPES
Phenotype and Number Stimulation Index* 
(Mean « 1 standard error)
'Near^normal* phenotype (n = 7) 1.78 - 0.50
Bilateral undescended testes (n =16) 6.79 - 4.11
Delayed puberty (n = 6 ) 6.02 - 4.62
Klinefelter*’8 syndrome (a - 2) 3.98 « 1.38
Short stature (n =31) 3.09 « 1.03
Testicular feminization syndrome (n = 4) 2.51 0.91
Hypogonadism (a = 24) 1,45 - 0.30
Unilateral imdescended testes (a = 6 ) 1,39 - 0.40
Prader'«Willi syndrome (n = 2) 0.87 " 0.01
XO/XY syndrome (n = 2) 0,83 0.24
XX/XY syndrome (n = 1) 3.00
* stimulation Index =icimuiaïion inaex Basal DHA excretion
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has shown that a raised A/Ae ratio, which may indicate hypothalamic 
disorders, is caused by a change in the metabolism of the principal 
androgens and not by abnormal steroid production*
The ratios of the daily urinary androsterone to the daily urinary 
aetiocholanolone excretion, calculated from the basal excretion and from 
the excretion on the third day of HCG stimulation, are shown in columns 
I and J respectively of Table 3*X, These ratios, are compared to the 
normal A/Ae ratios found by Johnsen (1968).
It will be noted from Table 3*X that the basal A/Ae ratios found in 
many of the patients investigated are above the normal range and many of 
these elevated ratios are not suppressed by stimulation of testosterone 
synthesis by the administered HCG.
In order to discover if the A/Ae ratio is related to the phenotype 
of the patients investigated, the patients were grouped according to height 
and pubertal status and the mean A/Ae ratio calculated for each group.
These results are shown in Table 3.XV.
It will be noted from this table that patients with *near-normal* 
phenotype in this investigation, having normal daily basal and post“ 
stimulation excretion of both androsterone and aetiocholanolone, have a 
mean A/Ae ratio within the normal range. This ratio is not significantly 
different from that found in the published normal cases of Johnsen (1968) 
and it does not alter significantly following stimulation v;ith HCG. The 
ratios in the other phenotypes are thus compared to that found in these 
*near™normal' patients.
Patients with hypogonadism (small penis, small scrotum and micro- 
testes), who have very low basal daily excretion levels of both androsterone 
and aetiocholanolone, have an elevated A/Ae ratio. This ratio is 
significantly (0.01-4 p < 0.02) above that found in the hiear-normal’ 
patients. As the stimulation of androsterone and aetiocholanolone
JLOÜ
TABLE 3.XV RATIO OF URINARY ANDROSTERONE TO URINARY AETIOCHOLANOLONE IN
VARIOUS PHENOTYPES
Phenotype and Number
Normals (Johnsen, 1968) 
<n = 1 1 2 )
Mean A/Ae ratio
(- i standard error)
BASAL
1.04
(range 0.51^2.10)
DAY 3
*Near-normal* phenotype 
(n = 7)
1.79 - 0,30 1.74 « 0.29
Hypogonadism 
(n = 24)
6.06 - 1.59* 3.29 - 0.57*
Klinefelter*s syndrome 
(n = 2 )
5.63 : 1.80 2,94 - 0.11*
Testicular feminization syndrome 
(n = 4)
3,83 ™ 1.51 2,28 « 0.54
Bilateral undescended testes 
(n = 16)
2.92 A 0.95 2.89 ™ 0.72
Short stature 
(n = 29)
2,15 - 0.34 2.30 « 0.37
XO/XY syndrome 
(n = 2 )
2.08 - 0.65 2.07 - 1.01
Delayed puberty 
(n = 6 )
2.01 ™ 0.34 1.70 - 0,27
Unilateral undescended testes 
(n = 5)
1.57 - 0.20 1.69 - 0.18
* Significantly different from *near™normal* phenotype
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excretion following HCG is normal in these patients, it is possible that 
the defect may be of hypothalamic origin or, alternatively, caused by 
abnormal androgen metabolism.
Two patients with Klinefelter®s syndrome (protocols 8 and 9), who 
have a normal daily excretion of androsterone but a decreased excretion of 
aetiocholanolone, have an elevated A/Ae ratio. This ratio is just not 
significantly above that found in the 'near-normal* patients. The rise of 
androsterone and aetiocholanolone excretions following HCG is also 
raised in these patients. This is consistent with abnormal androgen 
metabolism.
Four patients with the testicular feminization syndrome, with basal 
androsterone and aetiocholanolone excretions within the normal range, 
have a raised A/Ae ratio although this is not significantly above that of 
'near-normal* patients. As the response of androsterone and 
aetiocholanolone excretion to HCG administration was normal in these 
patients, normal androgen metabolism must be postulated. This is consistent 
with the defect being an end-organ insensitivity to androgen in such patients.
Patients with bilateral undescended testes have an A/Ae ratio which, 
although raised, is not significantly different (0 .2 < p < 0 .5 ) from that of 
•near-normal* patients* These patients have a good increase in androsterone 
and aetiocholanolone excretion following HCG from very low basal levels.
The defect in these patients is thus probably related to partial 
gonadotrophin failure.
In patients with short stature, having very low basal daily 
excretions of both androsterone and aetiocholanolone, the A/Ae ratio is 
not significantly different from that found in the 'near-normal* patients.
It is therefore postulated that the extremely low excretion of androgen 
metabolites in these patients is not caused by abnormal metabolism but 
rather by reduced synthesis of androgens.
— -LOU •"
In patients with delayed puberty, who have similarly very low basal 
daily excretion of androsterone and aetiocholanolone, the A/Ae ratio is 
similarly not significantly different from that found in patients of 
'near-normal* phenotype. Again it is probable that the extremely low daily 
excretion of the androgen metabolites in these patients reflects a low 
synthesis of androgens and it is this low androgen production which 
induces the delayed puberty. ^
The patient with the XX/XY genotype (protocol 40), who has extremely 
low basal levels of androsterone and aetiocholanolone excretion, also has 
a greatly elevated A/Ae ratio. The A/Ae ratio of 11.00 is statistically 
significant when compared with that of 'near-normal* patients, and this 
is consistent with an abnormal androgen production that would be 
expected in subjects with ovotestes.
Two patients with the XO/XY syndrome have A/Ae ratios not significantly 
different from that found in 'near-normal* patients. As the basal daily 
levels of androsterone and aetiocholanolone excretion in these patients 
are within the normal range and increase normally with HCG administration, 
it would appear that the metabolism of androgens in this syndrome is 
identical with that of normal males.
Two patients with precocious puberty (protocols 77 and 78) have 
greatly elevated A/Ae ratios. The mean A/Ae ratio of 8.42 is significantly 
above that of 'near-normal* patients. This elevated A/Ae ratio may be 
related either to an over-production of androgens or to an abnormal 
androgen metabolism.
The A/Ae ratios in three patients with the Prader-Willi syndrome were 
very variable. Although the mean A/Ae ratio of 10.29 is grossly elevated 
this is not significantly above that of 'near-normal* patients owing to 
large variation. However, it is interesting that Johnsen (1968) described 
elevated A/Ae ratios in patients with similar phenotypes (ie hypogonadism 
with obesity) and related this to a hypothalamic defect.
When the A/Ae ratios on the third day of HCG are compared to the A/Ae 
ratios of the basal day (Table 3.XV) no significant change in androgen 
metabolism is noted. However, there is a trend towards lower (normal) 
results following HCG. Note, too, that in a patient with the XX/XY 
genotype and ovotestes the grossly elevated A/Ae ratio of the basal day 
is reduced to the normal level following HCG administration. This is 
consistent with an abnormal basal androgen metabolism which is normalised, 
although not greatly elevated, by stimulation of the Leydig cells with 
gonadotrophin. Thus it may be that the gonadotrophin (HCG) administered 
has other extra-testicular effects which influence metabolic pathways and 
even tissue sensitivity to metabolically active androgens.
Epiandrosterone
Very few normal levels for the daily urinary excretion of epiandrosterone 
(Sp-hydroxy-Sa-androstan-ly-one) in children and adolescents have been 
reported in the literature. Paulsen £t (1966) found undetectable 
urinary levels in children before 9 years of age and reported low levels 
of urinary epiandrosterone in only three male children in early puberty.
Uozumi ^  (1969) confirmed the negligible urinary epiandrosterone
excretion in young children and reported mean levels of daily urinary 
epiandrosterone excretion in early puberty, adolescence and throughout 
adulthood in males. In females they reported negligible epiandrosterone 
excretion until adulthood and even then the levels were below those found 
in males, Feher (1967a) reported levels of urinary epiandrosterone in 
normal adults and in patients with various endocrine disorders.
The basal daily urinary epiandrosterone excretion rates found in 
this investigation (Table 3.XVI) were initially compared to the normal 
values reported by Uozumi e^ (1969), The basal urinary epiandrosterone 
excretion (column C, Table 3.XVI) was plotted against patient age. This 
graph is shown in Figure 3,8, Mere it will be noted that the shaded area
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TABLE 3.XVI DAILY URINARY EXCRETION OF EPIANDROSTERONE AND THE EFFECT OF
ADMINISTERED HCG
Protocol Age(Years)
Epiandrc
Exci'î
(Rg/2'
?sterojie 
îtion 
;■ hrs) Protocol
- -------- 1
Age
(Years)
Epiandrosterone 
Excretion 
(gg/24 hrs)
Basal Day 3 Basal Day 3
A B C D A B C D
1 0*4 129 356 41
1
4.2 1 6
2 2.8 78 1,163 42 13.0 2 13
3 3.3 120 124 43 14,0 15 4
4 10.1 2 6 44 14.0 5 5
5 6.0 1 1 45 16,0 49 11
6 12.3 8 19 46 16.0 9 76
7 14.8 657 640 47 16.0 12 16
8 8.7 45 10 48 16.0 17 37
9 14.0 238 3,289 49 16.1 4 12
10 8.1 42 47 50 17.1 5 6
11 8.5 10 20 51 3.8 81 4
13 11.0 11 10 52 6.8 64 57
14 11.5 73 2 53 10.9 742 2,078
15 12.2 17 6 54 11.0 105 611
16 14.3 15 10 55 12.6 53 7
17 15.0 46 30 56 13.7 247 533
18 5.4 2 7 57 13.9 261 316
19 6.0 10 8 58 4.5 572 415
20 8.3 47 164 59 5.4 33 46
21 10.1 15 17 60 9.5 57 6
22 10.3 16 42 61 9.6 136 161
23 11.8 196 202 62 10.0 194 ND*
24 15.0 100 9 63 10.9 486 497
25 15.3 382 ND 64 14.4 214 158
26 4.1 4 1 65 15.0 36 42
27 6.0 50 4 66 15.6 24 13
28 7.3 19 195 67 20.0 14 36
29 8.2 1 7 68 26,0 24 23
30 10.8 2 4 69 12.1 353 1,388
31 10.8 12 3 70 19.9 291 276
32 11.0 8 8 71 6,3 83 5
33 11.2 4 3 72 8.0 6 11
34 11.9 1 26 73 15.5 40 17
35 13.5 7 1 74 8.3 1 2
36 14.8 4 5 75 7.0 23 17
37 15.0 15 39 76 9.0 119 20
38 16.1 16 6 79 17.2 10 6
39 19.0 6 6 80 14.0 34 89
40 4.1 4 14
ND = Not Detectable
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Figure 3.8 The mean basal urinary epiandrosterone excretion by 
patients grouped by age and pubertal status. The 
shaded area represents the mean - 2 SD of normal 
urinary excretion of epiandrosterone found in this 
investigation.
KEY:
^  Mean normal excretion found in this investigation 
O Mean normal excretion (Uozumi £t al., 1969)
Mean excretion in patients vdth raised urinary excretion of 
epiandrosterone
of the graph represents the range (« 2 SD) of normal daily urinary 
epiandrosterone excretion found in this investigation.
There is an extremely low daily excretion of urinary epiandrosterone 
throughout the prepubertal, pubertal and adolescent age groups studied.
Note, too, the absence of any significant rise in daily epiandrosterone 
excretion as occurred with the other 11-deoxy-l7-oxosteroids during the 
late prepubertal or pubertal periods# As there ^ is no sudden rise at 
puberty it is improbable that the main precursor of epiandrosterone is 
testosterone, as reported by Fukushima ^  (1954), since normally there
is a marked rise in testosterone at puberty.
It will also be noted further from Figure 3.8 that this normal range 
of daily urinary epiandrosterone excretion closely resembles that found in 
the normal cases of Uozumi et al. (1969). However, the daily basal urinary 
epiandrosterone excretion in other patients in my series was greatly 
elevated. No correlation was found in these patients between the phenotype 
and elevated epiandrosterone excretion, although it is interesting that the 
majority of these patients had undescended testes. It is probable that the 
elevated daily urinary epiandrosterone excretion found in these patients 
reflects abnormal androgen metabolism. The precursors of epiandrosterone 
were therefore studied to investigate the possibility of abnormal androgen 
metabolism in these patients.
Dorfman and Shipley (1956) reported three theoretical pathways 
between testosterone and epiandrosterone. The normally accepted pathway 
of catabolism proceeds through A^-androstenedione and 5a-androstanedione 
and favours the formation of androsterone (the Sa-metabolite)« 
Epiandrosterone synthesis and its urinary excretion are therefore normally 
low. Metabolism of testosterone in androgen*-dependent tissues may, however, 
take place through 5a«"dihydrotestosterone and 5a-androstane™36 ,176°*diol to 
yield epiandrosterone, whilst the third possible metabolic pathway proceeds 
through A^-androstcne^S^ jlYp-'diol and dehydroepiandrcsterone.
Raised urinary epiandrosterone excretion can therefore be caused 
by a relative change in the activities of 3a:- or 3p-dehydrogenase in 
favour of 3p-enzyme, or possibly by tissue metabolism of another 
androgen (probably DHA) in the event of either inadequate levels of 
testosterone or tissue insensitivity.
In order to evaluate further the state of the 3a« and Sp-dehydrogenases, 
the basal daily urinary epiandrosterone excretion in my series was plotted 
against the basal urinary excretion of androsterone for each patient.
This graph is shown in Figure 3.9.
There the shaded area of the graph represents the normal ratio of 
urinary excretion of androsterone to the urinary excretion of 
epiandrosterone (A/EpiA ratio). All patients in this investigation with 
normal basal levels of urinary epiandrosterone excretion are within this 
range, in agreement with the mean A/EpiA ratio of 12,25 calculated from 
the data of Uozumi a^. (1969), The lower limit of this normal range 
was taken as an A/EpiA ratio greater than 5, after scrutiny of the normal 
range of urinary epiandrosterone excretion, as shown in Figure 3,8.
All patients with elevated levels of epiandrosterone excretion have 
a low A/EpiA ratio and are therefore below the normal range. These patients 
were divided into two groups for further evaluation, patients with a 
raised daily epiandrosterone excretion and with an A/EpiA ratio greater 
than 1 , and those with a raised urinary epiandrosterone excretion and 
with an A/EpiA ratio less than 1.
In each of these groups of patients the basal daily urinary 
epiandrosterone excretion was compared to that of other steroids.
Spearman correlation coefficients were calculated between the excretion 
rates of these steroids in each group of patients. These are shown, where 
significant 5 in Table 3,XVII.
There it will be noted that for patients with a normal basal urinary 
epiandrosterone excretion, the excretion of epiandrosterone is
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Piqûre 3.9 The basai urinary excretion of epiandrosterone by 
individual patients compared to the basal urinary 
excretion of androsterone. The shaded area reoresents 
the mean ratio (Uozumi c_t , 1969) and normal range 
found, in 'near-normal* patients in this investigation.
KEY: O Patients with normal A/EpiA ratio
O Patients with elevated A/EpiA ratio ( E p i a A)
^ Patients with elevated A/EpiA ratio (Hpia>A)
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TABLE 3.XVII SIGNIFIOW SPEARMAN CORRELATIŒ COEFFICIENTS OF BASAL 
URïî'fARY EFJANDRQSTERaNE EXCRETION WITH BASAL URINARY 
EXCRETION OF OTHER STEROIDS
Steroid*
Patients with 
Normal 
Epiandrosterone 
Excretion
Patients with 
Elevated Epiandrosterone Excretion
EpiA <  A EpiA > A
A 0.690 0.934 0.787
Ae 0.476 0.730 0.725
DHA 0.617 0.806 0.750
5a—D i d 0.480 «
53-Diol 0.449 «
33-Diol 0.328 0.452
FT *• 0.618
___
* Abbreviations used: A Androsterone
Ae Aetiocholanolone
DMA Dehydroepiandrcsterone
5a^Diol 5a-Androstsno-3a,l73^diol
5p^Diol 53™AndroGtane^3a,176^diol
33-Diol 5a*"Androstane‘"*33 ,l?3-diol
PT Plasma testosterone
significantly correlated with the urinary excretion of androsterone, 
aetiocholanolone, dehydroepiandrostcrone and the three androstanediols.
It is therefore possible that in these patients epiandrosterone production 
is dependent on the relative activities of and A^-Sg-reductase
enzymes reducing A^-androstenedione, and on the relative activities of 
3a« and 33-dehydrogenase reducing 5a-androstanedione (ie the normal
hepatic metabolism of androgens, Figure 1.2, page 15), DHA catabolism
1
to epiandrosterone in these patients would then proceed through 
A^-androstenedione, as a A^-reductase, involved in direct metabolism of 
DHA to epiandrosterone, has not been identified. The androstanediols 
would of course arise from further metabolism of the 17-oxosteroids.
It is interesting that in these patients the urinary excretion of 
epiandrosterone was significantly correlated with the pubertal (r - 0.358) 
and gonadal (r = 0.368) status.
In patients with a raised basal urinary excretion of epiandrosterone 
but less than that for androsterone (A/EpiA ratio>l) the excretion of 
urinary epiandrosterone is significantly correlated with the urinary 
excretion of androsterone, aetiocholanolone, dehydroepiandrcsterone and 
5a-androstane-33,173-diol.
Two possible explanations for the raised epiandrosterone excretion 
in these patients can be postulated. Firstly, the raised epiandrosterone 
excretion may arise from a change in the relative activities of the 
A^-5a- and A^-53-reductases reducing androstenedione to give a preponderance 
of 5a™reduced metabolites. A change in the relative activities of the 
3a"" and 33“dehydrogenases to reduce the formed 5a-androstanedione, giving 
a preponderance of Sp^reduced metabolites, would also be necessary to 
produce high urinary excretion of epiandrosterone (some six times normal 
levels) in combination with normal levels of urinary androsterone excretion* 
Under these conditions DHA catabolism to epiandrosterone would presumably 
take place through A^^androstenedione.
Secondly, a direct metabolism of DMA to epiandrosterone, involving 
an unidentified A -reductase, may be postulated. Under these conditions 
androsterone could then arise from epiandrosterone, probably through 
5a-androstanedione (the 3-oxo intermediate) as described by Baulieu ^  a1.
(1965). In the patients with elevated urinary epiandrosterone excretion 
it should be noted that the urinary excretion of androsterone, 
aetiocholanolone and DHA is not significantly different from normal 
excretion. This precludes a change in the relative activities of 
A"^ -5cc“ and A^“5p-reductases and 3a'« and 33«dehydrogenases and favours the 
second hypothesis of direct formation of epiandrosterone from DMA.
If this second hypothesis of direct metabolism from DHA is accepted, 
it can then be postulated that when general tissue metabolism cannot 
utilize testosterone, either because of inadequate testosterone synthesis 
or tissue insensitivity to testosterone, then DHA becomes the principal 
anabolic hormone (Hamilton, 1974a), DHA production then rises in such 
patients and the urinary excretion of epiandrosterone increases.
A very brief comment on patients of this group with raised urinary 
excretion of epiandrosterone may clarify these points. Of the 19 patients 
investigated in this group, 5 (26 per cent) were found to have primary 
testicular failure with low levels of testosterone, A further 6 patients 
(32 per cent) had very low levels of plasma testosterone, whilst 3 patients 
(16 per cent) presented with varying degrees of tissue insensitivity 
(ie near normal plasma levels of testosterone but with micropenis and 
microscrotum). One of the patients with elevated urinary epiandrosterone 
excretion had precocious puberty. The raised urinary epiandrosterone 
excretion in this patient is certainly not secondary to tissue 
insensitivity or testosterone insufficiency but probably due to treatment 
of the patient during the period of investigation with cyproterone acetate, 
a potent antiandrogen. This drug has recently been reported to inhibit
5
Sp-'-hydroxy-A -steroid dehydrogenase (Goldman, 1972).
In these patients raised urinary epiandrosterone excretion may 
indicate a somatic defect, secondary either to tissue insensitivity to 
testosterone, or to testicular insufficiency (ie testosterone lack). In 
these circumstances, the soma cannot utilize testosterone and growth and 
development are dependent on the weaker androgen, DHA.
In patients with a raised basal urinary excretion of epiandrosterone 
above that of androsterone (A/EpiA ratio<l) the^ excretion of urinary 
epiandrosterone is significantly correlated with the urinary excretion of 
androsterone and aetiocholanolone. It is therefore possible that in these 
patients epiandrosterone production is dependent on the relative activities 
of and A^«53-reductase enzymes reducing A"^-androstenedione and on
the relative activities of 3a- and 33-dehydrogenases reducing the formed 
5a-androstanedione, Furthermore, as the urinary excretions of androsterone 
and aetiocholanolone are significantly below normal (0,001 < p <0,01) in 
these patients, it is postulated that the raised urinary epiandrosterone 
excretion arises from a change in the relative activities of these two 
enzyme systems to give a preponderance of 5a« and 5a,33-reduced products 
respectively. This hypothesis explains the raised urinary epiandrosterone 
excretion in association with subnormal urinary excretion of the other 
ll-deoxy-17-oxosteroids as seen in these patients.
It is interesting that of the 18 patients investigated in this group,
12 (67 per cent) have undescended testes. Furthermore, in all these 
patients with undescended testes the urinary excretion of epiandrosterone 
exceeds that of the combined excretions of the other ll«deoxy-17-'Oxosteroids 
It is therefore postulated that the raised urinary epiandrosterone excretion 
found in the patients with undescended testes may reflect abnormal steroid 
metabolism in the cryptorchid testes and this intrinsic metabolic defect 
may cause non-descent of the testes.
of the remaining patients within this group, 3 patients were of short 
stature but with normal levels of human growth hormone, 2 patients have 
hypogonadism, whilst the remaining patient bad previously been treated with 
cyclophosphamide for the nephrotic syndrome. Cyclophosphamide 
(1-bis-(2-chloroethyl)amino-l«oxo"2-az0"6-oxaphosphoridine), a heterocyclic 
mustard, is Imown to cause testicular tubular damage but is believed to
have no effect on interstitial tissue (Kumar ^  , 1972). These
£
patients are distinguished from those with undescended testes by lower 
levels of urinary epiandrosterone excretion and they may therefore represent 
intermediate examples in severity of the enzyme defect postulated.
On stimulation with HCG, the daily urinary excretion of epiandrosterone 
was remarkably variable.^ Of the patients investigated, the response 
(column D, Table 3.XVI) was increased above the basal excretion in .41 per 
cent* No response occurred in 26 per cent, whilst for the remaining 
patients (33 per cent) there was a diminished excretion of urinary 
epiandrosterone below basal levels.
Although no general correlation was found between the response of 
epiandrosterone excretion after HCG stimulation to the phenotype of the 
patient, it should be noted that patients with gynaecomastia have 
extremely raised epiandrosterone excretion after HCG. As the basal 
urinary epiandrosterone excretion in these patients is significantly 
above normal, and is in association with low or normal levels of the other 
ll-deoxy“l7-oxosteroids, it is postulated that in these patients there is 
a partial deficiency of 3p-hydroxysteroid dehydrogenase. This enzyme 
deficiency may, however, be limited to the testicular or gynaecomastia 
tissue only, as complete or partial deficiencies of adrenal 
3p-hydroxysteroid dehydrogenase are characteristic of congenital adrenal 
hyperplasia with the salt-losing syndrome, ambiguous genitalia and often 
early death (Goldman et a],, 1964: Janne et al., 1970), Recently, Parks
et al» (1971) reported a 13-year-old maie child with this enzyme defect
who had severe gynaecomastia™
llB-Hydroxyandrosterone
The daily urinary excretion of llp-hydroxyandrosterone of the 
patients investigated is shown in Table 3<,XVIII, The basal urinary 
excretion of llp-hydroxyandrosterone (column C, Table 3.XVIII) was plotted 
against the age of the patient. This graph is shown in Figure 3.10.
It will be seen that the shaded area of the graph represents the 
range (- 2 SD) of daily urinary llp-hydroxyandrosterone excretion 
calculated from the combined results of Vestergaard (1965), Paulsen ^  al. 
(1966) and Tanner and Gupta (1968) for normal children and adolescents, 
as shown in Table 3.XIX. This shaded area therefore represents, for the 
present purposes, the normal range of daily llp-hydroxyandrosterone excretion.
The shape of this curve is of interest. There is a low daily excretion 
of llp-hydroxyandrosterone for patients less than 10 years. This then 
rises more rapidly before puberty. At puberty there is no rapid rise, as 
seen with androsterone excretion. Again, as the adrenal cortex is the 
main source of production of llp-hydroxyandrosterone, the prepubertal rise 
in the daily urinary llp-hydroxyandrosterone excretion probably represents 
the phenomenon of 'adrenarche* whilst the absence of a pubertal rise is 
consistent with the fact that all precursors of llB-hydroxyandrosterone 
are adrenal and not testicular in origin.
The basal daily excretion of llB-hydroxyandrosterone in patients of 
short stature (height percentile 4!3) is very low, although it increases 
with age normally. Between 6 and 9 years of age the basal daily excretion 
of llp-hydroxyandrosterone is not significantly different from normal.
In the late prepubertal age group, 9 to 13 years, the daily excretion of 
llB-hydroxyandrosterone is significantly below the normal range 
(0.005< p< 0,01) whilst in the pubertal and adolescent age groups
TABLE 3.XVIII DAILY URINARY EXCRETION OF llB-HYDROXYAMDROSTERONE 
AND ilp^HYDROXYAHTIOCHOI-ANOLONE AND THE EFFECT OF 
ADMINISTERED HCG
Protocol Age
(Years)
U p  “OH—A 
Excretion 
(jj.g/24 hrs)
llp^OH—Ae 
Excretion 
(gg/24 hrs)
Basal Day 3 Basal Day 3 Basal Day 3
A B C D E F G H
2 2.8 1,102 1,159 _ .
11 8.5 176 848 113 859 1.56 0.99
16 14.3 128 120 248 60 0.52 2.00
23 11.8 332 278 64 140 5.19 1.99
26 4.1 139 139 37 31 3.76 4.48
27 6.0 109 108 *ca *.* ..
28 7.3 374 368 31 72 12.06 5.11
33 11.2 593 584
35 13.5 120 120 136 106 0.88 1.13
37 15.0 459 574 M vn
38 16.1 274 258 ma
39 19.0 296 332 84 58 3.52 5,72
44 14.0 430 492 54 315 7.96 1.56
45 16.0 475 404 66 128 7.20 3.16
46 16.0 614 617 — — **
47 16.0 1,341 1,269 278 450 4.82 2.82
48 16.0 449 427 - tS!
49 16«1 530 546 341 138 1.55 3,96
55 12.6 364 300 47 90 7.74 3.33
56 13.7 710 w 18 r* 39.44
59 5.4 198 209 89 39 2.22 5.36
60 9.5 18 103 5 88 3.60 1.17
62 10.0 39 36 67 78 0.58 0.46
65 15.0 1,749 1,768 1,047 993 1.67 1.78
68 26.0 1,100 1,108 177 110 6.21 10.07
69 12.1 2,282 2,242 242 344 9.43 9.19
70 19.9 3,359 3,027 *=a ma
73 15.5 403 442 438 399 0.92 1.11
75 7.0 266 274 259 188 1.03 1.46
78 5,0 324 40 8.10
* Normal values 
Forsyth (1974)
Age group llp-OH-A/ilG-OH-Ae ratio
i‘^'6 1*4
7-10 1.6
11-17 1.7
Adults 3,0
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Fi,cure 3,10 The basal urinary excretion of 118-hydroxyandrosterone 
in patients grouped by age, height and pubertal status. 
The shaded area represents the nean a 2 5D 
116-hydroxyandroster one excretion by normal subjects as 
shown in Table 3.XIX. Numbers refer to protocols of 
patients mentioned in the text.
KEY: O Patients with undescended testes
0 Patients with short stature (height percentiles <3)
Other patients
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TABLE 3.XIX MEAN DAILY URINARY EXCRETION OF llp^HYDROXYANDROSTERONE 
AND 11(3-HYDR0XYAETI0CH0LAN0L0NE IN NORMAL CHILDREN AND 
ADOLESCENTS^-
Age Range 
(years)
r- — ..— .— .’... ..-
113‘*>0H Androsterone 
(pg/24 hrs)
..... . .....  ........... —
llp-OH Aetiocholanolone 
(p.g/24 hrs)
. . . . 1
3*«6 103 - 23 48 « 16
n = 4 n = 8
5«9 129 « 48 117 - 28
n = 13 n = 16
9-13 78 « 17 114 - 10
n = 36 n = 41
13-16 553 - 83 338 - 151
n = 3 n ” 4
16 + 1000 « 40 910 - 510
n = 2 n = 2
* Mean “ 1 standard error calculated from the normal 
results of Vestergaard (1965), Paulsen et al. 
(1966) and Tanner and Gupta (1968)
this excretion, although rising, remains subnormal (O.OK p< 0*05). As 
the urinary excretion of llp-hydroxyandrosterone rises normally with age 
in these patients with short stature and, furthermore, is at a normal 
level when adjusted to a normal urinary creatinine excretion normal 
adrenal function must be concluded. The low urinary excretion of 
llp-hydroxyandrosterone in such patients is probably related to the 
reduced adrenal gland size.
1
The basal daily excretion of llB-hydroxyandrosterone in patients with 
bilateral undescended testes, although not significantly above normal, is 
generally within the high normal range of excretion. However, the basal 
urinary excretion of llS^hydroxyandrosterone in the eldest patient with 
undescended testes (protocol 69, aged 12.1 years), at 2,282 jig per 24 
hours, is well above the normal range of excretion (78 - 17 ytg per 24 
hours),
The basal daily excretion of llg-hydroxyandrosterone in patients with 
unilateral undescended testes is variable. In one such patient (protocol 
55) the value is significantly raised (0.002< p <0.005) whilst in a further 
patient (protocol 35) the excretion of llp-hydroxyandrosterone is 
significantly below normal (0.005< p < 0.01),
In hypogonadal patients (small external genitalia) the basal excretion 
was within the normal range, whilst in one patient with the Laurence-Moon- 
Biedl syndrome (in which hypogonadism is one of the presenting features) 
the basal excretion of ll6™hydroxyandrosterone was within the high normal 
range and is consistent with such patients with bilateral undescended testes.
In a patient with precocious puberty (protocol 78) the basal excretion 
was significantly above (0.02<p <0.05) the normal range for chronological 
age. However, it is noteworthy that the excretion in this patient (324 j-ig 
per 24 hours) is at the mean level when plotted against the patient’s 
advanced bone age.
X ! (
The basal daily urinary excretion of llf3”hydroxyandrosterone in three 
patients with Cushing's syndrome was generally raised. One of these 
patients (protocol 37) had a normal excretion of llp-hydroxyandrosterone, 
whilst in the two other patients with Cushing's syndrome this was signifi­
cantly above normal (0, O K  p < 0,02), This is consistent with the elevated 
corticosteroid production in this syndrome and these are precursors of 
urinary llp-hydroxyandrosterone. ^
The fact that the post-stimulation excretion of llp-hydroxyandrosterone 
was not significantly different from the basal levels is consistent with 
the established concept that the precursors of llp-hydroxyandrosterone are 
of adrenal and not testicular origin.
3. Is - Hy dr oxy ae t i o ch o 1 an o 1 on e
The basal daily excretion of llp-hydroxyaetiocholanolone (column E,
Table 3.XVIII) of the patients investigated was plotted against the age
of the patient. This graph is shown in Figure 3.11.
It will be noted that the shaded area of the graph represents the
range (- 2 SD) of daily urinary llB-hydroxyaetiocholanolone excretion 
calculated from the combined results of Vestergaard (1965), Paulsen £t al.
(1966) and Tanner and Gupta (1968), as shown in Table 3.XIX. This shaded 
area therefore represents, for the present purposes, the normal range of 
daily llp-hydroxyaetiocholanolone excretion.
Again, there is a low daily excretion of lljS-hydroxyaetiocholanolone 
by patients less than 10 years of age. The level then rises more rapidly 
before puberty. Again, as the adrenal cortex is the main source of 
llp-hydroxyaetiocholanolone, this rise probably represents the phenomenon 
of 'adrenarche'. The absence of a further pubertal rise is consistent 
with the fact that all precursors of llS-hydroxyaetiocholanoione are of 
adrenal and not testicular origin.
All basal daily excretions of llB-hydroxyaetiocholanolone of the 
patients investigated were within the limits of the normal range (- 2 SD),
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Figure 3.11 The basal urinary excretion of 113-hydroxyaetiocholanolone 
in patients grouped by age, height and pubertal status.
The shaded area represents the mean - 2 SD 
113-hydroxyaetiocholanolone excretion by normal subjects 
as sho\\Ti in Table 3.XIX.
KEY: O patients with short stature (height percentiles<3)
O Patients with undescended testes 
* Other patients
JL Y y
The small number of determinations prevented statistical comparison of 
patients grouped by phenotype. However, as the normal range of excretion 
of ll3""hydroxyaetiocholanolone is so variable, it is probable that if 
more analyses had been carried out the results would not yield values 
significantly different from normal.
Hie basal daily excretion of ll(3*“hydroxyaetiocholanolone in patients 
of short stature is again, however, in the low normal range of excretion, 
as seen with llfB'-hydroxyandrosterone studies. The corresponding values 
for patients with bilateral undescended testes is, however, much lower 
than that for the 5a-epimer, Normal excretion levels of 
llp«"hydroxyaetiocholanolone were found in four patients, whilst in a 
further two patients with this phenotype very low levels were found.
(kt stimulation with HCG, the daily urinary excretion of 
ll(3*™hydroxyaetiocholanolone was very variable. Although increased 
excretion of ll6*-hydroxyaetiocholanolone was noted in nearly half of the 
patients tested, diminished excretion following stimulation was noted in 
one-third of the patients. No correlation was found between the response 
to HCG and the phenotypes of the patients investigated and mean post­
stimulation daily excretion of llp-hydroxyaetiocholanolone was not 
significantly different from the basal excretion.
Ratio of llB"hydroxyandrosterone to ll6~hydroxyaetiocholanolone 
Although the stereoisomers llB-hydroxyandrosterone and 
lljB^hydroxyaetiocholanolone are structurally similar, they arise from 
diverse origins. llg-Hydroxyandrosterone is formed mainly from the 
metabolism of adrenal androgens (eg A^-androstenedione) whilst 
ll|3-hydroxyaetiocholariolone arises largely from the metabolism of cortisol 
(Bradlow ejt aj.., 1967). The ll-oxy-*l7-oxosteroids thus include metabolites 
of both A^-androstenedione and cortisol.
Normal values for the ratio of urinary lip-hydroxyandrosterone to 
urinary llp-hydroxyaetiocholanolone (llp-OH-A/llp-OH-Ae ratio) have 
recently been reported by Forsyth (1974) who has shovai a gradual rise in 
the lip-OH-A/llp-OH-Ae ratio from childhood (when the contribution from 
cortisol metabolites is greater than adrenal androgen metabolites) and 
she concludes that this gradual rise reflects the mixed origin of the 
ll-oxy-iy-oxosteroidso
The ratios of the daily urinary llS-hydroxyandrosterone to the daily 
urinary llp-hydroxyaetiocholanolone excretion calculated from the basal 
excretion and from the excretion on the third day of HCG stimulation are 
shown in columns G and H respectively of Table 3,XVIII. These ratios are 
compared to the normal llp-OH-A/llp-OH-Ae ratios found by Forsyth (1974).
It will be noted from Table 3.XVIII that the basal llp-OH-A/llp-OH-Ae 
ratios found in many of the patients investigated are greatly elevated.
On stimulation of testosterone synthesis by administration of HCG, however, 
many of these elevated ratios were reduced to normal.
In order to abolish the age«effect of rising llp-OH-A/llp-OH-Ae 
ratios, and to facilitate comparison of individual ratios, the results 
shown in Table 3.XVIII were divided by the normal value for the 
llp-OH-A/llp""OH-Ae ratio. Values thus obtained above unity indicate, 
therefore, an increased llp-OH^A/llp-OH-Ae ratio, whilst values less than 
unity indicate an llp-OH-A/llp-OH-Ae ratio below normal. The comparison 
of this index of llp'-OH-A/llp-OH-Ae ratio with phenotype is shoivn in Table 3.XX 
There it will be noted that the small number of determinations of the 
llp-OH”A/ll0”OH“Ae ratio in the patients investigated, and the diversity of 
those obtained, prevented further statistical analysis.
In patients of short stature the mean basal Il8-0H-A/Tl8-0H-Ae ratio 
is very similar to those found in normal cases by Forsyth (1974). This 
ratio does not alter following stimulation of testosterone synthesis by
TABLE 3.XX CORRELATIF OF THE RATIO OF URINARY llp-HYDROXYANDROSTERONE 
TO 113«KYDR0XYAETI0CH0UN0L0NE EXCRETIF IN THE VARIOUS 
PATIENTS INVESTIGATED
Index of 
11Q«-0H”A/116”0K-Ae ratio*
(Mean « 1 standard error)
RASAL DAY 3
Short stature 
(n = 9)
1,32 ^ 0.45 1.24 - 0.24
Bilateral undescended testes 
(n = 5)
3,73 : 1.24 2.69 " 0.86
Cushing’s syndrome 
(n = 1)
0.98 1.05
Hypogonadism with obesity 
(n “ 1)
24.65
Laurence^Moon-Biedl syndrome 
(n = 1)
1.59 3.83
Precocious puberty 
(n = 1)
5.79
* Ratio of ll6“hydroxyandrosteroîie/llB«hydroxyaetiocholanolone in 
patient divided by the normal value of this ratio for age 
(Forsyth, 1974)
administered HCG. Analysis of individual ratios gives a variable picture. 
Most patients are found to have a low basal ratio, this being caused by a 
subnormal daily urinary excretion .of llp-hydroxyandrosterone.
In patients with bilateral undescended testes the mean basal 
llp-0H»A/ll(3“0H-Ae ratio is greatly elevated and falls following stimulation 
of testosterone synthesis by the administration of HCG. The elevated
llp-OH-A/llp-OH-Ae ratios in these patients (3.7 times normal) are
1
attributed to increased daily urinary llp-hydroxyandrosterone excretion.
As urinary ll|3-hydroxyandrosterone excretion reflects adrenal androgen 
production, it is postulated that in these patients with subnormal 
ll-deoxy-lT-oxosteroid excretion, the adrenal is attempting to compensate 
for a testicular insufficiency.
The basal llp-OH-A/llB-OH-Ae ratio in one patient with the 
Laurence-Moon-Biedl syndrome, in whom bilateral undescended testes and 
hypogonadism are two of the presenting features, is within the normal 
range. On stimulation of testosterone production by the administration 
of HCG however, this ratio is greatly raised, suggesting increased adrenal 
androgen secretion. As the basal daily urinary excretion of 
113-hydroxyandrosterone and llp-hydroxyaetiocholanolone are both within 
the normal range, and the ll-deoxy-17-oxosteroid excretion is reduced, 
this is yet again indicative of testicular insufficiency and related 
a dr en a1 c ompen sat ion.
In a patient with hypogonadism and obesity (protocol 56) the 
llP'"OH"'A/ll3-OH“Ae ratio is greatly raised. On analysis, this elevated 
ratio (approximately 25 times normal) is found to be caused by an 
extremely diminished daily urinary excretion of llB-hydroxyaetiocholanolone 
with a normal daily urinary llB-hydroxyandrosterone excretion. As 
llp-hydroxyaetiocholanolone excretion reflects cortisol secretion, the 
cortisol production in this patient is probably extremely low. It is
- JLÜj -
interesting that Van Herle et (1967) found very low plasma cortisol 
levels in 2 out of 43 obese boys they investigated.
The basal llp-OH-A/llp-OH-Ae ratio in a patient with Cushing’s 
syndrome (in whom obesity and hypogonadism are two of the presenting 
features) is normal and does not alter following stimulation of testosterone 
synthesis by administration of HCG. On analysis the normal ratio in this
patient (protocol 65) is caused by a greatly raised excretion of
1
llp-hydroxyandrosterone and greatly raised excretion of 
llp-hydroxyaetiocholanolone. These elevated levels indicate adrenal 
’hyperfunction’. It is interesting that llp-hydroxyandrosterone is 
elevated in this patient, indicating increased synthesis of adrenal 
androgens as previously found by Jailer £t (1959) and James (1961) 
in patients with Cushing’s syndrome.
In a patient with precocious puberty (protocol 78) the llp-OH-A/llg-OH-Ae 
ratio was greatly raised. This elevated ratio, nearly six times normal, is 
found on analysis to be caused by raised urinary excretion of 
llp-hydroxyandrosterone. This surely indicates increased secretion of 
adrenal androgens characteristic of this phenotype (Gupta and Zimprich, 1966).
5
à '«Androstene-SB ,17B"”diol_and the androstanediols
The results for the daily urinary excretion of 5a-androstane-"3oc,173-diol,
5
53-andtostane-3Q’,l73“diol, A -androstene-30,l7p-diol and 5a-androstane-33,l7B- 
did are shown in Table 3.XXI, There it will be noted that the urinary 
excretion values of these dihydroxysteroids are much lower than the 
corresponding urinary l7-oxosteroids. In several patients the daily basal 
excretion of these steroids is below the sensitivity of the method 
(approximately 0.5 pg per 24 hours) and their absence can be confidently 
assumed.
On stimulation with HCG, the daily urinary excretion of
5
A -androstene-33,l73"diol and the androstanediols is approximately doubled 
following HCG stimulation although considerable individual variation is noted.
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A^-Androstene-33,176-diol
Very few workers have reported values for the urinary excretion of 
A^-androstene-33,l7p«“diol (A^-diol), Wilson et ^1« (1961) found a 
urinary A^-diol excretion of 500 \ig per 24 hours in a normal adult male.
This is in agreement with Bongiovanni (1966) who recorded a value of
37.7 mg per lOO litres in pooled adult male urine. Shackieton ^  (1968)
5
reported very low levels of A «diol excretion in neonates (range 2-88 pg 
per 24 hours) rising to a mean level of 370 pg per 24 hours in adults.
The basal urinary excretion of A^«diol found in this investigation 
is shown in column G, Table 3,XXI. There it will be noted that the basal
5
urinary A -diol excretion is extremely low in the majority of the 
patients investigated. Urinary A^-diol was undetected in 20 patients 
(25 per cent) and extremely low (<5 pg per 24 hours) in a further 29 
cases (37 per cent). Absence of published normal values and a shortage 
of personal patients reckoned to have a normal urinary A^»diol excretion 
prevented statistical analysis of these lov? results.
These very low levels of urinary A^-diol excretion were analysed 
against the phenotyp(B of the patients investigated. It is interesting 
that of the 49 patients with undetected or extremely low levels of urinary 
A^-diol, 17 (35 per cent) have undescended testes, 19 (39 per cent) are of 
short stature, whilst many of the remaining patients are indeed hypogonadal 
(micropenis, microscrotum).
It has previously been shown that patients with bilateral undescended
testes have undetectable or significantly subnormal excretion of urinary
5 . . * 5DHA (the precursor of A -diol with a similar A -SB-hydroxysteroid structure)
It is therefore probable that such patients with extremely reduced levels
5
of A'-30>'.hydroxysteroids have a deficiency of 17,20-desrnolase for 
I7o-hydroxy-pregnenolone (an immediate precursor of DHA). Alternatively, 
there may be a deficiency of l?D-reductase for DHA, although this is 
unlikely in these patients since DHA is likewise extremely low.
Patients of short stature have an extremely low excretion of
urinary A^«diol and low or low-normal urinary excretion of D1L'\, As
these patients have reduced levels of urinary compounds with the 
5A ‘-33“hydroxysteroid structure, it is possible that this results from 
either a reduced activity of l7,20“desmolase or, more likely, a general 
endocrinological hypofunctioning secondary to the stature of these patients. 
Patients with hypogonadism have previously been shown to have normal
> 5
excretion of urinary DHA (the 17-oxo precursor of A -diol). As these
5
patients have extremely reduced excretion of urinary A -did, it is 
postulated that the hypogonadism in these patients is due to a deficiency 
of 173-reductase. A deficiency of this enzyme could cause extremely low 
levels of testosterone synthesis and thus subnormal ’androgenicity*.
A^-Diol, originally thought to be merely a peripheral metabolite of 
DHA, has since been shown to be an intermediate metabolite in the formation
5
of testosterone from DHA (Baulieu et ad., 1963), The source of A -did 
has, for several years, been believed to be the adrenal and A^-diol has 
been tentatively identified in adrenal vein plasma (Wieland _al., 1965).
More recently, however, A^-diol has been identified in high concentration 
in spermatic venous plasma (Laatikainen et al., 1971) and may thus arise 
by testicular elaboration (synthetic or metabolic).
It is interesting that the basal urinary A^-diol excretion of the 
patients investigated correlates with the basal urinary excretion of DMA 
(r = 0.233; p = 0.042) but does not correlate with the basal urinary 
excretion of testosterone (r ~ 0.071; p = 0.302), As testosterone arises 
in the male almost entirely by testicular secretion, and DHA is mainly of 
adrenal origin, this correlation is consistent with the source of A'^ -diol 
being adrenal and not testicular. It is interesting that correlations 
were also found between urinary A^-diol and the other 33-metabolites, 
epiandrosterone (r = 0.223; p - 0.045) and 5a-androstane-33,l76-‘diol
lüü
(r = 0*599; p<0.00l). This may be taken as further evidence of a direct 
33-pathway between DHA and epiandrosterone (page 169).
To facilitate further study of the effect of HCG on the urinary 
excretion of A^-diol the patients investigated were again grouped according 
to height and pubertal status, and the mean stimulation index calculated 
for each group. As it was considered unethical to give normal children 
HCG, patients investigated with ’near-normal’ phenotype were again used 
for comparison.
The urinary excretion of A -diol by ’near-normal’ patients in this 
investigation is approximately doubled following HCG stimulation, although 
considerable variation is noted (1,90 - 0.76), This variation is noted 
throughout the grouped phenotypes and prevented further statistical 
analysis, all groups being similar to ’near-normals’ (0 ,2 < p < 0 .5 ). 
5a-Androstane-3a,17B-diol
A considerable volume of experimental evidence has been accumulated 
in recent years to suggest that testosterone must be metabolised to 
several closely-related steroids in androgen-dependent tissues in order 
to effect a maximal biological stimulus in its target cells. The most 
important of these metabolites outside the liver is iTG-hydroxy-androstane-S-or 
(dihydrotestosterone). It has been reported that dihydrotestosterone in the 
blood does not arise from direct secretion and may therefore reflect events 
occurring in peripheral target tissues (Ito and Horton, 1971), As 
5a-androstane-3a,173^diol (Scc-diol) is the main metabolite of 
dihydrotestosterone at least in normal individuals (Mauvais-Jarvis ^  ,
1968) the determination of urinary 5o:-diol excretion is of clinical interest.
Since urinary 5o:<«diol originates not only from testosterone metabolism 
in target tissues but also from the hepatic catabolism of testosterone and 
dihydrotestosterone (Mauvais-Jarvis et , 1970a), the excretion of 
urinary Scc-diol is compared with that of urinary testosterone glucuronoside
XOV
which is formed only in the splanchnic compartment (Horton and Tait, 1966), 
Recently, Mauvais-Jarvis et (1973) have shown that the difference 
between urinary 5a-diol and testosterone excretion reflects the fraction 
of testosterone which has been metabolised in extra-hepatic tissues 
through dihydrotestosterone to 5o:«diol. This difference in metabolic 
activity is therefore a reflection of ’androgenicity’.
The basal urinary excretion of 5a-diol is shown in column C, Table 
3.XXI, It will be noted there that the basal urinary excretion of 5a«diol 
is extremely lov/ in the majority of the patients investigated. Although 
urinary Sa-diol was not detected in only one patient, extremely low 
levels (<!' 5 |ig per 24 hours) were found in a further 30 cases (39 per cent). 
Absence of published normal values in children and adolescents, and shortage 
of patients with normal urinary 5a~diol excretion in this investigation, 
again prevented statistical analyses of these low results. It should be 
noted, however, that all patients with extremely low excretion of urinary 
5oc”diol have clinical symptoms of inadequate androgen status (non­
masculinized body form often in association v/ith hypogonadism and delayed 
puberty),
The basal urinary excretion of 5a-diol was plotted against the basal 
urinary excretion of testosterone for each patient. This graph is shown 
in Figure 3,12. It will be noted from this graph that the shaded area 
represents a urinary excretion of 5d-diol less than that of testosterone.
All values above this shaded area therefore represent urinary 5a-diol 
excretions above those of testosterone, whilst the amount of extra-hepatic 
formation of 5a-diol from the metabolism of testosterone in androgen- 
dependent tissues is shown by reference to the scales at the left and 
right-hand side of the graph,
Mai.tvais-Ja.rvis ^  (1973) investigated adult females with
idiopathic hirsutism and acne vulgaris, as well as normal males and females,
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Figure 3.12 The basal urinary excretion of 5r:-androstanediol compared to 
the basal urinary testosterone excretion. The shaded area 
represents a basal urinary 5e-ancrostansdioL excretion below 
that of testosterone (probably arising completely from 
hepatic metabolisn of testosterone). See text for explanation.
KEY;
O
Patients with normal androgen status 
Patients with inadequate androgenicily
with reference to their 5a«diol excretion. Their findings indicate that 
a daily excretion of extra-hepatic formed da^diol not less than 30 pig per 
day is a constant feature of the androgenic phenomena of hirsutism and 
acne vulgaris. From my findings relative to the clinical types investigated, 
I confirm that this lower limit of 30 pig per 24 hours excretion of 5ct-diol 
is always associated with reasonable features of ’paediatric’ masculinity. 
This Sa-diol is of extra-hepatic origin, ie it derives from the metabolism
of testosterone in the androgen-dependent tissues.
It wi11 be noted from the graph that the majority of the patients 
investigated have low levels of urinary 5a«diol excretion arising from 
extra-hepatic metabolism of testosterone. These low levels are consistent 
with the lack of androgenicity noted in these patients. These patients 
are further subdivided when urinary testosterone excretion is considered.
It will be noted from Figure 3.12 that many of the patients with
very low levels of urinary 5a-diol excretion have extremely low levels of
urinary testosterone excretion. The lack of androgenicity in these 
patients is therefore probably due to inadequate testosterone production 
and not to tissue insensitivity. It is interesting that nearly all of 
these patients have undescended testes and clinical symptoms of ’severe’ 
hypogonadism (rudimentary scrotum and micropenis),
The remaining patients with low levels of urinary 5oc-diol excretion 
have normal levels of urinary testosterone excretion. The lack of andro- 
genicity in these patients is therefore probably due to tissue 
insensitivity or to a defect in the metabolism of testosterone within the 
target cells. It is Interesting that the majority of these patients are 
of small stature but without clinical signs of hypogonadism or delayed 
■puberty.
In four patients with the testicular feminization syndrome the 
urinary excretion of So-diol is similar to that of testosterone.
As urinary testosterone is derived mainly from the splanchnic compartment 
(Horton and Tait, 1966) it would appear that there is no extra-hepatic 
formation of 5a-diol in these patients. This is in agreement with the 
results of Mauvais-Jarvis e_t (1968, 1970a, 1973) who found the
excretion of 5a-diol was equal to that of testosterone in adult patients 
with this syndrome.
Likewise, in two patients wdth Klinefelter*s syndrome the urinary 
excretion of Sa-diol was found to be similar to the urinary excretion of 
testosterone. It is therefore probable that in these patients there is 
again no extra-hepatic formation of 5a-diol, and testosterone is not 
metabolised in the target tissues. In the patient with 47,XXY karyotype 
this is probably due to inadequate testosterone synthesis, whilst in the 
46,XX-male this may be due to tissue insensitivity or a defect in the 
metabolism of testosterone.
Tlie remaining patients all had levels of urinary 5a-diol excretion 
above 30 gg per 24 hours and adequate androgen status. It is interesting 
that two of these patients are females, and have XO/XY chromosomal 
mosaicism with clinical signs of increased androgenicity, ie enlarged 
clitoris, laryngeal development.
The basal urinary excretion of 5a-diol is above the normal adult 
male range (133 - 25 gg per 24 hours; Mauvais-Jarvis et , 1973) in 
five patients. Three of these patients were in early puberty at the time 
of investigation and it is therefore probable that 5a-diol production 
increases dramatically during puberty. During early puberty testosterone 
synthesis and excretion are still low, yet the growth of the testis is 
maximal. It is therefore postulated that 5o:-reduced metabolites of 
testosterone (or other androgens) may play an important role in initiation 
or maintenance of this high rate of testicular growth. During adolescence, 
the rate of testosterone synthesis increases and the formation of fa-reduced 
metabolites is therefore suppressed (Oshima et al,, 1970).
It is interesting that in this investigation the urinary excretion 
of 5a-diol was significantly correlated with age (r = 0.307; p - 0.003), 
bone age (r - 0.339; p = 0.002), pubertal status (r = 0.310; p = 0.005), 
gonadal status (r = 0.345; p = 0.002) and the urinary excretion of 
testosterone (r - 0.234; p = 0.026). Further significant correlations 
were also found between the urinary excretion of 5a-diol and the 
individual and grouped l7-oxosteroids and individual androstanediols.
To facilitate further study of the effect of administered HCG on the 
urinary excretion of 5a-diol the patients investigated were again grouped 
according to height and pubertal status, and the mean stimulation index 
calculated for each group. These indices are shown in Table 3.XXII.
It will be noted from this table that the urinary excretion of 
5a-diol by ’near-normal’ patients in this investigation is approximately 
trebled after HCG stimulation, although again considerable individual 
variation is noted. Those patients with ’near-normal’ phenotype are 
again used for comparison of the various phenotypes investigated.
Patients with short stature have a normal increase in 5a-diol 
excretion following HCG. This is further evidence for normal testicular 
function in these patients, low levels of excretion probably being related 
to the small body size.
Patients with delayed puberty have a low or normal basal urinary 
excretion of 5a-diol and have a small increased 5a-diol excretion 
following HCG stimulation. This response, only half that of ’near-normal’ 
patients, is just significantly subnormal (0,02< p ^ 0.05). Likewise, 
patients with severe hypogonadism, having similar basal 5a-diol excretion, 
have a very poor increase following HCG. This response (1.12 - 0.16), 
only one-third that of ’near-normal’ patients, is very significant 
(0.002< p< 0,005). These results are, of course, in keeping with the 
poor androgenicity of such patients (Mauvais-Jarvis et al., 1973).
TABLE 3.XXXI EFFECT OF ADMINISTERED HUMAN CHORIONIC GONADOTROPHIN 
F  THE DAILY URINARY EXCRETION OF 5a«ANDROSTANE-3a,17B“DIOL BY
DIFFERENT PHENOTYPES
Phenotype and Number  ^ Stimulation Index* 
(Mean ^ 1 standard error)
’Near-normal* phenotype (n = 5) 3.19 - 0.58
Short stature (n = 12) 3.08 « 0.98
Delayed puberty (n = 4) 1.52 - 0o42**
Unilateral undescended testes (n ” 4) 1.35 « 0.24**
Hypogonadism (n = 18) 1.12 « 0.16**
Bilateral undescended testes (n « 16) 0.97 « 0.11**
^ . , , . , Urinary 5oc-diol (3rd day)^ Stimulation Index = Basal urinary 5a-diol
** Significantly below ’near«normal*
Four patients with unilateral undescended testes have extremely lovj 
basal urinary excretion of 5a-diol and have a low increase following HCG, 
This response is significantly below that seen in ’near-normal’ patients 
(0.02< p < 0.05). However, patients with bilateral undescended testes, 
also having a very low basal excretion of 5oc-diol, have no response to 
HCG, the post-stimulation excretion being generally equal to the basal 
excretion of 5a-diol. This response is significantly different 
(O.OOK p< 0.002) from that of ’near-normal’ patients. Such low levels 
of urinary 5a-diol excretion with poor response to HCG suggest insignificant 
’extra-hepatic* metabolism of testosterone and are in keeping with the 
poor clinical features.
56-Androstane-3o,176-diol
Robel ejt (1966a) have shown that most of the urinary excretion 
of 5j3-androstane~3o:,l7(3-diol (50-diol) arises from the metabolism of 
testosterone glucuronoside whilst only a minor fraction is formed from 
the metabolism of free testosterone. As testosterone glucuronoside 
circulates in plasma in concentrations similar to that of testosterone 
(Burger et ad., 1964) it is possible that this metabolite is an important 
factor in the transport of testosterone.
Although 5(3-metabolites of androgens are generally believed to be 
inactive (Baulieu, 1970) it is perhaps presumptuous to assume that only 
5a-reduction of testosterone is relevant to its action in all tissues.
Levere and Granick (1967) have shown that red blood cell formation is 
selectively stimulated by 53-androstane metabolites, whilst recently 
Parsons (1970) has shown that 5(3-diol is the major metabolite of 
testosterone in chick blastoderm at a time commensurate with the initiation 
of erythropoiesis.
As 5(3-diol is the main metabolite of testosterone glucuronoside and 
the urinary excretion of this metabolite exceeds that of 5a-diol
(Mauvais-Jarvis and Baulieu, 1965), the determination of urinary excretion 
of 5p*=diol may be of clinical interest.
The basal urinary excretion of 53-diol is shown in column E, Table 
3.XXI. It will be noted there that the basal urinary excretion of 5p-diol 
exceeds that of 5a-diol. Urinary 5f3«diol excretion was undetected in 
only one patient, whilst extremely low levels (< 5 pg per 24 hours) 
were only found in a further three patients. Although Berthou et al.
(1971) have recently reported normal values for the urinary excretion of 
5p-diol in adults, the absence of published normal values in children and 
adolescents and the low number of patients with normal urinary excretion 
of 5(3-diol in this investigation again prevent statistical analyses of 
these low results. It should be noted, however, that these patients with 
extremely low excretion of urinary 5[3-diol have clinical symptoms of 
inadequate genital development (microgenitalia and hypospadias).
Having investigated a large number of male patients with gonadal 
problems, it is possible to associate the urinary excretion of 53-diol 
with the development of the external genitalia, good genital development 
accompanying high urinary excretion of 50“diol. By reference to the 
clinical observations in the patients investigated and the results of 
Berthou (1971) on normal males and females, a minimum daily
urinary excretion of 50 pg per 24 hours has been taken as the lower 
limit of 5(3-diol excretion commensurate with normal genital development.
The basal urinary excretion of 5(3-diol correlates with the basal 
urinary excretion of testosterone (r = 0.405; p<0.00l). This correlation 
is in agreement with testosterone glucuronoside (the major fraction of 
urinary testosterone), being the precursor of 50-diol. The basal urinary 
excretion of 53-diol was therefore compared to that of testosterone,
Tire basal urinary excretion of 56-diol wa.s plotted against the basal 
urinary excretion of testosterone for each patient- This graph is shown
in Figure 3.13. It will be noted from this graph that all patients with 
a low basal urinary excretion of 56-diol have very low levels of urinary 
testosterone. All of these patients have inadequate genital development 
and many show clinical symptoms of severe hypogonadism. The poor genital 
status observed in these patients is therefore probably due to inadequate 
testosterone production.
It should be noted that the low basal urinary excretions of 5p“diol
Ï
and testosterone found in these patients are not related to age, with the 
exception of two young patients with the testicular feminization syndrome. 
These two patients (protocols 1 and 2) have normal levels of urinary 5(3-diol 
excretion for age, and will be considered later.
Of the remaining patients with low levels of urinary 5f3-diol excretion, 
11 (38 per cent) show severe hypogonadism, 9 (31 per cent) have bilateral 
undescended testes with associated hypogonadism, 8 (28 per cent) are of 
short stature, whilst the remaining patient (protocol 4) presented with 
the complete form of the testicular feminization syndrome.
The remaining patients all have basal urinary excretions of fg-diol 
above 50 |ig per 24 hours and normal genital development with the exception 
of 7 patients. Two patients with XO/XY mosaicism (protocols 6 and 7), 
associated with gross ciitoral enlargement, have normal male levels of 
urinary 5j3”‘diol excretion. It is interesting that both of these females 
showed ciitoral enlargement, one having a phallus (before amputation) of 
3-4 cm. Similarly, the basal urinary excretion of 5|3-diol is within the 
normal male range in three patients with the testicular feminization 
syndrome (protocols 1, 2 and 3). It is interesting that clinically two 
of these patients show mild ciitoral enlargement and it is reasonable to 
assume that these three ’girls* will show further masculinisation 
at puberty and therefore have the incomplete form of this syndrome.
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The remaining two patients have a normal male phenotype, bilateral 
undescended testes and poor genital development. Their basal urinary 
excretion of Sp-diol is, however, within the normal range. It is 
interesting that on application of testosterone cream to the genital area 
in these patients extremely good results were obtained (ie penile growth 
and appearance of pubic hair). Sp^Diol may therefore have a prognostic value.
As expected from the above results, the basal urinary excretion of 
5P"diol was significantly correlated with bone age (r = 0.199; p = 0.046), 
genital development (r = 0.332; p - 0.003) and the urinary excretion of 
testosterone (r = 0.405; p <0.001). Further correlations were noted 
between the urinary excretion of 53*-diol and the individual androstanediols, 
androsterone and epiandrosterone.
On facilitate study of the effect of HCG on the urinary excretion of 
Sp-'-diol the patients were again grouped according to phenotype and the 
mean stimulation index calculated for each group. These indices are 
shown in Table 3.XXIII,
It will be noted from this table that the urinary excretion of 5B"diol 
by *near"normal* patients in this investigation is increased approximately 
2,5 times after HCG stimulation, although again considerable individual 
variation is noted. These patients with 'near-normal* phenotype are again 
used for comparison of the various phenotypes investigated.
Patients with unilateral undescended testes, having a basal urinary 
53-diol excretion ranging from very high to very low, have a normal, 
although extremely variable, response following HCG administration.
Patients with delayed puberty also have a variable basal urinary 
5p*™diol excretion which is increased poorly following HCG. This response 
(1.15 ^ 0.27) is statistically significantly below that of *near~normal* 
patients (0,002<p <0.005) and is in agreement with the retarded genital 
growth of such patients.
TABLE 3,XXIXI EFFECT OF ADMINISTERED HUMAN CHORIONIC GONADOTROPHIN 
ON THE DAILY URmARY EXCRETIOi OF 5[3-“ANDROSTANE-3a,17B«DI0L BY
DIFFERENT PHENOTYPES
Phenotype and Number
■JlWtTnnwi'BwtJK i.rm l i s r l t n . n-n»ri ■<■■—  ^ Stimulation Index*
(Mean « 1 standard error)
•Near«*normal ^ phenotype (n = 7) 2,57 - 0,23
Unilateral undescended testes (n = 6) 2.41 « 1.33
Delayed puberty (n = 5) 1.15 " 0.27**
Short stature (n = 26) 1*14 w Go16**
Bilateral undescended testes (n = 14) 1.00 « 0,26**
Hypogonadism (n = 21) 0.86 - 0,15**
* 1 . . T 1 Urinary 58-™diol (3rd day HCG)* Stimulation Index ~ Basal urinary 5(3'-diol
** Significantly below ®near“->normal* patients
Patients of short stature, having a low basal urinary 5p™diol excretion, 
have a lowered response following HCG, This response, less than half of 
that of 'near-normal* patients, is- highly significantly subnormal 
(p< 0.00005) and cannot be explained by the short stature alone. However 
many of these patients with short stature did have small external genitalia. 
Patients with bilateral undescended testes, having very low basal
urinary excretion of 5p“diol, have no response following HCG, the excretion
1
of Sp-diol being the same as basal excretion. This lack of response is 
very significant (0,0002< p < 0,0005) and similar to that noted with 5a-diol.
Hypogonadal patients, having low or normal levels of urinary excretion 
of 5P“diol, have decreased 5p-dioi excretion following HCG, This response 
is highly significantly below that of 'near-normal' patients (p< 0.00005).
This decreased excretion may reflect changes in the hepatic metabolism of 
testosterone,
5cc™Androstane-“33 ,170-diol
nwiOMLimi'rn-iTui Mi■ pitwfw ■ i».■
5a'“Androstane“3p, ITp-diol (3p-diol) has been shown to be a metabolite 
of testosterone in the human prostate benignly hypertrophied (Chamberlain 
et al., 1966), Baulieu et al, (1968) studied the effects of 30-diol on 
tissue culture of rat prostate and reported that this metabolite maintained 
growth and secretion of the epithelial cells. The physiological importance 
of 3p“diol has since been emphasized by Baulieu (1970) and Robel (1971)
3(3“Diol has been identified as a sulpho-conjugate in plasma (Cronholm 
and Sjovall, 1968), as both free and as a sulpho-conjugate in human 
faeces (Janne et^  jQ,, 1971) and recently in urine following S-glucuronidase 
hydrolysis (Berthou ej: , 1972).
The basal urinary excretion of 36"'diol by the patients in this 
investigation is shown in column I, Table 3.XXI, It will be noted there 
that this is very low in the majority. Urinary 3G-diol excretion was 
undetected in 6 patients (8 per cent), whilst extremely low levels
(<5 jig per 24 hours) were found in a further 25 cases (33 per cent).
Although Berthou et (1972) have recently reported normal values for
the urinary excretion of 3p-diol in 5 adults, the absence of published 
normal values for children and adolescents, and the low number of patients 
with normal urinary excretion of 3(3-diol in this investigation, again 
prevented statistical analyses of these low results. It should be noted, 
however, that 7 patients (23 per cent) with extremely low urinary excretion 
of 3p-diol have bilateral undescended testes, whilst 12 patients (39 per 
cent) have either severe hypogonadism or delayed puberty.
The basal urinary excretion of 3j3*-diol of the patients investigated 
correlates with the basal urinary excretion of 5o:-diol (r ~ 0.354; p<0.00l). 
No correlation was found between the basal urinary excretion of Sp-diol 
and the basal urinary excretion of testosterone (r = 0.009; p = 0.470).
This is in agreement with the results of Mauvais-Jarvis ^  ad. (1970b) 
who have shown that 80 per cent of administered 3(3“diol was metabolised 
in vivo to 5oc“diol (the 3a-epimer) and androsterone and may explain the 
low urinary excretion of 3{3”diol.
The basal urinary excretion of 3p-diol was plotted against the basal 
urinary excretion of 5a«diol for each patient. This graph is shown in 
Figure 3.14. It will be noted that many of the patients with very low 
levels of urinary Sp^diol excretion have also extremely low levels of 
urinary Sa-diol excretion. As So-diol and 3g-diol are metabolites of 
testosterone within the target cells, it is probable that many of these 
patients lack such a metabolism and have either a tissue insensitivity to 
testosterone or alternatively primary testicular failure. This is no 
doubt the case in two of these patients with the testicular feminization 
syndrome (protocols 1 and 4) and a further six patients with primary 
testicular failure (protocols 18, 19 and 22-25). However the majority of 
these patients with low excretion of both 5a-diol and 33-diol are of
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Figure 3,14 The basai urinary excretion of Sa-androstane-SG,17G“diol
B»a*MMJ'-«i iw ii.i.Miiii i—iw-i ii i iBii Wi n i *
(3p-diol) compared with the basal urinary 
5cc-androstanediol (Sa-diol) excretion in individual 
patients. See text for explanation.
short stature and in most cases their low excretion is probably related 
to their small body size.
The remaining patients with low levels of urinary fa-diol excretion 
have normal or elevated urinary excretion of 3{3-diol. It is interesting 
that nearly all of these patients have severe hypogonadism (rudimentary 
scrotum, micropenis) and many have undescended testes.
The mean ratio of the urinary excretion of So-diol to the urinary
excretion of 3(3“diol (the 3a/3(3 epimers ratio) in these patients is 
0.24 - 0.20 (SD) which is statistically highly significantly different 
(p< 0.001) from that found by Berthou e^ _al. (1972) in three normal 
adult males (5.09 ~ Oo82)e
These patients have been shown to have extremely low urinary 
excretion of testosterone which may reflect inadequate testicular production 
of testosterone. It has previously been postulated that when general 
tissue metabolism cannot utilize testosterone because of inadequate 
production, then DilA becomes the principal anabolic Cl9 hormone (Hamilton, 
1974), DHA production thus increases in such patients and the urinary 
excretion of epiandrosterone increases correspondingly. Under these 
conditions the urinary excretion of 3(3-diol (a metabolite of epiandrosterone) 
will also increase as noted in these patients.
The remaining patients all have normal urinary excretion of SG-diol 
as judged by a normal ratio of the urinary excretion of 5a-diol to that
of 33“diol<, The mean 3a/3Q epimer ratio in these patients is 4,48 which
is in good agreement with that found in normal adult males by Berthou ejt ad.
(1972) and the conversion of plasma Sa^^dihydrotestosterone to Sa-diol/ 
33-diol ratio of 4.90 in normal adult males found by Mahoudeau e_t ad. (1971).
To facilitate further study of the effect of HCG on the urinary 
excretion of 33-diol the patients investigated were again grouped according 
to height and pubertal status and the mean stimulation index calculated
for each group. Patients investigated with 'near^normal' phenotype 
were again used for comparison. These indices are shown in Table 3.XXIV,
It will be noted from this table that the urinary excretion of 
Sp-^diol by 'near-normal* patients in this investigation is increased 
approximately 1=4 times after HCG stimulation.
Patients with short stature, having very low basal urinary Sp-diol
excretion, have a good response to HCG administration. Tliis response
1
(1,58 « 0,18) is very similar to that of ’near-normal* patients and 
evidence for normal testicular function in these patients.
Patients with delayed puberty, having normal basal urinary excretion 
of 33«diol, have a normal response to HCG administration. However, patients 
with hypogonadism, having normal or raised urinary excretion of Sg-diol, 
have a decreased excretion of 3(3«diol following HCG, This decrease is 
significantly below that of ’near-normal* patients (0*0l< p<0.02) and 
this, in combination with the raised urinary excretion of epiandrosterone, 
is further evidence for a partial deficiency of I7p-reductase previously 
postulated in such patients (page 187),
Patients with unilateral undescended testes, having very low basal 
urinary excretion of Sg-diol, have no response to HCG administration. 
Furthermore patients with bilateral undescended testes have a decreased 
excretion of 3G-diol following HCG. This decrease is again significantly 
below that of ’near-normal’ patients (0.0l<p<0.02) but not significantly 
below that of patients with unilateral undescended testes. These results, 
again in combination with the elevated urinary excretion of epiandrosterone, 
suggest a partial deficiency of iTp-reductase in many of these patients 
with undescended testes.
Two patients with severe gynaecomastia, having elevated urinary excretion 
of 38-diol, have extremely raised urinary excretion of 30-diol following HCG, 
The response to HCG in these patients (10,70 - 6.05) is consistent with my
iUD
TABLE 3.XXIV EFFECT OF ADMINISTERED HUMAN CHORIONIC GONADOTROPHIN 
m  THE DAILY URINARY EXCRETION OF 5cc-ANDROSTANE-33 ,l7p“DI0L BY
DIFFERENT PHENOTYPES
Phenotype and Number  ^ Stimulation Index*
(Mean « 1 standard error)
•Near»»nornial* phenotype (n = 5) 1.40 - 0.20
Short stature (n = 26) 1.58 - 0.18
Delayed puberty (n = 5) 1.24 i 0.20
Unilateral undescended testes (n = 6) 1.00 « 0.35**
Hypogonadism (n = 18) 0.78 « 0.12**
Bilateral undescended testes (n - 10) 0.74 - 0.14**
i.r ii&Mij I* muM'im, iiiïmaajv^.'in.TMasg3aLga.Æiii.’Wj.'utm:atcaggvj?«ie^tctgWM*ny
* Stimulation Index = ina^ 36-diol (3rd day HCG) Basal urinary 36™diol
** Significantly below *near»“normal' patients
postulate of a partial deficiency of Sp-hyclroxysteroid dehydrogenase 
in these patients.
Numerous results and statistical calculations have been presented 
in this chapter. IThese results will now be discussed and related more 
particularly to the clinical condition of the patients. Indeed an 
attempt will be made to explain the clinical findings in relation to 
both how much testosterone is elaborated and how the body responds at 
the tissue level to it.
CHAPTER 4
D I S C U S S I O N
It is now generally accepted that the determination of the total 
urinary 17-oxosteroid excretion is of limited use in assessing testicular 
function. Only 24 per cent of testosterone secreted by the testes is 
metabolized to such compounds (Hall ^  > 1974) and the testicular
contribution to the total 17-oxosteroids is only half that of the adrenal
component•
In this investigation quantitation of the total urinary 17-oxosteroids 
by the Ziramermann reaction gave extremely variable results which in the 
majority of patients were greater than the sum of individual 17-oxosteroids 
quantitated by flame ionization detection following gas liquid chromatography 
(GLC-FID). The difference between these results, the non-steroid
chromogenic material, is often considerable and is an indication of the
non-specificity of the Zimmermann reaction* This non-specificity has been 
noted previously by Goldzieher and Axelrod (1962) and more recently 
quantitated by Mattbijssen and Goldzieher (1971).
The determination of the urinary total l7-oxosteroids as a routine 
clinical test is of little value other than to indicate gross abnormalities 
in excretion. Nonetheless very low excretion of these compounds was found 
in older patients of short stature and patients with delayed puberty and 
this is likely to be significant. However, the quantities measured gave 
indication of the relative steroid mass for the loading of TLC and GLC 
systems.
Large variation was found in the volumes of serial 24-hour urine 
specimens despite the well organised ward conditions for urine collection. 
This variation does not appear to be related to age but is probably due 
in part to incomplete collection. The daily urinary creatinine excretion 
■was found to be significantly more constant for individual patients than 
the 24-hour urine volume although significant variation still persisted.
This residual variation may be due in part to diurnal rhythm in the case of 
incomplete collection.
— iS.I.U —
Several investigators have noted high variability in the daily 
urinary creatinine excretion and have attempted to explain this (Wray and 
Scott Russell, 1960; Doolan ejt , 1962; Paterson, 1967; Scott and 
Hurley, 1968; Curtis and Fogel, 1970; Turner and Cohn, 1975), Alterations 
in dietary protein have been implicated as a source of variability but 
frequently refuted or held to be of minimal importance (Folin, 1905b;
Cramer et , 1967; Curtis and Fogel, 1970). Physical activity, unless 
extreme, also seems to have little effect on creatinine variation 
(Tanner, 1968; Chattaway et , 1969). Similarly urinary volume has 
little effect under normal conditions (Cranièf ^t , 1967; and this 
investigation) 15 ml per kilogram per day being adequate for excretion.
In this investigation no effect of HCG on the daily creatinine excretion 
was noted either over the short period of test (6,000 I.U. daily for 
three days) or on longer therapeutic usage (1,500 I.U. alternate days for 
one month, protocol 79).
Several groups of workers have found the daily urinary creatinine 
excretion more constant than the 24-hour urine volume (Doolan , 1962;
Bleiler and Schedl, 1962; Paterson, 1967; Curtis and Fogel, 1970) whilst 
others have disputed this (Cramer £t al,, 1967; Scott and Hurley, 1968; 
Chattaway ^ t , 1969). This constancy was used throughout this 
investigation as a measure of the completeness of collection of 24-hour 
urine samples. Applegarth ^  (1968) have previously stressed the
usefulness of creatinine excretion from their study of amino acids in 
children.
hben the daily urinary creatinine excretion was plotted against age 
an interesting correlation was found. The urinary creatinine excretion 
of patients with normal stature was found to rise gradually during the 
prepubertal period and increase rapidly in parallel with the normal 
growth spurt at puberty.
The urinary creatinine excretion in patients of short stature was 
significantly below, although parallel to, the normal excretion whilst 
in patients with delayed puberty, not having a pubertal growth spurt, the 
urinary creatinine excretion rose gradually and approached the much lower 
excretion found in the older patients of short stature. Patients with 
precocious puberty and advanced bone age had an elevated urinary creatinine
excretion. It is generally accepted that creatinine is a product of
i
protein catabolism and that the urinary excretion of creatinine is 
significantly related to lean body mass, active protoplasmic mass, weight 
and surface area (Doolan et , 1962; Bleiler and Schedl, 1962; Turner 
and Cohn, 1975), Hie results of this investigation are in agreement with 
the established concepts that the urinary creatinine excretion is 
significantly related to stature (Graystone, 1968),
Those patients with abnormal urinary creatinine excretion also had 
an abnormal urinary excretion of both grouped and individual steroids.
VÛïcn these results of steroid excretion were adjusted to a normal 
creatinine excretion many of these results, particularly those from 
patients of short stature, were adjusted to the normal range whilst 
abnormal results still persisted in several patients with precocious puberty, 
delayed puberty and hypogonadal patients of short stature. Thus many 
patients with short stature alone had a normal urinary 17-oxosteroid 
excretion when compared to their creatinine output. Patients with delayed 
puberty and hypogonadal patients had a subnormal urinary 17-oxosteroid 
excretion when compared to their creatinine output, whilst two patients 
with precocious puberty had an elevated urinary steroid excretion 
even after correction for a normal creatinine output. These results 
suggest that many of the subnormal results of steroid excretion in 
patients of short sta/cure alone relate to the smaller endocrine gland 
size with reduced secretion of anabolic hormones.
Conversely, patients with persisting abnormal urinary excretion of 
androgens and androgen metabolites after correction to a normal creatinine 
excretion probably have endocrine disorders of the testes or adrenals. 
Comparison of the results of urinary steroid analyses with the urinary 
creatinine excretion may therefore have diagnostic use in the study of 
patients with growth disorders in association with abnormal endocrine function.
It will be noted that in my large group of patients the urinary
I
excretion of testosterone is significantly lower than normal in patients of 
short stature, bilateral undescended testes, hypogonadism and delayed 
puberty. Diminished urinary testosterone excretion has been reported 
previously by Schmidt and Starcevic (1967) in delayed puberty, Moxham and 
Nabarro (1968) in hypogonadism, Scurry ef (1971) in hypogonadism and 
delayed puberty and more recently in prepubertal boys with cryptorchidism, 
hypogonadism or delayed puberty by Rudd et af. (1973).
My finding of normal or elevated levels of plasma testosterone in 
these patients is surprising. Most investigators of like patients have 
found decreased concentration of plasma testosterone (Rivarola ^  af., 1970; 
Anderson et 3 I., 1972; Perheentupa ^  ^1., 1972; Dessypris and Adlercreutz, 
1972; Boyar et al., 1973; Stewart-Bentley and Horton, 1973; Rudd et al.,
1973; Walsh ^  ®Li*> 1976), Over-estimation of plasma testosterone in 
these patients reported in this thesis is unlikely as the same methods of 
purification, detection and quantitation were employed for both plasma 
and urinary testosterone determinations. Moreover, very low concentrations 
of plasma testosterone have been detected (15 ng per 100 ml) and very good 
agreement has been found between these results and results obtained when 
duplicate samples were analysed by a competitive protein binding assay 
(five patients).
Despite controversy in the past, recent studies have demonstrated a 
circadian rhythm of plasma testosterone levels (DeLacerda et al,, 1973;
Boyar ^  âi* » 1975; Southren and Gordon, 1975; Scholler ajl. , 1975).
Highest levels have been found about the time of awakening whilst 
lowest levels are found in the evening. However, the amplitude of this 
rhythm is small (10-25 per cent) and DeLarcerda ^t (1973) have found 
that only 20 per cent of the total variance of hourly integrated 
testosterone levels was due to a time effect. Moreover mean daily levels 
of plasma testosterone were attained by 11 am (Scholler e^ , 1975), the 
time of sampling used throughout this investigation.
The circhoral rhythm of plasma testosterone levels has much greater 
amplitude (Baker ^  , 1975), A close temporal relationship between
the nocturnal rises of LH and testosterone in pubertal boys has been 
found by Boyar et aj., (1975) suggesting that the Leydig cells respond 
rapidly to LH. No significant correlation has been found between LH and 
testosterone levels in data obtained at short time intervals (Alford ^  ,
1973). However, these workers found such a correlation between testosterone 
levels and LH levels in the preceding sample when using continuous sampling 
over three hours. This suggests that the testicular response may be 
delayed two to four hours which is in agreement with the delay of four to 
six hours noted in testosterone rise following intravenous HCG administration 
(Maurer et al., 1973).
Circhoral rhythm of plasma testosterone levels could explain some 
of the high levels of plasma testosterone noted in this thesis. However, 
more frequent sampling was considered unethical in the young patients 
investigated.
Doering £t ^1. (1975) have recently found a further variation in 
plasma testosterone levels. They described a circatrigintan rhythm of 
23 days (range 8-30 days) with an amplitude similar to the circadian rhythm. 
Such a rhythm, if present in children, should not affect the plasma 
testosterone levels over the short period of test (4-5 days) but again may 
explain some of the high plasma testosterone levels.
Normal or elevated plasma testosterone in combination with subnormal 
urinary testosterone excretion can be explained by an increased binding 
in plasma to testosterone-binding p-globulin (TeBG). High plasma 
testosterone levels due to increased TeBG levels have been reported in 
pregnancy and in hyperthyroidism (Vermeulen _et , 1969; Pohlman _et al. , 
1969; Vermeulen and Verdonck, 1972), Such elevated levels of plasma 
testosterone are not usually accompanied by virilization as only the free 
non-protein-bound testosterone fraction is biologically active. Vermeulen 
and Verdonck (1972) also reported increased levels of TeBG-bound 
testosterone in prepubertal boys and in adult hypogonadal males. It can 
readily be envisaged that the plasma testosterone in these hypogonadal 
prepubertal boys is probably nearly quantitatively bound to TeBG.
Vermeulen ejt al. (1969) observed an inverse correlation between the 
metabolic clearauice rate of testosterone (MGR ) and the binding capacity 
and binding index of TeBG. They postulated that testosterone bound to 
TeBG is not as readily metabolized as the unbound hormone. Further work 
by Vermeulen and Verdonck (1972) has shown a significant correlation 
between the MGR and the apparent free testosterone concentration.
Moreover, these authors also observed that increased binding of testosterone 
to TeBG was characterized by a relative Increase of 50 over 5o: metabolites 
of testosterone and a decrease in its iTp-hydroxy metabolites. They 
relate this change in metabolism to a decreased target organ metabolism of 
testosterone.
Subnormal urinary excretion of testosterone in combination with 
normal or elevated plasma testosterone may arise alternatively by tissue 
insensitivity to testosterone. Under these conditions there is less 
degradation of circulating testosterone secondary to a poor utilization 
of testosterone by testosterone-dependent tissues. If this were so, then 
free testosterone can only be cleared by urinary loss or liver metabolisn.
It is now generally accepted that testosterone must be metabolized 
to dihydrotestosterone, Sa-androstane-3a,173-diol (Soc-diol) and 
5a«androstane-3p,17p-diol (3p«diol) in order to exert a maximal biological 
stimulus in the classical androgen-dependent organs (Baulieu eJt 1968;
Baulieu, 1970; 1973). The most important of these metabolites outside the 
liver is dihydrotestosterone. Ito and Horton (1971) reported that 
dihydrotestosterone in the blood does not arise from direct secretion and 
may therefore reflect events occurring in the peripheral target tissues. 
Giorgi (1971), using a superfusion technique, elegantly demonstrated
the formation and intracellular retention of radioactively labelled 
5a-dihydrotestosterone from radioactively labelled testosterone in biopsies 
of human prostate. Shimazaki ejb (1966) located the prostate 5a-reductase 
in the microsomes and noted its absolute specificity for NADPH, Bruchovsky 
and Wilson (1968) found that up to half of the 5a-reductase is associated 
with the nuclear fraction in accessory sexual glands and they demonstrated 
the formation of androstanediols in the soluble cytoplasmic fraction of 
these tissues. Frederiksen and Wilson (1971) studied the kinetic properties 
of the Sa-reductase in rat prostate in detail and from consideration of 
the levels of testosterone, NADPH and the total enzymic activity of the 
gland they concluded that the reaction is limited only by the levels of 
available testosterone. As 5a-diol is the main metabolite of 
dihydrotestosterone, at least in normal individuals (Mauvais-Jarvis ^  al., 
1968), the determination of urinary 5a-diol excretion is of clinical interest, 
However, since urinary 5a-diol originates not only from testosterone 
metabolism in target tissues but also from the hepatic catabolism of 
testosterone and dihydrotestosterone (Mauvais-Jarvis ^t al,, 1970a), the 
urinary excretion of fa-diol must be compared to that of urinary 
testosterone glucuronoside which is formed only in the splanchnic 
compartment (Horton and Tait, 1966). The difference between the urinary
5«-diol excretion and testosterone therefore reflects target organ 
metabolism of testosterone and is an index of androgenicity (Mauvais-Jarvis 
et ; 1973).
We (the writer and Dr William Hamilton; Hamilton 1974a) have confirmed 
that 5cc“diol is a good reflection of androgenicity and have found a lower 
limit of extra-hepatic formed 5a-diol of 30 gg per day as commensurate 
with 'paediatric' masculinity. ^
Recently Kuttenn and Mauvais-Jarvis (1975) reported values of urinary 
excretion of testosterone glucuronoside and urinary excretion of 5a»*diol 
in normal boys and adults and several patients with abnormal sex development. 
Tiiey found much lower levels of urinary 5&-diol excretion in four prepubertal 
boys (6-26 gg per 24 hours) than in three postpubertal patients (93-138 gg 
per 24 hours).
Very recent work in adults by Doberne and New (1976) reported lower 
levels of urinary excretion of 5o;«diol than those of Mauvais-Jarvis jct al. 
0973). Although they were unable to support the hypothesis that the 
difference between urinary testosterone and urinary 5o.'“diol excretion 
represents the amount of extra-hepatic da-reduction of testosterone, they 
affirmed their use in the clinical evaluation of patients,
Robel ejt (1966a, 1966b) have shown that most of the urinary 
excretion of 5(3“androstane“3o:,176-diol (50-diol) is formed from the 
metabolism of testosterone glucuronoside whilst only a minor fraction arises 
from the metabolism of free (unconjugated) testosterone. Furthermore, as 
the urinary excretion of 5(3-diol exceeds that of Sa'-diol (Berthou a.1., 
1971) y the determination of the urinary 5(3-diol excretion may be of 
clinical significance.
Having investigated a large series of male patients with gonadal 
problems, it was possible to associate the urinary excretion of 56-diol 
with the development of the external genitalia, good development of the
penis accompanying high urinary excretion of 5|3"diol. By reference to the 
clinical observations in the patients investigated, and the results of 
Berthou e^ (1971) on normal males and females, a minimum daily urinary
50-diol excretion of 50 gg per 24 hours was found to be commensurate with 
normal genital development.
The urinary excretion of epiandrosterone (EpiA) was found to be raised 
in several patients in this investigation, with primary testicular failure 
and inadequate testosterone production, DHA was postulated as the 
principal anabolic hormone in such patients v/ith inadequate testosterone 
production and a direct metabolism of DHA to EpiA was suggested from 
studies of androgen metabolism. Raised urinary excretion of EpiA, then, 
may indicate a somatic defect secondary either to testosterone lack or 
tissue insensitivity to testosterone. In these circumstances, the soma 
cannot utilize testosterone and growth and development are dependent on 
the weaker androgen, DHA (Hamilton, 1974a), When testosterone is utilized 
as the anabolic hormone, the urinary excretion of EpiA is low. The 
urinary excretion of EpiA may therefore give an indication of somatic 
sta-tus of the patient.
The urinary metabolites of testosterone may then have clinical 
significance as indicators of androgenicity, genital development and 
somatic utilization of testosterone. The urinary excretion of these 
metabolites has been found of clinical use, especially when compared to 
the urinary and plasma testosterone levels, in assessing the pubertal 
development of many patients with gonadal disorders.
Abnormal gonadotrophin levels, raised plasma testosterone levels and 
tissue insensitivity to testosterone have recently been reported in the 
complete form of the testicular feminization syndrome (Judd et a1., 1972), 
This syndrome is characterized clinically by a female phenotype with 
.normal feminization, absent Mullerian derivatives and sparse or absent
sexual hair in association with the 46,XY karyotype and cryptorchidism.
Since the syndrome is manifest despite normal (Southren ^  , 1965;
French et , 1966; Rivarola _et aJ. , 1967) or elevated (Judd > ^972)
levels of plasma testosterone, then the aetiology of this ^ ndrome lies in 
the utilization of androgens. Despite the normal or raised levels of 
plasma testosterone these patients have normal female psycho-sexual 
differentiation and expression. ^
Psycho-sexual differentiation is believed to be controlled by the 
androgens and oestrogens which act on the anterior hypothalamus to determine 
behaviour, create sexual differentiation of the brain and control 
gonadotrophin secretion. Sexual desire is no doubt also involved. Although 
there is strong support for both androgen and oestrogen neurones, Stumpf 
(1970) postulated that the androgen neurones are in fact oestrogen 
neurones which will respond to androgens when these are present in 
sufficient amounts. Later work by Naftolin ^  af. (1971, 1972) in mature 
rats and human foetuses demonstrated that in both sexes androgens 
(testosterone and androstenedione) are aromatized to oestrogens by 
receptor cells in the hypothalamus. It is the oestrogen so formed that is 
now thought to determine sexual identity (Naftolin and Ryan, 1975).
In the testicular feminization syndrome the characteristically high 
gonadotrophin levels can be reduced by testosterone (presumably following 
conversion to oestrogens) and this is the only androgen effect that can be 
elicited in this syndrome- Thus in the testicular feminization syndrome 
although systemic sensitivity to testosterone is lost, the diencephalic 
cells retain their capacity to convert androgens to oestrogens. It is 
quite clear from this experiment of nature that the ability of the tissue 
to utilize testosterone is significant not only in determining the body 
form but also in determining the psycho-sexual differentiation and what 
the patient thinks of 'her' body form. Therefore in what follows I will
relate the metabolism of testosterone to the physical form of the patients 
and attempt to deduce whether their problem is primarily one of testosterone 
lack or of primary tissue insensitivity or an amalgamation of both. I will 
leave the concept of hormone-induced psycho-sexual identity to the 
interested reader.
TABLE 4.1 CLINICAL DETAILS OF FOUR PATIENTS WITH THE TESTICULAR FEMINIZATION
SYNDROME 1
Protocol Age (Years)
Bone Age 
(Years)
Height
Percentile
Weight
Percentile
1 0.4 0.4 50 50
2 2,8 3.0 50-75 50-75
3 3.3 2.0 10 10
4 10.1 10.0 97 75
In Table 4.1 are shown the clinical data of four patients with the 
testicular feminization syndrome. Their ages ranged from 5 months to 
lO.l years at the time of investigation. It is of interest that three 
patients, protocols 1, 2 and 4, show a high normal basal plasma testosterone 
concentration with an extremely good rise by the third day of HOC 
administration. Singularly patient 3 has a normal low basal plasma 
testosterone concentration but there is no rise following HCG, It must 
therefore be argued that this patient has in addition primary testicular 
failure. Further evidence for this is shown in the urinary testosterone 
results and retarded bone age for this patient. It can therefore be 
assumed that while osseous maturation is dependent on androgens in normal 
males, in these patients with the testicular feminization syndrome bone 
maturation is dependent on circulating oestrogen (Rosenfield et , 1971).
These patients with testicular feminization are taken as the prime 
example of tissue insensitivity and form the basis of the argument that a
study of the urinary androgen metabolites, as represented in the 
androstanediols, is of significance in determining the tissue metabolism 
of testosterone.
Clinically patients 1 and 4 are examples of the complete form of 
the syndrome, their external genitalia being exactly those of a normal 
female. Patients 2 and 3 have been interpreted as clinical examples of 
the partially expressed syndrome, as both have a small but significant 
degree of clitoral enlargement and have presumably partial insensitivity 
to testosterone (Rosenfield et , 1971; Madden ^  > 1975).
TABLE 4. II EXCRETION OF 5a-ANDROSTANE-3cc ,173-DIOL AND 5(3 - ANDROS TANE-3a , 178-DIG
IN FOUR PATIENTS WITH TESTICULAR FEMINIZATION
Protocol
Age
(Years)
5a«diol (pg/24 hrs) 53-diol (pg/24 hrs) 1
Basal Day 3 Basal Day 3
1 0.4 12 26 16 59
2 2.8 11 56 44 402
3 3.3 1 SO 109 254
4 10.1 9 17 12 20
It will be noted from Table 4.II that the basal urinary excretion of 
5a-diol is low in all patients. This is in agreement with the results of 
Kuttenn and Mauvais-Jarvis (1975) for prepubertal patients. Following 
stimulation with HCG the urinary excretion of 5a-diol remains low (< 30 ug 
per 24 hours; Mauvais^Jarvis et a^ . , 1973) in patients 1 and 4 and a poor 
androgenic status must be concluded. These patients will thus lack the 
rugged body form of the true male. Conversely, patients 2 and 3 have a 
good rise in the urinary excretion of fa-diol following HCG and therefore 
if untreated these patients will masculinize at puberty. Kuttenn and 
Mauvais-Jarvis (1975) have recently found high levels of 5a-diol 
excretion in adult patients with partial testicular feminization.
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From the data on the urinary excretion of 5B-diol the four patients 
again divide themselves into the two groups. Patients 1 and 4, with the 
complete form of the syndrome, have a low basal urinary excretion of 
5|3-diol which remains low following HCG. However, patients 2 and 3, with 
the incomplete form of testicular feminization, have much higher basal 
urinary excretion of 5f3-diol which rises to very high levels following HCG, 
If 53-diol excretion is indeed an index of the genital status then further 
clitoral enlargement will occur in patients 2 and 3 at puberty.
Compare these results with those from a normal pubertal patient 
(protocol 66, Chapter 5). This boy, aged 15.6 years at investigation, was 
of normal height and weight for age and had a bone a,ge (15.5 years) 
equivalent to his chronological age. He had a normal basal level of plasma 
testosterone and a good response to administered HCG, The basal urinary 
excretion of testosterone was also normal for age and again stimulated 
normally following administered HCG. Of interest and significance is the 
high basal urinary excretion of 5a-diol (230 pg per 24 hours) which remains 
high throughout stimulation (Kuttenn and Mauvais-Jarvis, 1975), It will 
also be noted that the urinary excretion of Sp-diol is at a high basal 
level and remains high following HCG. These results are in keeping with a 
normal pubertal boy with normal genital development.
Now observe the urinary excretion of epiandrosterone in this patient 
(protocol 66, Table 4.Ill), Here it will be noted that the basal excretion
TABLE 4.Ill URINARY EXCRETION OF EPIANDROSTERONE AND EFFECT OF
HCG
Protocol Age Epiandrosterone (jjg/24 hrs)
(Years) Basal Day 3
1 0,4 129 356
2 2.8 78 1,163
3 3.3 120 124
4 10.1 2 6
66 15.6 24 13
of epiandrosterone is at a normal low level (Uozumi et ^1., 1969) and 
remains low following HCG. This is in agreement with normal testosterone 
metabolism. Compare this with the- urinary excretion of epiandrosterone 
in patients 1, 2 and 3 with testicular feminization. These patients have 
an abnormally high basal urinary excretion of epiandrosterone which remains 
high following HCG. Abnormal metabolism of androgens must be concluded,
DHA being the main anabolic hormone. The extremely high value for patient 
2 following HCG is then probably due to a partial deficient activity of 
173-reductase. Such a defect has been postulated in other patients with 
incomplete testicular feminization (Neher and Kahnt, 1966; Saez ^  , 1971)
These two groups represent extremes in the spectrum of patients 
investigated. One is a normal male with the 46,XY karyotype with normal 
testicular function, whilst the other group have a female phenotype with 
the 46,XY karyotype due to the testicular feminization syndrome. While 
generally having good testicular function which is capable of responding 
to an HCG stimulus, this group differ from the normal male particularly in 
respect of the urinary excretion of 5a-»diol, 53-diol and epiandrosterone.
It is the urinary excretion of these three metabolites that, I postulate, 
reflects the difference in tissue sensitivity to testosterone. Thus 
patients with a high urinary excretion of 5a»diol (>30 |ig per 24 hours) 
have a good androgenic status, patients with a high urinary excretion of 
53"diol (> 50 pg per 24 hours) have a good genital status and patients 
with a low urinary excretion of epiandrosterone (< 50 pg per 24 hours) 
have a good somatic status.
Within the remaining patients investigated and now to be discussed 
I will point out patients who have poor testicular function (in that their 
plasma testosterone levels are low and do not rise significantly following 
HCG) and those who have normal levels of plasma testosterone but show 
altered excretion of the urinary androgen metabolites. The significance of 
these variants will be discussed.
Consider now the effect of an extra X chromosome in a male karyotype.
Two patients are presented here for study, one a typical case of Klinefelter*s 
syndrome with a 47,XXY karyotype, and a patient who has the XX-male syndrome 
but on whose X chromosome Y chromosome material has been detected in the 
testes by Dr Ferguson-Smith (personal communication) and will thus be 
considered a variant of Klinefelter*s syndrome. These patients will then
be considered as being modified in their testosterone effects somatically
i
by the influence of the extra X chromosome, while their testicular function 
will be regarded in the light of the known pathology of the Klinefelter 
testis. Clinical data for these two patients are presented below (Table 4,IV).
table 4. IV CLINICAL DATA OF PATIENTS WITH KLINEFELTER'S SYNDROME
Protocol Age (Years)
Bone Age 
(Years)
Height
Percentile Karyotype
Pubertal
Stage*
8
9
8.7
14.0
8.3
14.0
90
25
47,XXY 
46, XX
PI G1 
P3 G4
* Tanner (1962)
It is clear from the biochemical data presented for these two boys 
(protocols 8 and 9, Chapter 5) that both have a low normal plasma 
testosterone level which is satisfactorily increased following HCG. The 
good response to HCG is also reflected in an appropriate increase in the 
urinary excretion of testosterone from very low basal levels. These 
results are in agreement with those of Paulsen et al. (1968), Gabrilove 
e/c aT. (1970) and Stewart-Bentley and Horton (1973). Therefore while it 
is the rule that patients with Klinefelter Ls syndrome undergo testicular 
atrophy (Lipsett ejfc al., 1966; Hudson et , 1967; Stewart-Bentley and
Horton, 1973; lonescu £t ^^ 1. , 1974), at the ages of these boys when investi' 
gated the testicular capacity to produce testosterone was not significantly 
impaired (Franchimont et al., 1974).
The basal urinary excretion of the ll-deoxy-lT'-oxosteroids was 
generally significantly below normal and in particular these patients 
had a very low basal urinary excretion of aetiocholanolone which is in 
agreement with the results of Johnsen (1956). The response of these 
individual 17-oxosteroids to administered HCG was, however, significantly 
above normal, normal levels for age being reached by the second day 
of stimulation.
Observe, however, the considerable change in the urinary androgen 
metabolites which has occurred as the result of the extra X chromosome. 
Significantly there is low or undetectable urinary excretion of 5a«diol 
in both patients reflecting the poor androgenicity of these patients. In 
the younger patient the urinary excretion of 56-diol is low, this in 
agreement with his hypogonadism, whilst in the older patient there is 
normal excretion of 5p-diol which correlates well with the clinical 
features for he has adequate penis and scrotum although his pubic hair 
is of the female distribution. In the younger patient (protocol 8, XXY) 
the urinary excretion of epiandrosterone is normally low and therefore he 
has normal somatic response to circulating testosterone and is likely to 
grow to normal or above average proportions. It will be seen that already 
he is on the 90th percentile for height and the fact that his bone age is 
retarded indicates that his period of linear growth is longer than his 
chronological age would indicate and therefore he is likely to grow the 
taller. The older patient (protocol 9, XX) has an extremely high excretion 
of epiandrosterone which indicates he cannot utilize testosterone as the 
main anabolic hormone and he is using the weaker androgen, DHA. Tîîis 
correlates well with his clinical status, his height is retarded, he is of 
■poor physical build and he has marked gynaecomastia. As the basal urinary 
excretion of 33-diol was also greatly raised and the response of these 
compounds to administered HCG was significantly above normal a deficiency 
of 3B-hydroxyste.roid dehydrogenase is indicated.
De la Chapelle (1972), in a review of the XX^male syndrome, reported 
that the incidence of gynaecomastia in patients with this syndrome (32 per 
cent) is similar to that found in patients with Klinefelter*s syndrome 
(40 per cent). The patient investigated here had marked gynaecomastia and 
as a similar enzyme defect was found in a younger patient with slight 
gynaecomastia (protocol 53, Chapter 5) it was postulated that SS-^hydroxysteroid 
dehydrogenase deficiency may be a feature of patients with gynaecomastia.
I
However, as complete or partial deficiencies of adrenal 38“hydroxysteroid 
dehydrogenase are characteristic of congenital adrenal hyperplasia with 
the salt-losing syndrome, ambiguous genitalia and often early death 
(Janne £t , 1970), it was assumed that the enzyme deficiency postulated 
in the two patients in this investigation may be limited to the gynaecomastic 
tissue only. Recently Miller ^  (1974) have confirmed this finding by
in yijtro incubation studies of gynaecomastia tissue obtained from six 
patients at mastectomy.
Subsequent analysis of the urinary androgen metabolites of the patient 
with severe gynaecomastia following ACTH stimulation (protocol 80) shows 
a very good rise in androsterone and aetiocholanolone in the correct 
proportions, but there is no significant increase in epiandrosterone excretbn. 
This indicates that the defect is not of adrenal but is likely to be of 
testicular origin. Recently Janne ^  (1974) and Rosenfield £t (1974)
have both reported a testicular defect in 3g-hydroxysteroid dehydrogenase 
in pubertal patients with congenital adrenal hyperplasia and gynaecomastia.
XO/X.Y mosaicism in the female is characterized by poorly developed 
secondary sexual characteristics, with evidence of virilization (enlarged 
clitoris, hypertrichosis and masculine voice), a unilateral testis with a 
contralateral streak gonad, unilateral or bilateral Mullerian duct 
derivatives (fallopian tube, uterus) and often stigmata of Turner's syndrome. 
The clinical data on two patients with the XO/XY syndrome are given in Table 
4.V.
TABLE 4oV CLINICAL DATA IN PATIENTS WITH THE XO/XY SYNDROME
Protocol Age(Years)
Bone Age 
(Years)
Height 
Percent ile
Clitoral
Enlargement
Testicular
Histology
' 6 12.3 12.5 10 ++ Adenomatous clumped 
Leydig cells. 
Sertoli only.
7 14,8 15.2 25 ++ +
-------1
Adenomatous clumped 
Leydig cells, 
Hyalinized tubules.
It will be noted that both patients have normal basal plasma testosterone 
levels with adequate rises following HCG stimulation. This rise is reflected, 
somewhat unimpressively, in the urinary excretion of testosterone. This 
correlates well with the histological finding of a single testis with 
large clumps of Leydig cells in these patients. It is in accord also 
clinically with the enlarged clitoris noted in these patients. Therefore 
androgen-dependent tissues here are responding to the increase in testosterone 
levels, the basal levels being in the male range.
When the urinary androgen metabolites are considered it will be seen 
that the urinary excretion of 5a-diol is low and this is against a true 
androgenic status. It is clear that these patients represent an amalgam of 
the male and female phenotypes. Since basically they are examples of 
Turner variants it is readily appreciated that their androgenic status is 
inadequate. The urinary excretion of 5g-diol is high in both patients and 
this is in keeping with their masculine type of phallic enlargement. In ' 
patient 6 the urinary excretion of epiandrosterone is normally low and 
therefore one can anticipate that as this patient grows older she is likely 
to be taller than the usual short stature of the typical Turner syndrome. 
Conversely, patient 7 has a very high level of epiandrosterone excretion and 
this is against a good somatic status. This patient has almost reached her 
final adult stature (143 cm at investigation) and she is clearly then of the 
typical Turner type.
Protocol 5 is a true hermaphrodite with XX/XY mosaicism. At the age 
of 6,0 years her bone age was 5.8 years and her height on the 50th percentile, 
The clinical stigmata were those of an enlarged organ with a single perineal 
opening. The basal urinary excretion of all ancbrogen metabolites was 
extremely low and the administered HCG in general had no effect although 
the results were variable. These results are again not compatible with 
normal testicular function although the increase in plasma testosterone 
following HCG suggests some, although limited, Leydig cell function. It 
is no surprise therefore to find that this patient had bilateral ovotestes 
(Figure 1.7, page 42) the testicular component of which resembled primitive 
testicular tubules. This patient was somatically more female than male 
and is being raised successfully in the female sex.
The remaining patients will be classified mainly by their biochemical 
data. In Table 4.VI are the clinical data from eight patients who have
TABLE 4.VI CLINICAL DATA OF PATIENTS OF SHORT STATURE DUE TO DEFICIENT hGH
Protocol Age(Years)
Bone Age 
(Years)
Height
Percentile hGH LH
Pubertal
Stage
10 8.1 6,4 < 3 GO PO
11 8.5 5.4 < 3 « G1 Pi
12 10.1 7.5 < 3 G1 PI
13 11.0 7.3 < 3 — - G1 Pi
14 11.5 8.2 < 3 - G1 Pi
15
(Retest of 12)
12.2 8.6 < 3 — G1 PI
16 14.3 9.4 <3 « G1 PI
17 15.0 12.4 <3 - » G2 P2
been demonstrated to be deficient in human growth hormone (hGH) reserve 
following insulin hypoglycaemia. These patients have been accepted at 
the clinical level as being hGH deficient and suitable for hGH administration, 
It will be seen that all, with the exception of patient 11, are in addition
deficient in luteinizing hormone (LH) production as judged from an 
LHRH stimulation teste
All patients show normal basal levels of plasma testosterone with 
generally a small increase following HCG, These increases in plasma 
testosterone levels were reflected in the urinary excretion of testosterone. 
The slight increase in testosterone production inferred following HCG is 
due probably to the quiescent testicular state in the absence of endogenous 
LH stimulation. As many of these patients had deficient FSH production 
this is in agreement with the results of Odell et^  (1973) that FSH 
induces sensitivity to LHo One patient (protocol 10) indeed showed no rise 
in the plasma testosterone concentration following HCG although the basal 
level was raised.
All patients show very low urinary excretion of 5a«diol (< 8 |ig per 
24 hours) and poor androgenicity must be concluded. Three patients 
(protocols 14, 16 and 17) have in addition a low excretion of 5(3-diol, 
this indicating a poor genital status and supported by the finding of 
small infantile penis and very small testes (< 3 ml volume) in these 
patients. It must be concluded that apart from having a poor testicular 
potential (as LH is absent) these patients show evidence that the external 
genitalia do not metabolize testosterone normally. These three patients 
will, with the continued absence, show poor androgenic and genital 
development probably ultimately being classed as hypogonadal males.
Four patients (protocols 10, 11, 13 and 15), while showing a very low 
urinary excretion of 5a-diol, have a good urinary excretion of Sgfdiol,
These four patients also have small external genitalia and testes, despite 
a good genital status, inferring that given appropriate LH stimulation the 
prognosis for adequate genital development is good.
All the patients in this group have a low urinary excretion of 
epiandrosterone, this signifying a good somatic status. Thus if given
- “
adequate replacement hGH therapy, and if the patients can attain adequate 
levels of endogenous testosterone, then good linear growth is assured.
It has been suggested by some that both testosterone and hGH are 
necessary for the normal male adolescent growth spurt (Zachmann and Trader, 
1970)« Moreover, these authors consider hGH may even be necessary to 
produce normal development of the secondary sex characteristics, although 
this mechanism of action remains obscure (Zachma|in, 1972), The synergistic 
action of testosterone and hGH on growth may be simply additive (Tanner 
^t al,, 1971) or even multiplicative (Trader et ^1., 1964),
The findings in this investigation could support such a synergistic 
action of testosterone and hGH on growth, in that patients who do not 
respond satisfactorily to growth hormone, and have such a pattern of 
androgen metabolites, would benefit from a therapeutic trial of growth 
hormone/androgen therapy.
In Table 4,VII are shown the clinical data of eight patients who had 
no rise of plasma testosterone concentrations following HCG. These patients 
fall into three distinct clinical and biochemical groups.
ta b l e 4.VII CLINICAL DATA OF TATIENTS WITH TRIMARY TESTICULAR FAILURE
Trotocol Age
(Years)
Bone Age 
(Years)
Height 
Tercentile hGH
Pubertal
Stage
18 5,4 4.2 3 + Tl G1
19 6,0 4.3 < 3 + PI Gl
20 8.3 8.3 10 + Pi Gl
21 10,1 10.1 50 + PI Gl
22 10,3 9.0 3 Pi Gl
23 11.8 11.8 10-25 + PI G2
24 15.0 12.0 < 3 + P2 G2
25 15.3 14.2 3 P2 G2
The two youngest patients (protocols 18 and 19) are of short stature, 
with normal levels of hGH and retarded bone age. Both have very small
Vtestes (volumes 0.5 ml and <1 ml respectively). The levels of urinary 
testosterone excretion and plasma testosterone concentration were at 
normal levels for age but did not rise following HCG. The urinary 
excretion of 5or-diol was very low in each patient whilst the urinary 
excretion of Sp-diol and epiandrosterone were at normal levels. Therefore 
these patients have a poor androgenic status, but normal genital and 
somatic latency. Clinically these patients were deduced to have primordial 
dwarfism with primary testicular failure. Cheek el: aj.* (1966) studied 
muscle cell size in children with primordial dwarfism and found gross 
reduction in the number of muscle cells, although individual cell size was 
normaly and they postulated an iu utero failure of adequate cell multiplication, 
In later work Cheek ei: jU.* (1968) found a correlation between total cell 
population and urinary testosterone glucuronoside excretion, low levels of 
urinary testosterone being associated with small cell numbers. The primary 
testicular failure noted in these patients may therefore cause inadequate 
cell division.
Patients 20, 21 and 23 are taller than the other patients within this 
group (height percentiles 10-50) and their bone ages are equivalent to their 
chronological ages. Two of these, patients 21 and 23, are now knovm to 
have testicular agenesis and it is possible that the other patient (protocol 
20), who presented with bilateral cryptorchidism, may also have testicular 
agenesis. All have low levels of plasma testosterone with no rise 
following HCG administration. The urinary excretion of Sa-diol was 
normally high in all patients as was the urinary excretion of 56-diol.
The urinary excretion of epiandrosterone was normally low in two patients 
but high in patient 23. It must be concluded that these patients would 
have reasonable chance of developing into normal adult males were it not 
for the fact that their testes are incapable of producing testosterone for 
systemically there is no reason why they cannot utilize testosterone (with 
the exception of patient 23) if it was present in physiological amounts.
The remaining patients within this set, patients 22, 24 and 25, are 
of short stature with normal levels of hGH and retarded bone age. All 
have small testes (< 8 ml volume). The plasma testosterone concentration 
in these patients is normal or high normal but does not rise following 
HCG. All patients within this group have a poor androgenic status as 
Judged from the low urinary excretion of 5a-diol, whilst the two older 
patients have a good genital status inferred from the high urinary 
excretion of Sp-diol. As these patients have normal levels of LH it must 
be concluded that the testes in these patients are maximally stimulated 
and their prognosis for future development is poor»
The remaining patients in this thesis show a variable clinical 
picture and are thus grouped according to the urinary excretion of 
5oï-diol, 5P“diol and epiandrosterone. The biochemical findings in these 
patients will now be discussed and correlated with the clinical data.
The prognosis for future development will be given where possible.
The first group to be considered (Group A) have a low urinary 
excretion of 5o>diol, a low urinary excretion of 58-diol and a low urinary 
excretion of epiandrosterone. Their clinical data are given in Table 4.VIII 
It will be noted from this table that five patients (protocols 29,
30, 35, 38 and 39) are of short stature despite normal levels of hGH and 
normal systemic testosterone utilization. These five patients, however, 
all have other basic problems in addition to small testes and their 
short stature is believed to be part of those syndromes. All other 
patients are within the normal to upper percentiles for height and thus 
they have no growth problem, in keeping with their good somatic status.
Their main problem is small testes, many undescended, in addition to 
their presenting symptom of microgenitalia.
It is interesting that patients 26, 2? and 28 are brothers with 
familial inheritance of bilateral undescended testes. The two older
TABLE 4,VIII CLINICAL DATA OF PATIENTS IN GROUP A (GOOD SOMATIC STATUS ONLY)
Protocol Age(Years)
Bone Age 
(Years)
Height
Percentile hGH
Pubertal
Stage
26 4.1 4,1 75 + Pi Gl UU*
27 6.0 6.0 75 + Pi Gl UU
28 7.3 7.3 97 + PI Gl UU
29 8.2 8.2 < 3 Pi Gl
30 10.8 10.5 -<:3
1
50-75
+ Pi Gl
31 10.8 10.8 Pi Gl
32 11.0 10.9 25-50 -j- Pi Gl u
33 11.2 11.6 75 + Pi GO UU
34 11.9 10.1 25-50 P2 G2 UU
35 13.5 9.4 < 3 -1- Pi Gl u
36 14.8 13.0 10 P2 Gl
37 15.0 12.5 50 + P2 Gl
38 16.1 12.0 < 3 + PI G2
39 19.0 16.0 <3 + P4 G4 
Following HCG/HMG
* UU = bilateral undescended testes; U = unilateral undescended testis
brothers had undergone successful bilateral orchidopexy before investigation, 
whilst the younger brother (protocol 26) presented with bilateral undescended 
testes, hypospadias and a very immature divided foreskin. Despite 
successful orchidopexy in the two older brothers these three patients show 
very similar urinary excretion of androgen metabolites, steroids of both 
adrenal and testicular origin being very low. Recently Walsh jet _^ 1. (1976) 
have found similar results for plasma testosterone in patients with 
familial bilateral undescended testes.
In view of the fact that all patients within this group have normal 
basal plasma testosterone concentrations and adequate response following 
HCG stimulation, a normal hypothalamo-pituitary-gonadal axis must be 
inferred. However, LHRH tests performed on the two eldest patients 
(protocols 38 and 39) showed impaired response to LHRH indies ting that 
endogenous LH could not maintain plasma testosterone in the post-pubertal age 
group.
It is interesting that the bone age is equal to the chronological age 
below 12 years of age but in older patients there is significant retardation 
in bone maturation. These results are in agreement with my postulate of 
normal LH levels in the younger patients within this group and progressive 
failure with age.
patient 34 has phocomelia, affecting his upper limbs, in consequence 
to treatment of his mother during the first trimester of pregnancy with 
thalidomide (o:™phthalidoglutarimide) the well-known teratogenic drug 
originally used as a sedative to alleviate the symptoms of morning sickness.
0
0 I 0 I 0 I 0
H H
THALIDOMIDE AMINOGLUTETHIMIDE
Thalidomide is very similar in structure to aminoglutethimide and 
both these drugs share the same side^effects, with the exception of 
teratogenicity. Aminoglutethimide, an anticonvulsant, also causes adrenal 
inhibition of glucocorticosteroid and mineralocorticosteroid synthesis 
by inhibition of 20a-hydroxyiase in the side-chain cleavage of cholesterol, 
and is often used in the treatment of adrenal hyperplasia. It is possible 
that thalidomide may also cause inhibition of 20o:«-hydroxylase and if this 
is so this may explain the bilateral testicular undescent and severe 
hypogonadism noted in this patient.
In conclusion, therefore, this group show poor androgenic status, 
poor genital status but generally grow well. They may also show 
evidence of LH deficiency in older patients, being under the third 
percentile for height as they do not have a pubertal growth spurt.
The second group for consideration (Group B) have a low urinary 
excretion of So'^diol, a high urinary excretion of fp^diol and a low 
urinary excretion of epiandrosterone and therefore have, by inference, 
good genital and somatic latency. Their clinical data are shown in Table 4,IX.
TABLE 4.IX CLINICAL DATA OF PATIENTS IN GROUP B (POOR ANDROGENIC STATUS ONLY)
Protocol Age(Years)
Bone Age 
(Years)
Height
Percentile hGH
Mean Parental 
Height Percentile
Pubertal
Stage
40 4.1 3.5 3 ' + Pi Gl
41 4.2 2.4 -c 3 + Congenital
scholiosis
Pi Gl
42 13.0 11.5 10-25 + 10 Pi Gl
43 14.0 11.8 < 3 + 3 Pi G2
44 14.0 10.0 3 + 10
Cushing *s
P2 G2
45 16.0 16.0 3 10 Pi G2
46 16.0 14.0 4 3 + 3 P2 G2
47 16.0 15.0 < 3 H- P2 G2
48 16.0 14.0 10 + Cyclophosphamide
treated
P2 G2
49 16.1 14.5 4. 3 P2 02
50
Repeat of 45
17.1 17.2 3 + P3 G4
i
While patients of group A were generally of above average height, the 
patients in this group are all of short stature, despite normal levels of hGH 
and good somatic latency. One might reasonably have expected these patients 
to have been taller, but there were good physical or genetic reasons for 
these patients to be of short stature. Patient 41 had congenital scholiosis 
while patient 42 had severe anoxia during the third uterine month and in 
addition the mean parental height was low. Four other patients were of small 
genetic origin (patients 43^46) whilst another patient had the nephrotic 
syndrome and had received cyclophosphamide as therapy. Cyclophosphamide 
(l-bis-(2 chloroethyl)amino-l-oxo-2-azQ-'6 oxaphosphoridine) is a
heterocyclic mustard used as a cytostatic drug and is known to cause 
inhibition of spermatogenesis although it is not believed to affect the 
interstitial cells (Kumar e_t , 1972; Vilar, 1974), It is of interest, 
in light of the repeat test on patient 45 (protocols 50 and 79), that 
although when first tested at 16 years of age he was under the third 
percentile for height, one year later he is only on the third percentile
and bone age is equal to chronological age. Thus patients in this group
1
are likely to be small if their genetic pattern is small despite a good 
somatic latency.
All patients within this group presented with retarded gonadal 
development despite good genital latency as inferred from the high urinary 
excretion of 5(3-dioi. This discrepancy may be related to the low urinary 
excretion of Scx-diol in these patients, Vermeulen (1972) observed
a good correlation between the urinary excretion of 50'-'diol and the apparent 
free testosterone concentration. Therefore these patients may have increased 
binding of testosterone, as noted in other patients with hypogonadism 
(Vermeulen and Verdonck, 1972). Under these conditions there is an increased 
conversion of testosterone to 56-metabolites (Vermeulen and Verdonck, 1972), 
Alternatively these patients may have a partial deficiency of 
5a-reductase as several patients (41, 43 and 47) show abnormal excretion of 
androsterone and aetiocholanolone whilst all show diminished urinary 
excretion of androsterone.
There is evidence that these patients will enter into a late puberty 
since the retest of patient 45 (protocol 50) showed raised gonadotrophin 
levels and raised adrenal function, whilst patient 49 has since entered 
into a seemingly normal but delayed puberty.
The third group for consideration (Group C) have a low urinary 
excretion of 5o;-diol, a high urinary excretion of 53“diol and a high 
urinary excretion of epiandrosterone and therefore by inference have 
good genital latency. Their clinical data are shown in Table 4.X.
TABLE 4.x c l i n i c a l DATA OF PATIENTS IN GROUP C (GOOD GENITAL STATUS ONLY)
Protocol
Age
(Years)
Bone Age 
(Years)
Height
Percentile
Weight
Percentile
Pubertal
Stage
51 3.8 3.8 50 75 Pi Gl
52 6.8 6.8 10 25-50 Pi Gl
53 10.9 10.9 75 90 Pi Gl
54 11.0 12.5 90 97 P2 G2
55 12.5 12.7 50
1
50
90 P2 G2
56 13.7 13.9 75-90 P2 G2
57 13.9 13.5 <3 10 Pi G2
There it will be noted that these patients are of normal bone age and 
genital development. However these patients generally show obesity, this 
in combination with normal or above normal height. It is interesting that 
the short stature of patient 57 is of genetic origin.
This group of patients all have good levels of plasma testosterone 
with normal rises following HCG and thus normal testicular function must be 
inferred. Similarly normal adrenal function must be concluded from the 
normal urinary excretion of individual 17-oxosteroids noted in these patients 
Their problem is thus one of metabolism and is in keeping with the high 
urinary excretion of epiandrosterone noted in these patients. It was 
inferred that these patients were of poor somatic latency, yet all grow 
well and it must be concluded that other factors are causing raised urinary 
epiandrosterone in these patients. It is interesting that in patients 51,
52 and 55 the urinary excretion of epiandrosterone falls following HCG 
whilst in patient 53, with gynaecomastia, the grossly elevated 
epiandrosterone excretion is probably due to a partial 33-hydroxysteroid 
dehydrogenase defect as postulated earlier (page 225),
The next group for consideration (Group D) have a low urinary excretion 
of 5a-diol, a low urinary excretion of 55-diol and a raised u r i n a r y
C4Ù (
excretion of epiandrosterone and therefore have poor potential* Their 
clinical data are shown in Table 4.XI.
TABLE 4.XI CLINICAL DATA OF PATIENTS IN GROUP D (POOR POTENTIAL)
Protocol Age(Years)
Bone Age 
(Years)
Height
Percentile
Undescended
Testes
Pubertal
Stage
58 4.5 6.5 25^50 UU Pi GO
59 5.4 6.0 10-25 i UU PI GO
60 9.5 ... 50 UU Pi GO
61 9.6 11.0 97 UU Pi Gl
62 10.0 3 UU Pi Gl
63 10.9 8.0 50 UU Pi GO
64 14.4 12.1 <3 '• Pi Gl
There it will be seen that although these patients were of variable 
height and had varying degrees of bone maturation nearly all of them show 
bilateral undescended testes and severe hypogonadism. The majority of these 
patients have a normal plasma testosterone concentration and good response 
to HCG and therefore their problem is probably one of metabolism as they 
have adequate response to HCG (Walsh et , 1976). It is therefore of 
interest that these patients with bilateral undescended testes all had 
a low basal urinary excretion of androsterone, aetiocholanolone and DHA 
but an elevated urinary excretion of EpiA. The urinary excretion of 
EpiA is normally much lower than that of the other ll-deoxy-17-oxosteroids 
(Uozumi et , 1969) and therefore these results imply abnormal metabolism 
of the androgens. This abnormal metabolism was confirmed by the elevated 
A/Ae ratio in most patients. The undetectable or significantly subnormal
5
urinary excretion of both DHA and A “'diol implys a deficiency of 
17,20“-desmolase in these patients with bilateral undescended testes. The 
low urinary excretion of both 5:f-diol and 56™diol probably indicates 
reduced androgenicity (hypogonadism) and not tissue insensitivity
- 238 «
(Mauvais-Jarvis ^  s 1968) as both of these metabolites had a poor 
response to administered HCG.
The final group for discussion (Group E) have good urinary excretion 
of 5a«diol, normal urinary excretion of Sfi^diol and low urinary excretion 
of epiandrosterone and therefore have normal latency for development*
Their clinical data are shoxvn in Table 4.XII. There it will be noted that
TABLE 4.XII CLINICAL DATA OF PATIENTS GROUP E (NORMALS)
Protocol Age(Years)
Bone Age 
(Years)
Height
Percentile
Pubertal
Stage
65 15.0 15.0 50 P3 G3
66 15. 6 15.5 50 P3 G3
67 20.0 19.5 50 P5 G5
68 26.0 26.0 50 P5 G5
all these patients have normal bone maturation, are of normal height and 
normal development of secondary sexual characteristics. Their gonadal 
development and testicular size are in agreement with their normal urinary 
excretion of androstanediols whilst all, with the exception of patient 65, 
show normal adrenal function inferred from the urinary excretion of 
individual l7»oxosteroids. Patient 65 presented with Cushing's syndrome 
and it is of interest that he showed a raised aetiocholanolone/androsterone 
ratio typical of this syndrome (James, 1961).
Similar grouping of the remaining patients considered in this thesis 
produced several very small groups of one to two patients and thus aetiology 
and prognosis cannot be given. However, all of these patients when 
considered individually show urinary excretion of androgen metabolites 
equivalent to their development.
The urinary metabolites of testosterone may then have clinical 
significance as indicators of androgenicity, genital development and
somatic utilization of testosterone. The urinary excretion of these 
metabolites has been found clinically suggestive, especially when compared 
to the urinary and plasma testosterone levels, in assessing the pubertal 
development of many patients with gonadal disorders,
'rhe method of assessing testicular function, developed and applied 
in this investigation and described in this thesis, aims at estimating the
ability of the testes to produce testosterone and the ability of the soma
1
in general to utilize the available testosterone. It does not resolve the 
quest for the basic aetiology of many gonadal disorders but it points to 
several enzyme defects which may contribute to the aetiology of such 
disorders.
CHAPTER 5
P R O T O C O L S
The results from individual patients are tabulated in this Chapter. 
These results are included merely as an addendum for the reader who may 
wish to compare individual results within patients.
Patients are identified here by first name and initial of the 
surname only for ethical reasons* The reader requiring further 
information is referred to the case records at the relevant hospital 
of admission,
1
The following abbreviations are used in the tables;«
ND Not detectable
NM Not measured (used in cases where the
retention time of a particular steroid 
differs by more than 0.2 minutes from 
the retention time of the standard 
steroid).
P Pubertal hair stage (Tanner, 1962)
G Genital stage (Tanner, 1962)
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
Allison P«
Royal Northern Infirmary, Inverness
047512
0,4 years
0.4 years
50
Pi Gl (female)
Testicular feminization syndrome 
46,XY
u r i n a r y c r e a t i n i n e 48-76 (mean 61) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.20 mg per 24 hours
Day 1 0.27
Day 2 0*21
Day 3 0.12
URINARY TESTOSTEROnIE Basal 0,22 fig per 24 hours
Day 1 0.25
Day 2 0.41
Day 3 0.78
PLASMA TESTOSTERONE Basal 479 ng per 100 ml
Day 3 1,886
URINARY ANDROGEN METABOLITES \xg per 24 hours
'
Basal Day 1 Day 2 Day 3
5cf-Androstane-3o: ;l76^diol 12 15 14 26
5(3""Androstane-”3a ,l7G-diol 16 29 31 59
A^-Androste ne-38,176-di o1 ND ND ND ND
5oC’-Androstane-3|3 ,17p-diol ND ND ND ND
Androsterone 19 9 3 13
Aetiocholanolone 8 8 7 16
be h y d r o e p i a nd r os t e r one 23 58 83 128
Epiandrosterone 129 194 354 356
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day:
Protocol 2
Name Allison Q,
Hospital of admission RHSC, Glasgow
Hospital number '136443
Chronological age 2,8 years
Bone age 3,2 years
Height percentile 50-75
Pubertal stage PI Gl (female)
Clinical diagnosis Testicular feminization syndrome
Karyotype 46,XY
1
URINARY CREATININE 90-206 (mean 149) mg per 24 hours
u r i n a r y 17-o x o s t h r o i d s Basal 0.12 mg per 24 hours
Day 1 0.12
Day 2 0.23
Day 3 0.31
URINARY TESTOSTERONE
t~rrTT~t>iiTnn ■ .............. ■mi 11 n i wi, ,1#,, w n w m »  n 1 tiiwi Basal 0.19 |ig per 24 hours
Day 1 NM
Day 2 1.51
Day 3 0.96
PLASMA TESTOSTERONE Basal 501 ng per 100 ml
Day 3 3,446
URINARY ANDROGEN METABOLITES |xg per 24 hours
Basal Day 1 Day 2 Day 3
5o-Androstane™3a,17B™diol 11 12 . 15 56
56^Androstane-3&,17g-diol 44 56 128 402
A^-Androstene™3|3 ,176-diol ND ND ND ND
5cc-Androstane-33 ,17p-diol 113 152 190 562
Androsterone 152 167 160 277
Aetiocholanolone 56 74 105 97
Dehydroepiandrosterone ND ND ND ND
E p i and r os terone 78 96 121 1,163
113-Hydroxyandrosterone 1,102 NM NM 1,159
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day
Protocol 3
Name Sandra T.
Hospital of admission RHSC, Glasgow
Hospital number 135192
Chronological age 3.3 years
Bone ige 2,0 years
Height percentile 10
Pubertal stage Pl Gl (female)
Clinical diagnosis Testicular feminization syndrome
Karyotype 46,XY 1
URINARY CREATININE 209-300 (mean 246) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0o58 mg per 24 hours
Day 1 0.15
Day 2 0.03
Day 3 0.03
URINARY TESTOSTERONE Basal 1.12 pg per 24 hours
Day 1 NM
Day 2 1,23
Day 3 1.27
PIJ\SMA TESTOSTERONE Basal 76 ng per 100 ml
Day 3 77
u r i n a r y ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,173-dioi 1 21 37 80
53“Androstane-3c£,l73"diol 109 117 184 254
A^-Androstene™3p,173-diol 29 58 ND ND
5oc“Androstane-33 ,l7p-diol 153 243 163 190
Androsterone 133 136 206 287
Aetiocholanolone 16 9 63 41
Dehydroepiandrosterone 80 84 95 139
Epiandrosterone 120 124 124 124
Patient was administered HCG (6,000 I.U* per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
Allison A,
RHSC, Glasgow 
122910
10.1 years
10.0 years 
97
Pl Gl (female)
Testicular feminization syndrome
46, XY
1
URINARY CREATININE 512-651 (mean 587) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.58 mg per 24 hours
Day 1 0.58
Day 2 1.18
Day 3 1.35
URINARY TESTOSTERONE Basal 2,31 fjtg per 24 hours
/ Day 1 2.63
Day 2 5.47
Day 3 6,88
PLASMA TESTOSTERONE Basal 1,079 ng per loo ml
Day 3 15,219
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3o: j,17'p-diol 9 37 59 17
5(3«Androstane“"3o: ,173-diol 12 33 24 20
A^-Androstene-33,17p-diol ND ND ND ND
5a-Androstane-3p,170-diol 30 64 86 53
Androsterone 150 200 223 272
Aetiocholanolone 79 90 115 125
Dehydroepiandrosterone 19 71 148 44
Epiandrosterone 2 19 27 6
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day:
Protocol
Name
Hospital of admission 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
Andrea S. 
Vienna 
6.0 years 
5.8 years 
50
Pl Gl (female) 
XX/XY syndrome 
46,XX/46,XY
URINARY CREATININE 211-467 (mean 299) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1 0.03 mg per 24 hours
Basal 2 0.05
Day 1 0.24
Day 2 0.53
Day 3 0.32
URINARY TESTOSTERONE Basal 1 0.18 jig per 24 hours
Basal 2 0.19
Day 1 0.18
Day 2 0.18
Day 3 0.19
PLASMA TESTOSTERONE Basal 158 ng per 100 ml
Day 3 283
URINARY ANDROGEN METABOLITES \ig per 24 hours
Basal 1 Basal 2 Day 1 Day 2 Day 3
Sa-Androstane-Scx ,17j3-diol 1 1 1 1 1
5[3 -Andr 031 ane- 3a, 176- di o 1 1 3 2 1 1
5
A -Androstene-36,17p“diol 1 1 1 1 1
5a-Androstane-33,17p-diol 1 1 1 1 1
Androsterone 11 11 13 18 13
Aetiocholanolone 1 1 99 45 12
Dehydroepiandrosterone 1 1 52 31 3
Epiandrosterone 1 1 17 14 1
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol 6
Name Dianne W.
Hospital of admission Newcastle General Hospital,
Childrens Dept, Newcastle upon Tyne
Hospital number 13146
Chronological age 12,3 years
Bone age 12,0 years
Height percentile 10
Pubertal stage P3 G2 (female)
Clinical diagnosis XO/XY syndrome
Karyotype 45,XO/46,XY
URINARY CREATIÎ4INE 356-734 (mean 567) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 2,10 mg per 24 hours
Day 1 3,08
Day 2 1,33
Day 3 0.83
URINARY TESTOSTERONE Basal 0,31 \ig per 24 hours
Day 1 0.34
Day 2 0.63
Day 3 0,77
PLASMA TESTOSTERONE Basal 479 ng per 100 ml
Day 3 845
URINARY ANDROGEN ME TA BOLITES f.ig per 24 hours
Basal Day 1 Day 2 Day :
5a:-Androstane™3a ,l7p«diol 38 15 21 8
Sp-Androsta-ne-Bo: ,17p-diol 50 127 23 46
A -Androstene“3p,176-diol 8 8 7 7
5a*«Androstane-3p ,l7p-diol. 9 8 7 9
Androsterone 467 650 666 761
Ae t i oc h o1anolon e 327 483 267 717
Dehydroepiandrosterone 157 77 79 77
Epiandrosterone 8 23 8 19
Patient was administered HCG (6,000 I*U. per day) intramuscularly on days 1-3
Protocol
Manie
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
Moira McC, 
RHSC, Glasgow 
6320
14.8 years 
15,2 years 
25
P3 G3 (female)
XO/XY syndrome 
45,XO/46,XY
1
URINARY CREATININE 670-987 (mean 821) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1,02 mg per 24 hours
Day 1 0.88
Day 2 0.85
URINARY TESTOSTERONE Basal 2.12 pg per 24 hours
Day 1
Day 2 2 c 59
PLASMA TESTOSTERONE Basal 225 ng per 100 ml
Day 2 711
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2
5oC“Androstane“3ct: ,173“diol 29 28 21
53-Androstane”3a,173-diol 140 131 112
A^-Androstene-33,173-diol ND ND ND
5a-Andr os t ane-3p,17p « di 01 ND ND ND
Androsterone 418 436 488
Aetiocholanolone 153 161 153
Dehydroepiandrosterone 146 154 172
Epiandrosterone 657 639 623
Patient was administered HCG (6,000 I.U. per day) intramuscularly
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
8
James B.
RHSC, Glasgow 
75439 
8o7 years 
803 years 
90
Pl Gl
Klinefelter*s^syndrome 
47,XXY
URINARY CREATININE 524-659 (mean 588) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.02 mg per 24 hours
Day 1 0.79
Day 2 1.01
Day 3 1.03
URINARY TESTOSTERONE Basal 0.22 pg per 24 hours
Day 1 0.37
Day 2 0.47
Day 3 0.66
PLASMA TESTOSTERQNE Basal 78 ng :per 100 ml
Day 3 289
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a"Androstane™3a,17p-diol ND ND ND ND
53-Androstane-3cx ,17(5-d i d 37 8 9 13
A^-Androstene-33,173-diol ND ND 5 22
5a-Androstane-3p,17p-diol 44 15 7 4
Androsterone 52 68 135 235
Aetiocholanolone 7 15 44 76
Dehydroepiandroste rone 11 18 38 59
Epiandroste rone 45 6 9 10
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day:
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
Alexander G.
RHSC, Glasgow 
16663
14.0 years
14.0 years 
10-25
P2 G3
Gynaecomastia, XX«male 
46,XX
URINARY CREATININE 1,034-1,392 (mean 1,191) mg per 24 hours
URINARY 17-»0X0STER0IDS Basal 1.42 mg per 24 hours
Day 1 2.12
Day 2 1.24
Day 3 2.07
URINARY TESTOSTERONE Basal 3.62 |ig per 24 hours
Day 1 6.66
Day 2 8.70
Day 3 9.87
PLASMA TESTOSTERONE Basal 350 ng per 100 ml
Day 3 1,166
URINARY ANDROGEN METABOLITES
5a«Androstane*“3a: ,178-diol 
5p-Androstane-3a,170-diol 
A^-Androstene-3p,176-diol 
5#™Androstane-30,l7p^diol 
Andresterone 
Aetiocholanolone 
Dehydroepiandresterone 
Bp i andro s t e r one
pg per 24 hours
Basal
1
51
ND
60
268
70
128
238
Day 1 
1
383
ND
54
374
113
276
581
Day 2 
4
520
ND
1,005
680
252
308
3,289
Day 3 
12 
81 
ND 
NM 
751 
269 
332 
2,469
Patient was administered HCG (6,000 1.11. per day) intramuscularly on days 1-3
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
10
Harvey C.
RHSC, Glasgow
172158
8.1 years
6.4 years
< 3
GO Pi
hGH deficient;deficient
URINARY CREATININE 126-353 (mean 270) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.10 mg per 24 hours
Day 1 0.04
Day 2 0.04
Day 3 0.02
URINARY TESTOSTERONE Basal 1.00 Rg per 24 hours
Day 1 0.51
Day 2 1.03
Day 3 1.35
PLASMA TESTOSTERONE Basal 523 ng per lOO ml
Day 3 515
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5o;-Androstane"3a ,l7p*-diol 1 1 1 3
5p-Andr os t ane« So,173-di01 131 78 127 127
A*^-Androstene-3p ,173-diol 4 3 4 6
5a-Androstane-33,173-diol 65 37 41 31
Androsterone 128 67 77 58
A e t i oc ho1ano1one 16 10 17 22
Dehydroepiandrosterone 28 17 13 18
Epi an dr os t e r on e 42 22 32 87
Patient was administered HCG (6,000 I.U. per day) int r amus c u1arly on day;
Protocol 11
N ame John B.
Hospital of admission RHSC, Glasgow
Hospital number 185142
Chronological age 8.5 years
Bone age 5.4 years
Height percentile < 3
Pubertal stage G1 Pi
Clinical diagnosis hGH deficient^
URINARY CREATININE 196-345 (mean 279) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,06 mg per 24 hours
Day 1 0.16
Day 2 0.82
Day 3 1.01
URINARY TESTOSTERONE Basal 0.74 Rg per 24 hours
Day 1 0.80
Day 2 1,00
Day 3 1.17
PLASm TESTOSTERONE
UF* ft HIM #11,. LKMMli'l*
Basal 103 ng per 100 ml
Day 3 241
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a:*"Androstane“3a ,17P"diol 8 6 12 15
53-Androstane-3a,l7p-diol 90 53 69 72
A/-Androstene-33,173-diol 148 63 25 22
foc-Androstane-Sp ,17p-diol 128 32 27 102
Androsterone 54 31 115 613
Aetiocholanolone 35 25 90 234
De hy dr o e p i an dr o s t e r on e 13 17 19 41
Epiandrosterone 10 13 12 20
llP'^Hydroxyandrosterone 176 190 387 848
1ip-Hy dr oxy aetiocholanolone 113 129 542 859
Patient was administered HCG (6,000 I.Ue per day) intramuscularly on day I  « 1
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
12
John S*
RHSC, Glasgow 
153068
10.1 years 
7«5 years 
< 3  
Gl Pi
hGH deficient,^ LH deficient
URINARY CREATININE 113-148 (mean 133) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,27 mg per 24 hours
Day 1 0.36
Day 2 0.58
Day 3 0.70
URINARY TESTOSTERONE Basal 0.37 Rg per 24 hours
Day 1 0.39
Day 2 0.68
Day 3 1.58
PLASMA TESTOSTERONE Basal 384 ng per 100 ml
Day 3 535
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
13
Paul C.
RHSC, Glasgow 
175691
11.0 years
7,3 years 
<  3 
Pi Gl
hGH deficient, LH deficient
URINARY CREATININE 294-509 (mean 385) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,37 mg per 24 hours
Day 1 1,10
Day 2 0.88
Day 3 0.42
URINARY TESTOSTERONE Basal 1.41 Rg per 24 hours
Day 1 1.69
Day 2 1.79
Day 3 1.95
PLASMA TESTOSTERŒE Basal 112 ng per loo ml
Day 3 238
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
Sa-Androstane-Sa ,17l3“diol 1 2 1 2
53“Androstane”’3a,17(3-diol 91 72 48 34
A'^-Androstene-33 ,173-diol 2 18 7 8
5a-Androstane-33,173-diol 12 18 10 5
Androsterone 18 15 17 10
Aetiocholanolone 6 33 31 12
Dehydroepiandros terone 1 2 2 3
Epiandrosterone 11 13 12 10
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1—3
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
14
Graham MeA 
RHSC, Glasgow 
189459
11,5 years
8.2 years 
< 3  
Pi Gl
hGH deficient, LH deficient, 
surgically corrected bilateral 
undescended testes
URINARY CREATININE 283-374 (mean 338) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.45 mg per 24 hours
Day 1 0,41
Day 2 0.37
Day 3 0.44
URINARY TESTOSTERONE Basal 0.16 Rg per 24 hours
Day 1 0.07
Day 2 0,17
Day 3 0,26
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5o:-Androstane™3a ,17p-diol 2 2 3 3
5p-Androstane-3a,l73-diol 5 2 4 4
A^-Androstene-36,l7p-diol 7 2 46 5
5a-Androstane-3p,l7p-diol 46 61 970 39
Androsterone 4 20 35 57
Aetiocholanolone 2 1 6 30
Dehydroepiandrosterone 2 1 4 4
Epiandrosterone 73 1 6 2
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
15
John S.
RHSC, Glasgow 
153068 
12*2 years 
8.6 years 
<  3 
Pi Gl
hGH deficient
URINARY CREATININE 496-787 (mean 664) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,99 rag per 24 hours
Day 1 0.62
Day 2 0.09
Day 3 0.30
URINARY TES TOSTERONE Basal 1.93 Rg per 24 hours
Day 1 1,11
Day 2 6.25
Day 3 7,14
URINARY ANDROGEN METABOLITES Rg per 
Basal
24 hours 
Day 1 Day 2 Day 3
5a™Androstane-3a,17p-diol 4 4 5 5
5'3-Axidrostane-3a ,176-diol 49 47 52 77
A^-Androstene-3(3 ,l7|3-diol 12 14 13 16
5cc“Androstane“3p ,l?p-diol 3 3 6 9
Androsterone 359 335 362 481
Aetiocholanolone 199 92 157 161
Dehydroepiandrosterone 48 20 53 55
Epiandrosterone 17 4 11 6
Patient was administered HCG (6,000 I.U. per day) int ramuscu1arly on days
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
16
Brian L,
RHSC, Glasgow 
3596
14,3 years 
9.4 years 
<3
Pi Gl
hGH deficient
1
URINARY CREATININE 360-679 (mean 578) mg per 24 hours
URINARY 17-0X0STER0ÏDS Basal 0o99 mg per 24 hours
Day 1 1.02
Day 2 0.92
Day 3 0.78
URINARY TESTOSTERONE Basal 3.31 Rg per 24 hours
Day 1 3.83
Day 2 5.77
Day 3 7.55
PLASMA TESTOSTERŒE Basal 679 ng 1per 100 ml
Day 3 853
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5o:-Andr OS t an e-3a, 17(3 - d i o 1 1 3 4 6
5(3 - Andr o s t ane« 3a yl7(3-diol 39 28 35 40
A^-Androstene-3p,170-diol 25 7 9 15
5a-Androstane-33,170-diol 18 3 4 8
Androsterone 111 113 227 192
Ae t i oc h o 1 ano 1 one 95 103 165 162
De h y dr o e p i a nd r os t e r on e 50 52 33 48
Epiandrosterone 15 8 10 10
llp-Hydroxyandrosterone 128 117 125 120
llp-Hydroxyaetiocholanolone 248 98 133 60
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
17
William McM.
Western Infirmary, Glasgow
•592994/4
15.0 years
12«4 years
< 3
G2 P2
hGH deficient
1
URINARY CREATININE 422-847 (mean 785) mg per 24 hours
URINARY 17-0X0STER0ÏDS Basal 0.43 mg per 24 hours
Day 1 0.75
Day 2 1.18
Day 3 1.47
URINARY TESTOSTERONE Basal 3.37 Rg per 24 hours
Day 1 3.75
Day 2 4.83
Day 3 7,57
PLASMA TESTOSTERaNE Basal 476 ng per loo mi
Day 3 683
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,l70-diol 1 4 3 3
50“Androstane-“3o:, ITp-diol 18 19 25 26
A .-Androstene-3B ,170-diol 1 1 6 1
5a-Androstane“33,l7p-diol 1 1 1 2
Androsterone 96 216 339 4 87
Aetiocholanolone 199 347 489 626
Dehydroepiandrosterone 202 232 283 281
Epiandrosterone 46 28 48 30
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
18
Alexander S,
RHSC, Glasgow
160290
5,4 years
4*2 years
< 3
PI Gl
Primordial dwarfism
1
URINARY CREATININE 88-148 (mean 109) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.19 mg per 24 hours
Day 1 0.10
Day 2 0.11
Day 3 NM
URINARY TESTOSTERONE Basal 2.99 Rg per 24 hours
Day 1 2.29
Day 2 1,03
Day 3 1.13
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a«Androstane«3o: ,170-diol 1 1 1 1
Sp-Androstane-ScïjlTp-diol 61 99 3 2
A^-Androstene-3p,170-diol 20 16 35 10
5a-Androstane-3p,l7p^diol 9 7 20 122
Androsterone 42 40 59 97
Aetiocholanolone 2 1 1 1
Dehydroepiandrosterone 4 2 2 7
Epi andr o s t e r on e 2 2 3 7
Patient was administered HCG (6,000 I.U. per day) intr amuscularly on dayi
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
19
Thomas F«
RHSC, Glasgow
133309
6.0 years
4.3 years
< 3
PI Gl
Primordial dwarfism, 
bilateral undescended testes
URINARY CREATININE 51-147 (mean 147) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.38 mg per 24 hours
Day 1 NO
Day 2 ND
Day 3 0.14
URINARY TESTOSTERONE Basal 4.00 Rg per 24 hours
Day 1 2.58
Day 2 2.06
Day 3 1.30
PLASMA TESTOSTERONE Basal 92 ng per 100 ml •
Day 3 74
u r i n a r y ANDROGEN METABOLITES
Tiff in.— f 'f— r— ■"■V *'. T — ww.— ..A.
Rg per 24 hours
Basal Day 1 Day 2 Day 3
Sa-Androstane-Sa,170-diol 2 1 1 1
50-Androstane“3a' ,170-diol 71 27 19 19
A^-Androstene-30,170-diol 5 4 2 1
5a-Androstane-30,170-diol 7 8 8 6
Androsterone 28 14 9 8
Ae t ioc h Q1an o1one 19 8 1 1
Dehydroepiandrosterone 4 4 1 2
Epiandrost e r one 10 20 7 S
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
20
Alan S.
RHSC, Glasgow
129234
803 years
8.3 years (but slowing)
10
Pi Gl
Bilateral undescended testes, 
? testicular agenesis
URINARY CREATININE 358-512 (mean 456) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.38 mg per 24 hi
Day 1 0.70
Day 2 0.63
Day 3 0.64
URINARY TESTOSTERONE Basal 1.41 Rg per 24 hi
Day 1 1.51
Day 2 1.79
Day 3 1.92
PLASMA TESTOSTERONE Basal 30 ng per loo ml
Day 3 35
u r i n a r y ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 3
5a“Androstane-3cc,l70-diol 50 76 286
5P"Androsfane-3a,17p-diol 128 100 260
A^-Androstene-30,170-diol 5 8 44 266
5a-Androstane-30,170-diol 325 320 360
Androsterone 298 259 362
Ae tiocho1an 01one 54 48 73
Dehy dr oepi andr os t e r one 70 130 195
Epiandrosterone 47 54 164
Patient was administered HCG (6,000 I.U. per day) intramuscul
Protocol 21
Name Paul S.
Hospital of admission RHSC, Glasgow
Hospital number 177539
Chronological age 10ol years
Bone age 10,1 years (stationary)
Height percentile 50
Pubertal stage Pi Gl
Clinical diagnosis Testicular agenesis
URINARY CREATININE 226-355 (mean 354) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1,71 mg per 24 hours
Day 1 4.15
Day 2 3,39
Day 3 2,56
URINARY TESTOSTERONE Basal 6,09 Rg per 24 hours
Day 1 6.22
Day 2 4.36
Day 3 7.87
PLASm TESTOSTERONE Basal 37 ng per 100 ml
Day 3 67
URINARY ANDROGEN METABOLITES Rg per 24 hour s
Basal Day 1 Day 2 Day 3
5o:-Androstane"3a ,170-diol 36 26 11 6
50-Androstane-3o: ,170-diol 153 35 156 274
A'^’-Andr os t en e- 36 ,176 - di o 1 4 20 32 19
5a»“Androstane“3B ,170-diol 213 17 122 36
Androsterone 126 216 154 115
Aetiocholanolone 82 174 93 360
Dehydroepiandrosterone 17 57 97 255
Epiandrosterone 15 4 8 167
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day;
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical daignosis
22
Colin C.
RHSC, Glasgow 
276382
10.3 years
9.0 years 
3
pi Gl
Bilateral undescended testes
1
URINARY CREATININE 425-660 (mean 616) mg per 24 hour s
URINARY 17-OXQSTEROIDS Basal 1.02 mg per 24 hours
Day 1 0.93
Day 2 1.01
Day 3 0.64
URINARY TESTOSTERONE Basal 3.96 Rg per 24 hours
Day 1 4.07
Day 2 4.18
Day 3 4.98
PLASMA TESTOSTERONEriffwrarimFmrTm Basal 295 ng per loo ml
Day 3 309
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane“3a,170-diol 4 3 4 4
50-Androstane"-3a ,170-diol 38 31 19 21
A -Androstene-30,170-diol 2 10 3 2
5a-Androstane”30,170-diol 23 16 6 12
Androsterone 146 133 108 161
Aetiocholanolone 66 75 71 103
Dehydroepiandrosterone . 36 44 24 9
Epiandrosterone 16 15 11 42
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
23
Frank L„
RHSC, Glasgow 
121441 
11.8 years
11.5 years (stationary)
10-25
Pi G2
Testicular agenesis
URINARY TESTOSTERONE Basal 0.22 R g per 24 hours
Day 1 0.15
Day 2 0.06
Day 3 0.21
PLASMA TESTOSTERONE Basal 70 ng per loo ml
Day 3 39
URINARY ANDROGEN METABOLITES Mg per 24 hours
Basal Day 1 Day 2 Day :
A^-Androstene-30,170-diol 16 21 15 6
5a-Androstane-30 ,l?p*-diol ND ND ND ND
Androsterone 705 661 565 404
Aetiocholanolone 147 194 96 92
Dehydroepiandrosterone ND ND ND ND
Epiandrosterone 196 186 294 202
110-Hy d r oxy an dr os t e r one 332 255 206 278
110-Hydroxy aetiocholanolone 64 129 93 140
Patient was administered HCG (6,000 I.U. per day) Intramuscularly on da'
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
24
Donald McK.
Western Infirmary, Glasgow 
571631/X
15.0 years
12.0 
<  3 
P2 G2
Short stature, hGH normal
1
URINARY CREATININE 584-651 (mean 619) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1,43 rag per 24 hours
Day 1 1,26
Day 2 1.69
Day 3 2.37
URINARY TESTOSTERONE Basal 10.33 Rg per 24 hours
Day 1 6,06
Day 2 6.03
Day 3 5.98
PLASMA TBS TOS TER m E Basal 327 ng per 100 ml
Day 3 318
URINARY ANDROGEN METABOLITES Rg per 
Basal
24 hours 
Day 1 Day 2 Day 3
5o:*-Androstane-3a’ ,170-diol 4 4 3 6
5 B-An dr os t an e-3a,170-di o1 48 35 37 60
A^«Androstene-33,170-diol 12 3 3 25
5a-Androstane“30,170-diol 17 8 4 6
Androsterone 141 132 130 190
Aetbcholanolone 109 80 104 153
Dehydroepiandrosterone 31 4 7 11
Epiandrosterone 100 2 6 9
Patient was administered HCG (6,000 I,U. per day) intramuscularly on dav
Protocol 25
Name Robin T.
Hospital of admission RHSC, Glasgow
Hospital number 166237
Chronological age 15.3 years
Bone age 14.2 years
Height percentile < 3
Pubertal stage P2 G2
Clinical diagnosis Short stature, hGH normal
urinary CREATININE 619-809 (mean 740) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.44 mg per 24 hours
Day 1 0.59
Day 2 0.56
URINARY TESTOSTERONE Basal 12.61 Rg per 24 hours
Day 1 4.87
Day 2 8.85
PLASMA TESTOSTERONE Basal 1,021 ng per loo ml
Day 2 666
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2
5o:-Androstane-3a ,173-diol 32 NM 34
Sp-Androstane-Sa,170-diol 75 138 99
A^-Androstene-30,170-diol ND ND ND
5 a-Andr o s t an e- 30 ,170 - di o 1 ND ND ND
Androsterone 135 120 140
Aetiocholanolone 80 70 87
Dehydr oepi andr osterone 251 415 371
Epiandrosterone 382 1,216 932
Patient was administered HCG (6,000 I.U. per day) intramuscularly on
days 1 and 2,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
26
Gary B.
RHSC, Glasgow 
176616
4.1 years
4.1 years 
75
Pi Gl
Bilateral undescended testes, 
Hypospadias ‘
URINARY CREATININE 150-201 (mean 168) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 
Day 1 
Day 2 
Day 3
0.16
0,10
0.18
0.16
mg per 24 hours
URINARY TESTOSTERONE Basal 
Day 1 
Day 2 
Day 3
0.53
0.60
0.74
0.81
Rg per 24 hours
PLASMA TESTOSTERONE 
URINARY ANDROGEN METABOLITES
Basal 
Day 3
|ig per
75 ng per 100 ml 
194
24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane"3a,170-diol 1 1 9 1
50-Androstane-3a,l70“diol 18 30 48 28
A^-Androstene-Sp,170-diol ND 1 ND ND
5a-Androstane-3p,170-diol 1 1 1 1
Androsterone 16 14 18 39
Aetiocholanolone 1 1 2 4
Dehydroepiandrosterone 3 1 1 4
Epi and r o s t e r on e 4 62 11 1
110-Hy dr oxy androsterone 139 140 138 139
ll0“Hydroxyaetiocholanolone 37 31 NM NM
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day:
Protocol 27
Name Michael B.
Hospital of admission RHSC, Glasgow
Hospital number 176617
Chronological age 6.0 years
Bone age 6.0 years
Height percentile 75
Pubertal stage Pi Gl
Clinical diagnosis Surgically corrected bilateral
undescended testes
URINARY CREATININE 175-256 (mean 215) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.11 mg per 24 hours
Day 1 0.11
Day 2 0.02
Day 3 0.11
URINARY TESTOSTERONE Basal 0.94 [ig per 24 hours
Day 1 1.04
Day 2 1.07
Day 3 lol2
PUSMA TESTOSTERONE Basal 109 ng per lOO ml
Day 3 303
URINARY androgen METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5o-Andros t ane-3a,170-di ol 6 6 2 6
50 - And r os t an e 3a, 170 - di o 1 14 32 22 4
A^-Androstene-30,l7B™diol 18 2 13 5
5a-Androstane“30,17b-diol 19 1 14 1
Androsterone 1 6 1 2
Aet iocholanolone 1 1 8 1
Dehydroepiandrosterone 40 1 28 9
Epiandrosterone 50 4 5 4
110 Hy dr oxy an d r o s t e r on e 109 107 111 108
Patient was administered HCG (6,000 I,U. per day) intramuscu1arly on day;
Protocol 28
Name Stuart B.
Hospital of admission RHSC, Glasgow
Hospital number 176618
Chronological age 7,3 years
Bone age 7,3 years
Height percentile 97
Pubertal stage Pi Gl
Clinical diagnosis Surgically corrected bilateral
undescended testes
URINARY CREATININE 231-331 (mean 276) rag per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,23 rag per 24 hours
Day 1 0,34
Day 2 0,15
Day 3 0.09
URINARY TESTOSTERONE Basal 1.04 |ig per 24 hours
Day 1 1.14
Day 2 1.50
Day 3 1,55
PLASMA TESTOSTERONE Basal 103 ng per 100 ml
Day 3 418
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
50'»'And rest an e-3a ,170-diol 2 10 1 1
50“Androst an e-3a,170-di o1 38 82 53 117
A^-Androstene-30,170-diol 89 284 115 54
5a-Androstane-3p,l70™diol NM NM NM NM
Androsterone 9 35 . 16 30
Aetiocholanolone 4 2 1 1
Dehydroepiandrosterone 1 6 39 41
Epiandrosterone 92 195 62 19
110-Hydr ox y an dr osterone 374 370 376 363
110-Hy dr oxy a e t i oc h o1anolone 31 39 41 72
Patient was administered HCG (6,000 I.U, per day) intramuscularly on day;
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
29
John F.
RHSC, Glasgow 
102110
8,2 years 
4*5 years 
< 3  
Pi Gl
Small stature, hGH normal, alopecia, 
hypogonadism 1
URINARY CREATININE 190-218 (mean 203) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.35 mg per 24 hours
Day 1 0.28
Day 2 0.37
Day 3 0.35
URINARY ITSTOSTERONEgi»trma;a»aar«TaTK«acaTTcafWFCW.T>itttwi>iiHumwjB*.atHgMWo>^ Basal 0.06 |ig per 24 hours
Day 1 0.07
Day 2 0.08
Day 3 0.11
PLASMA TESTOSTERONE Basal 16 ng per 100 ml
Day 3 89
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3o: ,170=-diol 1 1 6 1
50 - An dr os t an e- 3a , 170 - di ol 5 3 5 1
A^-Androstene-30,170-diol 1 3 8 1
5a*=Androstane«30 ,170-diol 1 2 6 1
Androsterone 7 15 11 16
Aetiocholanolone . 4 5 5 2
Dehydroepiandrosterone 1 2 68 5
Bp i an dr 0 s t e r one 1 2 41 7
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
30
Douglas A.
RHSC, Glasgow 
90102
10.8 years
10.5 years 
< 3  
PI Gl
Short stature, hGH normal
1
URINARY CREATININE 273-978 (mean 663) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.49 rag per 24 hours
Day 1 1,38
Day 2 1,51
Day 3 1.61
URINARY TESTOSTERONE Basal 4.16 Rg per 24 hours
Day 1 4.56
Day 2 5.97
Day 3 8.97
PLASMA TESTOSTERÇNH Basal 208 ng per 100 ml
Day 3 634
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,l73*“diol 4 5 20 27
50-Androstane-3a,170-diol 24 35 46 55
A^-Androstene-36,170-diol 7 2 4 5
5a-Androstane-30,170-dioI 16 6 10 29
Androsterone 186 208 321 475
Aet iocholanolone 138 135 255 370
D e h y d r o e p i a n d r o s t e r o n e 25 25 61 32
Epiandrosterone 2 19 39 4
Patient was administered HCG (6,000 per day) intramuscularly on days I-»3
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
31
Gary F,
RHSC, Glasgow 
168317
10.8 years
10.8 years 
50-75
Pi Gl
Turner phenotype
URINARY CREATININE 466-602 (mean 537) mg per 24 hours
URINARY 17-OXOSTEROIDS
1 nil. 1 wifcHiwi I l f  ITFI r ii[.rnT..ririir ii i nni i iWMi
Basal 0.40 mg per 24 hours
Day 1 0,65
Day 2 0.89
Day 3 0.97
URINARY TESTOSTERONE Basal 1.83 Rg per 24 hours
Day 1 1.83
Day 2 2.43
Day 3 4.34
plasma TESTOSTERONE Basal 380 ng per loo ml
Day 3 626
URINARY ANDROGEN METABOLITES Rg pdr 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,17p«diol 28 32 15 14
50-Androstane-3oc,170-diol 23 17 7 2
A »«Androstene-30 ,170-diol 3 10 14 31
5a-Androstane-30,170-diol 19 3 4 5
Androsterone 285 299 332 479
Aetiocholanolone 129 124 129 178
Dehy dr oe p i andr oster on e 57 44 49 40
Epiandrosterone 12 1 6 3
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3
Protocol 
N ame
Hospital of admission 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
32
Alisdair R.
RHSC, Edinburgh 
11oO years
10.9 years 
25-50 
Pi Gl
Prader-Willi syndrome, 
unilateral undescended testis 
1
URINARY CREATININE 521-684 (mean 613) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.66 mg per 24 hours
Day 1 0.71
Day 2 0,33
Day 3 0.09
URINARY TESTOSTERONE Basal 4.18 Rg per 24 hours
Day 1 4.20
Day 2 4,34
Day 3 4.64
PLASMA TESTOSTERŒE Basal 224 ng per 100 ml
Day 3 675
URINARY ANDROGEN METABOLITESekti**fera.-LiMTniâwitivjiiTh'<we*iMSHiitiiSn3ettATR'aft3TKj«iTCrtiLi«-TBi.i*i‘iwTTïtj*»Gïerc*'efrmaw«&mtif Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,170-diol 1 1 1 1
50-An dr ostane-3a,170-diol 11 8 8 9
A^-Androstene-30,170-diol 1 1 1 1
5a-Androstane-30,170-diol 1 1 1 1
Androsterone 250 43 49 154
Aetiocholanolone 108 35 26 69
D e h y d r oe p i an d r o s t e I’ on e 50 36 18 43
Epiandroste rone 8 25 5 8
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days
Protocol 33
Name Frederick G.
Hospital of admission RHSC, Glasgow
Hospital number 52714
Chronological age 11,2 years
Bone age 11,6 years
Height percentile 75
Pubertal stage Pl GO
Clinical diagnosis Bilateral undescended testes j
mental deficiency
URINARY CREATININE 110-433 (mean 265) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.19 mg per 24 hours
Day 1 0.20
Day 2 0,21
Day 3 0.29
URINARY TESTOSTERONEW1J «riTi^i.wm it L'iwigi; BÏrwdcrw Basal 0.66 Rg per' 24 hours
Day 1 0.87
Day 2 0,97
Day 3 1.16
PIASMA TESTOSTERONE Basal 57 ng per 100 ml
Day 3 161
URINARY ANDROGEN METABOLITES Rg per 24 hour s
Basal Day 1 Day 2 Day 3
5a-Androstane-3a ,l70*'»diol 8 3 10 4
5p-A.ndrostane”*3a: ,170-diol 14 7 14 15
And rostene“30,l70“diol 9 2 3 2
5a-Androstane"30,170-dioi 7 2 4 4
Androsterone 169 237 193 195
Aetiocholanolone 89 140 71 99
Dehydroepiandrosterone 12 20 9 21
Epiandrosterone 4 1 4 3
110 =»’Hy dr oxy andr os t e r on e 593 583 663 584
Patient was administered HCG (6,000 I,U, per day) intramuscularly on days 1-3
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
34
David L,
RHSC, Glasgow 
48753
11.9 years 
lOol years 
25-50 
P2 G2
Phocomelia, bilateral undescended testes
1
URINARY CREATININE 244-324 (mean 290) rag per 24 hours
urinary 17-OXOSTEROIDS Basal 1.02 mg per 24 hours
Day 1 0.64
Day 2 0.48
Day 3 0.62
URINARY TESTOSTERONE Basal 7.96 pg per 24 hours
Day 1 10.96
Day 2 11.14
Day 3 15.32
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a«Androstane“3a ,17p«diol 3 4 4 5
53*“Androstane-3a‘ ,l7p-diol 12 17 6 80
A^«Androstene-3p ,17f3-"diol 13 15 4 14
5a-Androstane-33 ,l7|3"diol 4 7 51 33
Androsterone 114 90 113 129
Aetiocholanolone 413 430 451 520
Debydroepiandrosterone 244 232 330 110
Ep i and r o vS t e r one 1 10 3 26
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
35
David
RHSC, Glasgow 
100998 
13o5 years
9.4 years
Pi Gl
Short stature, hGH normal, 
unilateral undescended testis
URINARY CREATININE 438-732 (mean 594) rag per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.83 rag per 24 hours
Day 1 0.86
Day 2 1.34
Day 3 1.29
PIJVSMA TESTOSTERONE Basal 103 ng per loo ml
Day 3 274
URINARY ANDROGEN METABOLITES Ug per 24 hours
Basal Day 1 Day 2 Day 3
Soc-Androstane-Soc ,l?p“diol 1 1 1 1
SfB-Androstane-Sa ,l7p-diol 35 35 36 38
A^-Androstene™3(3 ,l7p-diol 1 9 19 28
5a-Androstane-Sp,l7p-diol 8 6 6 5
Androsterone 166 163 228 292
Aetiocholanolone 111 106 135 163
Dehydroepiandrosterone 25 20 28 35
Epiandrosterone 7 2 2 1
llg^Hydroxyandrosterone 120 119 121 120
1Ip-Hydroxyaetiocholanolone 136 117 112 106
Patient was administered HCG (6,000 I,U. per day) intramuscularly on day;
Protocol
Name
Hospital of admission 
Hospital number 
Chronolo^al age 
Bone age
36
Edward G. 
RHSC, Glasgow 
168779 
14.8 years 
13.0 years
Height percentile 10
Pubertal stage P2 Gl
Clinical diagnosis Delayed puberty
URINARY CREATININE 572-742 (mean 669) mg per 24 hours
ÜRIÎ'ÎARY 17-OXOSTEROIDS Basal 0,20 mg per 24 hours
Day 1 0.35
Day 2 0,15
Day 3 0,30
URINARY TESTOSTERONE
>.mjjw3Lwwr«gia«rc**gnn iiii'i i, j i i  ;i,i
Basal 1,25 |ig per 24 hours
Day 1 2.54
Day 2 3.51
Day 3 4.19
PLASMA TESTOSTERONE
•Tifqmm«mv4E»ra:Qaanuarjaiiunw.!i>TmaRuadB9U9pic;i*M>dmnBU
Basal 1,031 iig per 100 ml
Day 3 1,754
URINARY ANDROGEN METABOLITES
■T in• "T~TT-"tTfTrfr-*—----1----f~ii TTi«iimi i-i ■ 11TTTn~miiTnii~i»tni i■ ft.TimiTrtirtitrtMiTi-ri^mn
per 24 hours
Basal Day 1 Day 2 Day 3
Sct-Androstane-Sa ,l7p-diol 1 2 3 1
5 p ■ An d r o s t a n e - 3c:,  17 p - d i o 1 2 13 5 2
A^™Androstene-3p,l7p-diol 1 5 17 12
5a-Androstane-3p,l7p-diol 1 1 1 1
Androsterone 50 50 loo 124
Aetiocholanolone 36 35 84 109
Dehydjroepiandros terone 5 5 12 8
Ep i an dr 0s t e r one 4 3 4 5
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days
Protocol 37
Name Paul K.
Hospital of admission Gartnavel General Hospital, Glasgow
Chronological age I5e0 years
Bone age 12,5 years
Height percentile 50
Pubertal stage P2 Gl
Clinical diagnosis Cushing *s syndrome
URINARY CREATININE 1,146-1,471 (mean 1 ,260) mg per 24 hoiu
URINARY 17-OXOSTEROIDS Basal 0,72 mg per 24 hours
Day 1 1,28
Day 2 1.24
Day 3 1.16
URINARY TESTOSTERONEn, i ii iw iwiim i ; in Basal 39.30 |ig per 24 :hours
Day 1 «
Day 2 117.65
Day 3 133.92
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a~Androstane-3a,17p'-diol 1 1 1 3
5p-Androstane-3o:,l7p“diol 41 70 12 32
A^-Androstene-3p,l7p«diol 1 10 17 7
5a-Androstane-3p,l7p«diol 2 1 5 1
Androsterone 397 502 582 470
Ae t i oc ho1ano1one 481 524 583 457
Dehydroepiandrosterone 38 39 35 61
Epiandrosterone 15 23 21 39
llp-Hydroxyandrosteron e 456 557 602 574
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3
Protocol
Name
38
James S.
Hospital of admission Western Infirmary, Glasgow
Hospital number ‘488014
Chronological age 16*1 years
Bone age 12,0 years
Height percentile < 3
Pubertal stage Pi 02
Clinical diagnosis Short stature, hGH normal,
LH and FSH deficient
URINARY CREATININE 291-585 (mean 518) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.95 mg per 24 hours
Day 1 1.28
Day 2 1.71
Day 3 0*58
UjONARY TESTOSTERONE Basal 0.59 pg per 24 hours
Day 1 0.61
Day 2 0.61
Day 3 0.70
PLASMA TESTOSTERONE Basal 309 ng per lo o  ml
Day 3 661
URINARY ANDROGEN METABOLITES gg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane«3a,l7p-diol 8 13 21 26
5p-Androstane-3a ,17P"“diol 26 76 52 14
A‘^-Androstene™38 ,178-diol 4 1 9 1
Sa-Androstane-Sp,17p-diol 3 1 4 1
Androsterone 31 43 169 226
Aetiocholanolone 23 31 53 215
Dehydroepiandrosterone 3 18 94 4
Epiandrosterone 16 23 83 6
llp-Hydr oxy an (ir o s t e r on e 274 110 258 139
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1»3
Protocol 39
Name Gordon M,
Hospital of admission Western Infirmary, Glasgow
Hospital number 505081
Chronological age 19.0 years
Bone age 16.0 years
Height percentile
Pubertal stage P4 G4
Clinical diagnosis Short stature, hGH normal,
LH and FSH deficient
URINARY CREATININE 594-736 (mean 683) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.25 mg per 24 hours
Day 1 0.21
Day 2 0.60
Day 3 0,48
URINARY TESTOSTERONE Basal 3,65 pg per 24 hours
Day 1 2.25
Day 2 5,43
Day 3 6,25
PLASMA TESTOSTERONE■KHCrWiriWtr^-B tPirao iwu«ia»»«pawa»» ■ tw t rj* Basal 399 ng per 100 ml
Day 3 1,693
URINARY androgen METABOLITES ng per 24 ;hours
Basal Day 1 Day 2 Day 3
5aAnd ros 1: an e- 3a y 17B- di ol IS 25 25 54
5p-Androstane-3a yl7p-diol 44 50 26 45
5
A -Androstene“-3f3 ,l7p-diol 5 2 4 4
Sa-Androstane-Sp yl7|3-diol 10 20 9 10
Androsterone 478 500 662 872
Aetiocholanolone 336 347 419 539
De hydr oe p i an dr os t e r on e 69 45 65 89
Epian dr osterone 6 4 4 6
1Ip-Hy dr oxy an dr o st e r on e 296 330 314 332
lip - Hy dr ox y a e t i Q c h o 3. an o 1 on e 84 153 27 58
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day;
Protocol 40
Name Ishfaq M.
Hospital of admission RHSC, Edinburgh
Hospital number 175913
Chronological age 4ol years
Bone age 3,5 years
Height percentile 3
Pubertal stage Pl Gl
Clinical diagnosis Male Itirner phenotype
URINARY CREATININE 92-107 (mean 106) mg per 24 hours
URINARY 17-OXOSTEROIDSM ir> inoiin i« iaiM i iniiiTH iifTTTrrr-*n rrrnn KfTMUMiiii rmniriim iifian iiiiifi ■ Basal 0.13 mg per 24 hours
Day 1 0.14
Day 2 0.18
Day 3 0.19
PLASMA TESTOSTERONE Basal 142 ng per 100 ml
Day 3 368
urinary androgen METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane“-3a ,l7|3-diol 9 2 4 5
5(3-Androstane“3a ,17p-diol 90 84 105 149
A^-Androstene-3p,170-diol 22 4 3 3
Sa-Androstane-Sp,l7P“diol 76 100 75 96
Androsterone 79 85 86 124
Aetiocholanolone 10 15 14 33
Dehydroepiandrosterone 67 68 68 66
Epiandr os te rone 4 19 9 14
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
41
Raymond McV,
RHSC, Glasgow 
141860 '
4.2 years
2.4 years
Pl Gl
Short stature, hGH normal, 
scoliosis, mentally retarded
URINARY CREATININE 19-54 (mean 33) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.15 mg per 24 hours
Day 1 0.11
Day 2 0.08
Day 3 0.05
URINARY TESTOSTERONE Basal 6.54 pg per 24 hours
Day 1 6.68
Day 2 9.91
Day 3 12.58
PLASMA TESTOSTERONE Basal 77 ng per 100 ml
Day 3 467
URD'îARY ANDROGEN METABOLITES He per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,170-diol 1 7 10 73
5{3-Atidr os t ane™ 3cc, 17(3- die 1 57 204 629 1,424
A^“Androstene-33 ,l7(3-diol 2 3 6 38
5a-Androstane-30 ,l7j3-diol 1 1 1 2
Androsterone 7 13 16 17
Aetiocholanolone 23 6 9 13
Dehydr oe p i andr osterone 4 1 2 3
Ep i an dr o s t e r on e 1 2 3 6
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
42
Cliffe J.
RHSC, Glasgow 
127572
12,9 years
11.5 years 
10-25 
Pl Gl
Unilateral undescended testis, 
obesity '■
URINARY CREATININE
URINARY 17-OXOSTEROIDS
URINARY TESTOSTERONE
PLASMA TESTOSTERONE
URINARY ANDROGEN METABOLITES
Sa-Androstane-Sa,l7p-diol 
5{3-Androstane-3ct ,173-diol 
A^-Androstene-3(3,173-diol 
5o:-Androstane””3p ,l7p-diol 
Androsterone 
Aetiocholanolone 
De hy dr oe p i an dr os t e r one 
Epiandrosterone
368-556 (mean 446) mg per 24 hours
Basal 0.30 mg per 24 hours
Day 1 0.31
Day 2 0.55
Day 3 0.61
Basal 3.96 j.ig per 24 hours
Day 1 4.06
Day 2 4.12
Day 3 5.12
Basal 334 ng* per 100 ml
Day 3 656
\xg per 24 hours
Basal Day 1 Day 2 Day 3
10 9 12 14
132 221 224 325
87 18 19 36
5 8 13 13
79 381 410 501
63 237 406 406
5 5 29 15
2 5 8 13
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
43
Thomas A*
Western Infirmary, Glasgow
573695
14.0 years
11.8 years
<3
Pl G2
Short stature, hGH normal
1
URINARY CREATINItlE 540—688 (mean 544) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,65 mg per 24 hours
Day 1 1.40
Day 2 0.72
Day 3 0.57
URINARY TESTOSTERONE Basal 5.24 pg per 24 hours
Day 1 7.75
Day 2 8,11
Day 3 9.54
PLASMA TESTOSTERONE Basal 276 ng per lo o  ml
Day 3 773
URINARY ANDROGEN METABOLITES • pg per 24 hours
Basal Day 1 Day 2 Day 3
5#-Androstane-3a,176-diol 7 4 10 20
5{3-Androstane-3a ,170-diol 94 45 63 125
A^-Androstene-30,l7p-diol 11 3 4 11
5a-Androstane«»3p ,l7p^diol 4 2 3 5
Androsterone 121 174 247 588
Aetiocholanolone 218 172 235 576
Dehydroepiandrosterone 25 23 28 38
Epiandrosterone 15 2 4 4
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
44
Thomas G*
Western Infirmary, Glasgow 
'5940196
14.0 years
10.0 years 
3
P2 G2
Cushing’s syndrome
1
URINARY CREATININE 716—816 (mean 770) mg per 24 hours
URINARY 17-OXOS TEROIDS Basal 2,45 mg per 24 hours
Day 1 2.90
Day 2 3.35
Day 3 3.99
URINARY TESTOSTERONE Basal 15,37 |ig per 24 hours
Day 1 15.81
Day 2 16.79
Day 3 18,28
PLASMA TESTOSTERONE Basal 322 ng per loo ml
Day 3 705
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a-All dr os t an e- 3a, 170 - di o 1 14 15 17 40
50-Androstane™3a,176“diol 77 53 85 71
A^r-Androstene-3S ,170-diol 1 2 4 18
5a-Androstane-30,170-diol 2 2 1 4
Androsterone 152 260 440 501
Aetiocholanolone 117 234 365 412
Dehydroepiandrosterone 53 21 30 128
Epiandrosterone 5 2 5 5
llp-Hydroxyandrosterone 430 513 663 492
1Ip-Hydroxyaetiocholanolone 54 171 349 315
Patient was administered HCG (6,000 I.U, per day) intramuscularly on day;
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
45
David A,
Western Infirmary, Glasgow 
323308
16.0 years
16.0 years 
< 3
Pl G2
Short staturehGH normal, delayed puberty
URINARY CREATININE 572-1,013 (mean 788) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.38 mg per 24 hours
Day 1 1.33
Day 2 1.75
Day 3 1.08
urinary TESTOSTERaNE Basal 0.14 pg per 24 hours
Day 1 0.27
Day 2 0.47
Day 3 0.56
PIJVSMA TESTOSTERONE Basal 55 ng per loo ml
Day 3 198
URINARY ANDROGEN METABOLITES PS per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane™3a,170-diol 10 8 8 16
Sp-Androstane-So: ,l70«diol 69 68 48 53
A^-Androstene-30,170-diol 2 3 10 4
5a-Androstane-30,170-diol 3 3 2 5
Androsterone 74 121 233 260
Aetiocholanolone 61 101 180 252
Dehydroepiandrosterone 5 29 27 145
E p i an dr o s t e r on e 53 32 11 11
110 - Hy dr oxy a n dr os t e r on e 465 368 338 404
110 - Hy dr oxy ae t i o c h o 1 an o 1 one 66 155 194 128
Patient was administered HCG (6,000 I.U. per day) intramuscu 1 ar 1 y on days
Protocol 46
Name John H,
Hospital of admission Western Infirmary, Glasgow
Hospital number 557664
Chronological age 16.0 years
Bone age 14*0 years
Height percentile < 3
Pubertal stage P2 G2
Clinical diagnosis Short stature, hGH normal
URINARY CREATININE 570-740 (mean 652) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.14 mg per 24 hours
Day 1 1.78
Day 2 1.55
Day 3 2,26
urinary TESTOSTERONE Basal 0,75 jig per 24 hours
Day 1 0,88
Day 2 1,11
Day 3 1.33
PlYiSMA TESTOSTERONE Basal 304 ng per 100 ml
Day 3 3,346
URINARY ANDROGEN METABOLITES jig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane*“3o: ,170-diol 21 23 28 54
50-Androstane»™3a ,170-diol 103 96 76 93
A -Androstene-Sp,170-diol ND ND ND ND
Sa-Androstane-Sp,17p™diol 9 10 1 25
Androsterone 113 150 233 567
Aetiocholanolone 58 97 183 533
Dehydroepiandrosterone 32 53 81 272
Epiandrosterone 9 17 29 76
lip - Hy dr oxy an dr o s t e r on e 614 612 601 617
Patient was administered HCG (6,000 I.U. per day) intramuscular3.y on days 1-3
Protocol
Name
Hospital of admission 
Chronological age 
Bone age
47
Michael K.
Western Infirmary, Glasgow 
16*0 years
15,0 years
Height percentile <  3
Pubertal stage P2 G2
Clinical diagnosis Short stature, hGH normal
URINARY CREATININE 431-845
\
(mean 599) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.91 mg per 24 hours
Day 1 1,61
Day 2 4,65
Day 3 1.56
URINARY TESTOSTERONE Basal 9.29 pg per 24 hours
Day 1 10.28
Day 2 12.38
Day 3 18.98
PLASMA TESTOSTERŒE Basal 299 ng per loo ml
Day 2 501
Day 4 841
urinary ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a==>Andr os t an e- 3a, 170 - di o 1 16 5 10 14
Sp-Androstane-Sa,170-diol 85 40 160 292
A^“Androstene-3B,170-diol ND ND ND ND
5a™Androstane™3p,170^diol 15 6 3 9
Androsterone 61 186 191 565
Aetiocholanolone 62 351 386 937
Dehydroepiandrosterone 27 216 100 161
Epiandrosterone 12 42 27 16
110 “ Hy d j: oxy an dr o s t e r on e 1,341 1,153 1,168 1,269
llp-Hydroxyae tiocholanolone 278 438 450 NM
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day;
Protocol 48
Name David T.S.
Hospital of admission RHSC, Glasgow
Hospital number 29929
Chronological age 16.0 years
Bone age 14.0 years
Height percentile 10
Pubertal stage P2 G2
Clinical diagnosis Nephrotic syndrome,
Cyclophosphamide treated
URINARY CREATININE 420«872 (mean 828) mg per 24 hours
urinary 17-OXOSTEROIDS Basal 3,43 mg per 24 hours
Day 1 3.85
Day 2 3 c 92
Day 3 3.72
urinary testosteroneMa70i«i'5'*rigr3iar3&at.ia*<iacTt.*ncytoiarj WacJTTn laaty^ Basal 3.79 |ig per 24 hours
Day 1 4.68
Day 2 6.35
Day 3 6,70
plasma testosterone Basal 392 ng per 100 ml
Day 3 540
urinary ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,l70'”’diol 16 44 11 23
50«Androstane-3a; ,170-diol 76 31 33 96
A^-Androstene-30,170-diol ND NO ND ND
5 a-Andr ostane“33,l70-diol 4 3 12 2
Androsterone 4 212 83 535
Aetiocholanolone 4 102 28 314
Dehydroepiandrosterone 18 39 6 190
Epi andro 3 ter one 17 16 4 37
113-Hy dr oxy andr osterone 449 428 422 427
Patient was administered HCG (6,000 I.U , per day) intramuscularly on day:
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile % 
Pubertal stage 
Clinical diagnosis
49
John R.
Hawkhead Hospital, Paisley
108069
16*1 years
14.5 years
< 3
P2 G2
Short stature, hGH normal, delayed puberty
URINARY CREATININE 486-777 (mean 650) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.13 mg per 24 hours
Day 1 0,84
Day 2 0.90
Day 3 0.92
URINARY TESTOSTERONE Basal 3.02 jig per 24 hours
Day 1 3.25
Day 2 4.08
Day 3 4 e 94
PLASMA TESTOSTERGNE Basal 372 ng per lOO ml
Day 3 1,417
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a-/mdrostane-3ü: ,170-diol 25 88 38 67
50-Androstane-3a,l70-diol 60 186 76 101
A -Androstene-30,170-diol 6 14 12 10
Sa-Androstane-Sp,170-diol 89 54 51 66
Androsterone 559 582 770 916
Aetiocholanolone 312 248 288 378
Dehydroepiandrosterone 77 80 34 9
Epiandrosterone 4 48 14 12
113-Hydroxyandrosterone 530 4 30 703 546
113 - H y d r 0 X y a e t i 0 c h 01 a n 010 n e 341 126 174 138
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol 50
Name David A.
Hospital of admission Western Infirmary, Glasgow
Hospital number 323308
Chronological age 17.1 years
Bone age 17.2 years
Height percentile 3
Pubertal stage P3 G4
Clinical diagnosis Short stature,^ hGH normal, delayed pub«
After 1 month HCG/HMG treatment
URINARY CREATININE 632-2,063 (mean 1,020) rag per 24 hours
URINARY 17-OXOSTEROIDS Basal 0,44 mg per 24 hours
Day 1 0,85
Day 2 1.26
Day 3 1.03
URINARY TESTOSTEROiE Basal 3,03 jig per 24 hours
Day 1 6.72
Day 2 13,98
Day 3 13.86
PLASfvlA TESTOSTERONE Basal 47 ng per 100 ml
Day 1 100
Day 2 134
Day 3 202
URINARY ANDROGEN MBTABOLIITS pg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane”3a,170-diol 3 14 9 10
56-Androstane-"3a ,l7S-diol 80 50 61 67
Androstene-30,170-diol 1 1 1 2
5ct-An dr os t an e- 3Q , l7B-diol 1 1 1 1
Androsterone 250 230 504 623
Aetiocholanolone 151 181 395 578
Dehydroepi andr osterone 13 23 59 77
Epiandr os t er one 5 4 7 6
Patient was administered IJCG (6 ,000 I.U. per day) intramuscularly on day;
Basal day was 2 weeks after treatment.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
51
Gordon B. 
RHSC, Glasgow 
176010
3.8 years
3.8 years 
50
Pl Gl
Hypogonadism
URINARY CREATININE 276-370 (mean 320) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.37 mg per 24 hours
Day 1 0.34
Day 2 0.40
Day 3 0.49
URINARY TESTOSTERONE Basal 0.81 Rg per 24 hours
Day 1 0.94
Day 2 1.78
Day 3 3.49
PLASMA TES TOSTERON E Basal 157 ng per 100 ml
Day 3 924
URINARY ANDROGEN METABOLITESen»ie*Br»i..TEHi*««a«!ti46MBnsBn*iaOT.iiMi Uïa»a^*ucsrvcmaaB Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-An dr os t ane- 3 a, 17p - diol 13 12 7 5
50-Androstane™3a ,170-diol 78 72 44 45
A^-Androstene-30,173-diol 4 4 11 5
5o:-Androstane-30 ,170-diol 5 3 2 2
Androsterone 56 55 72 107
Aetiocholanolone 40 118 59 86
Dehydroepiandrosterone 170 32 10 5
Epiandrosterone 81 19 9 4
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
52
Hugh M,
RHSC, Glasgow 
182897
6.8 years
6.8 years 
3
Pl Gl
Short stature, hGH normal
1
URINARY CREATININE 76-176 (mean 80) mg per 24 hours
URINARY 17-OXOSTEROIPS Basal 0.19 mg per 24 hours
Day 1 0,15
Day 2 0.20
Day 3 0.25
URINARY TESTOSTERONE Basal 1.47 Rg per 24 hours
Day 1 1*85
Day 2 1,99
Day 3 2.95
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,170-diol 4 3 2 5
50“Androstane™3a,170-diol 51 33 27 163
A^-Androstene-30,170-diol 3 3 2 8
5a^Androstane-3p,170-diol 3 2 2 1
Androsterone 96 217 105 35
Aetiocholanolone 81 101 61 38
Dehydroepiandrosterone 7 11 3 108
Epiandrosterone 64 57 35 57
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
53
Alan R.
RHSC, Glasgow 
35487
10.9 years
10.9 years 
75
Pl Gl
Bilateral undescended testes, 
gynaecomastia^
URINARY CREATININE, 11*111 M i l ■ i i . - . - i M i M . a i j L A f t J i ■■ I iinraaw 633-673 (mean 648) mg per 24 hours
URINARY 17-OXOS TEROIDS Basal 1.07 mg per 24 hours
Day 1 0.96
Day 2 0.72
Day 3 1.27
URINARY TESTOSTERONE
cnKXaauuwsneFaB^faeaAKCyBcwmrwajtaunsjmMiuMMHizaaiMB^M
Basal 6.37 Rg per 24 hours
Day 1 6.35
Day 2 9.76
Day 3 7.62
PLASMA TESTOSTERONE Basal 857 ng per 100 ml
Day 3 2,870
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,170-diol 29 25 29 30
50“Androstane™3a jlTp-diol 153 130 111 126
A^^Androstene-30,176-diol ND ND ND ND
5a-Androstane-36,170^diol 83 1,078 2,875 386
Androsterone 107 104 139 244
Aetiocholanolone 45 44 31 76
De h y dr oe pi an dr os t e r on e ND ND ND ND
Epiandrosterone 742 3,938 10,103 2,078
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
54
Gordon W,
RHSC, Glasgow 
160073
11.0 years 
12«7 years 
90
P2 G2
Unilateral undescended testis
URINARY CREATININE 442-906 (mean 525) rag per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.71 mg per 24 hours
Day 1 0.82
Day 2 0.95
Day 3 1.30
URINARY TESTOSTERONE Basal 0.99 Rg per 24 hours
Day 1 NM
Day 2 NM
Day 3 4.27
PLASMA TESTOSTERONE Basal 427 ng per 100 ml
Day 3 551
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3o:,i70*»diol 14 66 NM NM
50"Androstanc-3a,170-diol 308 329 346 240
A^-Androstene-38 ,170^-diol NM NM NM NM
5a:“Androstane-30 ,170-diol 33 45 17 9
Androsterone 755 624 508 1,005
Aetiocholanolone 33 57 42 93
Dehydroepiandrosterone 96 123 144 94
E p i andr o s t e r on e 105 101 592 611
Patient was administered HCG (6,000 I.U. per day) intramuscularly on day:
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
55
Neil Mo 
RHSC, Glasgow 
123788
12.6 years
12.5 years 
50
P2 G2
Unilateral undescended testis
1
URINARY CREATININE 613-981 (mean 683) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1,32 mg per 24 hours
Day 1 1.40
Day 2 1.84
Day 3 2.00
URINARY TESTOSTERONE Basal 5.52 Rg per 24 hours
Day 1 4,93
Day 2 NM
Day 3 20.40
PLASMA TESTOSTERONErr-iT—' . ..... — ^ ^  ■ im i.i. . 1 Basal 356 ng per 100 ml
Day 3 1,106
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1
5o:-Androstane- 3a ,170-diol 18 NM
50-Androstane™3ajl70-diol 643 5,731
5A -Androstene-36,170™diol 145 51
5a«‘«Androstane«30 ,l?0^diol 62 21
Androsterone 705 405
Aetiocholanolone 597 221
Dehydroepiandrosterone 386 64
E pi andro s t e rone 53 7
110-Hydroxy an dr os t e r on e 364 300
110 -Hy dr oxy ae t i och ol and one 47 90
Patient was administered HCG (6,000 I.U. per day) intramuscularly on
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
56
Peter M.
RHSC, Glasgow 
176803
13.7 years 
13o9 years 
50
P2 Gl
Obesity, hypogonadism
1
URINARY creatinine 627-70'7 (mean 672) mg per 24 hours
URINARY 17-OXQSTEROIDS Basal 0.79 mg per 24 hours
Day 1 1.17
Day 2 1.22
Day 3 1.14
PLASMA TESTOSTERONE Basal 109 ng per 100 ml
Day 3 142
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,170-diol 6 58 49 118
Sp-Androstane-Sa,170-diol 86 237 187 264
A^-Androstene-30,170-diol ND MD ND ND
5a“Androstane-30 ,176«»diol 3 3 19 17
Androsterone 609 1,008 961 1,433
Aetiocholanolone 379 500 605 981
Dehydroe p i an dr os t e r on e 499 997 686 823
Epiandrosterone 247 532 334 533
110-Hydroxyandrosterone 710 NM NM NM
110-Hydroxyaetiocholanolone 18 NM NM NM
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
57
John C,
RHSC, Glasgow 
166792
13.9 years
12,0 years 
<3 
Pl G2
Short stature, hGH normal, hypogonadism
URINARY CREATININE 257-493 (mean 472) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.91 mg per 24 hours
Day 1 1.78
Day 2 1.16
Day 3 0.93
URINARY TESTOSTERONE Basal 0.95 Rg per 24 hours
Day 1 NM
Day 2 2.22
Day 3 2.68
PLASMA TESTOS TERg\)E Basal .380 ng per 100 ml
Day 3 2,286
URINARY ANDROGEN METABOLITES Rg per 24 hours
Basal Day 1 Day 2 Day 3
5 An dr os t ane- 3cc, 170 - di o 1 6 6 10 3
50-Androstane™3a,l76-diol 65 114 73 29
A^-And.rostene-33 ,170-diol 23 18 17 10
5o:<»Androstane-38 ,170-diol ND ND ND ND
Androsterone 162 198 212 229
Aetiocholanolone 53 72 98 98
Dehydroepiandrosterone 98 112 136 225
Epiandrosterone 261 295 294 316
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1“3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
58
Alasdair C.
RHSC, Glasgow 
106507
4.5 years
6.5 years 
25-50
Pl GO
Prader-Willi syndrome, 
bilateral undescerided testes
URINARY CREATININE
URINARY 17-0X0STER0ÏDS
URINARY TESTOSTERONE
PLASMA TESTOSTERONE
URINARY ANDROGEN METABOLITES
5cC“>Androstane-3a ,170-diol 
50«Androstane-3a,170-diol 
A^-Androstene-30,170-diol 
5a-Androstane“30,170-dioI 
Androsterone 
Aetiocholanolone 
Deh y dr oe p i an dr osterone 
E p i an dr os t e r one
432-508 (mean 480) mg per 24 hours
Basal 0.56 rag per 24 hours
Day 1 0.70
Day 2 0.37
Day 3 0.62
Basal 1.03 Rg per 24 hours
Day 1 1.09
Day 2 1.05
Day 3 1.55
Basal 817 ng per loo ml
Day 3 857
Rg per 24 hours
Basal Day 1 Day 2 Day 3
4 4 4 4
ND ND ND ND
24 54 34 48
ND ND ND ND
17 38 40 36
20 16 20 21
ND MD ND ND
572 299 292 415
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Procotol
Marne
Hospital of admission 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
59
Arshad R.
Luton & Dunstable Children*s Annexe
5*4 years
600 years
10-25
Pi GO
Laurence-Moon^Biedl syndrome, 
bilateral undescended testes
1
URINARY CREATININE 247-304 (mean 272) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.15 mg per 24 hours
Day 1 0,70
Day 2 0.95
Day 3 0.73
URINARY TESTOSTERONE Basal 0.29 pg per 24 hours
Day 1 0.32
Day 2 0.37
Day 3 0*46
PLASMA TESTOSTERONE
■emuKKMPAXBB^rtmn snxftWKiWsnvNtf
Basal 155 ng per 100 ml
Day 3 512
urinary androgen metabolites pg per 24 hours
Basal Day 1 Day 2 Day 3
5a--Andr 0 s t ane-Soc, 17!3di 01 3 3 3 3
5p^Androstane-3o,17p™diol 28 70 22 30
A^^Androstene™3pjl73“diol 22 66 26 23
Sa^Androstane^-Sp ,17p™diol 20 28 23 34
Androsterone 3 3 6 9
Aetiocholanolone 15 16 7 28
Dehydroepiandrosterone 3 12 4 11
Ep i andr 0 s t e r on e 33 41 29 46
1 Ip -’•Hy dx: oxy an dr ester on e 198 203 192 209
lip - Hy dr oxy ae t i och 01 an 0 1 one 89 94 64 39
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
60
Scott M,
RHSC, Glasgow 
183093 
9*5 years 
9*5 years 
50
Pi GO
Bilateral undescended testes 
after orchidopexy twice
URINARY CREATININE 105-521 (mean 498) mg per 24 hours
URINARY 17-OXOSTEROIDS11I i i^ i i  1 n ■ lafTratnang’iseaa Basal 0c30 mg per 24 hours
Day 1 0.23
Day 2 0.38
Day 3 0 e 44
URINARY TESTOSTERONE Basal 2.53 pg per 24 hours
Day 1 2.59
Day 2 2.65
Day 3 2.74
PLASMA TESTOSTERONE Basal 50 ng per 100 ml
Day 3 253
URINARY ANDROGEN METABOLITES
PMwrgs»BKrwn«gwfawrayMTii'.nu.<mMHaTWBar«i»«iaiwmjwgwgt«^ fciW33aawgy*J>tfa>janiaL.c*.»*»tw»aew»Br«p Ug per 24 hours
Basal Day 1 Day 2 Day 3
Sa-Androstane-So: ,l7(3-diol 5 9 3 4
53-Androstane™3oc jl7|3‘“diol 54 70 25 12
A^ -AndrOvStene*"3(3 ,17p™-diol 4 64 86 128
5a™Androstane-33 ,17j3-diol 16 23 85 181
Androsterone 15 83 104 67
Aetiocholanolone 8 44 20 20
Dehydroepiandrosterone 4 20 21 222
Epiandrosterone 57 SO 55 6
1Ip-Hydr oxy andr os t e r on e 18 162 115 103
11B-Hy dr oxy ae ti o ch o1an o1on e 5 84 63 88
Patient was administered HCG (6,000 I,H, per day) intramuscularly on days 1-3
- vXU/i
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
61
Brian D.
RHSC, Glasgow 
156169
9,6 years
11,0 years 
> 97 
Pi G1
Unilateral undescended testis after surgery
URINARY CREATININE 318-573 (mean 433) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.53 mg per 24 hours
Day 1 0.45
Day 2 0.22
Day 3 0.25
URINARY TESTOSTERONE Basal 1.38 pg per 24 hours
Day 1 u.
Day 2 1*62
Day 3 3.49
PLASMA TESTOSTERONE Basal 177 ng per 100 ml
Day 3 1,098
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5oc-Androstane“3cc ,17g-diol 6 6 2 12
5p-Androstane-3o: ,173-diol 13 23 8 5
5
A -Androstene-^Sp ,173-diol ND ND ND ND
5o:-Androstane-33 ,17p-diol 6 39 18 7
Androsterone 56 54 78 99
Aetiocholanolone 35 38 37 74
De h y dr oe p i andr os te r on e 72 17 20 137
Epi andr os t e r one 136 143 136 161
Patient was administered HCG (6,000 I,U. per day) intramuscularly on day
Protocol
Naine
Hospital of admission 
Hospital number 
Chronological age 
Height percentile 
Pubertal stage 
Clinical diagnosis
JUJ - 
62
Douglas S,
Southern General Hospital, Glasgow 
•156051
10.0 years 
<  3 
Pi G1
Short stature, hGH normal, 
bilateral undescended testes
1
urinary CREATININE 219-223 (mean 221) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.00 mg per 24 hours
Day 1 0.79
Day 2 Go 66
urinary testosterone Basal 0.56 Pg per 24 hours
Day 1 1.88
Day 2 3.08
PLASMA TESTOSTERONE
# II III! 1 H 1 WIIII IIIH IWII II ■
Basal 398 ng per 100 ml
Day 2 768
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2
5a-“Androstane*'3a ,l73“diol 7 26 15
53-Androstane™3a,173-diol 21 16 28
A^-Androstene-3 3 ,173^diol ND 3 3
5a-Androstane™33,173-diol 9 19 8
Androsterone 23 21 30
Aetiocholanolone 10 8 14
Dehydroepiandrosterone ND ND ND
Epi andr osterone 194 308 241
113-Hydroxyandrosterone 39 NM 36
113-Hydroxyaetiocholanolone 67 NM 78
Patient was administered HCG (6,000 I.U. per day) ia t r amu s c u1a r1y
1 and 2
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
63
William L,
RHSC, Glasgow 
44279
10,9 years 
8*0 years 
50
PI GO
Bilateral undescended testes
1
URINARY CREATININE 469—621 (mean 341) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0o84 mg per 24 hours
Day 1 0.73
Day 2 0.67
Day 3 0.50
URINARY TESTOSTERONE Basal 0.64 pg per 24 hours
Day 1 0.58
Day 2 2.32
Day 3 2.75
PLASMA TESTOSTERONE Basal 336 ng per 100 ml
Day 3 992
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
Soc-Aiidr ostane™3a,l?3™diol 10 12 14 18
Sp-Androstane-Sa ,l73«“diol 4 6 11 15
A'^-Androstene-Sp ,l?3-diol 4 4 5 7
5oc-Androstanc-3p ,17p-diol 2 2 2 2
Androsterone 100 106 117 137
Aetiocholanolone 60 66 90 129
De hyd r o e p i androsterone 229 158 201 242
Epian dros t e r on e 486 376 465 497
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3
- dUO ”
Protocol 64
Name Grant McF.
Hospital of admission RHSC, Glasgow
Hospital number 164487
Chronological age 14.4 years
Bone age 12.1 years
Height percentile < 3
Pubertal stage Pi G1
Clinical diagnosis Short stature,^ hGH normal, delayed puberty
URINARY CREATININE 354—606 (mean 452) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.71 mg per 24 hours
Day 1 0.35
Day 2 0.92
Day 3 0.45
URINARY TESTOSTERONE Basal 0o72 pg per 24 hours
Day 1 1.08
Day 2 1.48
Day 3 1.94
PIJISMA TESTOSTERONE Basal 1,736 ng per 100 ml
Day 3 3,270
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5oc-Androstane"-3a ,l7B-clioi 5 9 5 4
5p-Androstarie™3a ,l73“diol 37 39 41 17
A^-Androstene-36 jl7|3-diol ND ND ND ND
Sa-Andr 0 s t ane- 3p , 17p - di o 1 12 43 47 21
Androsterone 157 180 311 326
Aetiocholanolone 60 64 165 164
Dehydroepiandrosterone 35 15 120 113
E p i andr o s t e r on e 214 240 154 158
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
65
Edward M*
Gartiiavel General Hospital, Glasgow
'480603
15.0 years
15*0 years
50
P3 G3
Cushing*s syndrome
1
URINARY CREATININE 741-894 (mean 782) mg per 24 hours
urinary 17-OXOSTEROIDS Basal 0.91 mg per 24 hours
Day 1 0.41
Day 2 1.25
Day 3 5.19
URINARY TESTOSTERONE
00 l a f  full nrn«'i iT itrt i> iir in iiiiitri'i i niri—JriTTirii nini«Ti~ininiT nii ■niiii.i
Basal 5.47 pg per 24 hours
Day 1 5.52
Day 2 6.41
Day 3 7.49
PLASMA TESTOSTERONE
rflre.tiStea**»T«*Ta-rei.5eeeûe«<roflî,ZiaVT<»* MTiPrU^^m'ta-mV^rra n  >
Basal 376 ng per 100 ml
Day 3 860
urinary androgen METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
Sa'-Aiidrostane-So: ,17(3-diol 239 147 6 . 30
5 [3 - An d r 0 s t an e- 3 a', 17 p “■ d i 01 243 215 134 155
An dr os t ene- 33 j 17p - di o 1 19 17 21 10
5cf-Androstane-33 ,173-diol 1 1 ND 1
Androsterone 505 632 767 732
Aetiocholanolone 715 992 1,478 1,182
Dehydroepiandrosterone 128 141 289 298
B p i an dr o s t e r on e 36 40 60 42
113 - Hy d r oxy an dr o s t e r on e 1,749 1,747 1,750 1,768
113 Î i y d r oxy ae t i 0c h o 1 ano 1 on e 1,047 962 1,599 993
Patient was administered HCG (6,000 I.TJ. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
66
Paul C.
RHSC, Glasgow 
172449
15.6 years
15.5 years 
50
P3 G3
Normal, early puberty
URHnIARY CREATININE 263-778 (mean 611) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.99 mg per 24 hours
Day 1 3,17
Day 2 1.17
Day 3 1.80
URINARY TESTOSTERONE Basal 9.92 pg per 24 hours
Day 1 10.64
Day 2 18.62
Day 3 19.58
PLASMA TESTOSTERONE Basal 483 ng per 100 ml
Day 3 1,345
URINARY ANDROGEN METABOLITES gg per 24 hours
Basal Day 1 Day 2 Day 3
5a~An drost an e-3a,17p-di ol 230 153 194 49
53-An drostane-3a,173-di0 1 75 59 67 58
A*^«“Andr 0 s t one- 33,173 - di 01 23 2 21 76
5a«An d r 0 s t an e-38,176-di 0 1 53 26 15 , 38
Androsterone 486 401 890 1,200
Aetiocholanolone 188 228 393 585
Dehydroepiandrosterone 92 79 123 90
Epi. an drosterone 24 16 25 13
Patient was administered HCG (6,000 1.U» per day) intramuscularly on days 1-3
Protocol 67
Name David F,
Hospital of admission Western Infirmary, Glasgow
Hospital number 535688
Chronological age 20.0 years
Bone age 19.5 years
Height percentile 50
Pubertal stage P5 G5
Clinical diagnosis Normal
1
URINARY CREATININE 569-734 (mean 654) mg per 24 hours
URINARY 17-OXOS TEROIDS Basal 5.69 mg per 24 hours
Day 1 5.40
Day 2 5,70
Day 3 6.50
URINARY TESTOSTERONE Basal 14,26 pg per 24 hours
Day 1 18.81
Day 2 19.38
Day 3 15.76
PLASMA TESlOSTHRONE Basal 350 ng per 100 ml
Day 3 840
urinary ANDROGEN METABOLITES p.g per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,l7p^diol 73 126 97 61
5p-Androstane-3a,l?3“diol 168 133 115 116
A^-Androstene-36 ,l7j3-diol 216 148 157 114
5a-Androstane-33;l7p-diol 95 53 55 59
Androsterone 1,455 2,191 1,688 1,438
Aetiocholanolone 1,695 2,350 1,904 1,853
De h y dr oe p i an dr os t e r on e 79 327 311 226
Epiandrosterone 14 36 17 15
Patient was administered HCG (6,000 1,0. per day) intramuscularly on days 1-3,
Protocol 68
Name Gordon Ao
Hospital of admission Outpatient, RHSC, Glasgow
Chronological age 26.0 years
Bone age 26.0 years
Height percentile 50
Pubertal stage P5 G5
Clinical diagnosis Normal male
URINARY CREATININE 923-1,
1
380 (mean 1,190) mg per 24 hou rs
URINARY 17-OXOSTEROIDS Basal 2.48 rag per 24 hours
Day 1 1.82
Day 2 3.94
Day 3 4.16
URINARY TESTOSTERONE Basal 42.85 per 24 hours
Day 1 44 c 82
Day 2 61.90
Day 3 85.52
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5cx-Androstane-3o:,l73-diol 119 23 36 29
5p-Androstane-3a,173-diol 114 80 215 225
A^-Androstene-33,173-diol 3 2 5 3
5a«Androstane-36,173-diol 19 22 9 15
Androsterone 2,326 2,444 3,254 3,521
Aetiocholanolone 1,470 1,421 2,100 2,000
Dehydroepiandrosterone 446 255 531 501
Epiandrosterone 24 8 31 23
lip-Hy dr oxy and roster one 1,100 1,105 1,090 1,108
lip'-Hydroxy aetiocholanolone 177 110 138 110
Patient was administered HCG (6,000 I.U, per day) intramuscularly on day
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
69
David S,
RHSC, Glasgow 
113005
12.1 years 
9ol years 
10
PI G1
Bilateral undescended testes
URINARY CREATININE 295-655 (mean 458) mg per 24 hours
URINARY ly-OXOSTEROIDS Basal 1,05 mg per 24 hours
Day 1 2.22
Day 2 1.21
Day 3 1.21
URINARY TESTOSTERONE Basal 1.33 |ig per 24 hours
Day 1 1.89
Day 2 4.00
Day 3 4.42
PLASMA TESTOSTERONE Basal 1,238 ng per lOO ml
Day 3 11,305
URINARY ANDROGEN METABOLITES |xg per 24 hours
5o;-Androstane-3o£ ,17p-diol
5P“Androstane-3o: ,173-diol
A -Androstene-33,i7p-diol )
5cc-Androstane-3e ,176-diol ^
Androsterone
Aetiocholanolone
Dehydroepiandrosterone
Epiandrosterone
1 Ip Hy dr oxy an dr o s t e r on e
113-Hyd r oxy ae t i oc h o1an o1on e
Basal Da.y 1 Day 2 Day 3
223 61 NM 32
144 275 NM 192
9,538 1,176 81,432 500
44 4 262 275 250
169 193 287 363
NM NM NM NM
353 NM 740 1,388
2,282 2,197 2,341 2,242
242 ] 24 189 344
Patient was administered HCG (6,000 I.U, per day) intramuscularly on days 1-3,
Protocol 70
Name Frederick S.
Hospital of admission Gartnavel General Hospital, Glasgow
Hospital number 494378
Chronological age 19.9 years
Bone age 18.0 years
Height percentile 25«50
Pubertal stage P2 G2
Clinical diagnosis Cushing's syndrome , delayed puberty
URINARY CREATININE 570-680 (mean 605) mg per 24 hours
URINARY TESTOSTERONE Basal 3.84 pg per 24 hours
Day 1 4c76
Day 2 6.07
Day 3 8.02
PLASMA TESTOSTERŒE Basal 120 ng per loo ml
Day 3 335
URINARY ANDROGEN METABOLITES |Lig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,173-dioi 263 368 405 638
Sp-Andr ost ane-3ct, 173-diol 440 462 703 814
A'^-Androstene-33 ,l7P“diol 300 272 314 197
5a-Androstane-3p,l7p«diol NM 146 175 126
Androsterone 1,498 1,873 1,933 2,703
Aetiocholanolone 444 700 854 1,410
Dehydroepiandrosterone 189 207 111 408
Epiandrosterone 291 260 236 276
llp-Hydroxyandrosterone 3,339 3,310 3,042 3,027
Patient was administered HCG (6,000 I,U. per day) intramuscularly on days 1-3.
Protocol
Name
71
Paul F.
Hospital of admission RHSC, Glasgow
Hospital number 121995
Chronological age 6ü3 years
Bone age 3ol years
Height percentile <  3
Pubertal stage PI GO
Clinical diagnosis Short stature, hGH normal,
bilateral undescended testes
URINARY CREATININE 90-175 (mean 125) mg per 24 hours
URINARY 17-OXOSTBROIDS Basal 0.50 mg per 24 hours
Day 1 1,52
Day 2 0.49
Day 3 0.98
URINARY TESTOSTERONE*1 «uaiMoemii wnmmwn ii iirrium iiii#, Basal 0.81 iig per 24 hours
Day 1 1.11
Day 2 1.41
Day 3 2.96
PLASMA TESTOSTERONE Basal 86 ng per lOO ml
Day 3 318
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a«Androstane-3a,i?3-diol 50 73 60 73
53*”Androstane-“3a 5173-diol 39 35 27 37
A^-Androstene-3(3 ,173-diol ND ND ND NO
Sa-Androstane-Sp,l7p-diol 3 1 1 1
Androsterone 34 46 30 38
Aetiocholanolone 7 10 4 7
Dehydroepiandrosterone 10 30 3 9
E p i an dr oster on e S3 116 2 5
Patient was administered HCG (6,000 I.U, per day) intramuscularly on day
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Rone age
Height percentile 
Pubertal stage 
Clinical diagnosis
72
Brian R,
Hawkhead Hospital, Paisley 
147394
8.0 years
6.5 years 
10
PI G1
? Prader-Willi syndrome
1
URINARY CREATININE 310-496 (mean 394) mg per 24 hours
URINARY 17-OXOSTEROXDS Basal 0.33 mg per 24 hours
Day 1 0.13
Day 2 0.21
Day 3 0.10
URINARY TESTOSTERONEWf niwiifm ifiTTiT m^rmTt’-i-r-n-i-T'^'iT—t-1-1---- Basal 2,25 pg per 24 hours
Day 1 0.97
Day 2 2.12
Day 3 1.69
PLASMA TESTOSTERONE«iMf*ÉWi«w»fl«rc«worB*Bti.*atiriaeT*wjtTitid|W0iSW«!irBTOMjrs»âa Basal 317 ng per loo ml
Day 3 302
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a™Androstane-3a,l7p-diol 189 29 7 36
Sp-Androstane-Sa,170-diol 23 9 6 10
A^-Andr 081 ene- 3j3 ,17B - di 01 ND 23 11 3
5o-Androstane-3p,17p-diol 42 38 202 39
Androsterone 194 49 104 103
Ae t i GO ho 1 ano 1 on e 7 18 15 19
Dehydroepiandrosterone 31 20 32 27
E p i andr o s t e r on e 6 5 16 11
Patient was administered HCG (6,000 I.U. per day) int r amu s c u1a r1y on day
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
73
Melville M,
RHSC, Glasgow 
175689
15.5 years
12.6 years stationary 
< 3
P2 G2
Short stature, hGH normal
1
URINARY CREATININE 526-646 (mean 568) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.65 mg per 24 hours
Day 1 1.04
Day 2 1.58
Day 3 1.73
URINARY TESTOSTERONE Basal 1,84 pg per 24 hours
Day 1 2o07
Day 2 2.79
Day 3 3,84
PLASMA TESTOSTERONE Basal 139 ng per 100 ml
' Day 3 520
URINARY ANDROGEN METABOLITES |ig per 24 hours
Basal Day 1 Day 2 Day 3
5a«>Androstane‘“3a ,l7|3-diol 149 NM NM NM
5(3“Andr os t ane- 3a,17g-diol 9 NM NM NM
A^-Androstene™30,l7g-diol ND NO ND ND
5amAndrostane-3p ,l7(3-diol 33 36 70 21
Androsterone 426 415 666 693
Aetiocholanolone 355 446 678 676
Dehydroepiandrosterone 87 68 98 76
Epiandrosterone 40 34 46 17
113-Hy dr oxy androsterone 403 388 606 442
113-Hydr oxy ae t i oc h c1an 01on e 438 410 280 399
Patient was administered HCG (6,000 I.Uc per day) in t r amu s c u1 ar X y on day
Protocol 74
Name Ian S*
Hospital of admission RHSC, Glasgow
Hospital number 162001
Chronological age 8,3 years
Height percentile <3
Pubertal stage Pi G1
Clinical diagnosis Short stature, hGH normal
URINARY CREATININE
I
174-313 (mean 246) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.50 mg per 24 hours
Day 1 0,90
Day 2 0.68
Day 3 0.18
URINARY TESTOSTERONE ' Basal 3.25 pg per 24 hours
Day 2 2.41
Day 3 2.85
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 2 Day 3
5o:-Androstane-3a ,173-diol 2 2 4
5p-Androstane-3a,173-diol 154 88 144
A -Androstene«33,173-diol 11 4 3
5a-Androstane-3$,l?p-diol 277 18 67
Androsterone 70 72 106
Aetiocholanolone 27 36 49
Dehydroepiandrosterone 7 3 6
Epiandrosterone 1 6 2
Patient was administered HCG (6,000 I.U. per' day) intramuscularly on
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
75
James S«
RHSC, Glasgow 
142333 
7*0 years
7.0 years 
25-50 
PI G1
Bilateral undescended testes
URINARY CREATININE
URINARY 17-OXOSTEROIDS
urinary TESTOSTERONE
URINARY ANDROGEN METABOLITES
5cc-Androstane-3oc,l73-diol
5p“Androstane“3a,176-diol
A^-Androstene-36,l7g™diol
5a-Aiidrostane-33 ,173™diol
Androsterone
Aetiocholanolone
Dehydroepiandrosterone
Epiandrosterone
113 « Hyd r oxy an dr os t e r on e
113-Hydr oxy ae t ioc ho1ano1one
310-458 (mean 426) mg per 24 hours
Basal 0.79 mg per 24 hours
Day 1 0.66
Day 2 0.84
Day 3 0.64
Basal 3.14 pg per 24 hours
Day 1 2.67
Day 2 6.86
Day 3 7.43
pg per 24 hours
Basal Day 1 Day 2 Day 3
34 9 3 22
116 98 53 50
ND ND ND ND
2 1 2 1
60 49 46 41
10 16 37 19
ND ND ND ND
23 21 12 17
266 335 406 274
259 280 266 188
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days i"3.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
76
Iain S.
RHSC, Glasgow 
178150
9.0 years
9.0 years 
50
pi 01
Hypogonadism
URINARY CREATININE 500-745 (mean 625) mg per 24 hours
urinary 17-OXOSTEROIDS Basal 0.87 rag per 24 hours
Day 1 0,65
Day 2 0*90
Day 3 1.06
URINARY TESTOSTERONE Basal 4.26 pg per 24 hours
Day 1 3.37
Day 2 2.46
Day 3 2,05
PLASMA TESTOSTERONE Basal 106 ng per 100 ml
Day 3 248
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3
5a-Androstane-3a,l?3-diol 21 4 13 11
53™Andro8tane-3a,173^diol 66 50 89 106
A^-Androstene-3 3,l73“diol 4 3 4 4
5o:-Androstane««33 ,l73™diol 65 116 151 208
Androsterone 316 271 384 426
Aetiocholanolone 79 73 101 116
Dehy dr oe p i andr os t e r one 28 38 9 11
Epiandrosterone 119 13 17 20
Patient was administered HCG (6,000 I.U. per day) intramuscularly on days 1-3,
Protocol
Name
Hospital of admission
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
77
Jeremy W*
Royal Manchester Children's Hospital, 
Manchester
74760
9.5 years
14.0 years
>97
P4 G4
Precocious puberty (pineal tumour)
URINARY CREATININE 719-915 (mean 820) mg per 24 hours
URINARY TESTOSTERONE Basal 9.8 pg per 24 hours
Day 1 1.82
Day 2 1.42
Day 3 0.61
Day 4 0.96
Day 5 0.43
PLASMA TESTOSTERONE Basal 28,900 ng per 100 ml
Day 1 394
Day 3 992
Day 4 716
URINARY ANDROGEN METABOLITES
j T.iMfMyiPCWMtw™ ««mnw.i I ji L11 «.-.«a i-rTm-ai i urn;
Scc-Androstane-Soc ,173-diol 
Sp-Androstane-Sa,173-diol 
A'^-Androstene-36 ,178-diol 
5o:-Androstane“36 ,l7p-diol 
Androsterone 
Aetiocholanolone 
Dehydroepiandrosterone 
Epiandros te rone
pg per 24 hours
Day 1 Day 2 Day 3 Day 4 Day 5
19 13 25 13 6
27 80 110 56 29
ND ND ND ND ND
1 64 220 179 49
1,439 50 35 145 11
128 10 45 51 64
364 53 41 148 55
425 127 44 96 48
Basal day (22.11.73) pretreatment and diagnosis of tumour. 
Day 1 (10.1.74) treatment with cyproterone acetate.
Day 2 (22.1,74) tumour removed.
Day 3 (30.1.74) LIIRH (100 pg I.V.).
Day 4 (6.2.74) general patient review.
Day 5 (19.3.74) general patient review.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
78
David D,
RHSC, Glasgow
173987
5.0 years
10.5 years
>97
P3 G3
Precocious puberty, testicular tumour?
1
URINARY CREATININE 458-600 (mean 507) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 0.20 :mg per 24 hours
Day 1 0.39
Day 2 0.11
Day 3 0.39
Day 4 0.26
URINARY TESTOSTERONE Basal 22.75 \ig per 24 hours
PLASMA TESTOSTERQNE Basal 4,452 ng per 100 ml
PLASMA DEHYDROEPIANDROSTERQNE Basal 21 |ig per 100 ml
URINARY ANDROGEN METABOLITES pg per 24 hours
Basal Day 1 Day 2 Day 3 Day 4
5a*”Androstane™3a ,17p-diol 2 4 19 172 53
53"“Androstane-3o: ,l73‘"diol 805 84 213 193 364
A^-Androstene-3 3 ,173-diol ND ND ND ND ND
5a-Andr os t an e-33,176-diol 2 6 3 8 4
Androsterone 325 317 202 431 372
Aetiocholanolone 58 51 32 105 141
De hy d r oe p i an dr os t e r one 5 1 1 ND 11
Epiandrosterone 22 7 6 17 22
ll3‘"'Hydroxyandrosterone 324 489 103 493 660
113-Hydroxyaetiocholanolone 40 60 17 ND ND
patient was administered Dexamethazone (0,5 mg, 4 times daily, orally on 
days 1 and 2^  2,0 mg, 4 times daily, orally on days 3 and 4)*
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis
79
David A,
Western Infirmary, Glasgow
323308
17*2 years
17.2 years
3
P3 G4
Short stature, hGH normal, delayed puberty 
Last week of HCG/HMG treatment
URINARY CREATININE 632-2,063 (mean 1,020) mg per 24 h our s
URINARY 17-OXOSTEROIDS Day 1 1.67 mg per 24 hours
Day 2 1.31
Day 3 0*95
Day 4 1.99
URINARY TESTOSTERQNB Day 1 6.60 |ig per 24 hours
Day 2 3.23
Day 3 8.19
Day 4 5*85
PLASMA TESTOSTERONE Day 1 40 ng per 100 ml
Day 3 89
URINARY ANDROGEN METABOLITES
o « iwuTusfanuaa amœæmmaaacnewramMmf wwagrar;»
pg per 24 hours
Day 1 Day Ïi Day 3 Day 4
5oc-Androstane-3a,17p-diol 14 14 14 9
Sp-Androstane-So: ,17P“diol 70 110 91 89
5A -Androstene-36,173™diol 1 2 1 2
5a*»Androstane-36 ,176-diol 1 2 1 2
Androsterone 281 221 259 219
Aetiocholanolone 242 201 226 206
Dehydroepiandrosterone 40 37 50 36
Epiandroste rone 10 18 12 6
Patient was administered HCG (1,600 I.U. per day) intramuscularly on
days 1 and 3 and HMG (1,000 I.U. per day) on days 2 and 4.
Protocol
Name
Hospital of admission 
Hospital number 
Chronological age 
Bone age
Height percentile 
Pubertal stage 
Clinical diagnosis 
Karyotype
80
Alexander G,
RHSC, Glasgow 
16663
14cO years
14.0 years 
10-25 
P2 G3
Gynaecomastiaj, XX-male 
46,XX
URINARY CREATININE 1,034-1,392 (mean 1,191) mg per 24 hours
URINARY 17-OXOSTEROIDS Basal 1.46 mg per 24 hours
Day 1 1.63
Day 2 2.92
Day 3 3*71
URINARY ANDROGEN METABOLITES
in H'wmi f  e<i ........a im !ig per 24 hours
Basal Day 1 Day 2 Day 3
5a-Andr ostane-3o: ,l7p-diol ND ND ND ND
5{3'“Androstane-3o: ,l7(3*“diol 18 9 19 20
A -Androstene-33,173-diol 14 14 26 58
5cC"-*Androstane-3p ,17p-diol NO . ND ND ND
Androsterone 933 1,113 735 745
Aetiocholanolone 421 439 378 417
Dehydroepiandrosterone 502 403 635 792
Epiandrosterone 34 31 66 89
Patient was administered Corticotrophin (ACTH; 40 mg per day) intramuscularly 
on days 1-3.
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Tne' evaluation of testicular Leydig cell function is of
considerable clinical value in the investigation of gonacal problems
in childhood and adolescence* Testicular function was assessed in
the patients deer: in this thesis by the estimation of the basal
plasma testosterone concentration^ the basal daily urinary excretion
of testosterone and the individual androgen metabolites and the
changes in these parameters to administered KCG* This method therefore
not only gives an index of testosterone production but also allows
investigation of actual testosterone utilization by the patient*
“ 3 “
Following the addition of / H^/testosterone for
recovery purposes, aliquots of plasma were made alkaline by the 
addition of sodium hydroxide and the testosterone extracted with 
diethyl ether* Purification of the extracted residues effected 
by partition ai-id thin layer chromatography* The dried residues were 
dissolved in di chi or ome thane and ester if led with hepta^f luorobutyric 
anhydride for 30 minutes at room temperature* Following subsequent 
purification by thin layer chromatography, quantitation of 
testosterone“l7“heptafltîorobutyrate was made by electron capture 
detection on a Pye 104 gas liquid chromatograph* A correction w?as 
made for the recovery rate of radioactively labelled testosterone added 
initially to plasma samples*
A near total hydrolysis of urinary conjugates of testosterone 
was effected by incubation with (3“glucuronidase (750 F*u* per ml urine) 
at 37^C for 72 hours without inhibition of the sulphatase activity
of the enzyme preparation* Following the addition of / H /-
—  "* ^  tur# ^ It ^ ivi3
testosterone and extraction with diethyl ether, the urinary residues 
were purified, esterified and quantitated as for the plasma extracts* 
Similar hydro_}^ed and extracted urinary residues were purified 
by partition only* The dried residues were dissolved in dichloroncthane 
and esterifled with heptafluorobutyric anhydride at room temperature 
for 30 minutes* Quantitation of the individual androgen esters vrzis 
made from a tracing of various androgens as obtained from flame 
ionization detection of the compounds in a Pye 104 gas liquid 
c hr cm a t og r ap h *
All urine specimens were subjected to routine l7“Oxosteroid 
determination by the Zimmerraann reaction and creatinine determination 
by the Jaffe reaction* All urine results were subsequently adjusted 
to a constant daily creatinine excretion over the period of collection* 
The results from 80 patients investigated (age range 5 months to 
26 years) were analysed against chronological age, height and 
pubertal status of the patients* Patients with bilateral undescended 
testes had a greatly elevated urinary excretion of epiandresterone, 
implying abnormal androgen metabolism, and a significantly subnormal 
or undetectable urinary excretion of dehydroepiandrosterone and 
A^^androstenediol, implying a deficiency of I7,20“desmolase* Patients 
with hypogonadism also had a significantly subnormal or undetectable
5
urinary excretion of A -androstenediol but in combination with a 
normal urinary excretion of dahydrospiandrosterone, implying a 
deficiency of l7(3“reductase*
Patients with short stature, bilateral undescended testes, 
hypogonadism (niicrogenitalla) or delayed puberty had a significantly 
subnormal urinary excretion of testosterone in combination with a 
normal or elevated testosterone concentration* Partial tissue
insensitivity to testosterone and increased binding to testosterone 
binding globulin were advanced as possible explanations of the 
testosterone levels in these patients and these possibilities were 
discussed*
Testicular function was assessed in nine patients with abnormal 
sex chromosome constitution* T t^o patients with Klinefelters-yndrorae 
(47,XXY and 46,XX) had poor production and utilisation of testosterone* 
Four patients with the testicular féminisation syndrome had good 
testosterone production and variable, although generally poor, 
utilisation of testosterone, this suggesting partial or complete tissue 
insensitivity to testosterone, the accepted explanation of this syndrome 
Ttjo patients with the XO/XY mosaicism and female phenotype (unilateral 
testis and contralateral streak gonad) had fnear^normal* production of 
testosterone whilst a patient with the XX/XY genotype and bilateral 
ovotestes had extremely poor production and poor utilization of 
testosterone *
Clinical significance was given to the urinary excretion of 
three metabolites - Sa^androstanediol as an index of androgenicity, 
5(3“androGtanediol as an index of masculine genital development and 
epiandrosterone as an index of the somatic utilization of testosterone*
The possibility that the urinary excretion of these metabolites nay 
have prognostic significance in prepubertal patients was discussed*
